# DermaDex, full content

> AI-assisted skin condition triage and access to certified dermatologists in Canada. This file contains the full text of every published DermaDex article so an AI assistant can read the whole corpus at once. The short link index is at /llms.txt.

DermaDex is a Canadian healthtech company building AI-assisted dermatology tools. The model runs on the patient's device and provides triage, not diagnosis. All medical content cites primary sources (Health Canada, CIHI, Canadian Dermatology Association, AAD, PubMed, JAMA). Content below is reproduced for machine reading and remains the property of DermaDex Health Inc.

Source: https://www.dermadex.ca
Articles: 40

---

# Mole Mapping and Total Body Photography: Who Actually Needs It

URL: https://www.dermadex.ca/blog/mole-mapping-total-body-photography
Category: Prevention
Author: Maryam Sobhkhiz Sabet
Published: 2026-06-16

## TL;DR
Mole mapping is a tracking tool, not a diagnosis; only a biopsy confirms melanoma (Canadian Dermatology Association) | A 2021 systematic review of 14 studies and 12,082 people linked total body photography with thinner, earlier melanomas | Number needed to excise one melanoma with total body photography ranged from 3:1 to 14.3:1 (Hornung et al., 2021) | In Ontario, mole mapping is usually private, about CAD $150 to $400 per session, and not covered by OHIP | A 2025 JAMA Dermatology randomized trial tested 3D total-body photography in patients at high risk for melanoma

*As of June 16, 2026.*

Mole mapping and total body photography (TBP) are marketed as a way to catch skin cancer before it spreads. For some people, that is accurate. For most people with a few ordinary moles, it is more imaging than they need. This guide explains what the technology does, who genuinely benefits, what the evidence shows, and what it costs in Canada. [DermaDex](/) is a Canadian healthtech company that connects patients to certified dermatologists and builds artificial intelligence (AI)-assisted tools for skin assessment, so we field this question often.

## What is mole mapping and how does total body photography work?

**Short answer:** Mole mapping is a structured method of photographing your moles and comparing the images over time so a clinician can catch lesions that change. Total body photography (TBP) records standardized, high-resolution photos of your whole skin surface, while mole mapping often adds close-up dermoscopy of individual spots. Some clinics now use three-dimensional (3D) TBP systems and artificial intelligence (AI) software to flag lesions for review. The photos become a baseline. At follow-up, your clinician looks for new moles and changes in existing ones, which are the warning signs that matter most.

A typical session starts with overview photos taken from set angles and distances, so the same body region looks the same at every visit. Individual moles of interest are then captured with a dermoscope, a magnifier with polarized light that reveals patterns the naked eye misses. When clinics repeat dermoscopy on the same lesion over time, the technique is called sequential digital dermoscopy imaging (SDDI). The Canadian Dermatology Association (CDA) describes [melanoma](https://dermatology.ca/public-patients/diseases-conditions/skin-cancer/melanoma/) as the most dangerous common skin cancer, and the value of any imaging is that it makes subtle change visible before a tumor grows deep.

## Who actually needs mole mapping or total body photography?

**Short answer:** Most people with a handful of stable moles do not need mole mapping. It is aimed at people at higher risk of melanoma: those with many moles (often more than 50), atypical or dysplastic moles, a personal or family history of melanoma, fair skin that burns easily, or a weakened immune system. The CDA and the American Academy of Dermatology (AAD) tie surveillance to risk, not to everyone. If you have one or two ordinary moles, a periodic skin check and self-exams usually serve you better than a full imaging program.

Risk is the deciding factor. Canadian access pressures also matter here: the Canadian Institute for Health Information (CIHI) tracks long [wait times](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) for many specialist procedures, so a documented photographic baseline that a family physician can compare over time has practical value when dermatology appointments are months apart. For a deeper look at the warning signs themselves, see our guide to the [ABCDE melanoma warning signs](/blog/abcde-melanoma-warning-signs).

| Risk profile | Typical approach |
| --- | --- |
| 1 to a few stable, ordinary moles | Self-exams plus periodic clinician skin check |
| Many moles (often 50+) or several atypical moles | Discuss mole mapping or total body photography |
| Personal or family history of melanoma | Surveillance imaging often recommended |
| Fair, sun-sensitive skin with heavy past sun damage | Higher monitoring threshold; ask a clinician |
| Immunosuppression (for example, transplant patients) | Closer surveillance, sometimes with imaging |

## Does mole mapping detect skin cancer?

**Short answer:** Mole mapping does not diagnose cancer by itself. It helps clinicians detect melanoma earlier by making change visible, which can lead to thinner, more treatable tumors at the time of removal. A 2021 systematic review of 14 studies (12,082 people) found that patients monitored with TBP trended toward thinner melanomas and a higher proportion of in-situ (very early) tumors. Diagnosis still requires a clinician to examine a suspicious lesion and, when needed, take a biopsy. Photography guides the decision; the laboratory confirms it. No image, AI tool, or app replaces that biopsy step.

The evidence is strongest in higher-risk groups. In the same [systematic review](https://pubmed.ncbi.nlm.nih.gov/33578996/), the number of moles that had to be removed to find one melanoma ranged from about 3 to 1 up to 14.3 to 1, and tracking worked better for new lesions than for moles that had been watched for a long time. More recent work continues to test newer hardware: a 2025 [randomized clinical trial in JAMA Dermatology](https://pubmed.ncbi.nlm.nih.gov/40136310/) examined 3D total-body photography in patients at high risk for melanoma. The Centers for Disease Control and Prevention (CDC) notes that early detection matters because melanoma can [spread](https://www.cdc.gov/skin-cancer/about/index.html) to other parts of the body if it is not caught early.

## How much does mole mapping cost in Canada, and does OHIP cover it?

**Short answer:** In Ontario, a referral-based visit to a dermatologist to assess a worrisome mole is an insured service under the Ontario Health Insurance Plan (OHIP). Elective mole mapping or total body photography for screening, especially for low-risk people, is generally not an insured service and is paid privately. Private sessions in Canada commonly run about CAD $150 to $400, depending on whether dermoscopy and AI analysis are included, with lower fees for follow-up imaging. Coverage varies by province and by why the imaging is ordered, so confirm the cost and any referral requirements before you book.

The split is usually between assessment and screening. If a family doctor refers you because a specific spot looks suspicious, the dermatologist visit and any biopsy are covered as medically necessary care. The photographic screening program itself, done for monitoring rather than to assess a known problem, is typically the out-of-pocket part.

| Service | Typical Canadian cost | Usually covered by OHIP? |
| --- | --- | --- |
| Referral visit to assess a suspicious mole | No direct charge to patient | Yes, when referred and medically necessary |
| Biopsy of a worrying lesion | No direct charge to patient | Yes, as medically necessary care |
| Elective mole mapping or TBP screening | About CAD $150 to $400 per session | Generally no, paid privately |
| Follow-up imaging session | Often lower than the baseline fee | Generally no, paid privately |

## How does mole mapping compare with a self-exam and a regular skin check?

**Short answer:** Self-exams, a clinician skin check, and mole mapping work together rather than competing. Monthly self-exams using the ABCDE rule (Asymmetry, Border, Color, Diameter, Evolving) catch obvious changes between visits. A clinician skin check adds trained eyes and dermoscopy. Mole mapping adds a photographic memory so subtle change is not missed across appointments, which matters most for people with many or atypical moles. For most Canadians, regular self-exams plus a periodic professional check are enough. Mapping is an added layer for higher-risk patients, not a replacement for looking at your own skin.

The AAD recommends checking your own skin regularly and knowing your [ABCDEs](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes). Use this checklist at home, and book an assessment if any mole meets one or more of these signs.

| Letter | Stands for | What to look for |
| --- | --- | --- |
| A | Asymmetry | One half does not match the other half |
| B | Border | Edges are irregular, ragged, or blurred |
| C | Color | More than one shade, or uneven color |
| D | Diameter | Larger than about 6 mm (a pencil eraser) |
| E | Evolving | Any change in size, shape, color, or symptoms |

## What are the limits and privacy considerations of mole mapping?

**Short answer:** Mole mapping has real limits. It can miss melanomas that arise between moles or on areas that are hard to photograph, and it can flag harmless spots that lead to extra biopsies. Image quality, body positioning, and software differences all affect results. Privacy matters too: skin photographs are sensitive health information. In Ontario, they fall under the Personal Health Information Protection Act (PHIPA), so ask any clinic how images are stored, who can access them, and whether data stays in Canada. Sun protection still prevents more skin cancer than any amount of imaging.

Prevention does the heavy lifting. The World Health Organization (WHO) links [ultraviolet (UV) radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) to skin cancer risk, and the Public Health Agency of Canada offers practical [sun safety](https://www.canada.ca/en/public-health/services/sun-safety.html) guidance, including checking the UV index and covering up. Canadian summers carry high UV days even at northern latitudes, and reflected light off snow and water raises exposure in winter and spring. For more on daily protection, see our [sun protection and UV index guide for Canada](/blog/sun-protection-canada-uv-index). Mapping tells you what changed; sun habits change the odds.

## What else do people commonly ask about mole mapping?

**Short answer:** The questions below come up most often when patients weigh mole mapping. The quick version: mapping is a tracking tool, not a diagnosis; it is usually paid out of pocket in Ontario; it is most worthwhile for higher-risk people; and it supports earlier melanoma detection without replacing a biopsy. If you are unsure where you fall, a family physician or dermatologist can assess your personal risk and tell you whether photographic surveillance is likely to help you. Detailed answers to each common question follow below.

### What is mole mapping and how is it done?

Mole mapping is a structured way to photograph and track your moles so changes show up over time. A clinician or trained photographer takes standardized total body photography (TBP) images of your skin from set angles and distances, often with a digital camera or a 3D imaging booth. Individual moles of interest are then captured up close with a dermoscope, a magnifier with polarized light. The images become your baseline. At follow-up, usually every 6 to 12 months for higher-risk patients, the new photos are compared with the old ones to spot new moles or changes in existing ones. Some clinics add AI software that flags suspicious lesions for a clinician to review, but a person still makes the final call.

### How much does mole mapping cost in Ontario?

In Ontario, mole mapping is usually a private, out-of-pocket service rather than something covered by the Ontario Health Insurance Plan (OHIP). Prices vary by clinic and by what is included, but full body photography with dermoscopy commonly runs about CAD $150 to $400 per session, with lower fees for follow-up imaging. A visit to a dermatologist to assess a specific suspicious mole, made through a family doctor referral, is generally an insured OHIP service, and any biopsy of a worrying lesion is covered as medically necessary care. The screening photography itself is the part you typically pay for. Always confirm pricing, what the fee includes, and whether a referral is needed before you book.

### Is it worth getting mole mapping?

For higher-risk people, mole mapping is often worth it; for most others, it is optional. The evidence is strongest in patients with many moles, atypical moles, a personal or family history of melanoma, or fair, sun-sensitive skin. In those groups, tracking images helps clinicians catch melanoma earlier and remove fewer harmless moles unnecessarily. If you have a handful of stable, ordinary moles, regular self-exams and a periodic clinician skin check usually give you most of the benefit at no extra cost. The honest answer depends on your personal risk. A family physician or dermatologist can estimate that risk and tell you whether photographic surveillance is likely to change what happens to your skin.

### Does mole mapping detect cancer?

Mole mapping does not diagnose cancer on its own, but it helps detect melanoma earlier. By recording a baseline and comparing images over time, it makes change visible, and change is one of the clearest warning signs of melanoma. Studies in higher-risk patients link photographic monitoring with thinner, earlier-stage tumors at the time of removal. What mapping cannot do is confirm a diagnosis. Only a clinician examining the lesion, and a biopsy sent to a laboratory when needed, can tell whether a spot is cancer. Think of mole mapping as an early-warning system that points a clinician toward the right lesion, not as a test that returns a yes-or-no cancer result.

## When should you see a clinician instead of relying on photos?

**Short answer:** See a clinician whenever a mole is new, changing, itching, bleeding, or simply different from your others, no matter what any image or app suggests. This article is general information, not a diagnosis, and mole mapping is a tracking tool rather than a verdict. A photographic baseline is useful, but a trained clinician examining the lesion, with a biopsy when needed, is what confirms or rules out skin cancer. If you are higher risk or unsure, do not wait for your next scheduled imaging session. You can [reach our team](/contact) for help connecting to a certified dermatologist, and you can read more [about DermaDex](/about) and how we work.

## Sources

- Canadian Dermatology Association (CDA). "Skin Cancer." https://dermatology.ca/public-patients/diseases-conditions/skin-cancer/
- Canadian Dermatology Association (CDA). "Melanoma." https://dermatology.ca/public-patients/diseases-conditions/skin-cancer/melanoma/
- American Academy of Dermatology (AAD). "What to look for: ABCDEs of melanoma." https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes
- Centers for Disease Control and Prevention (CDC). "About Skin Cancer." https://www.cdc.gov/skin-cancer/about/index.html
- Hornung A, et al. "The Value of Total Body Photography for the Early Detection of Melanoma: A Systematic Review." International Journal of Environmental Research and Public Health, 2021. https://pubmed.ncbi.nlm.nih.gov/33578996/
- JAMA Dermatology. "3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial," 2025. https://pubmed.ncbi.nlm.nih.gov/40136310/
- Canadian Institute for Health Information (CIHI). "Wait Times for Priority Procedures in Canada." https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Public Health Agency of Canada. "Sun safety." https://www.canada.ca/en/public-health/services/sun-safety.html
- World Health Organization (WHO). "Ultraviolet radiation." https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation

## FAQ
### What is mole mapping and how is it done?
Mole mapping is a structured way to photograph and track your moles so changes show up over time. A clinician or trained photographer takes standardized total body photography (TBP) images of your skin from set angles and distances, often with a digital camera or a 3D imaging booth. Individual moles of interest are then captured up close with a dermoscope, a magnifier with polarized light. The images become your baseline. At follow-up, usually every 6 to 12 months for higher-risk patients, the new photos are compared with the old ones to spot new moles or changes in existing ones. Some clinics add AI software that flags suspicious lesions for a clinician to review, but a person still makes the final call.

### How much does mole mapping cost in Ontario?
In Ontario, mole mapping is usually a private, out-of-pocket service rather than something covered by the Ontario Health Insurance Plan (OHIP). Prices vary by clinic and by what is included, but full body photography with dermoscopy commonly runs about CAD $150 to $400 per session, with lower fees for follow-up imaging. A visit to a dermatologist to assess a specific suspicious mole, made through a family doctor referral, is generally an insured OHIP service, and any biopsy of a worrying lesion is covered as medically necessary care. The screening photography itself is the part you typically pay for. Always confirm pricing, what the fee includes, and whether a referral is needed before you book.

### Is it worth getting mole mapping?
For higher-risk people, mole mapping is often worth it; for most others, it is optional. The evidence is strongest in patients with many moles, atypical moles, a personal or family history of melanoma, or fair, sun-sensitive skin. In those groups, tracking images helps clinicians catch melanoma earlier and remove fewer harmless moles unnecessarily. If you have a handful of stable, ordinary moles, regular self-exams and a periodic clinician skin check usually give you most of the benefit at no extra cost. The honest answer depends on your personal risk. A family physician or dermatologist can estimate that risk and tell you whether photographic surveillance is likely to change what happens to your skin.

### Does mole mapping detect cancer?
Mole mapping does not diagnose cancer on its own, but it helps detect melanoma earlier. By recording a baseline and comparing images over time, it makes change visible, and change is one of the clearest warning signs of melanoma. Studies in higher-risk patients link photographic monitoring with thinner, earlier-stage tumors at the time of removal. What mapping cannot do is confirm a diagnosis. Only a clinician examining the lesion, and a biopsy sent to a laboratory when needed, can tell whether a spot is cancer. Think of mole mapping as an early-warning system that points a clinician toward the right lesion, not as a test that returns a yes-or-no cancer result.

---

# When Should You See a Dermatologist Instead of Your Family Doctor?

URL: https://www.dermadex.ca/blog/dermatologist-vs-family-doctor
Category: Healthcare Access
Author: Maryam Sobhkhiz Sabet
Published: 2026-06-03

## TL;DR
About 4 million Canadian adults had no primary care provider in 2023, the lowest access among 10 peer countries (CIHI) | A family doctor handles most acne, eczema, and rashes; a dermatologist is for changing moles, suspected skin cancer, and treatment-resistant disease | Use the ABCDE rule (Asymmetry, Border, Color, Diameter over 6 mm, Evolving) to flag a mole for urgent review (American Academy of Dermatology) | Statistics Canada found about 15.8% of people aged 12+ had no regular health care provider in 2017 | Written by Maryam Sobhkhiz Sabet, Family Physician and DermaDex co-founder, as of June 2, 2026

*As of June 2, 2026.*

Skin problems are one of the most common reasons Canadians book a medical appointment, and most of them are handled well in primary care. The harder question is knowing when a skin concern needs a specialist. As a family physician and co-founder of [DermaDex](/), I see both sides of this line every week: the cases a family doctor can settle in one visit, and the ones that need a dermatologist's training, tools, and a biopsy. This guide explains where that line sits, which red flags should move you up the queue, and how referrals and wait times work in Canada. This is general information, not a diagnosis. If you have a specific concern, speak with a licensed clinician.

## What is the difference between a family doctor and a dermatologist?

**Short answer:** A family doctor is your first point of contact for almost any skin problem and treats the large majority of them. A dermatologist is a physician with several additional years of specialty training focused only on skin, hair, and nails, and handles complex, uncertain, or serious cases.

Both are fully licensed doctors, so the difference is depth and scope. Family physicians manage a wide range of conditions across the whole body, including common skin complaints like acne, eczema, and minor infections. Dermatologists complete extra residency training and use specialized tools such as the dermatoscope, plus in-office procedures like skin biopsies and excisions, to diagnose and treat harder problems. The Canadian Dermatology Association (CDA) keeps a public directory of certified specialists and patient resources at [dermatology.ca](https://dermatology.ca/public-patients/). If you want to understand how that magnified examination works, see our explainer on [dermoscopy](/blog/dermoscopy-explained).

## When should you see a dermatologist instead of your family doctor?

**Short answer:** See a dermatologist when a skin problem is changing, spreading, painful, or not responding to standard treatment, or when your family doctor recommends a specialist opinion or a biopsy. New or changing moles and any spot that looks suspicious for skin cancer should always be assessed promptly.

Start with your family doctor for most issues. Ask about a referral when a rash has not improved after a few weeks of treatment, when a condition keeps coming back, when symptoms affect your sleep, work, or mental health, or when the diagnosis is unclear. Certain situations warrant faster attention: a mole that has changed, a sore that will not heal, a growing or bleeding lump, or a personal or family history of melanoma. If you are worried a lesion could be cancer, read our guide on [basal cell carcinoma](/blog/basal-cell-carcinoma-signs-treatment), the most common form, and book an assessment rather than waiting.

## Which skin symptoms are red flags you should not ignore?

**Short answer:** The clearest red flags are a new or changing mole, a sore that does not heal within a few weeks, and any growth that bleeds, itches, or grows quickly. Dermatologists and the American Academy of Dermatology (AAD) teach the ABCDE rule to spot a mole that needs urgent review.

ABCDE stands for Asymmetry, Border, Color, Diameter, and Evolving. It is a simple checklist you can use at home between professional skin checks. It does not replace a clinician's exam, but it helps you decide when to act. The AAD publishes the full method with photos at [aad.org](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes).

| Letter | What it stands for | What to look for |
|--------|-------------------|------------------|
| A | Asymmetry | One half of the mole does not match the other half |
| B | Border | Edges are ragged, notched, scalloped, or blurred |
| C | Color | More than one shade, or uneven brown, black, red, white, or blue |
| D | Diameter | Larger than 6 mm, about the size of a pencil eraser, though some melanomas are smaller |
| E | Evolving | The spot changes in size, shape, or color, or starts to itch, crust, or bleed |

If a spot meets one or more of these signs, do not wait for it to get worse. Sun exposure is the main preventable cause of skin cancer, and the Public Health Agency of Canada explains protection steps at [canada.ca](https://www.canada.ca/en/public-health/services/sun-safety/skin-cancer.html).

## How do dermatologist referrals and wait times work in Canada?

**Short answer:** In most provinces you need a referral from a family doctor or nurse practitioner to see a dermatologist under public coverage, and wait times vary widely by region and by how urgent your case looks. Urgent cancer referrals are usually seen faster than routine cosmetic or chronic concerns.

Under plans such as the Ontario Health Insurance Plan (OHIP), a medically necessary dermatology consult is covered, but the family doctor acts as the gatekeeper who decides urgency and writes the referral. Access to that first appointment is the bottleneck. The Canadian Institute for Health Information (CIHI) reports that the share of Canadian adults with a regular primary care provider fell from 93% in 2016 to 86% in 2023, the lowest among 10 peer countries, leaving an estimated 4 million adults without one, as shown in its [primary health care data](https://www.cihi.ca/en/primary-health-care). Statistics Canada found a similar gap, with about 15.8% of people aged 12 and older reporting no regular provider in its [2017 survey](https://www150.statcan.gc.ca/n1/pub/82-625-x/2019001/article/00001-eng.htm). Fewer family doctors means longer queues before a referral is even written.

## What skin problems can your family doctor handle on their own?

**Short answer:** Your family doctor can manage most everyday skin conditions, including mild to moderate acne, eczema, common rashes, fungal infections, warts, and many cases of psoriasis, often without any referral at all.

Primary care is well suited to first-line treatment and follow-up. A referral is reserved for cases that are severe, unclear, or not improving. The table below shows the usual split, though every patient is different and your doctor will judge your specific case.

| Skin concern | Often handled by a family doctor | Better suited to a dermatologist |
|--------------|----------------------------------|----------------------------------|
| Acne | Mild to moderate, first-line creams and antibiotics | Severe, scarring, or treatment-resistant acne |
| Eczema and common rashes | Standard cases with topical treatment | Widespread or relapsing disease not responding to treatment |
| A new or changing mole | Initial check and referral if needed | Dermoscopy, biopsy, and diagnosis |
| Suspected skin cancer | Initial assessment and urgent referral | Confirming the diagnosis and removal |
| Psoriasis | Mild, localized cases | Moderate to severe disease needing systemic or biologic therapy |

For background on the conditions a family doctor sees most, the AAD keeps a plain-language library at [aad.org](https://www.aad.org/public/diseases/a-z). When something falls outside that everyday range, that is the moment to ask about a specialist.

## How can you get a faster skin assessment in Canada?

**Short answer:** Teledermatology and store-and-forward photo review can shorten the wait by getting your case in front of a certified dermatologist without an in-person visit first. Services like DermaDex use secure photo submission and artificial intelligence (AI) triage to flag urgent cases sooner.

When local wait times stretch for months, a digital skin assessment is a practical option, especially for people in rural or northern communities. With store-and-forward review, your family doctor or you submit clear photos and a short history, and a specialist reviews them remotely. DermaDex connects Canadians to certified dermatologists this way and keeps all images encrypted under the Personal Health Information Protection Act (PHIPA) and related privacy law. To learn what AI can and cannot do in this setting, read [how AI skin checks work](/blog/how-ai-skin-checks-work). You can read more about our team on the [about page](/about), or reach us through [contact](/contact) if you are a patient or clinic with a question.

## How do I know if I should go to a dermatologist?

**Short answer:** Book with your family doctor first for most skin concerns, then ask for a dermatologist referral when a problem is changing, persistent, or not responding to treatment.

Good reasons to escalate include a mole or spot that has changed in size, shape, or color, a sore that has not healed in a few weeks, a rash that keeps returning despite treatment, acne that is scarring, or a condition that is affecting your sleep, work, or confidence. A personal or family history of melanoma, many atypical moles, or a weakened immune system also lower the threshold for specialist care. If you are unsure, your family doctor can examine the area and decide whether a referral is needed. When you cannot reach a family doctor quickly, a secure teledermatology assessment can get a specialist opinion sooner. Trust your instinct: a spot that worries you is worth showing to a clinician.

## What are the 5 warning signs of skin cancer to look for?

**Short answer:** The five warning signs follow the ABCDE rule taught by the American Academy of Dermatology: Asymmetry, Border irregularity, Color variation, Diameter over 6 mm, and Evolving change.

A mole is more concerning when one half does not match the other (Asymmetry), the edges are ragged or blurred (Border), it shows more than one color (Color), it is wider than a pencil eraser at about 6 mm (Diameter), or it changes over time or starts to itch, crust, or bleed (Evolving). Evolution is often the most important sign, so any spot that looks different from your others, the so-called ugly duckling, deserves a look. These signs apply mainly to melanoma; other skin cancers can appear as a pearly bump or a sore that will not heal. None of these signs confirm cancer on their own, but any of them is a reason to see a clinician promptly rather than waiting.

## How bad does my skin need to be to see a dermatologist?

**Short answer:** It does not need to be severe. Persistence, change, uncertainty, or a real impact on your daily life are all valid reasons to seek dermatology care, even if the problem looks minor.

You do not have to wait until a condition is dramatic. A small but changing mole can matter more than a large but stable patch of dry skin. Reasonable triggers for a referral include a rash that has not cleared after standard treatment, acne that is leaving marks, a spot that is new or different, or symptoms that disrupt your sleep or mood. Cost and access shape this in Canada, since a medically necessary consult is publicly covered but cosmetic-only concerns usually are not. If you are not sure whether your issue qualifies, your family doctor or a teledermatology service can review it and tell you whether a specialist visit is warranted.

## What is the rule of 2 in dermatology?

**Short answer:** There is no single official standard called the rule of 2 in dermatology. The phrase is used informally, most often as a practical reminder to get any new or changing skin lesion checked if it lasts beyond about two weeks or keeps growing.

Different clinicians use the term in different ways, so it is worth treating it as a memory aid rather than a formal guideline. A common version is the two-week rule for referral: a sore that has not healed in two weeks, or a lesion that has clearly grown over two months, deserves a professional assessment. Others use it to describe applying a topical treatment twice daily, or rechecking a worrying spot in two weeks. Because the term is not standardized, the safest approach is the underlying message: do not let a changing or non-healing skin problem drift for weeks without showing it to a clinician.

## Sources

- Canadian Institute for Health Information (CIHI), Primary health care, 2023. https://www.cihi.ca/en/primary-health-care
- Statistics Canada, Primary health care providers (2017), catalogue 82-625-X. https://www150.statcan.gc.ca/n1/pub/82-625-x/2019001/article/00001-eng.htm
- American Academy of Dermatology (AAD), What to look for: ABCDEs of melanoma. https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes
- American Academy of Dermatology (AAD), Diseases A to Z. https://www.aad.org/public/diseases/a-z
- Canadian Dermatology Association (CDA), Public and patient resources. https://dermatology.ca/public-patients/
- Public Health Agency of Canada, Skin cancer and sun safety. https://www.canada.ca/en/public-health/services/sun-safety/skin-cancer.html

## FAQ
### How do I know if I should go to a dermatologist?
Book with your family doctor first for most skin concerns, then ask for a dermatologist referral when a problem is changing, persistent, or not responding to treatment. Strong reasons to escalate include a mole or spot that has changed in size, shape, or color, a sore that has not healed in a few weeks, a rash that keeps returning despite treatment, scarring acne, or a condition that hurts your sleep, work, or confidence. A personal or family history of melanoma, many atypical moles, or a weakened immune system also lower the threshold. If you are unsure, your family doctor can examine the area and decide. When a family doctor is hard to reach, a secure teledermatology assessment can get a specialist opinion sooner. A spot that worries you is always worth showing to a clinician.

### What are the 5 warning signs of skin cancer to look for?
The five classic warning signs follow the ABCDE rule from the American Academy of Dermatology: Asymmetry, Border irregularity, Color variation, Diameter over 6 mm, and Evolving change. A mole is more concerning when one half does not match the other, the edges are ragged or blurred, it shows more than one color, it is wider than a pencil eraser at about 6 mm, or it changes over time and starts to itch, crust, or bleed. Evolution is often the most important sign, so any spot that looks different from your others, the so-called ugly duckling, deserves attention. These signs apply mainly to melanoma; other skin cancers can show up as a pearly bump or a sore that will not heal. None confirm cancer alone, but any one of them is a reason to see a clinician promptly.

### How bad does my skin need to be to see a dermatologist?
It does not need to be severe. Persistence, change, uncertainty, or a real impact on your daily life are all valid reasons to seek dermatology care, even when the problem looks minor. A small but changing mole can matter more than a large but stable patch of dry skin. Reasonable triggers for a referral include a rash that has not cleared after standard treatment, acne that is leaving marks, a spot that is new or different, or symptoms that disrupt your sleep or mood. Cost and access shape this in Canada, since a medically necessary consult is publicly covered but cosmetic-only concerns usually are not. If you are unsure whether your issue qualifies, your family doctor or a teledermatology service can review it and tell you whether a specialist visit is warranted.

### What is the rule of 2 in dermatology?
There is no single official standard called the rule of 2 in dermatology. The phrase is used informally, most often as a practical reminder to get any new or changing skin lesion checked if it lasts beyond about two weeks or keeps growing. Different clinicians use the term in different ways, so treat it as a memory aid rather than a formal guideline. A common version is the two-week rule for referral: a sore that has not healed in two weeks, or a lesion that has clearly grown over two months, deserves a professional assessment. Others use it to mean applying a topical treatment twice daily, or rechecking a worrying spot in two weeks. Because the term is not standardized, the safest takeaway is the underlying message: do not let a changing or non-healing skin problem drift for weeks without showing it to a clinician.

---

# Squamous Cell Carcinoma of the Skin: Symptoms and Treatment

URL: https://www.dermadex.ca/blog/squamous-cell-carcinoma-skin
Category: Conditions
Author: Mohsen Khoddami
Published: 2026-05-22

## TL;DR
Squamous cell carcinoma (SCC) is the second most common skin cancer, after basal cell carcinoma (American Academy of Dermatology) | Most SCCs grow slowly and stay in the skin; roughly 2 to 5 percent spread beyond the original site (NIH StatPearls) | Most skin cancers are caused by ultraviolet radiation and are largely preventable (Government of Canada) | Broad-spectrum sunscreen of at least SPF 30, shade, and protective clothing are the most effective ways to lower risk (Canadian Dermatology Association) | DermaDex connects patients across Canada with certified dermatologists where specialist wait times can stretch for months

*As of May 21, 2026.*

Squamous cell carcinoma is one of the most frequently diagnosed cancers in Canada, and most cases trace back to years of sun exposure. The reassuring part is that when it is caught early, it is usually straightforward to treat and cure. This guide from [DermaDex](/) explains what squamous cell carcinoma looks like, how quickly it can progress, how dermatologists treat it, and when a spot is worth getting checked.

## What is squamous cell carcinoma of the skin?

**Short answer:** Squamous cell carcinoma (SCC) is a cancer that begins in the flat, squamous cells (a type of keratinocyte) in the outer layer of the skin, called the epidermis. It is the second most common skin cancer after basal cell carcinoma (BCC), and both belong to a group called non-melanoma skin cancer.

SCC usually develops on areas that collect the most ultraviolet (UV) light over a lifetime: the face, ears, lower lip, scalp, neck, forearms, and the backs of the hands. Many tumours grow slowly and stay confined to the skin, where they are highly treatable. A smaller share can grow into deeper tissue or, less often, spread to nearby lymph nodes. The Canadian Dermatology Association (CDA) notes that finding skin cancer early makes treatment simpler and outcomes better, which is why knowing the signs matters. You can read more about the condition on the [CDA squamous cell carcinoma page](https://dermatology.ca/public-patients/diseases-conditions/skin-cancer/squamous-cell-carcinoma/).

## What are the early signs and symptoms of squamous cell carcinoma?

**Short answer:** The most common early signs are a rough, scaly red patch, a firm raised bump, or a sore that does not heal (or heals and then reopens). These usually appear on sun-exposed skin and may itch, feel tender, crust, or bleed when bumped.

SCC can look different from one person to the next, which is why any spot that is new, changing, or stubborn deserves attention. Some tumours grow out of a pre-cancerous actinic keratosis, a dry scaly patch caused by sun damage. The American Academy of Dermatology (AAD) lists several patterns worth watching for, summarized below.

| Warning sign | What it can look like |
|--------------|------------------------|
| Persistent scaly patch | Rough, red or skin-coloured, may itch or feel tender |
| Firm raised bump | Dome-shaped nodule, sometimes with a central crust or dip |
| Non-healing sore | An open sore that bleeds, crusts, and will not heal within weeks |
| Wart-like growth | A raised, rough growth that may bleed when knocked |
| Changing actinic keratosis | A pre-cancerous dry, scaly spot that thickens or turns tender |

If a spot fits any of these descriptions and lasts more than a few weeks, have it examined. The AAD describes these early changes on its [SCC symptoms page](https://www.aad.org/public/diseases/skin-cancer/types/common/scc/symptoms). Our overview of [basal cell carcinoma](/blog/basal-cell-carcinoma-skin) explains how the two most common skin cancers differ.

## What causes squamous cell carcinoma and who is most at risk?

**Short answer:** Cumulative UV radiation from sunlight and tanning beds is the main cause of SCC, because it damages the DNA in skin cells over time. People with fair skin, a history of sunburns, older age, a weakened immune system, or heavy lifetime sun exposure carry the highest risk.

UV radiation reaches the skin in two forms: UVA (ultraviolet A), which penetrates deeply and ages the skin, and UVB (ultraviolet B), which causes sunburn. Both contribute to skin cancer, according to the [World Health Organization (WHO)](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation). Other risk factors documented in the medical literature include tanning bed use, prior radiation therapy, long-standing wounds or scars, certain human papillomavirus (HPV) infections, arsenic exposure, and immune suppression. Organ transplant recipients, for example, can have a sharply higher SCC risk than the general population because of the medicines that prevent organ rejection, as detailed in a StatPearls clinical reference from the U.S. National Institutes of Health (NIH), available through the [NIH National Library of Medicine](https://www.ncbi.nlm.nih.gov/books/NBK441939/). The [Government of Canada](https://www.canada.ca/en/public-health/services/sun-safety/skin-cancer.html) notes that most skin cancers are linked to UV exposure and are largely preventable.

## How quickly does squamous cell carcinoma grow and spread?

**Short answer:** Most squamous cell carcinomas grow slowly over months and stay in the skin, where they are very treatable. A minority grow faster and invade deeper tissue, and roughly 2 to 5 percent spread beyond the original site, usually to nearby lymph nodes, most often when treatment is delayed.

The chance that an SCC will spread depends on features that dermatologists call high-risk: a tumour larger than about 2 centimetres, growth deep into the skin, location on the lip or ear, rapid enlargement, recurrence after earlier treatment, and a weakened immune system, as outlined in the [NIH StatPearls reference](https://www.ncbi.nlm.nih.gov/books/NBK441939/). This is why timing matters. A small SCC removed early carries an excellent outlook, while a neglected one can become harder to treat and more likely to spread. Predicting the exact speed of any single tumour is unreliable, so prompt assessment is safer than waiting to see what happens.

## How do dermatologists diagnose squamous cell carcinoma?

**Short answer:** Diagnosis starts with a skin examination and is confirmed with a biopsy, where a small sample of the suspicious area is removed and examined under a microscope. A biopsy is the only way to know for certain whether a spot is SCC.

During a visit, a dermatologist inspects the lesion, often with a handheld magnifier called a dermatoscope, and checks nearby lymph nodes if there is any concern about spread. If a biopsy confirms SCC, the pathology report describes the tumour's depth and how abnormal the cells look, which guides treatment. For tumours with high-risk features, imaging is sometimes ordered to check deeper structures. The AAD describes biopsy as the standard step before any treatment decision on its [SCC overview page](https://www.aad.org/public/diseases/skin-cancer/types/common/scc). DermaDex helps patients reach this step sooner by connecting them with certified dermatologists, which you can read about on our [about page](/about).

## How is squamous cell carcinoma treated?

**Short answer:** Most squamous cell carcinomas are treated by surgically removing the tumour, and the great majority are cured when caught early. The best method depends on the tumour's size, location, depth, and risk features, ranging from minor in-office procedures to Mohs surgery, radiation, and, for advanced disease, immunotherapy.

| Treatment | Best suited for | What to expect |
|-----------|-----------------|----------------|
| Surgical excision | Most localized SCCs | The tumour and a margin of healthy skin are removed and checked under a microscope |
| Mohs micrographic surgery | High-risk tumours, face, ears, lips, recurrent SCC | Tissue is removed and mapped layer by layer until margins are clear, sparing healthy skin |
| Curettage and electrodesiccation | Small, low-risk SCCs | The growth is scraped and the base sealed with an electric current |
| Cryotherapy | Select superficial or in-situ lesions | The lesion is frozen with liquid nitrogen |
| Radiation therapy | Patients who cannot have surgery, or as add-on care | Targeted radiation given over several sessions |
| Topical or systemic therapy | SCC in situ (creams) or advanced disease (drugs) | Creams such as 5-fluorouracil, or PD-1 inhibitor immunotherapy for advanced cancer |

Mohs micrographic surgery, which removes and checks tissue layer by layer, offers high cure rates for high-risk and cosmetically sensitive areas while sparing healthy skin, as the AAD explains on its [SCC treatment page](https://www.aad.org/public/diseases/skin-cancer/types/common/scc/treatment). For advanced SCC that has spread, newer immunotherapy drugs that block a protein called PD-1 have widened the options. Your care team will tailor the plan to your situation.

*This article is educational and is not a diagnosis. Only a qualified clinician can examine your skin and recommend treatment.*

## How can you lower your risk of squamous cell carcinoma?

**Short answer:** Sun protection is the most effective way to lower SCC risk. Use broad-spectrum sunscreen with a Sun Protection Factor (SPF) of at least 30, seek shade during peak hours, wear protective clothing and a wide-brimmed hat, and avoid tanning beds entirely.

Canada's UV levels are highest from late spring through early fall, and they climb at higher altitudes and near reflective surfaces like water and snow. Health Canada advises checking the daily UV Index and taking precautions when it reaches 3 or higher, as described on its [UV radiation page](https://www.canada.ca/en/health-canada/services/sun-safety/what-is-ultraviolet-radiation.html). The CDA recommends reapplying sunscreen every two hours and after swimming or sweating, with more guidance on its [sun protection page](https://dermatology.ca/public/sun-protection/). Regular skin self-checks help you catch changes early. For a closer look at choosing and applying sunscreen, see our [sunscreen and SPF guide](/blog/sunscreen-spf-guide).

## When should you see a dermatologist in Canada?

**Short answer:** See a clinician for any spot that bleeds, crusts, or does not heal within a few weeks, or any growth that is new, enlarging, or changing. Early assessment leads to simpler treatment and better outcomes, so do not wait for a lesion to become painful.

Access to dermatology varies across Canada, and wait times for a specialist referral can stretch for weeks or months depending on your province and region. That delay is one reason suspicious skin lesions are sometimes caught later than they should be. Medically necessary skin cancer assessments and biopsies are generally covered by provincial health plans such as the Ontario Health Insurance Plan (OHIP). DermaDex was built to shorten that gap by connecting patients across the country with certified dermatologists and artificial intelligence (AI) assisted triage, which is especially helpful in areas with limited specialty care. Your health information is handled in line with Canadian privacy law, including the Personal Health Information Protection Act (PHIPA). If you have a spot you are worried about, [contact our team](/contact) or speak with your family doctor, who can examine the area and arrange a biopsy or referral.

## What are the most common questions about squamous cell carcinoma?

**Short answer:** Patients most often ask how to recognize SCC, how fast it spreads, how dangerous it is, and what it looks like at the start. The short version: learn the warning signs, act early, and get any non-healing or changing spot checked by a clinician.

### What are three signs of squamous cell carcinoma?

Three common signs are a rough, scaly red patch that may itch or feel tender; a firm, raised bump or nodule, sometimes with a crusted or sunken centre; and a sore that does not heal, or heals and then reopens, often bleeding or crusting. These usually show up on sun-exposed skin such as the face, ears, lips, scalp, neck, and backs of the hands. Some SCCs grow from a pre-cancerous actinic keratosis, a dry scaly spot caused by sun damage. Any of these signs that lasts more than a few weeks should be examined, because a biopsy is the only way to confirm the diagnosis. The American Academy of Dermatology lists these patterns among the most common early warning signs.

### How quickly does squamous cell skin cancer spread?

Most squamous cell carcinomas grow slowly over months and stay within the skin, where they are highly treatable. Speed varies by tumour. A minority grow faster and invade deeper tissue, and roughly 2 to 5 percent eventually spread beyond the skin, most often to nearby lymph nodes. The chance of spread rises with high-risk features: a tumour larger than about 2 centimetres, deep growth, location on the lip or ear, rapid enlargement, recurrence after earlier treatment, and a weakened immune system. Because delay raises the risk, the safest approach is to have a suspicious or non-healing spot evaluated early. An SCC removed while small carries an excellent prognosis, which is why prompt assessment matters more than trying to predict how fast a particular tumour might progress.

### How serious is squamous cell skin cancer?

Squamous cell carcinoma is usually not life-threatening when found and treated early, and the great majority of cases are cured with a single procedure. It is still a real cancer that should be taken seriously, because untreated tumours can grow into deeper tissue, damage nearby structures, and, in a small share of cases, spread to lymph nodes or beyond. Seriousness depends on the tumour's size, depth, location, and your immune status. People who are immunosuppressed, such as organ transplant recipients, tend to have more aggressive disease and need closer monitoring. The practical takeaway: most SCCs are very manageable, but outcomes are best when treatment is not delayed. If you notice a non-healing or changing spot, have it checked rather than waiting to see whether it clears on its own.

### What does the beginning of squamous cell carcinoma look like?

Early squamous cell carcinoma often looks unremarkable at first. It may begin as a small, rough, scaly patch that is red or skin-coloured, a persistent pink bump, or a spot that feels like a stubborn pimple or wart that will not go away. It can be tender, itch, crust over, or bleed with minor contact. Many SCCs start in an area of existing sun damage or from a pre-cancerous actinic keratosis. Because these early changes are easy to dismiss, the most reliable clue is persistence: a lesion that lasts beyond a few weeks, keeps returning, or slowly enlarges. On sun-exposed skin such as the face, ears, and hands, any such spot is worth showing to a clinician, who can perform a biopsy if needed to confirm whether it is cancer.

## Sources

- [Canadian Dermatology Association, Squamous Cell Carcinoma](https://dermatology.ca/public-patients/diseases-conditions/skin-cancer/squamous-cell-carcinoma/) (Canadian Dermatology Association)
- [American Academy of Dermatology, Squamous Cell Carcinoma: Signs and Symptoms](https://www.aad.org/public/diseases/skin-cancer/types/common/scc/symptoms) (American Academy of Dermatology)
- [American Academy of Dermatology, Squamous Cell Carcinoma: Overview](https://www.aad.org/public/diseases/skin-cancer/types/common/scc) (American Academy of Dermatology)
- [American Academy of Dermatology, Squamous Cell Carcinoma: Diagnosis and Treatment](https://www.aad.org/public/diseases/skin-cancer/types/common/scc/treatment) (American Academy of Dermatology)
- [World Health Organization, Ultraviolet (UV) radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) (World Health Organization)
- [Cutaneous Squamous Cell Carcinoma, StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK441939/) (U.S. National Institutes of Health, National Library of Medicine)
- [Government of Canada, Skin cancer](https://www.canada.ca/en/public-health/services/sun-safety/skin-cancer.html) (Public Health Agency of Canada)
- [Health Canada, What is ultraviolet radiation](https://www.canada.ca/en/health-canada/services/sun-safety/what-is-ultraviolet-radiation.html) (Health Canada)
- [Canadian Dermatology Association, Sun Protection](https://dermatology.ca/public/sun-protection/) (Canadian Dermatology Association)

## FAQ
### What are three signs of squamous cell carcinoma?
Three common signs are a rough, scaly red patch that may itch or feel tender; a firm, raised bump or nodule, sometimes with a crusted or sunken centre; and a sore that does not heal, or heals and then reopens, often bleeding or crusting. These usually show up on sun-exposed skin such as the face, ears, lips, scalp, neck, and backs of the hands. Some SCCs grow from a pre-cancerous actinic keratosis, a dry scaly spot caused by sun damage. Any of these signs that lasts more than a few weeks should be examined, because a biopsy is the only way to confirm the diagnosis. The American Academy of Dermatology lists these patterns among the most common early warning signs.

### How quickly does squamous cell skin cancer spread?
Most squamous cell carcinomas grow slowly over months and stay within the skin, where they are highly treatable. Speed varies by tumour. A minority grow faster and invade deeper tissue, and roughly 2 to 5 percent eventually spread beyond the skin, most often to nearby lymph nodes. The chance of spread rises with high-risk features: a tumour larger than about 2 centimetres, deep growth, location on the lip or ear, rapid enlargement, recurrence after earlier treatment, and a weakened immune system. Because delay raises the risk, the safest approach is to have a suspicious or non-healing spot evaluated early. An SCC removed while small carries an excellent prognosis, which is why prompt assessment matters more than trying to predict how fast a particular tumour might progress.

### How serious is squamous cell skin cancer?
Squamous cell carcinoma is usually not life-threatening when found and treated early, and the great majority of cases are cured with a single procedure. It is still a real cancer that should be taken seriously, because untreated tumours can grow into deeper tissue, damage nearby structures, and, in a small share of cases, spread to lymph nodes or beyond. Seriousness depends on the tumour's size, depth, location, and your immune status. People who are immunosuppressed, such as organ transplant recipients, tend to have more aggressive disease and need closer monitoring. The practical takeaway: most SCCs are very manageable, but outcomes are best when treatment is not delayed. If you notice a non-healing or changing spot, have it checked rather than waiting to see whether it clears on its own.

### What does the beginning of squamous cell carcinoma look like?
Early squamous cell carcinoma often looks unremarkable at first. It may begin as a small, rough, scaly patch that is red or skin-coloured, a persistent pink bump, or a spot that feels like a stubborn pimple or wart that will not go away. It can be tender, itch, crust over, or bleed with minor contact. Many SCCs start in an area of existing sun damage or from a pre-cancerous actinic keratosis. Because these early changes are easy to dismiss, the most reliable clue is persistence: a lesion that lasts beyond a few weeks, keeps returning, or slowly enlarges. On sun-exposed skin such as the face, ears, and hands, any such spot is worth showing to a clinician, who can perform a biopsy if needed to confirm whether it is cancer.

---

# Skin Cancer Screening in Canada: Where and How to Get Checked

URL: https://www.dermadex.ca/blog/skin-cancer-screening-canada
Category: Healthcare Access
Author: Maryam Sobhkhiz Sabet
Published: 2026-05-09

## TL;DR
Melanoma is among the more common cancers diagnosed in younger Canadian adults, per the Public Health Agency of Canada | A full body skin check takes about 10 to 15 minutes, is painless, and runs from scalp to soles | The ABCDE rule flags moles over 6 mm or changing in shape, color, or size (American Academy of Dermatology) | Dermatology visits in Canada can take weeks to months; suspected melanoma is triaged as urgent (CIHI) | Medically necessary skin exams are covered by provincial plans like OHIP with a valid health card

*As of May 8, 2026.*

A skin cancer check is one of the quickest things a clinician can do, yet many Canadians wait months for one or skip it because they do not know where to start. As a family physician and co-founder of [DermaDex](/), I see how that confusion delays care. This guide covers where to get checked, what a full body skin check involves, how long you might wait, what provincial plans pay for, and how to watch your own skin between visits.

This article is general information, not a diagnosis. If a spot worries you, see your family doctor or reach our team through [DermaDex](/contact).

## Who needs skin cancer screening in Canada?

**Short answer:** Anyone with a new, changing, or unusual spot should have it checked. Regular screening helps people at higher risk: those with fair skin, many moles, a personal or family history of skin cancer, a history of bad sunburns or tanning bed use, or a weakened immune system. Melanoma, the most serious skin cancer, is among the more common cancers diagnosed in younger Canadian adults, according to the Public Health Agency of Canada (PHAC).

Non-melanoma skin cancers, mainly basal cell and squamous cell carcinoma, are the most common cancers in Canada overall, and they are highly treatable when caught early. The United States Centers for Disease Control and Prevention (CDC) lists pale skin, light eyes, frequent sunburns, and outdoor work among the [risk factors for skin cancer](https://www.cdc.gov/skin-cancer/risk-factors/index.html). If several of these apply to you, raise skin checks at your next appointment instead of waiting for a problem to appear.

## Where can you get a skin cancer check in Canada?

**Short answer:** Most skin checks in Canada start with your family doctor or a walk-in clinic, who can examine a spot and refer you to a dermatologist if it looks concerning. Dermatology clinics handle full exams, dermoscopy, and biopsies, and virtual dermatology services can review photos to decide how urgently you need an in-person visit.

In most provinces you need a referral from a primary-care provider for a dermatologist visit to be covered. Where local wait times are long, virtual triage can move urgent cases forward faster.

| Setting | What they do | Referral needed? | Typical access |
| --- | --- | --- | --- |
| Family doctor or general practitioner | Check a worrying spot, do a basic skin exam, refer if needed | No | Days to weeks |
| Walk-in clinic | Assess a single lesion and provide a referral | No | Same day to a few days |
| Dermatologist | Full skin exam, dermoscopy, biopsy, treatment | Yes, in most provinces | Weeks to months |
| Virtual or teledermatology | Review photos, triage urgency, advise next step | Sometimes | Hours to days |

To understand who handles what, see our guide on [dermatologist vs family doctor](/blog/dermatologist-vs-family-doctor).

## What does a full body skin check involve?

**Short answer:** During a full body skin check you undress to your underwear, put on a gown, and the clinician examines your skin from scalp to soles under bright light, often using a dermatoscope to magnify suspicious spots. The exam usually takes 10 to 15 minutes and is painless. If a lesion looks worrying, the clinician may arrange a small biopsy.

The exam covers easy-to-miss areas like behind the ears, between the fingers and toes, the nails, and, with your consent, skin folds and the genital area. A dermatoscope is a handheld lens with a built-in light that reveals patterns invisible to the naked eye. Our explainer on [how dermoscopy works](/blog/dermoscopy-explained) covers this in detail. You can ask for a chaperone or pause the exam at any point.

## How do clinicians decide if a mole is suspicious?

**Short answer:** Clinicians use the ABCDE rule (Asymmetry, Border, Color, Diameter, and Evolving) along with dermoscopy to judge whether a mole needs a biopsy. A spot that meets several ABCDE criteria, or simply looks different from your other moles, deserves a closer look. The American Academy of Dermatology (AAD) promotes ABCDE as a simple check you can also do at home.

| Letter | Stands for | Warning sign |
| --- | --- | --- |
| A | Asymmetry | One half of the mole does not match the other |
| B | Border | Edges are ragged, notched, or blurred |
| C | Color | More than one shade, or uneven brown, black, red, white, or blue |
| D | Diameter | Larger than 6 mm, about the width of a pencil eraser |
| E | Evolving | Changing in size, shape, or color, or starting to itch or bleed |

The "ugly duckling" sign matters too. A mole that stands out from your others is worth flagging even if it does not tick every ABCDE box. You can review the AAD guidance on the [ABCDEs of melanoma](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes).

## How long are dermatologist wait times in Canada?

**Short answer:** Dermatology wait times in Canada commonly run from several weeks to many months, depending on your province and whether the referral is marked urgent. Suspected melanoma is usually triaged ahead of routine or cosmetic visits, so a worrying spot should be seen sooner than a general skin review.

The Canadian Institute for Health Information (CIHI) tracks [wait times for priority procedures](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada), though routine dermatology is not one of the federally benchmarked categories, so waits vary widely by region. In areas with long waits, virtual triage and artificial intelligence (AI) assisted photo review can help sort which cases need a fast in-person appointment. You can read about how that triage works on our [about page](/about).

## Does provincial health insurance cover skin cancer screening?

**Short answer:** Yes. A medically necessary skin exam by your family doctor or, with a referral, a dermatologist is covered by provincial plans such as the Ontario Health Insurance Plan (OHIP) when you have a valid health card. Purely cosmetic mole removal, and some private total body photography services, are not covered and may cost out of pocket.

Coverage rules differ by province, so confirm details with your clinic before booking. Total body photography and mole mapping are sometimes offered privately for people at high risk, because tracking many moles over time can catch subtle changes. Our guide to [mole mapping and total body photography](/blog/mole-mapping-total-body-photography) explains when it is worth considering and what it usually costs.

## How do you check your own skin between appointments?

**Short answer:** Examine your whole body about once a month in front of a full-length mirror, using a hand mirror for your back, neck, and scalp, and note anything new, growing, changing color, itching, or bleeding. Self-exams do not replace a clinician visit, but they help you catch changes early.

The AAD recommends [checking your skin](https://www.aad.org/public/diseases/skin-cancer/find/check-skin) on the same date each month so changes are easier to spot. Prevention lowers your risk in the first place. Health Canada advises limiting time in the midday sun, seeking shade, and using sunscreen with a Sun Protection Factor (SPF) of 30 or higher that blocks both ultraviolet A (UVA) and ultraviolet B (UVB) rays, as set out in its [sun safety](https://www.canada.ca/en/health-canada/services/sun-safety.html) guidance. The World Health Organization (WHO) classifies [ultraviolet (UV) radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) as a known cause of skin cancer, and the Canadian Dermatology Association (CDA) offers practical [sun protection](https://dermatology.ca/public/sun-protection/) advice.

## When should you book an appointment right away?

**Short answer:** Book promptly if a mole or spot changes in size, shape, or color, bleeds, will not heal, or looks different from your other moles. A sore that does not heal within a few weeks, or a lump that grows quickly, should be assessed without delay rather than watched at home for months.

Most spots people worry about turn out to be harmless, but early melanoma is highly treatable, so getting checked early is worth the visit. Bring a phone photo with a date so your clinician can compare the spot over time. You can reach our team through [DermaDex](/contact) if you are unsure where to start.

## Have more questions about getting screened?

**Short answer:** These are the questions patients ask me most often about skin cancer screening and full body skin checks in Canada. Each answer below is general guidance, and your own clinician can tailor advice to your skin type, history, and risk.

### What happens during a full body skin check?

You undress to your underwear and put on a gown, then the clinician examines your skin from your scalp down to the soles of your feet under bright light. They check easy-to-miss areas like behind the ears, between the toes, the nails, and skin folds, and with your consent the genital area. A dermatoscope, a handheld magnifier with a light, is used on any spot that looks unusual. The exam is painless and usually takes about 10 to 15 minutes. If a lesion looks suspicious, the clinician may take a small skin sample, called a biopsy, or refer you to a dermatologist. You can ask for a chaperone or pause the exam at any point.

### Can you get a full body skin check?

Yes. In Canada, a full body skin check usually starts with your family doctor or a walk-in clinic, who can examine your skin and refer you to a dermatologist if needed. In most provinces a referral from a primary-care provider is required for a specialist visit to be covered by your provincial plan. Dermatology clinics perform detailed exams with dermoscopy and can take biopsies. Where local wait times are long, virtual or teledermatology services can review your photos and decide how quickly you should be seen in person. If you have many moles or a personal or family history of skin cancer, ask specifically for a full skin examination rather than a check of one spot.

### What do you wear for a full body skin check?

You undress to your underwear and wear a gown the clinic provides, so the clinician can see your whole skin surface. It helps to remove nail polish and makeup beforehand, because skin cancers can appear under the nails and on the face, and to tie long hair up so the scalp can be checked. Wear clothing that is easy to take off and put back on. You can keep your underwear on, and the clinician will only examine covered areas, including skin folds or the genital region, with your specific consent. If being undressed makes you uncomfortable, you can ask for a chaperone, or request that the exam focus on the areas that concern you most.

### What is the 2 week rule for melanoma?

The two week rule comes from the United Kingdom's National Health Service, where a suspected skin cancer referral must be seen by a specialist within two weeks. Canada does not have an identical national rule, but the principle is the same: suspected melanoma is treated as urgent and triaged ahead of routine visits. The practical takeaway is to act quickly. If a mole is changing, bleeding, or does not heal, do not wait and watch it at home for weeks. Book an appointment with your family doctor, and ask that any referral be marked urgent if melanoma is suspected. Early melanoma is highly treatable, and a short effort to get assessed is well worth it.

## Sources

- Public Health Agency of Canada, "Melanoma skin cancer" — https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/melanoma-skin-cancer.html
- Centers for Disease Control and Prevention (CDC), "Risk Factors for Skin Cancer" — https://www.cdc.gov/skin-cancer/risk-factors/index.html
- Centers for Disease Control and Prevention (CDC), "Skin Cancer Screening" — https://www.cdc.gov/skin-cancer/screening/index.html
- American Academy of Dermatology (AAD), "What to look for: ABCDEs of melanoma" — https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes
- American Academy of Dermatology (AAD), "How to check your skin" — https://www.aad.org/public/diseases/skin-cancer/find/check-skin
- Canadian Institute for Health Information (CIHI), "Wait times for priority procedures in Canada" — https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Health Canada, "Sun safety" — https://www.canada.ca/en/health-canada/services/sun-safety.html
- World Health Organization (WHO), "Ultraviolet radiation" — https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation
- Canadian Dermatology Association (CDA), "Sun protection" — https://dermatology.ca/public/sun-protection/

## FAQ
### What happens during a full body skin check?
You undress to your underwear and put on a gown, then the clinician examines your skin from your scalp down to the soles of your feet under bright light. They check easy-to-miss areas like behind the ears, between the toes, the nails, and skin folds, and with your consent the genital area. A dermatoscope, a handheld magnifier with a light, is used on any spot that looks unusual. The exam is painless and usually takes about 10 to 15 minutes. If a lesion looks suspicious, the clinician may take a small skin sample, called a biopsy, or refer you to a dermatologist. You can ask for a chaperone or pause the exam at any point.

### Can you get a full body skin check?
Yes. In Canada, a full body skin check usually starts with your family doctor or a walk-in clinic, who can examine your skin and refer you to a dermatologist if needed. In most provinces a referral from a primary-care provider is required for a specialist visit to be covered by your provincial plan. Dermatology clinics perform detailed exams with dermoscopy and can take biopsies. Where local wait times are long, virtual or teledermatology services can review your photos and decide how quickly you should be seen in person. If you have many moles or a personal or family history of skin cancer, ask specifically for a full skin examination rather than a check of one spot.

### What do you wear for a full body skin check?
You undress to your underwear and wear a gown the clinic provides, so the clinician can see your whole skin surface. It helps to remove nail polish and makeup beforehand, because skin cancers can appear under the nails and on the face, and to tie long hair up so the scalp can be checked. Wear clothing that is easy to take off and put back on. You can keep your underwear on, and the clinician will only examine covered areas, including skin folds or the genital region, with your specific consent. If being undressed makes you uncomfortable, you can ask for a chaperone, or request that the exam focus on the areas that concern you most.

### What is the 2 week rule for melanoma?
The two week rule comes from the United Kingdom's National Health Service, where a suspected skin cancer referral must be seen by a specialist within two weeks. Canada does not have an identical national rule, but the principle is the same: suspected melanoma is treated as urgent and triaged ahead of routine visits. The practical takeaway is to act quickly. If a mole is changing, bleeding, or does not heal, do not wait and watch it at home for weeks. Book an appointment with your family doctor, and ask that any referral be marked urgent if melanoma is suspected. Early melanoma is highly treatable, and a short effort to get assessed is well worth it.

---

# Hives (Urticaria): Common Causes and How to Stop the Itch

URL: https://www.dermadex.ca/blog/hives-urticaria-causes
Category: Conditions
Author: Maryam Sobhkhiz Sabet
Published: 2026-04-27

## TL;DR
Up to 20% of people develop hives (urticaria) at least once, according to the American Academy of Dermatology | Each welt fades within 24 hours, but an outbreak lasting over 6 weeks is classed as chronic urticaria | Second-generation antihistamines are first-line treatment, per the 2022 EAACI international urticaria guideline | Hives with throat tightness, trouble breathing, or facial swelling are a medical emergency: call 911

*As of April 27, 2026.*

Hives can appear within minutes, turn the skin into raised itchy welts, and vanish a few hours later without leaving a mark. For many people the trigger is never obvious, which makes the experience both uncomfortable and frustrating. This guide, written for patients and primary-care clinicians, explains what causes hives, how to calm the itch safely, and when raised welts signal something more serious. It is general health information, not a diagnosis. If your hives are severe, spreading, or come with swelling or trouble breathing, seek medical care right away.

## What are hives, and what is urticaria?

**Short answer:** Hives, known in medicine as urticaria, are raised itchy welts that form when cells in the skin release histamine and other chemicals, causing small blood vessels to leak fluid. The American Academy of Dermatology (AAD) reports that as many as 20 percent of people develop hives at some point in life. Each welt (called a wheal) usually fades within 24 hours, often reappearing in a new spot.

Welts can be a few millimetres across or merge into large patches, and they typically blanch (turn pale) when you press the centre. Some people also get deeper swelling of the lips, eyelids, hands, or feet, called angioedema. The [AAD overview of hives](https://www.aad.org/public/diseases/a-z/hives-overview) notes that the welts are usually pink or red on lighter skin and may look skin-coloured or slightly darker on brown and Black skin. Hives are not contagious, and most short-lived episodes are not dangerous, though they can be intensely itchy.

## What are the most common causes of hives?

**Short answer:** The most common causes of hives are allergic or immune reactions to foods, medications, infections, insect stings, and physical triggers such as heat, cold, pressure, or sunlight. In many short cases, a recent viral infection is the culprit. According to the AAD, a specific cause is identified in fewer than half of patients, which is normal and not a sign that anything was missed.

Histamine release is the final common pathway, but many different things can set it off. Viral infections (including the common cold) are a frequent trigger in both children and adults. Medications matter too: non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, certain antibiotics, and opioids can provoke welts, and Health Canada provides guidance on reporting suspected [drug side effects](https://www.canada.ca/en/health-canada/services/drugs-medication.html). Food reactions are another well-known cause, and Health Canada lists the priority [food allergens](https://www.canada.ca/en/health-canada/services/food-allergies-intolerances.html) that account for most severe reactions.

| Trigger category | Common examples | Typical timing |
|---|---|---|
| Foods | Peanuts, tree nuts, shellfish, egg, milk, sesame | Minutes to 2 hours after eating |
| Medications | NSAIDs, antibiotics, opioids, some blood-pressure drugs | Minutes to days |
| Infections | Common cold, other viral illnesses, strep | During or shortly after illness |
| Physical triggers | Heat, cold, pressure, sunlight, exercise, sweat | Minutes after exposure |
| Insect and contact | Bee or wasp stings, latex, plants, animal dander | Minutes to an hour |
| Stress and unknown | Emotional stress, no identifiable cause | Variable |

For a related rash that is often confused with hives, see our guide on [contact dermatitis](/blog/contact-dermatitis-causes) and how irritants and allergens trigger it.

## What is the difference between acute and chronic hives?

**Short answer:** Acute hives last less than six weeks and are usually linked to a clear trigger such as an infection, food, or medication. Chronic hives, called chronic urticaria, last six weeks or longer and frequently have no identifiable external cause. The 2024 review in the Journal of the American Medical Association (JAMA) notes that chronic spontaneous urticaria often persists for several years before resolving on its own.

The six-week mark is the dividing line used in international guidelines because it changes how clinicians investigate and treat. Acute cases rarely need blood tests; the history usually points to the cause. Chronic cases sometimes involve the immune system reacting against the skin itself (an autoimmune process), and they are more common in adults and in women. The [international EAACI urticaria guideline](https://pubmed.ncbi.nlm.nih.gov/34536239/), published by the European Academy of Allergy and Clinical Immunology (EAACI) in 2022, sets out a step-care approach that starts with antihistamines.

| Feature | Acute urticaria | Chronic urticaria |
|---|---|---|
| Duration | Under 6 weeks | 6 weeks or longer |
| Common cause | Infection, food, drug, sting | Often no external cause found |
| Testing needed | Usually none | Limited blood tests in some cases |
| Who to see | Family physician or walk-in | Family physician, then dermatology or allergy |

## How do you stop the itch and calm hives at home?

**Short answer:** Most hives respond to second-generation antihistamines such as cetirizine, loratadine, or fexofenadine, which control the histamine that drives the itch. Cool compresses, loose cotton clothing, and avoiding heat, alcohol, hot showers, and NSAIDs can ease symptoms while the welts settle. The EAACI guideline recommends second-generation antihistamines as the first-line treatment, with the dose increased under medical advice if standard dosing is not enough.

These non-drowsy antihistamines are available over the counter in Canadian pharmacies and are preferred over older sedating options for daytime use. Keep a simple diary of foods, medications, and activities to help spot a pattern. The [AAD treatment guidance](https://www.aad.org/public/diseases/a-z/hives-treatment) explains that short courses of oral corticosteroids may be used for severe flares, but these are not meant for long-term control. If hives keep returning despite regular antihistamines, that is the point to involve a clinician, because prescription options exist for stubborn chronic urticaria. The [AAD page on hive causes](https://www.aad.org/public/diseases/a-z/hives-causes) can help you identify avoidable triggers. People who also manage eczema may find overlap with our article on [eczema triggers and flare-ups](/blog/eczema-triggers-and-flare-ups).

## When do hives need urgent medical care?

**Short answer:** Hives become a medical emergency when they come with trouble breathing, throat tightness, swelling of the tongue or lips, dizziness, vomiting, or a fast heartbeat, because these can signal anaphylaxis, a severe allergic reaction. Call 911 immediately and use an epinephrine auto-injector if one has been prescribed. Do not wait to see if symptoms pass on their own.

Anaphylaxis can progress within minutes, so speed matters. Most ordinary hives never reach this stage, but knowing the warning signs is important, especially with a known food, drug, or insect-sting allergy. Even without breathing problems, see a clinician promptly if welts cover large areas, come with fever or joint pain, leave bruises, or last more than a day in the same spot. The Canadian Dermatology Association (CDA) offers [patient resources](https://dermatology.ca/public-patients/) on skin conditions, and a family physician can rule out conditions that mimic hives. When in doubt about breathing or swelling, treat it as an emergency.

## How does dermatology access in Canada affect hives care?

**Short answer:** Most hives in Canada are managed by family physicians, but stubborn or chronic urticaria sometimes needs a dermatologist or allergist, and specialist wait times can be long. Access varies by province, and referrals for non-urgent skin conditions can take weeks to months, which is why getting acute hives controlled at the primary-care level matters.

The Canadian Institute for Health Information (CIHI) tracks [health system wait times](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada), and access to specialty care remains uneven across regions. In Ontario, an initial assessment and antihistamine prescription are covered under the Ontario Health Insurance Plan (OHIP), and other provinces have equivalent public coverage for medically necessary visits. Canada's climate adds its own wrinkles: cold-induced hives can flare during winter, while heat and sun exposure trigger welts in summer. If your hives are not settling and a referral feels far off, virtual triage can help you reach the right level of care sooner. That is where [DermaDex](/) fits in.

## How can DermaDex help with stubborn or chronic hives?

**Short answer:** DermaDex is a Canadian healthtech company that pairs artificial intelligence (AI) assisted skin assessment with access to certified dermatologists, so people in areas with long wait times can get guidance faster. For hives, that means a structured review of your symptoms and photos to help decide whether self-care, a primary-care visit, or specialist referral is the right next step.

DermaDex does not replace your family physician or emergency care, and it does not diagnose anaphylaxis. It is built to shorten the path between noticing a problem and reaching appropriate care, with patient information handled according to Canadian privacy law, including the Personal Health Information Protection Act (PHIPA) in Ontario. You can read more about our team on the [about page](/about), and patients or clinics with questions can reach us through the [contact page](/contact). If your hives are tied to eczema or another inflammatory condition, our [eczema triggers guide](/blog/eczema-triggers-and-flare-ups) is a useful companion read. Always talk to a clinician before changing treatment.

## Frequently asked questions

### What can suddenly cause hives?

Sudden hives are most often caused by something your body recently encountered: a new food, a medication such as an NSAID or antibiotic, an insect sting, or a viral infection like the common cold. Physical triggers can also cause an instant outbreak, including heat, cold, pressure on the skin, sweat from exercise, or sunlight. In many sudden cases, a clear cause is never found, which the AAD considers normal for acute urticaria. The welts usually appear within minutes to a couple of hours of the trigger. If a sudden outbreak comes with swelling of the lips or tongue, throat tightness, or difficulty breathing, treat it as a possible severe allergic reaction and call 911 right away.

### What gets rid of hives fast?

The fastest reliable relief comes from a second-generation oral antihistamine such as cetirizine, loratadine, or fexofenadine, available over the counter in Canadian pharmacies. These calm the histamine that drives the itch and swelling, usually within an hour or two. While you wait, a cool compress, a lukewarm (not hot) shower, and loose cotton clothing help. Avoid known triggers, alcohol, NSAIDs, and overheating, since these can worsen welts. The EAACI guideline supports antihistamines as first-line treatment, with the dose raised under medical advice if needed. Severe flares may need a short course of oral steroids prescribed by a clinician. If hives come with breathing trouble or facial swelling, that is anaphylaxis until proven otherwise: use prescribed epinephrine and call 911.

### What do stress hives look like?

Stress hives look the same as hives from any other cause: raised welts that are pink or red on lighter skin and skin-coloured or slightly darker on brown and Black skin. They are usually itchy, blanch (turn pale) when pressed, and can range from small spots to large merging patches. They often show up on the chest, neck, face, and arms, and individual welts tend to fade within a day while new ones appear elsewhere. Stress does not usually cause hives entirely on its own; more often it amplifies an existing tendency toward urticaria or lowers the threshold for other triggers. If stress-related welts keep returning for six weeks or more, that points to chronic urticaria and is worth discussing with a clinician.

### How long do hives last for?

Any single hive welt usually fades within 24 hours, often moving to a new area of skin as it clears. A whole outbreak is called acute urticaria when it resolves within six weeks, which covers the large majority of cases. When hives keep coming and going for six weeks or longer, they are classed as chronic urticaria. The 2024 JAMA review notes that chronic spontaneous urticaria commonly lasts a few years before settling on its own, though antihistamines and other treatments can control symptoms in the meantime. If a single welt stays fixed in one spot for more than 24 hours, leaves a bruise, or comes with pain, see a clinician, because that pattern can point to a different condition.

## Sources

- American Academy of Dermatology (AAD), "Hives: Overview." https://www.aad.org/public/diseases/a-z/hives-overview
- American Academy of Dermatology (AAD), "Hives: Causes." https://www.aad.org/public/diseases/a-z/hives-causes
- American Academy of Dermatology (AAD), "Hives: Diagnosis and Treatment." https://www.aad.org/public/diseases/a-z/hives-treatment
- Canadian Dermatology Association (CDA), Patient Resources. https://dermatology.ca/public-patients/
- Health Canada, "Food allergies and intolerances." https://www.canada.ca/en/health-canada/services/food-allergies-intolerances.html
- Health Canada, "Drugs and medication." https://www.canada.ca/en/health-canada/services/drugs-medication.html
- Kolkhir P, et al. "Chronic Spontaneous Urticaria: A Review." JAMA, November 5, 2024. https://pubmed.ncbi.nlm.nih.gov/39325444/
- Zuberbier T, et al. "The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for urticaria." Allergy, 2022. https://pubmed.ncbi.nlm.nih.gov/34536239/
- Canadian Institute for Health Information (CIHI), "Wait times for priority procedures in Canada." https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada

## FAQ
### What can suddenly cause hives?
Sudden hives are most often caused by something your body recently encountered: a new food, a medication such as an NSAID or antibiotic, an insect sting, or a viral infection like the common cold. Physical triggers can also cause an instant outbreak, including heat, cold, pressure on the skin, sweat from exercise, or sunlight. In many sudden cases, a clear cause is never found, which the AAD considers normal for acute urticaria. The welts usually appear within minutes to a couple of hours of the trigger. If a sudden outbreak comes with swelling of the lips or tongue, throat tightness, or difficulty breathing, treat it as a possible severe allergic reaction and call 911 right away.

### What gets rid of hives fast?
The fastest reliable relief comes from a second-generation oral antihistamine such as cetirizine, loratadine, or fexofenadine, available over the counter in Canadian pharmacies. These calm the histamine that drives the itch and swelling, usually within an hour or two. While you wait, a cool compress, a lukewarm (not hot) shower, and loose cotton clothing help. Avoid known triggers, alcohol, NSAIDs, and overheating, since these can worsen welts. The EAACI guideline supports antihistamines as first-line treatment, with the dose raised under medical advice if needed. Severe flares may need a short course of oral steroids prescribed by a clinician. If hives come with breathing trouble or facial swelling, that is anaphylaxis until proven otherwise: use prescribed epinephrine and call 911.

### What do stress hives look like?
Stress hives look the same as hives from any other cause: raised welts that are pink or red on lighter skin and skin-coloured or slightly darker on brown and Black skin. They are usually itchy, blanch (turn pale) when pressed, and can range from small spots to large merging patches. They often show up on the chest, neck, face, and arms, and individual welts tend to fade within a day while new ones appear elsewhere. Stress does not usually cause hives entirely on its own; more often it amplifies an existing tendency toward urticaria or lowers the threshold for other triggers. If stress-related welts keep returning for six weeks or more, that points to chronic urticaria and is worth discussing with a clinician.

### How long do hives last for?
Any single hive welt usually fades within 24 hours, often moving to a new area of skin as it clears. A whole outbreak is called acute urticaria when it resolves within six weeks, which covers the large majority of cases. When hives keep coming and going for six weeks or longer, they are classed as chronic urticaria. The 2024 JAMA review notes that chronic spontaneous urticaria commonly lasts a few years before settling on its own, though antihistamines and other treatments can control symptoms in the meantime. If a single welt stays fixed in one spot for more than 24 hours, leaves a bruise, or comes with pain, see a clinician, because that pattern can point to a different condition.

---

# Melasma: Why It Happens and How to Treat It Safely

URL: https://www.dermadex.ca/blog/melasma-causes-treatment
Category: Conditions
Author: Mohsen Khoddami
Published: 2026-04-14

## TL;DR
Up to 90% of melasma cases occur in women, most often in medium-to-dark skin tones (StatPearls, NCBI Bookshelf) | Broad-spectrum SPF 30+ sunscreen, ideally tinted with iron oxides, is first-line for every patient (American Academy of Dermatology) | Triple combination cream (hydroquinone, tretinoin, mild steroid) has the strongest topical evidence for melasma | Most patients see fading in 8 to 12 weeks, but melasma is chronic and recurs without ongoing sun protection | Melasma treatment is often considered cosmetic and not covered by OHIP, so plan for out-of-pocket costs

*As of April 13, 2026.*

Brown patches that spread across the cheeks, forehead, and upper lip are one of the most common concerns I see in clinic, and most of them turn out to be melasma. Melasma is harmless to your physical health, but it is persistent, it tends to return, and the wrong product can make it darker instead of lighter. This guide explains why melasma happens, which treatments are supported by evidence, and how to fade it safely. [DermaDex](/) is a Canadian healthtech company that connects patients with certified dermatologists and uses AI (artificial intelligence) tools to help sort skin concerns sooner.

## Why does melasma happen?

**Short answer:** Melasma happens when pigment-producing skin cells called melanocytes become overactive and deposit excess melanin in the skin, driven mainly by sun exposure, heat, and hormones. It is far more common in women and in people with medium-to-dark skin tones, and it often runs in families. Ultraviolet and visible light are the biggest day-to-day triggers, while pregnancy, birth control pills, and hormone therapy explain why it frequently starts or worsens at those times. Thyroid problems and certain medications can add to the risk. Because the cause is multi-factor, lasting control depends on managing sunlight, heat, and any hormonal driver together.

Several triggers work together. Ultraviolet A and B (UVA and UVB) light and visible light, including the blue light from the sun, stimulate melanocytes directly. Hormonal shifts from pregnancy (where it is nicknamed the "mask of pregnancy"), birth control pills, and hormone therapy are common drivers. Genetics play a strong role, and a family history is frequent. Heat itself, thyroid disease, and some photosensitizing medications or cosmetics can also contribute. According to [StatPearls on the NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK459271/), melasma overwhelmingly affects women and people with darker skin types, which is why sun protection and hormone awareness matter so much.

## What does melasma look like on the face?

**Short answer:** Melasma shows up as flat, brown to grey-brown patches with irregular but fairly symmetric borders, usually on the cheeks, forehead, upper lip, nose, and chin. It does not itch, hurt, or change quickly the way a suspicious mole might. The patches are usually larger and more blotchy than freckles, and they tend to sit on both sides of the face in a mirror-image pattern. Colour can look light tan on fairer skin or deep grey-brown on darker skin. Dermatologists grade it by depth, since surface pigment fades more readily than deeper pigment. Any single spot that looks different deserves a closer look.

The most common pattern sits across the cheeks and bridge of the nose, but it can appear anywhere sun reaches, including the forearms and neck. Dermatologists often describe melasma by depth: epidermal (surface pigment, usually responds better), dermal (deeper, harder to treat), and mixed. We confirm the diagnosis by clinical exam, sometimes using a Wood's lamp or dermoscopy. Because a single new or changing dark spot can be something more serious, it is worth knowing how pigment problems differ. Our guide on [seborrheic keratosis versus melanoma](/blog/seborrheic-keratosis-vs-melanoma) explains the warning signs. The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/a-z/melasma-overview) has reference images that match these patterns.

## What is the most effective treatment for melasma?

**Short answer:** The most effective treatment pairs strict daily sun protection with a topical lightening agent. The strongest evidence supports a triple combination cream that combines hydroquinone, tretinoin, and a mild corticosteroid, used in short, supervised courses. Sunscreen is the part most people underuse, yet a broad-spectrum Sun Protection Factor (SPF) 30 or higher, tinted with iron oxides to block visible light, makes or breaks results. Single-agent hydroquinone, azelaic acid, kojic acid, niacinamide, vitamin C, and tranexamic acid are useful alternatives or add-ons. Procedures such as peels and lasers are reserved for stubborn cases, because aggressive treatment can worsen pigment.

Sun protection is not optional. A broad-spectrum sunscreen of Sun Protection Factor (SPF) 30 or higher, ideally tinted with iron oxides to block visible light, is the foundation of every plan. On top of that, topical agents reduce pigment over weeks to months. The [AAD guidance on melasma treatment](https://www.aad.org/public/diseases/a-z/melasma-treatment) and [its causes and triggers](https://www.aad.org/public/diseases/a-z/melasma-causes) describe the main options. The table below summarizes how the common choices fit together.

| Treatment | How it works | Where it fits | Notes for safe use |
|-----------|--------------|---------------|--------------------|
| Broad-spectrum sunscreen, SPF 30+ (tinted with iron oxides) | Blocks UVA, UVB, and visible light that drive pigment | First line for every patient | Reapply every two hours outdoors; tinted mineral formulas block visible light better |
| Hydroquinone | Slows melanin production | First-line topical, often prescription | Use under medical guidance; prolonged high-strength use can darken skin (ochronosis) |
| Triple combination cream (hydroquinone, tretinoin, mild steroid) | Combines lightening, cell turnover, and anti-inflammatory action | Strongest topical evidence | Short, supervised courses only |
| Azelaic acid, kojic acid, niacinamide, vitamin C | Reduce pigment with less irritation | Maintenance and pregnancy-safer options | Slower acting; good for sensitive skin and long-term use |
| Tranexamic acid (topical or oral) | Lowers the signaling that boosts pigment | Add-on for stubborn cases | Oral form needs screening for clotting risk |
| Chemical peels, lasers, microneedling | Remove or break up existing pigment | Second or third line | Can worsen melasma if too aggressive, especially in darker skin |

## How do you get rid of melasma safely without making it worse?

**Short answer:** Go slowly, protect against sun and heat every day, and avoid harsh do-it-yourself acids or aggressive lasers that can inflame the skin and deepen pigment. Consistency over months beats any quick, intense treatment. The safest sequence is sunscreen first, then one gentle evidence-based topical, then in-clinic procedures only if needed and only under supervision. Rushing is the main way people make melasma worse, because inflammation from strong peels, home acids, or hot laser settings triggers post-inflammatory hyperpigmentation, especially in medium and darker skin tones. Build a routine you can keep for months, not a one-week sprint that backfires.

Melasma is easy to flare. Strong peels, undiluted home acids, and overpowered laser settings can cause post-inflammatory hyperpigmentation, especially in medium and darker skin tones. Start with sun protection and a gentle, evidence-based topical, then step up only with professional guidance. Reapply sunscreen through the day, wear a wide-brimmed hat, and seek shade. Health Canada's [sun safety guidance](https://www.canada.ca/en/health-canada/services/sun-safety.html) and the [Canadian Dermatology Association (CDA)](https://dermatology.ca/public-patients/sun-protection/) both stress daily, year-round protection. If you are pregnant, ask about pregnancy-safer options such as azelaic acid before starting anything new.

## Can melasma be removed permanently?

**Short answer:** No. Melasma is a chronic, relapsing condition with no reliable permanent cure. Even cleared patches often return with sun exposure, heat, or hormonal changes, so the realistic goal is long-term control rather than a one-time fix. People who manage it well tend to think in terms of remission and maintenance, not removal. With steady sun protection, gentle maintenance topicals, and attention to hormonal triggers, many keep the pigment faint for years. Procedures can lighten what is already there, but nothing on the market stops melasma from coming back once protection or treatment lapses, which is why ongoing care matters more than any single session.

Many patients keep melasma faint for years by combining maintenance topicals with daily broad-spectrum, visible-light sun protection and sensible habits. Treating a hormonal trigger, such as reviewing birth control options with your doctor, can help. Lasers and peels may lighten pigment, but they do not prevent recurrence and can worsen it if overdone, so they are not a shortcut to permanence. The [World Health Organization (WHO)](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) notes that ultraviolet radiation reaches skin even on cloudy days, which is one reason melasma comes back when sun protection slips. Treat it like a chronic condition that needs ongoing care.

## How does melasma care work in Canada?

**Short answer:** In Canada you usually reach a dermatologist through a family doctor referral, and waits can run weeks to months. Provincial plans like the Ontario Health Insurance Plan (OHIP) cover medically necessary visits, but melasma treatment is often considered cosmetic and paid out of pocket. Expect prescription creams, peels, and laser sessions to carry their own fees on top of any consultation. Because the condition is benign, it ranks low for urgent referral, which lengthens the wait for cosmetic concerns. Remote and AI-assisted triage services exist partly to close that gap and give patients reliable guidance sooner, especially where local specialists are scarce.

Because melasma is not dangerous, it sits low on referral priority lists, and wait times for non-urgent dermatology can be long across the country. That gap is part of why [DermaDex](/about) builds AI-assisted triage and remote dermatologist access, so patients in areas with few specialists can get guidance sooner. You can learn how that screening works in our explainer on [how AI skin checks work](/blog/how-ai-skin-checks-work). Canada's climate matters too: ultraviolet exposure happens year-round, and snow reflects it in winter, as the [Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/skin-cancer/sun-safety/index.html) and Health Canada both note. If you have questions about access or coverage, [contact our team](/contact).

## When should you see a dermatologist about melasma?

**Short answer:** See a dermatologist if facial patches are not improving with sun protection and over-the-counter care, if you are unsure of the diagnosis, or if a single spot looks different, is changing, or has an unusual colour or border. Those features can point to something other than melasma. Booking a visit is also worth it when you want prescription-strength treatment matched to your skin tone, or when home measures have plateaued after a few months. A clinician can confirm that the pigment really is melasma, rule out other causes, and supervise stronger options safely rather than leaving you to guess on your own.

Melasma itself is benign, but pigment that is asymmetric, growing, bleeding, or new in one isolated spot deserves an in-person check to rule out skin cancer. A dermatologist can confirm the diagnosis, match treatment to your skin tone, and supervise stronger options like prescription creams or, when appropriate, oral tranexamic acid. The [AAD sunscreen guidance](https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/sunscreen-faqs) is a good starting point for prevention while you wait for care. This article is general education, not a diagnosis. If you are worried about a specific spot, talk to a clinician.

## Frequently asked questions

### What is the most effective treatment for melasma?

Daily broad-spectrum sun protection combined with a topical lightening agent is the most effective approach. The strongest evidence supports a triple combination cream that pairs hydroquinone with tretinoin and a mild corticosteroid, used in short, supervised courses. Hydroquinone on its own, plus agents like azelaic acid, tranexamic acid, vitamin C, and niacinamide, also help. Procedures such as peels or lasers are reserved for cases that do not respond, because they can worsen pigment if used too aggressively. The most common reason treatment fails is inconsistent sun protection, so a tinted sunscreen with iron oxides that blocks visible light matters as much as any cream. A dermatologist can match the plan to your skin tone and triggers.

### How do you get rid of melasma fast?

There is no safe overnight fix, and trying to rush it usually backfires. Most people see meaningful fading over 8 to 12 weeks of steady topical treatment plus strict sun protection, with fuller results around three to six months. Aggressive shortcuts like strong peels, lasers, or harsh home acids can inflame the skin and trigger more pigment, especially in medium and darker skin tones. The fastest realistic path is starting an evidence-based topical (often hydroquinone or a triple combination cream) early, applying tinted sunscreen every morning, and avoiding heat and unprotected sun. If you are pregnant, ask about pregnancy-safer options such as azelaic acid, since some treatments are not recommended. Patience and consistency beat any quick fix.

### How can I permanently remove melasma?

Melasma cannot be reliably removed for good. It is a chronic, relapsing condition, and even when patches clear, they often return with sun exposure, heat, or hormonal changes like pregnancy or birth control. The goal of treatment is long-term control, not a one-time cure. Many patients keep melasma faint for years by combining maintenance topicals (such as azelaic acid or low-strength agents) with daily broad-spectrum, visible-light sunscreen and sun-protective habits. Lasers and peels can lighten pigment but do not prevent recurrence and may worsen it if overdone. Treating any hormonal trigger and protecting against ultraviolet and visible light are what keep results lasting. Think of melasma management as ongoing care, not a finish line.

### How to remove melasma from face naturally?

Natural approaches can support treatment, but evidence for them is limited, and the single most effective natural step is rigorous sun protection. Ingredients with some research behind them include azelaic acid (derived from grains), vitamin C, niacinamide, and soy, which can gently reduce pigment with little irritation. Avoid popular do-it-yourself remedies like lemon juice or undiluted apple cider vinegar, which can irritate skin and even cause a sun-triggered burn that darkens pigment further. Shade, wide-brimmed hats, and a tinted mineral sunscreen do more than any kitchen remedy. If you prefer a gentle routine, ask a clinician about azelaic acid and a vitamin C serum. Natural does not always mean safe, so check before trying strong home acids.

## Sources

- American Academy of Dermatology (AAD), Melasma: Overview. https://www.aad.org/public/diseases/a-z/melasma-overview
- American Academy of Dermatology (AAD), Melasma: Diagnosis and Treatment. https://www.aad.org/public/diseases/a-z/melasma-treatment
- American Academy of Dermatology (AAD), Melasma: Causes. https://www.aad.org/public/diseases/a-z/melasma-causes
- American Academy of Dermatology (AAD), Sunscreen FAQs. https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/sunscreen-faqs
- StatPearls, NCBI Bookshelf (National Institutes of Health), Melasma. https://www.ncbi.nlm.nih.gov/books/NBK459271/
- World Health Organization (WHO), Ultraviolet radiation. https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation
- Health Canada, Sun safety. https://www.canada.ca/en/health-canada/services/sun-safety.html
- Canadian Dermatology Association (CDA), Sun protection. https://dermatology.ca/public-patients/sun-protection/
- Centers for Disease Control and Prevention (CDC), Sun safety. https://www.cdc.gov/skin-cancer/sun-safety/index.html

## FAQ
### What is the most effective treatment for melasma?
Daily broad-spectrum sun protection combined with a topical lightening agent is the most effective approach. The strongest evidence supports a triple combination cream that pairs hydroquinone with tretinoin and a mild corticosteroid, used in short, supervised courses. Hydroquinone on its own, plus agents like azelaic acid, tranexamic acid, vitamin C, and niacinamide, also help. Procedures such as peels or lasers are reserved for cases that do not respond, because they can worsen pigment if used too aggressively. The most common reason treatment fails is inconsistent sun protection, so a tinted sunscreen with iron oxides that blocks visible light matters as much as any cream. A dermatologist can match the plan to your skin tone and triggers.

### How do you get rid of melasma fast?
There is no safe overnight fix, and trying to rush it usually backfires. Most people see meaningful fading over 8 to 12 weeks of steady topical treatment plus strict sun protection, with fuller results around three to six months. Aggressive shortcuts like strong peels, lasers, or harsh home acids can inflame the skin and trigger more pigment, especially in medium and darker skin tones. The fastest realistic path is starting an evidence-based topical (often hydroquinone or a triple combination cream) early, applying tinted sunscreen every morning, and avoiding heat and unprotected sun. If you are pregnant, ask about pregnancy-safer options such as azelaic acid, since some treatments are not recommended. Patience and consistency beat any quick fix.

### How can I permanently remove melasma?
Melasma cannot be reliably removed for good. It is a chronic, relapsing condition, and even when patches clear, they often return with sun exposure, heat, or hormonal changes like pregnancy or birth control. The goal of treatment is long-term control, not a one-time cure. Many patients keep melasma faint for years by combining maintenance topicals (such as azelaic acid or low-strength agents) with daily broad-spectrum, visible-light sunscreen and sun-protective habits. Lasers and peels can lighten pigment but do not prevent recurrence and may worsen it if overdone. Treating any hormonal trigger and protecting against ultraviolet and visible light are what keep results lasting. Think of melasma management as ongoing care, not a finish line.

### How to remove melasma from face naturally?
Natural approaches can support treatment, but evidence for them is limited, and the single most effective natural step is rigorous sun protection. Ingredients with some research behind them include azelaic acid (derived from grains), vitamin C, niacinamide, and soy, which can gently reduce pigment with little irritation. Avoid popular do-it-yourself remedies like lemon juice or undiluted apple cider vinegar, which can irritate skin and even cause a sun-triggered burn that darkens pigment further. Shade, wide-brimmed hats, and a tinted mineral sunscreen do more than any kitchen remedy. If you prefer a gentle routine, ask a clinician about azelaic acid and a vitamin C serum. Natural does not always mean safe, so check before trying strong home acids.

---

# Ringworm (Tinea): How to Identify and Treat Fungal Skin Infections

URL: https://www.dermadex.ca/blog/ringworm-tinea-treatment
Category: Conditions
Author: Maryam Sobhkhiz Sabet
Published: 2026-04-02

## TL;DR
Ringworm is a fungal infection (tinea), not a worm; most body cases clear with antifungal cream in 2 to 4 weeks (AAD, CDC) | Apply antifungal about 2 cm beyond the visible border and keep going roughly 1 week after the rash fades to prevent relapse | Terbinafine 1% cream often clears body ringworm in 1 to 2 weeks; scalp and nail infections need prescription oral antifungals | Most ringworm in Canada is treated by a family physician or pharmacist, not a dermatologist, so a specialist referral is rarely needed

*As of April 1, 2026.*

Ringworm is one of the most common skin infections family physicians see, and it is also one of the most misunderstood. The name suggests a parasite, but there is no worm involved. This guide explains how to recognize ringworm (medically called tinea), how to treat it at home, and when a rash needs a clinician. [DermaDex](/) is a Canadian healthtech company that connects patients to certified dermatologists and offers artificial intelligence (AI)-assisted skin checks for people who face long waits for specialty care.

This article is general health information, not a diagnosis. If a rash is spreading, painful, or not improving with treatment, see a clinician.

## What is ringworm, and is it actually a worm?

**Short answer:** Ringworm is a fungal skin infection called tinea, not a parasite or worm. It is caused by dermatophytes, a group of fungi that feed on keratin in the outer layer of skin, hair, and nails.

The name comes from the ring-shaped rash it often produces, not from any organism. According to the Centers for Disease Control and Prevention (CDC), ringworm on the body is named tinea corporis, while the same fungi cause athlete's foot (tinea pedis), jock itch (tinea cruris), and scalp ringworm (tinea capitis). The most common culprit is the fungus Trichophyton rubrum. Because ringworm is a fungus and not a worm, anti-parasite medicines do nothing for it. The correct treatment is an antifungal. [See the CDC overview of ringworm](https://www.cdc.gov/ringworm/about/index.html).

## What does ringworm look like and what are the symptoms?

**Short answer:** Classic ringworm is a round or oval, scaly, itchy patch with a raised, advancing border and clearer skin in the center, which creates the ring appearance. Patches often look pink or red on lighter skin and gray, brown, or violet on darker skin.

A single patch can grow from a few millimetres to several centimetres over days to weeks, and there may be more than one. The edge is usually the most active part, with fine scale or small bumps, while the middle starts to clear. On the scalp, ringworm causes scaly bald spots and broken hairs rather than a clean ring. The American Academy of Dermatology (AAD) notes that ringworm is frequently itchy but not usually painful. Pain, pus, or rapid spreading suggests a bacterial infection on top and needs medical review. [Review AAD signs and photos of ringworm](https://www.aad.org/public/diseases/a-z/ringworm-overview).

## What causes ringworm and how does it spread?

**Short answer:** Ringworm is caused by dermatophyte fungi that spread through direct skin contact and through contaminated objects. You can catch it from another person, from pets such as cats and dogs, from soil, or from shared items like towels, combs, and gym mats.

Warm, moist conditions help the fungus grow, so sweating, tight clothing, and humid weather raise the risk. Contact sports such as wrestling spread it skin to skin, sometimes called tinea gladiatorum. People with diabetes, a weakened immune system, or untreated athlete's foot that spreads to other areas are more prone to it. Pets are a frequent and overlooked source, so a household animal with patchy hair loss should see a veterinarian. The CDC lists fungal spores surviving on surfaces and shared gear as common transmission routes. [Read the CDC on how ringworm spreads](https://www.cdc.gov/ringworm/about/index.html).

## How is ringworm treated?

**Short answer:** Most ringworm on the body clears with an over-the-counter antifungal cream applied once or twice daily for two to four weeks. Terbinafine and azole creams such as clotrimazole and miconazole are first-line, and you should treat about 2 cm beyond the visible edge.

Keep applying the cream for at least one week after the rash looks gone, because the fungus outlasts the redness. The AAD and CDC both stress finishing the full course to prevent relapse. Antifungal powders or sprays help in moist areas like the groin and feet. Scalp and nail infections do not respond to creams alone and need prescription oral antifungals, because the medicine has to reach the hair root or nail bed. Oral therapy is also used for widespread disease or rashes that fail topical treatment. Do not use a steroid cream by itself; it can mask the rash and let the fungus spread, a pattern called tinea incognito. [See CDC treatment guidance](https://www.cdc.gov/ringworm/treatment/index.html).

| Medication | Class | Form (Canada) | Typical use | Usual course |
|---|---|---|---|---|
| Clotrimazole 1% | Azole | Cream, over-the-counter | Mild body, groin, or foot ringworm | 2 to 4 weeks |
| Terbinafine 1% | Allylamine | Cream, over-the-counter | Body, groin, foot ringworm | 1 to 2 weeks (body) |
| Ketoconazole 2% | Azole | Cream, prescription | Cases needing a stronger topical | 2 to 4 weeks |
| Terbinafine tablets | Allylamine | Oral, prescription | Scalp, nail, widespread, or topical failure | 2 to 6 weeks |
| Griseofulvin | Antifungal | Oral, prescription | Scalp ringworm, often in children | 6 to 8 weeks |

Over-the-counter products are sold at any Canadian pharmacy, and a pharmacist can help you choose one. Prescription oral antifungals such as terbinafine need a clinician because they require attention to drug interactions and, in longer courses, occasional liver monitoring, as described in the National Institutes of Health (NIH) StatPearls review. [Read the NIH terbinafine overview](https://www.ncbi.nlm.nih.gov/books/NBK545218/).

## How long does ringworm take to clear, and when should you see a clinician?

**Short answer:** Body ringworm usually improves within one to two weeks of starting an antifungal and clears in two to four weeks. See a clinician if it does not improve after two weeks of correct treatment, keeps coming back, or involves the scalp or nails.

Other reasons to get medical care include a rash that is widespread, very inflamed, blistered, or weeping, signs of a bacterial infection such as pus and increasing pain, or any rash in someone with diabetes or a weakened immune system. A clinician can confirm the diagnosis with a simple skin scraping examined under the microscope or sent for fungal culture, which matters because several conditions copy the ring shape. In Canada, ringworm is almost always handled by a family physician, pharmacist, or walk-in clinic rather than a dermatologist, so you rarely need a specialist referral or a long wait. For more on this, see [how a family doctor and a dermatologist split skin care](/blog/dermatologist-vs-family-doctor).

## What other skin conditions look like ringworm?

**Short answer:** Several common skin conditions form round or ring-shaped patches and are regularly mistaken for ringworm, including nummular eczema, granuloma annulare, psoriasis, pityriasis rosea, and contact dermatitis. None of these are fungal, so antifungal cream will not fix them.

This matters because using the wrong treatment wastes time, and a steroid cream put on a true fungal infection can make it worse. The early bullseye rash of Lyme disease (erythema migrans) can also look like a large ring and needs different care. A fungal scraping settles the question quickly. If you are unsure what you are looking at, a photo-based skin check can help sort a likely fungal rash from an inflammatory one before you buy anything. [DermaDex AI skin checks](/blog/how-ai-skin-checks-work) are built for this kind of first triage, and a clinician reviews anything that looks concerning. The tinea corporis review in the NIH StatPearls library lists the full set of look-alikes. [See the NIH tinea corporis review](https://www.ncbi.nlm.nih.gov/books/NBK544360/).

## How can you prevent ringworm from coming back?

**Short answer:** Keep skin clean and dry, avoid sharing towels, clothing, and grooming tools, and treat related infections like athlete's foot at the same time. Most repeat cases come from an untreated source such as a pet, a family member, or your own feet.

Change out of sweaty clothes promptly, dry well between toes and in skin folds, and wear sandals in shared showers and changing rooms. Wash bedding, towels, and sports gear in hot water, and do not share items that touch skin or hair. If a household pet has bald or scaly patches, have it checked by a veterinarian, since reinfection from animals is common. The CDC notes that treating athlete's foot helps stop the fungus from spreading to the groin and body. [See CDC prevention advice](https://www.cdc.gov/ringworm/about/index.html). The Canadian Dermatology Association (CDA) also offers patient resources on common skin conditions. [Browse CDA patient information](https://dermatology.ca/public-patients/).

## How can DermaDex help with a suspected fungal skin infection?

**Short answer:** DermaDex lets you photograph a rash, get an AI-assisted assessment in minutes, and connect to a certified Canadian dermatologist when a case needs expert eyes. For a clear-cut ringworm, that often means quick reassurance and a treatment plan without a long referral wait.

Many Canadians wait months for a dermatology appointment, yet most ringworm never needs one. The value of an early skin check is sorting the simple fungal rashes that a pharmacist can treat from the look-alikes that need a doctor, so you do not delay care or treat the wrong thing. All images are stored securely on Canadian servers. To learn more about who we are, read [our story](/about), and reach our team through the [contact page](/contact). Remember that this article is general information and not a substitute for an in-person diagnosis.

**Frequently asked questions**

## What gets rid of ringworm fast?

**Short answer:** There is no instant cure, but the fastest reliable option for body ringworm is a topical allylamine such as terbinafine 1% cream. Applied once or twice a day, it often clears tinea corporis within one to two weeks.

Spread the cream about 2 cm past the visible edge, keep the area clean and dry, and keep applying for roughly a week after the rash looks gone so the fungus does not return. Avoid steroid creams, which can make a fungal infection worse. Scalp or widespread ringworm clears faster with prescription oral antifungals, but those need a clinician. If a rash is not improving after two weeks of correct use, see a family physician or pharmacist. [See AAD treatment guidance](https://www.aad.org/public/diseases/a-z/ringworm-treatment).

## What is the cause of ringworm?

**Short answer:** Ringworm is caused by dermatophytes, a group of fungi (mainly Trichophyton, Microsporum, and Epidermophyton species) that feed on keratin in skin, hair, and nails. It is not caused by a worm.

You catch it through direct skin contact with an infected person or animal, or by touching contaminated objects such as towels, clothing, combs, locker-room floors, and sports mats. Pets, especially cats and dogs, are a common and often missed source. Warm, damp conditions help the fungus grow, so sweating, tight clothing, humidity, and shared communal showers raise the risk. People with diabetes, a weakened immune system, or untreated athlete's foot are more likely to develop ringworm and to spread it to other body areas. [Read AAD on what causes ringworm](https://www.aad.org/public/diseases/a-z/ringworm-causes).

## What is the best medicine for ringworm?

**Short answer:** For most ringworm on the body, groin, or feet, the best first medicine is an over-the-counter topical antifungal such as terbinafine 1% cream or an azole like clotrimazole, miconazole, or ketoconazole.

Terbinafine often clears body ringworm in a slightly shorter course. The right choice depends on where the rash is and how severe it is, and a pharmacist can help you pick one. Scalp ringworm and fungal nail infections are different: topical creams cannot reach the hair root or nail bed, so they need prescription oral antifungals such as terbinafine, itraconazole, or griseofulvin (often used for scalp ringworm in children). Widespread rashes or ones that fail topical treatment also need oral therapy prescribed by a clinician. [See CDC treatment options](https://www.cdc.gov/ringworm/treatment/index.html).

## What can be mistaken for ringworm?

**Short answer:** Several non-fungal conditions form round or ring-shaped patches and are often mistaken for ringworm, including nummular (discoid) eczema, granuloma annulare, psoriasis, pityriasis rosea, and contact dermatitis.

The expanding bullseye rash of early Lyme disease (erythema migrans) can also resemble a large ring and needs different treatment. Because none of these are fungal, antifungal creams will not help them, and steroid creams used on a true fungal infection can make it spread and change its appearance. This is why a clinician may take a small skin scraping to check for fungus under the microscope or by culture before settling on a diagnosis. If you are unsure, a photo-based skin check can help sort a likely fungal rash from an inflammatory one. [See the NIH tinea corporis differential](https://www.ncbi.nlm.nih.gov/books/NBK544360/).

## Sources

- Centers for Disease Control and Prevention (CDC), About Ringworm: https://www.cdc.gov/ringworm/about/index.html
- Centers for Disease Control and Prevention (CDC), Ringworm Treatment: https://www.cdc.gov/ringworm/treatment/index.html
- American Academy of Dermatology (AAD), Ringworm Overview: https://www.aad.org/public/diseases/a-z/ringworm-overview
- American Academy of Dermatology (AAD), Ringworm Causes: https://www.aad.org/public/diseases/a-z/ringworm-causes
- American Academy of Dermatology (AAD), Ringworm Treatment: https://www.aad.org/public/diseases/a-z/ringworm-treatment
- National Institutes of Health (NIH), NCBI Bookshelf, StatPearls: Tinea Corporis: https://www.ncbi.nlm.nih.gov/books/NBK544360/
- National Institutes of Health (NIH), NCBI Bookshelf, StatPearls: Terbinafine: https://www.ncbi.nlm.nih.gov/books/NBK545218/
- Canadian Dermatology Association (CDA), Public and Patients: https://dermatology.ca/public-patients/

## FAQ
### What gets rid of ringworm fast?
There is no instant cure, but the fastest reliable option for body ringworm is a topical allylamine such as terbinafine 1% cream. Applied once or twice a day, it often clears tinea corporis within one to two weeks, faster than many azole creams. Spread the cream about 2 cm past the visible edge, keep the area clean and dry, and keep applying for roughly a week after the rash looks gone so the fungus does not return. Avoid steroid creams, which can make a fungal infection worse. Scalp or widespread ringworm clears faster with prescription oral antifungals, but those need a clinician. If a rash is not improving after two weeks of correct use, see a family physician or pharmacist.

### What is the cause of ringworm?
Ringworm is caused by dermatophytes, a group of fungi (mainly Trichophyton, Microsporum, and Epidermophyton species) that feed on keratin in skin, hair, and nails. It is not caused by a worm. You catch it through direct skin contact with an infected person or animal, or by touching contaminated objects such as towels, clothing, combs, locker-room floors, and sports mats. Pets, especially cats and dogs, are a common and often missed source. Warm, damp conditions help the fungus grow, so sweating, tight clothing, humidity, and shared communal showers raise the risk. People with diabetes, a weakened immune system, or untreated athlete's foot are more likely to develop ringworm and to spread it to other body areas.

### What is the best medicine for ringworm?
For most ringworm on the body, groin, or feet, the best first medicine is an over-the-counter topical antifungal. Terbinafine 1% cream and azoles such as clotrimazole, miconazole, or ketoconazole all work well, and terbinafine often clears body ringworm in a slightly shorter course. The right choice depends on where the rash is and how severe it is, and a pharmacist can help you pick one. Scalp ringworm and fungal nail infections are different: topical creams cannot reach the hair root or nail bed, so they need prescription oral antifungals such as terbinafine, itraconazole, or griseofulvin (often used for scalp ringworm in children). Widespread rashes or ones that fail topical treatment also need oral therapy prescribed by a clinician.

### What can be mistaken for ringworm?
Several non-fungal conditions form round or ring-shaped patches and are often mistaken for ringworm. Common look-alikes include nummular (discoid) eczema, granuloma annulare, psoriasis, pityriasis rosea, and contact dermatitis. The expanding bullseye rash of early Lyme disease (erythema migrans) can also resemble a large ring and needs different treatment. Because none of these are fungal, antifungal creams will not help them, and steroid creams used on a true fungal infection can make it spread and change its appearance. This is why a clinician may take a small skin scraping to check for fungus under the microscope or by culture before settling on a diagnosis. If you are unsure, a photo-based skin check can help sort a likely fungal rash from an inflammatory one.

---

# Actinic Keratosis: Causes, Treatment, and When It Becomes Precancer

URL: https://www.dermadex.ca/blog/actinic-keratosis-causes-treatment
Category: Conditions
Author: Mohsen Khoddami
Published: 2026-03-20

## TL;DR
Actinic keratosis is a precancerous skin growth caused by years of ultraviolet (UV) exposure (American Academy of Dermatology) | An estimated 40 to 60 percent of squamous cell carcinomas begin as untreated actinic keratoses (AAD) | Health Canada recommends broad-spectrum sunscreen of SPF 30 or higher, reapplied every 2 hours outdoors | Cryotherapy with liquid nitrogen clears roughly 67 to 99 percent of treated lesions (StatPearls, NCBI) | DermaDex connects Canadians to certified dermatologists for faster review of suspicious sun-damaged spots

*As of March 19, 2026.*

Actinic keratosis is one of the most common reasons Canadians are referred to a skin specialist, and one of the most treatable conditions when it is caught early. These rough, scaly patches form on skin that has taken in years of ultraviolet (UV) radiation, and a portion of them can progress to squamous cell carcinoma (SCC) if they are ignored. This guide explains what actinic keratosis is, why it forms, how dermatologists treat it, and when a sun-damaged spot deserves a closer look. [DermaDex](/) is a Canadian healthtech company that builds artificial intelligence (AI) assisted tools to help patients and clinicians get skin concerns reviewed sooner.

This article is general information, not a diagnosis. If you have a changing, bleeding, or non-healing spot, see a clinician.

## What is actinic keratosis?

**Short answer:** Actinic keratosis, also called solar keratosis, is a precancerous skin growth that appears as a rough, dry, scaly, or crusty patch on skin damaged by years of sun exposure. It is the most common precancer that dermatologists diagnose. The patches form in the outer layer of the skin when ultraviolet radiation damages skin cells called keratinocytes, and they are often easier to feel than to see, with a texture like fine sandpaper. Most people who develop one actinic keratosis go on to develop several, because the same sun exposure affects a wide area of skin rather than a single point.

The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-overview) classifies actinic keratosis as a precancer because a share of lesions can turn into skin cancer over time. Lesions show up most often on the face, scalp, ears, and the backs of the hands, and they tend to appear in adults over 40 who have accumulated decades of sun exposure. Some patches stay stable for years, while others grow, thicken, or change.

## What causes actinic keratosis?

**Short answer:** Actinic keratosis is caused by cumulative ultraviolet (UV) exposure, mostly from the sun and from indoor tanning beds. The more lifetime UV your skin absorbs, the higher your risk. Both ultraviolet A (UVA) and ultraviolet B (UVB) wavelengths damage the DNA inside skin cells, and that damage adds up across decades, which is why the condition is most common in adults over 40 and on the body areas that catch the most sun. The [World Health Organization (WHO)](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) classifies solar UV radiation as a known human carcinogen. Fair skin, light eyes and hair, a history of sunburns, outdoor work, and a weakened immune system all raise the risk further.

Risk is not the same for everyone. The table below shows the factors dermatologists weigh when they assess how likely a person is to develop actinic keratosis.

| Risk factor | Why it raises actinic keratosis risk |
|---|---|
| Fair skin (Fitzpatrick type I to II) | Less melanin means less natural protection from UV damage |
| Age over 40 | Reflects decades of accumulated sun exposure |
| Outdoor work or recreation | More lifetime hours of UV exposure |
| History of indoor tanning or sunburns | Adds concentrated UV damage to skin cell DNA |
| Weakened immune system | Reduces the body's ability to repair and clear damaged cells |

People with weakened immune systems, including organ transplant recipients, can develop actinic keratoses that are more numerous and that may progress faster, which is why this group is watched closely.

## What does actinic keratosis look like and where does it appear?

**Short answer:** Actinic keratosis usually looks like a rough, dry, scaly patch a few millimetres to a couple of centimetres across, often pink, red, tan, or skin-coloured, on chronically sun-exposed skin. The most common sites are the face, ears, bald scalp, lips, neck, forearms, and the backs of the hands. Because the condition sits on sun-exposed skin, location is a strong clue. The patches are frequently easier to feel than to see, and some develop a thick, horn-like surface. Others itch, burn, or feel tender, and their colour and size can change over time. On the lips, the condition is called actinic cheilitis.

A spot that grows quickly, bleeds, becomes a sore that will not heal, or hardens into a firm lump can signal squamous cell carcinoma and should be examined promptly. Because actinic keratosis can also be confused with harmless growths, our guide on [telling harmless spots from melanoma](/blog/seborrheic-keratosis-vs-melanoma) explains what dermatologists look for when they sort one from another.

## Will actinic keratosis turn into cancer?

**Short answer:** Most individual actinic keratoses do not become cancer, and some clear on their own, but a meaningful share progress to squamous cell carcinoma (SCC), a common skin cancer. Because there is no reliable way to predict which lesions will progress, dermatologists generally treat them rather than wait and watch. Estimates for how often a single lesion becomes SCC vary widely in the research, from well under 1 percent to as high as 16 percent per lesion per year, according to a [StatPearls review](https://www.ncbi.nlm.nih.gov/books/NBK557401/) on the National Center for Biotechnology Information (NCBI) Bookshelf. The risk rises with the number of lesions and the years of accumulated sun damage.

The [AAD reports](https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-overview) that an estimated 40 to 60 percent of squamous cell carcinomas begin as untreated actinic keratoses. That link is why clinicians treat the lesions and keep watching the surrounding skin, rather than dismissing a rough patch as cosmetic. You can read more about that cancer in our overview of [squamous cell carcinoma](/blog/squamous-cell-carcinoma-skin).

## How is actinic keratosis treated?

**Short answer:** Treatment depends on how many lesions you have and where they are. Common options include cryotherapy (freezing with liquid nitrogen), prescription creams such as 5-fluorouracil, photodynamic therapy, and minor procedures like curettage. Most are done in a clinic and clear the great majority of lesions. Dermatologists separate care into lesion-directed treatment, which targets one or a few visible spots, and field treatment, which covers a larger area of sun-damaged skin where many lesions, including ones too small to see, are present. Cryotherapy alone clears roughly 67 to 99 percent of treated lesions depending on freeze time, according to the [StatPearls review](https://www.ncbi.nlm.nih.gov/books/NBK557401/).

| Treatment | How it works | Best suited for | What to expect |
|---|---|---|---|
| Cryotherapy (liquid nitrogen) | Freezes and destroys the lesion | One or a few visible spots | Stinging, a blister or scab, healing over 1 to 2 weeks |
| 5-fluorouracil (5-FU) cream | Topical chemotherapy that targets abnormal cells | Many lesions across an area | Redness, crusting, and peeling for 2 to 4 weeks |
| Imiquimod cream | Activates the immune system against damaged cells | Field treatment of the face or scalp | Redness and inflammation over several weeks |
| Photodynamic therapy (PDT) | Light-activated solution destroys abnormal cells | Widespread or hard-to-treat areas | Burning during light exposure, redness for days |
| Curettage | Scraping the lesion, sometimes with cautery | Thick or horn-like lesions | A small wound that heals with a scab |

The [AAD notes](https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-treatment) there is no single best option for everyone, and the right choice is the one matched to your lesions and your skin. In Canada, in-office procedures such as cryotherapy and a diagnostic biopsy by a physician are generally covered by provincial health insurance like the Ontario Health Insurance Plan (OHIP) when they are medically necessary, while some prescription creams may carry a pharmacy cost depending on your drug coverage. Confirm the specifics with your clinic.

## How can you prevent actinic keratosis in Canada?

**Short answer:** Prevention comes down to sun protection. [Health Canada recommends](https://www.canada.ca/en/health-canada/services/sun-safety.html) broad-spectrum sunscreen of Sun Protection Factor (SPF) 30 or higher, shade during peak hours, protective clothing, and avoiding tanning beds. These steps lower the risk of both actinic keratosis and skin cancer. Canada's northern latitude does not remove ultraviolet (UV) risk, because the UV index climbs high in summer across the country, and snow, water, and sand reflect UV back onto the skin. The [Canadian Dermatology Association (CDA)](https://dermatology.ca/public-patients/sun-protection/), the Centers for Disease Control and Prevention (CDC), and Health Canada all give the same core advice on staying protected outdoors.

| Protection step | What to do |
|---|---|
| Sunscreen | Use broad-spectrum SPF 30 or higher, apply generously, and reapply every 2 hours |
| Timing | Limit sun exposure between 11 a.m. and 3 p.m. when the UV index is highest |
| Clothing | Wear a wide-brimmed hat, sunglasses, long sleeves, and tightly woven fabric |
| Tanning beds | Avoid them entirely, since they deliver concentrated UVA and UVB |

Reapply sunscreen after swimming or heavy sweating, and check the daily UV index before heading out, since it changes with season and cloud cover. Sun protection that starts in childhood lowers lifetime risk the most, but it helps at any age. For the screening side of prevention, see our guide on [skin cancer screening in Canada](/blog/skin-cancer-screening-canada).

## When should you see a dermatologist about actinic keratosis?

**Short answer:** See a clinician if you have a rough, scaly patch that lasts more than a few weeks, a spot that grows, bleeds, or hurts, or many sun-damaged patches across an area. A dermatologist can confirm the diagnosis and treat lesions before they progress to skin cancer. Self-checks help, but actinic keratosis and early skin cancer can look alike, and a dermatoscope or a biopsy is sometimes needed to tell them apart. People at higher risk, including fair-skinned adults, outdoor workers, and organ transplant recipients, benefit from regular skin checks. Specialist wait times in parts of Canada can stretch for months, which delays both diagnosis and treatment.

[DermaDex](/about) helps close that gap by connecting patients and primary-care clinicians to certified dermatologists for faster review of suspicious spots. If you have a concern you want looked at, [contact our team](/contact). This article is general information and not a substitute for a hands-on medical assessment, so book a visit if a spot is changing or you are unsure.

## Frequently asked questions about actinic keratosis?

**Short answer:** These are the questions Canadians most often ask about actinic keratosis, with brief evidence-based answers from a dermatologist. They cover whether the spots become cancer, the most effective treatments and creams, and the warning signs that mean a patch should be examined. None of this replaces a hands-on skin exam, so book a visit if a spot is changing, growing, or you are simply unsure about it.

### Will actinic keratosis turn into cancer?

Most individual actinic keratoses will not turn into cancer, and some clear on their own. A portion, though, can progress to squamous cell carcinoma (SCC), a common skin cancer. Estimates for how often a single lesion progresses range from under 1 percent to as high as 16 percent per year in the research summarized by StatPearls on the NCBI Bookshelf. The American Academy of Dermatology reports that 40 to 60 percent of squamous cell carcinomas begin as untreated actinic keratoses. Because there is no reliable way to predict which lesions will progress, dermatologists generally treat them rather than wait. If a patch grows quickly, bleeds, or becomes a sore that will not heal, have it examined promptly.

### What is the best treatment for actinic keratosis?

There is no single best treatment for everyone, and the right choice depends on how many lesions you have, where they are, and your skin. For one or a few spots, cryotherapy with liquid nitrogen is the most common in-office option and clears most treated lesions. When there are many lesions across an area of sun-damaged skin, dermatologists often choose field treatment with a prescription cream such as 5-fluorouracil (5-FU) or imiquimod, or photodynamic therapy. Thick, horn-like lesions may be scraped, a procedure called curettage. The American Academy of Dermatology stresses that the best option is the one matched to your specific case, chosen with your clinician. Many people use a combination of approaches over time.

### When to worry about actinic keratosis?

Worry, and seek care, when a spot changes. Warning signs include a patch that grows quickly, becomes thick or firm, bleeds, itches or hurts, or turns into a sore that does not heal. Any of these can signal a shift toward squamous cell carcinoma. You should also act if you have many lesions, if you are immune-suppressed for example after an organ transplant, or if a previously treated spot returns. A single stable, rough patch is lower risk, but because actinic keratosis and early skin cancer can look similar, a dermatologist's exam is the reliable way to tell them apart. When in doubt, get it checked rather than watch it for months.

### What is the best cream for actinic keratosis?

The prescription cream most often considered the strongest for field treatment is 5-fluorouracil (5-FU), a topical chemotherapy that targets abnormal cells across an area of skin. Other effective options include imiquimod, which works through the immune system, diclofenac gel, and tirbanibulin. Each has a different schedule and side-effect pattern, and 5-FU and imiquimod typically cause weeks of redness, crusting, and peeling as they work, which is expected. There is no single best cream for every patient. The choice depends on the number of lesions, their location, your skin, and how much visible reaction you can manage. A dermatologist matches the cream to your case, and over-the-counter moisturizers or acid creams are not a substitute for prescription treatment.

## Sources

- [American Academy of Dermatology (AAD), "Actinic keratosis: Overview."](https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-overview)
- [American Academy of Dermatology (AAD), "Actinic keratosis: Diagnosis and treatment."](https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-treatment)
- [American Academy of Dermatology (AAD), "Squamous cell carcinoma of the skin."](https://www.aad.org/public/diseases/skin-cancer/types/common/scc)
- [StatPearls, "Actinic Keratosis," National Center for Biotechnology Information (NCBI) Bookshelf.](https://www.ncbi.nlm.nih.gov/books/NBK557401/)
- [Centers for Disease Control and Prevention (CDC), "About Skin Cancer."](https://www.cdc.gov/skin-cancer/about/index.html)
- [Centers for Disease Control and Prevention (CDC), "Skin Cancer Prevention."](https://www.cdc.gov/skin-cancer/prevention/index.html)
- [Health Canada, "Sun safety."](https://www.canada.ca/en/health-canada/services/sun-safety.html)
- [World Health Organization (WHO), "Ultraviolet radiation."](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation)
- [Canadian Dermatology Association (CDA), "Sun protection."](https://dermatology.ca/public-patients/sun-protection/)

## FAQ
### Will actinic keratosis turn into cancer?
Most individual actinic keratoses will not turn into cancer, and some clear on their own. A portion, though, can progress to squamous cell carcinoma (SCC), a common skin cancer. Estimates for how often a single lesion progresses range from under 1 percent to as high as 16 percent per year in the research summarized by StatPearls on the NCBI Bookshelf. The American Academy of Dermatology reports that 40 to 60 percent of squamous cell carcinomas begin as untreated actinic keratoses. Because there is no reliable way to predict which lesions will progress, dermatologists generally treat them rather than wait. If a patch grows quickly, bleeds, or becomes a sore that will not heal, have it examined promptly.

### What is the best treatment for actinic keratosis?
There is no single best treatment for everyone, and the right choice depends on how many lesions you have, where they are, and your skin. For one or a few spots, cryotherapy with liquid nitrogen is the most common in-office option and clears most treated lesions. When there are many lesions across an area of sun-damaged skin, dermatologists often choose field treatment with a prescription cream such as 5-fluorouracil (5-FU) or imiquimod, or photodynamic therapy. Thick, horn-like lesions may be scraped, a procedure called curettage. The American Academy of Dermatology stresses that the best option is the one matched to your specific case, chosen with your clinician. Many people use a combination of approaches over time.

### When to worry about actinic keratosis?
Worry, and seek care, when a spot changes. Warning signs include a patch that grows quickly, becomes thick or firm, bleeds, itches or hurts, or turns into a sore that does not heal. Any of these can signal a shift toward squamous cell carcinoma. You should also act if you have many lesions, if you are immune-suppressed for example after an organ transplant, or if a previously treated spot returns. A single stable, rough patch is lower risk, but because actinic keratosis and early skin cancer can look similar, a dermatologist's exam is the reliable way to tell them apart. When in doubt, get it checked rather than watch it for months.

### What is the best cream for actinic keratosis?
The prescription cream most often considered the strongest for field treatment is 5-fluorouracil (5-FU), a topical chemotherapy that targets abnormal cells across an area of skin. Other effective options include imiquimod, which works through the immune system, diclofenac gel, and tirbanibulin. Each has a different schedule and side-effect pattern, and 5-FU and imiquimod typically cause weeks of redness, crusting, and peeling as they work, which is expected. There is no single best cream for every patient. The choice depends on the number of lesions, their location, your skin, and how much visible reaction you can manage. A dermatologist matches the cream to your case, and over-the-counter moisturizers or acid creams are not a substitute for prescription treatment.

---

# Seborrheic Keratosis vs Melanoma: How to Tell the Difference

URL: https://www.dermadex.ca/blog/seborrheic-keratosis-vs-melanoma
Category: Conditions
Author: Mohsen Khoddami
Published: 2026-03-08

## TL;DR
Seborrheic keratoses are benign growths that do not turn into skin cancer, per the American Academy of Dermatology (AAD). | The ABCDE rule flags melanoma: Asymmetry, Border, Color, Diameter over 6 mm, and Evolving (AAD). | When melanoma is found and treated before it spreads, the 5-year survival rate is about 99% (AAD). | A black, waxy stuck-on bump is usually a seborrheic keratosis, but only dermoscopy or biopsy can rule out melanoma. | DermaDex connects Canadians to certified dermatologists and stores scans on PHIPA-compliant Canadian servers.

*As of March 7, 2026.*

Few skin spots cause more worry than a dark, rough patch that seems to appear out of nowhere. Two of the most common explanations are a seborrheic keratosis, which is harmless, and melanoma, which is the most dangerous form of skin cancer. They can resemble each other closely enough to fool an untrained eye, and that overlap is exactly why people end up either anxious for no reason or falsely reassured when they should not be. As a dermatologist, I check spots like these every week. This guide explains how clinicians tell the two apart, which warning signs deserve a professional look, and how Canadians can get a spot reviewed without waiting months.

## What is the difference between seborrheic keratosis and melanoma?

**Short answer:** A seborrheic keratosis is a benign (non-cancerous) growth of surface skin cells, while melanoma is a malignant cancer that starts in pigment-producing cells called melanocytes. One is harmless and the other can be life-threatening if it spreads. A seborrheic keratosis stays on the skin surface and never turns into cancer. Melanoma can grow downward and travel through the lymph system and blood, which is why early detection matters so much. The two can look alike, especially when a keratosis is dark, so visual checks help but never replace a trained exam.

A seborrheic keratosis sits on top of the skin and feels waxy, warty, or scaly. It does not invade deeper tissue and does not spread to other organs. Melanoma behaves differently: it grows from melanocytes, can invade downward into the skin, and can travel through the lymphatic system and blood. According to the [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/a-z/seborrheic-keratoses-overview), seborrheic keratoses are among the most common non-cancerous growths in older adults, while melanoma, described by the [U.S. Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/skin-cancer/about/index.html), is the skin cancer most likely to spread and cause death.

## What does a seborrheic keratosis look like?

**Short answer:** A seborrheic keratosis usually looks like a waxy, warty, "stuck-on" bump in shades of tan, brown, or black, with a sharply defined edge that seems to sit on the skin surface rather than grow out of it. The surface is often rough, dull, and crumbly, sometimes with tiny clogged pores or seed-like cysts visible up close. Most are round to oval with a clean border, and they commonly appear on the back, chest, face, and scalp. They multiply with age, and a single growth is rarely a cause for concern on its own.

Most seborrheic keratoses share a recognizable look. They have a pasted-on appearance, as if you could pick them off with a fingernail. The surface is often rough, dull, and crumbly, with tiny clogged pores or seed-like cysts visible up close. Colors range from light tan to dark brown or near-black. They are frequently round to oval with a clean border. People develop them on the back, chest, face, and scalp. According to [StatPearls on the National Institutes of Health (NIH) bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK545285/), these growths increase steadily in number with age and are rarely a cause for concern on their own.

## Why do seborrheic keratoses appear in the first place?

**Short answer:** Seborrheic keratoses are driven mainly by age and genetics, not by sun damage or poor hygiene. They form when surface skin cells (keratinocytes) build up in a thickened, benign growth. Most people who develop one go on to grow several over the years, and they often run in families. They are not contagious, so you cannot catch them from another person or spread them across your own body by touch. Sun exposure may play a small role in some cases, but unlike melanoma, ultraviolet (UV) light is not the primary cause. There is nothing you did to bring them on.

These growths tend to run in families, and most people who get one go on to develop several over the years. Research summarized by [StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK545285/) links many seborrheic keratoses to acquired mutations in genes such as FGFR3 and PIK3CA, which is why they multiply with age. They are not contagious, and you cannot catch them from another person or spread them around your own body by touch. Sun exposure may play a small role in some cases, but unlike melanoma, ultraviolet (UV) light is not the primary driver. There is nothing you did to cause them.

## How can you tell a seborrheic keratosis from a melanoma?

**Short answer:** Seborrheic keratoses look "stuck-on," even-colored, and well-defined, while melanomas tend to be flat or slightly raised with uneven borders, multiple colors, and a tendency to change. The ABCDE rule helps flag melanoma: Asymmetry, Border irregularity, Color variation, Diameter over 6 millimeters, and Evolving over time. Seborrheic keratoses usually fail these flags because they are symmetric, evenly colored, and stable for years, while melanomas often check several boxes at once. A deeply pigmented keratosis can still mimic melanoma, so these rules guide you but never replace a trained assessment.

The single most useful screening tool for the public is the ABCDE rule from the [AAD](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes): Asymmetry, Border irregularity, Color variation, Diameter over 6 millimeters, and Evolving over time. Seborrheic keratoses usually fail to trigger these flags because they are symmetric, evenly colored, and stable. Melanomas often check several boxes at once. The catch is that some deeply pigmented seborrheic keratoses can mimic melanoma, and some melanomas can masquerade as a harmless bump. That is why visual rules guide you but do not replace a trained assessment.

| Feature | Seborrheic keratosis | Melanoma |
|---|---|---|
| Texture | Waxy, warty, "stuck-on" | Flat or raised, often smooth then changing |
| Border | Sharp, well-defined | Irregular, blurred, or notched |
| Color | Uniform tan, brown, or black | Mixed shades: brown, black, red, white, blue |
| Symmetry | Usually symmetric | Often asymmetric |
| Change over time | Stable for years | Grows, darkens, or evolves |
| Surface clues | Seed-like cysts, clogged pores | Bleeding, crusting, ulceration |

| ABCDE letter | What to look for |
|---|---|
| A: Asymmetry | One half does not match the other |
| B: Border | Edges are ragged, notched, or blurred |
| C: Color | More than one color in a single spot |
| D: Diameter | Larger than 6 mm, about a pencil eraser |
| E: Evolving | Changing in size, shape, color, or symptoms |

## When should you get a skin spot checked by a doctor?

**Short answer:** Get any spot checked if it is new in adulthood, changing, bleeding, itchy, or simply looks different from your other moles. A helpful guide is the "ugly duckling" sign: most of your moles resemble one another, so the one that stands out deserves attention. New or changing spots after age 40 warrant a closer look, since melanoma risk rises with age and cumulative sun exposure. A sudden burst of many keratoses at once is uncommon but worth mentioning to a doctor. When in doubt, have the spot assessed rather than watch and wait.

A practical guide is the "ugly duckling" sign: most of your moles tend to resemble one another, so the one that stands out deserves attention. New or changing spots after age 40 also warrant a closer look, since melanoma risk rises with age and cumulative sun exposure, as noted by the [CDC](https://www.cdc.gov/skin-cancer/risk-factors/index.html). One uncommon but important pattern is the sudden eruption of many seborrheic keratoses at once, which [StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK545285/) describes as a possible marker of internal disease in rare cases. If you are unsure whether a growth is a harmless keratosis or something more, that uncertainty alone is a good reason to book a check. You can [contact our team](/contact) to start.

## How do dermatologists diagnose and remove these spots?

**Short answer:** Dermatologists use a handheld dermatoscope to see structures invisible to the naked eye, and they confirm anything suspicious with a skin biopsy. Under the dermatoscope, a clinician can spot features specific to seborrheic keratoses, such as milia-like cysts and comedo-like openings, versus the disordered pigment networks seen in melanoma. When the picture is unclear, a biopsy sends tissue to a pathologist for a definitive answer. A confirmed keratosis can be removed by freezing, scraping, or shaving, usually for comfort or appearance. Melanoma is managed very differently, through surgical removal and staging.

A dermatoscope magnifies and lights the spot so the clinician can see patterns specific to seborrheic keratoses, such as milia-like cysts and comedo-like openings, versus the disordered pigment networks seen in melanoma. We explain this tool in our guide on [how dermoscopy works](/blog/dermoscopy-explained). When the picture is unclear, a biopsy sends tissue to a pathologist for a definitive answer. Removal of a confirmed seborrheic keratosis is usually for comfort or cosmetic reasons and is done with cryotherapy (freezing), curettage (scraping), or shave excision. Melanoma management is entirely different and is driven by surgical removal and staging, separate from how we handle a benign growth.

| Step | Seborrheic keratosis | Suspicious or melanoma-like spot |
|---|---|---|
| First look | Dermatoscope exam | Dermatoscope exam |
| Confirmation | Often clinical, biopsy if unclear | Biopsy almost always |
| Typical treatment | Freeze, scrape, or shave | Surgical excision and staging |
| Urgency | Elective, cosmetic | Time-sensitive |

## Is a seborrheic keratosis dangerous?

**Short answer:** No. A seborrheic keratosis is benign and does not turn into skin cancer. The only real risks are irritation, itching, or bleeding when it catches on clothing, and the chance that a melanoma is mistaken for one. The growth itself has no malignant potential, which reassures the millions of people who carry them. The genuine danger is misidentification: because a dark keratosis and an early melanoma can look alike, a spot you assume is harmless could occasionally be cancer. If a long-standing growth suddenly changes, bleeds without injury, or starts to itch and grow, treat that as a reason for assessment rather than reassurance.

The growth itself carries no malignant potential, which is reassuring for the millions of people who have them. The genuine danger is misidentification. Because a dark seborrheic keratosis and an early melanoma can look similar, a spot you assume is harmless could occasionally be cancer, and a real melanoma could be dismissed as "just a keratosis." This is the same reason we encourage prompt checks for other lesions, including the basal cell type covered in our article on [basal cell carcinoma signs and treatment](/blog/basal-cell-carcinoma-signs-treatment). If a long-standing keratosis suddenly changes, bleeds without injury, or starts to itch and grow, treat that change as a reason for assessment rather than reassurance.

## How can Canadians get a skin spot checked quickly?

**Short answer:** Canadians can start with a family doctor or a virtual dermatology service, then move to in-person care if a biopsy is needed. Tools like DermaDex help triage which spots need urgent attention while specialist wait times remain long. Access to dermatology in Canada is uneven, and referral waits can stretch for months in many provinces, especially outside major cities. A medically necessary biopsy is covered by provincial plans such as the Ontario Health Insurance Plan (OHIP), while purely cosmetic removal of a confirmed keratosis usually is not. Protecting your skin from ultraviolet (UV) exposure also lowers melanoma risk over time.

Access to dermatology in Canada is uneven, and waits for a specialist referral can stretch for months in many provinces, especially outside major cities. A medically necessary biopsy is covered by provincial plans such as the Ontario Health Insurance Plan (OHIP), while purely cosmetic removal of a confirmed seborrheic keratosis usually is not. [DermaDex](/) is a Canadian company that pairs artificial intelligence (AI) assisted triage with certified dermatologists, so worrying spots can be flagged sooner. Our scans are stored on Canadian servers under the Personal Health Information Protection Act (PHIPA). You can read more about our model on our [about page](/about), and you can learn how the technology works in [how AI skin checks work](/blog/how-ai-skin-checks-work). Protecting your skin from UV exposure, as [Health Canada](https://www.canada.ca/en/health-canada/services/sun-safety.html) advises, also lowers melanoma risk over time.

This article is general information and is not a diagnosis. A photo or description cannot replace an in-person exam. If a spot worries you, please have it assessed by a clinician.

## What is the best way to get rid of seborrheic keratosis?

**Short answer:** The best removal method depends on the size, location, and how thick the growth is. In a clinic, dermatologists most often use cryotherapy (freezing with liquid nitrogen), curettage (scraping after numbing), shave excision, or electrocautery. These are quick office procedures with low risk when done by a professional. There is no single "best" option for everyone, and a clinician will match the method to your skin. Because a seborrheic keratosis is benign, removal is usually elective and chosen for comfort or appearance. Keep in mind that cosmetic removal is often not covered by provincial health plans. Avoid picking, cutting, or burning growths at home, since that risks infection, scarring, and, more seriously, destroying a spot that should have been examined to rule out melanoma first.

## What is the root cause of seborrheic keratosis?

**Short answer:** The root cause is a combination of aging skin and genetics rather than anything you did. These growths form when surface skin cells multiply into a thickened, benign deposit. According to [StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK545285/), many seborrheic keratoses carry acquired mutations in genes such as FGFR3 and PIK3CA, which helps explain why they tend to run in families and increase in number with age. They are not caused by poor hygiene, and they are not contagious, so you cannot pass them to others or spread them across your own body. Unlike melanoma, ultraviolet (UV) light is not the main driver, though sun exposure may contribute in some cases. If many appear suddenly at once, mention it to your doctor, since that uncommon pattern occasionally warrants further review.

## What happens if seborrheic keratosis is left untreated?

**Short answer:** In most cases, nothing harmful happens if you leave a seborrheic keratosis alone, because it is benign and does not become cancerous. Many people keep theirs for life without any treatment. Over time, a growth may slowly enlarge, darken, or become raised, and it can get irritated, itchy, or bleed if it rubs against clothing, jewelry, or a waistband. None of that means it has turned into cancer. The one situation that needs attention is change you cannot explain: a spot you assumed was a keratosis that suddenly grows, shifts color, develops irregular borders, or bleeds without being knocked. Because melanoma can occasionally mimic a harmless keratosis, any meaningful change is a reason to have the spot reassessed by a clinician rather than continuing to ignore it.

## Is there a cream that gets rid of seborrheic keratosis?

**Short answer:** There is no reliable over-the-counter cream that removes a seborrheic keratosis. A prescription topical hydrogen peroxide 40 percent solution received U.S. Food and Drug Administration (FDA) approval in 2017 for raised seborrheic keratoses, but it was later discontinued by its maker and was never a mainstay in Canada. Some moisturizers and acid-based products may soften the surface or reduce flaking, yet they do not eliminate the growth. In-office procedures such as freezing, scraping, or shaving remain far more effective and predictable. Be cautious with online "mole removal" creams and acid kits, which can burn healthy skin, cause scarring, and dangerously destroy a spot that should have been examined first. If a growth bothers you, the safer path is an assessment with a clinician who can confirm it is benign and remove it properly.

## Sources

- American Academy of Dermatology (AAD), "Seborrheic Keratoses: Overview." https://www.aad.org/public/diseases/a-z/seborrheic-keratoses-overview
- American Academy of Dermatology (AAD), "Melanoma." https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma
- American Academy of Dermatology (AAD), "What to look for: ABCDEs of melanoma." https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes
- StatPearls, National Institutes of Health (NIH) National Library of Medicine, "Seborrheic Keratosis." https://www.ncbi.nlm.nih.gov/books/NBK545285/
- U.S. Centers for Disease Control and Prevention (CDC), "About Skin Cancer." https://www.cdc.gov/skin-cancer/about/index.html
- U.S. Centers for Disease Control and Prevention (CDC), "Skin Cancer Risk Factors." https://www.cdc.gov/skin-cancer/risk-factors/index.html
- Public Health Agency of Canada, "Melanoma skin cancer." https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/melanoma-skin-cancer.html
- Health Canada, "Sun safety." https://www.canada.ca/en/health-canada/services/sun-safety.html
- Canadian Dermatology Association (CDA), "Public and Patients." https://dermatology.ca/public-patients/

## FAQ
### What is the best way to get rid of seborrheic keratosis?
The best removal method depends on the size, location, and how thick the growth is. In a clinic, dermatologists most often use cryotherapy (freezing with liquid nitrogen), curettage (scraping after numbing), shave excision, or electrocautery. These are quick office procedures with low risk when done by a professional. There is no single "best" option for everyone, and a clinician will match the method to your skin. Because a seborrheic keratosis is benign, removal is usually elective and chosen for comfort or appearance. Keep in mind that cosmetic removal is often not covered by provincial health plans. Avoid picking, cutting, or burning growths at home, since that risks infection, scarring, and, more seriously, destroying a spot that should have been examined to rule out melanoma first.

### What is the root cause of seborrheic keratosis?
The root cause is a combination of aging skin and genetics rather than anything you did. These growths form when surface skin cells multiply into a thickened, benign deposit. According to StatPearls, many seborrheic keratoses carry acquired mutations in genes such as FGFR3 and PIK3CA, which helps explain why they tend to run in families and increase in number with age. They are not caused by poor hygiene, and they are not contagious, so you cannot pass them to others or spread them across your own body. Unlike melanoma, ultraviolet (UV) light is not the main driver, though sun exposure may contribute in some cases. If many appear suddenly at once, mention it to your doctor, since that uncommon pattern occasionally warrants further review.

### What happens if seborrheic keratosis is left untreated?
In most cases, nothing harmful happens if you leave a seborrheic keratosis alone, because it is benign and does not become cancerous. Many people keep theirs for life without any treatment. Over time, a growth may slowly enlarge, darken, or become raised, and it can get irritated, itchy, or bleed if it rubs against clothing, jewelry, or a waistband. None of that means it has turned into cancer. The one situation that needs attention is change you cannot explain: a spot you assumed was a keratosis that suddenly grows, shifts color, develops irregular borders, or bleeds without being knocked. Because melanoma can occasionally mimic a harmless keratosis, any meaningful change is a reason to have the spot reassessed by a clinician rather than continuing to ignore it.

### Is there a cream that gets rid of seborrheic keratosis?
There is no reliable over-the-counter cream that removes a seborrheic keratosis. A prescription topical hydrogen peroxide 40 percent solution received U.S. Food and Drug Administration (FDA) approval in 2017 for raised seborrheic keratoses, but it was later discontinued by its maker and was never a mainstay in Canada. Some moisturizers and acid-based products may soften the surface or reduce flaking, yet they do not eliminate the growth. In-office procedures such as freezing, scraping, or shaving remain far more effective and predictable. Be cautious with online "mole removal" creams and acid kits, which can burn healthy skin, cause scarring, and dangerously destroy a spot that should have been examined first. If a growth bothers you, the safer path is an assessment with a clinician who can confirm it is benign and remove it properly.

---

# Keratosis Pilaris: Why You Get Chicken Skin and How to Smooth It

URL: https://www.dermadex.ca/blog/keratosis-pilaris-treatment
Category: Conditions
Author: Maryam Sobhkhiz Sabet
Published: 2026-02-23

## TL;DR
Keratosis pilaris is harmless and affects up to 50-80% of adolescents and about 40% of adults (StatPearls, NIH) | Moisturizing plus a keratolytic such as urea 10-20% or lactic acid smooths most bumps within 4-6 weeks (AAD) | There is no cure, but keratosis pilaris often fades on its own by your 30s | KP is strongly linked to dry skin and eczema, and harsh scrubbing makes it worse | Canadian dermatology wait times can stretch for months (CIHI), so your family physician is the first stop

*As of February 22, 2026.*

Those small, rough bumps on the backs of your arms have a name, and a reassuring one. It is keratosis pilaris, often called "chicken skin," and as a family physician I see it almost every week. The first thing I tell patients is that it is harmless. It is not an infection, it is not dangerous, and it does not mean you are doing anything wrong with your skin care. It can be stubborn, but it responds well to the right routine. [DermaDex](/) is a Canadian health technology company that connects patients with certified dermatologists and uses artificial intelligence (AI) to help triage skin concerns, and questions about chicken skin are some of the most common ones we receive.

## What is keratosis pilaris, and why is it called chicken skin?

**Short answer:** Keratosis pilaris (KP) is a very common, harmless condition where dead skin cells plug hair follicles, creating small rough bumps that look and feel like permanent goosebumps or plucked poultry skin. It is not contagious and never turns into cancer. According to a [StatPearls review indexed by the United States National Institutes of Health (NIH)](https://www.ncbi.nlm.nih.gov/books/NBK546708/), keratosis pilaris affects roughly 50 to 80 percent of adolescents and about 40 percent of adults, which makes it one of the most frequent skin findings I see in primary care.

The bumps usually appear on the upper arms, the front of the thighs, the buttocks, and sometimes the cheeks in children. Each bump sits over a single hair follicle. The skin around them can look slightly pink or red, and the surface often feels like fine sandpaper. The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-overview) describes the texture as the hallmark sign, and it tends to be more noticeable in dry winter months, which matters in the Canadian climate where indoor heating pulls moisture out of skin for half the year.

## What causes the rough bumps on your arms?

**Short answer:** Keratosis pilaris happens when keratin, a protein that protects the skin, builds up and plugs the opening of a hair follicle. That plug traps the fine hair underneath and forms a small, firm bump. The [AAD notes](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-causes) that the exact trigger is not fully understood, but the tendency to form these plugs runs in families and is linked to dry skin and eczema.

Genetics play the biggest role. Keratosis pilaris often passes from parent to child, and many of my patients can point to a sibling or parent with the same arms. It is also closely tied to dry skin and to atopic dermatitis, the most common form of eczema. People with very dry skin or a history of eczema are more likely to have it, and flares often worsen in low humidity. Hormonal shifts matter too, which is why KP frequently appears or worsens during the teenage years and sometimes during pregnancy. It is not caused by poor hygiene, and scrubbing harder will not clear it.

## How do you get rid of keratosis pilaris at home?

**Short answer:** You cannot scrub keratosis pilaris away, but a steady routine of gentle exfoliation plus heavy moisturizing smooths most bumps within four to six weeks. The [AAD recommends](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-treatment) short, warm (not hot) showers, a mild cleanser, a keratolytic cream that dissolves the keratin plug, and a thick moisturizer applied while skin is still damp. Consistency matters more than intensity.

Here is the routine I give patients, and it mirrors [AAD self-care guidance](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-self-care):

- Keep showers short and warm rather than hot, since hot water strips natural oils.
- Use a fragrance-free, gentle cleanser instead of harsh soaps or rough loofahs.
- Apply a keratolytic product (one with urea, lactic acid, salicylic acid, or an alpha hydroxy acid) a few times a week.
- Moisturize at least twice a day, especially within a few minutes of bathing while skin is damp, which is the core of [the AAD's tips to relieve dry skin](https://www.aad.org/public/everyday-care/skin-care-basics/dry/dermatologists-tips-relieve-dry-skin).
- Run a humidifier during dry Canadian winters to add moisture back into the air.

Avoid picking or aggressive physical scrubbing. It irritates the follicles, can cause dark marks or scarring, and tends to make the redness worse. Improvement is gradual, so give any routine a full four to six weeks before deciding it is not working.

## Which ingredients actually smooth keratosis pilaris bumps?

**Short answer:** The ingredients with the best track record are humectants and keratolytics that loosen the keratin plug and pull water into the skin: urea, lactic acid, salicylic acid, glycolic acid, and ceramide-based moisturizers. The AAD lists these as the active components in over-the-counter creams that smooth KP. None of them cure the condition, but used consistently they soften the bumps and reduce roughness.

| Ingredient | Type | Common strength (over the counter) | How it helps keratosis pilaris |
|---|---|---|---|
| Urea | Humectant and keratolytic | 10% to 20% | Softens and dissolves the keratin plug while drawing water into the skin |
| Lactic acid | Alpha hydroxy acid (AHA) | 5% to 12% | Loosens dead cells and gently exfoliates the surface of each bump |
| Salicylic acid | Beta hydroxy acid | 0.5% to 2% | Penetrates oil in the follicle and helps clear the plug |
| Glycolic acid | Alpha hydroxy acid (AHA) | 5% to 10% | Speeds cell turnover and smooths rough texture over time |
| Ceramide moisturizer | Barrier repair moisturizer | Not applicable | Rebuilds the skin barrier and reduces the dryness that worsens KP |

A practical approach is to pair one exfoliating acid with one barrier moisturizer rather than stacking many actives at once. Acids can sting or cause redness on sensitive skin, so start a few times per week and build up slowly. If your skin becomes irritated, pull back and focus on moisturizing until it settles.

## When should you see a doctor about chicken skin in Canada?

**Short answer:** Keratosis pilaris itself rarely needs a doctor, but book a visit if the bumps become red, itchy, painful, or spreading, or if you are not sure whether a spot is KP or something else. In Canada, your family physician is the first stop and the visit is covered by your provincial plan, such as the Ontario Health Insurance Plan (OHIP). We can confirm the diagnosis, rule out look-alikes, and prescribe stronger creams if needed.

Most cases never require a specialist. When they do, referral wait times can be long. The [Canadian Institute for Health Information (CIHI)](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) tracks the strain on specialty access across the country, and dermatology referrals in many provinces stretch into months. That gap is part of why DermaDex exists. Our platform lets you share photos for an early read, and you can learn more about how [AI skin checks](/blog/how-ai-skin-checks-work) support, but never replace, a clinician. If a bump looks unusual, changes, bleeds, or does not fit the typical KP pattern, have it assessed in person. You can read more about distinguishing harmless growths from cancer in our guide to [seborrheic keratosis and melanoma](/blog/seborrheic-keratosis-vs-melanoma), or [contact our team](/contact) to ask about a review. This article is general information and not a diagnosis, so when in doubt, talk to a clinician.

## Can keratosis pilaris be cured for good?

**Short answer:** There is no permanent cure for keratosis pilaris, but it is very manageable and often fades on its own with age. The AAD notes that many people see clear improvement by their 30s, and bumps frequently become less noticeable over time even without treatment. The goal of any routine is to control roughness and redness, not to eliminate the condition forever.

Because KP is built into how some people's follicles behave, the bumps tend to return if you stop your routine. That is normal and not a sign of failure. Think of it like managing dry skin: ongoing maintenance keeps it under control. Prescription options exist for stubborn cases, including stronger keratolytics and topical retinoids, and a family physician or dermatologist can guide those. The [Canadian Dermatology Association (CDA)](https://dermatology.ca/public-patients/) and the AAD both stress gentle, consistent care over harsh treatments. Keeping skin moisturized through dry winters and protecting it from sun damage, as Health Canada recommends in its [sun safety guidance](https://www.canada.ca/en/health-canada/services/sun-safety/sun-safety-basics.html), supports overall skin health while you manage the bumps.

## What else do people ask about keratosis pilaris?

### How do I get rid of my keratosis pilaris?

You cannot remove keratosis pilaris permanently, but you can smooth it with a steady routine. The AAD recommends gentle exfoliation using a cream with urea, lactic acid, salicylic acid, or glycolic acid a few times a week, paired with heavy, fragrance-free moisturizer applied twice daily while skin is still damp. Keep showers short and warm rather than hot, skip harsh scrubbing and loofahs, and use a humidifier in dry months. Give any routine four to six weeks before judging it. Avoid picking, which can cause dark spots or scarring. If bumps stay red, itchy, or inflamed despite consistent care, your family physician can prescribe a stronger keratolytic or a topical retinoid and confirm the diagnosis.

### What is the main cause of keratosis pilaris?

The main cause is a buildup of keratin, a protective skin protein, that plugs hair follicles and traps the fine hair underneath, forming a small bump. The AAD explains that the tendency to form these plugs is largely genetic and runs in families. It is closely linked to dry skin and to atopic dermatitis, a common form of eczema, so people with either are more likely to have it. Flares often worsen in low humidity, which is why many Canadians notice it most in winter. Hormonal changes during the teenage years can trigger or worsen it. Keratosis pilaris is not caused by poor hygiene, infection, or anything you did wrong, and scrubbing harder will not make it go away.

### What vitamin deficiency causes keratosis pilaris?

No vitamin deficiency causes ordinary keratosis pilaris. This is a common misconception. True keratosis pilaris is a genetic, follicle-plugging condition, not a sign that you are missing a nutrient. There is a separate, rare condition called phrynoderma, linked to vitamin A and other nutritional deficiencies, that can look similar with rough, bumpy skin. Phrynoderma is uncommon in Canada and appears in the setting of significant malnutrition, not in a typical healthy person with bumpy arms. Taking vitamin A or other supplements will not clear standard keratosis pilaris and high-dose vitamin A can be harmful. If you have widespread rough skin alongside other symptoms, see your family physician to sort out the cause rather than self-treating with supplements.

### What can be mistaken for keratosis pilaris?

Several harmless and a few less harmless conditions can resemble keratosis pilaris. Folliculitis, which is inflammation or infection of hair follicles, can look similar but is often more red, tender, or pus-filled. Acne can appear as bumps on the arms or back. Atopic dermatitis (eczema) frequently overlaps with KP and can coexist. Other look-alikes include milia, small white cysts, and a condition called Darier disease. The bumps of KP are typically small, evenly scattered, painless, and rough to the touch, sitting over individual follicles. Because some conditions look alike, a clinician's exam is the most reliable way to confirm keratosis pilaris. If bumps are painful, rapidly changing, bleeding, or limited to one spot, have them checked in person rather than assuming it is chicken skin.

## Sources

- [American Academy of Dermatology (AAD), "Keratosis Pilaris: Overview"](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-overview)
- [American Academy of Dermatology (AAD), "Keratosis Pilaris: Causes"](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-causes)
- [American Academy of Dermatology (AAD), "Keratosis Pilaris: Diagnosis and Treatment"](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-treatment)
- [American Academy of Dermatology (AAD), "Keratosis Pilaris: Self-Care"](https://www.aad.org/public/diseases/a-z/keratosis-pilaris-self-care)
- [American Academy of Dermatology (AAD), "Dermatologists' Tips to Relieve Dry Skin"](https://www.aad.org/public/everyday-care/skin-care-basics/dry/dermatologists-tips-relieve-dry-skin)
- [StatPearls, National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), "Keratosis Pilaris"](https://www.ncbi.nlm.nih.gov/books/NBK546708/)
- [Canadian Dermatology Association (CDA), "Public and Patients"](https://dermatology.ca/public-patients/)
- [Canadian Institute for Health Information (CIHI), "Wait Times for Priority Procedures in Canada"](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada)
- [Health Canada, "Sun Safety Basics"](https://www.canada.ca/en/health-canada/services/sun-safety/sun-safety-basics.html)

## FAQ
### How do I get rid of my keratosis pilaris?
You cannot remove keratosis pilaris permanently, but you can smooth it with a steady routine. The American Academy of Dermatology recommends gentle exfoliation using a cream with urea, lactic acid, salicylic acid, or glycolic acid a few times a week, paired with heavy, fragrance-free moisturizer applied twice daily while skin is still damp. Keep showers short and warm rather than hot, skip harsh scrubbing and loofahs, and use a humidifier in dry months. Give any routine four to six weeks before judging it. Avoid picking, which can cause dark spots or scarring. If bumps stay red, itchy, or inflamed despite consistent care, your family physician can prescribe a stronger keratolytic or a topical retinoid and confirm the diagnosis.

### What is the main cause of keratosis pilaris?
The main cause is a buildup of keratin, a protective skin protein, that plugs hair follicles and traps the fine hair underneath, forming a small bump. The American Academy of Dermatology explains that the tendency to form these plugs is largely genetic and runs in families. It is closely linked to dry skin and to atopic dermatitis, a common form of eczema, so people with either are more likely to have it. Flares often worsen in low humidity, which is why many Canadians notice it most in winter. Hormonal changes during the teenage years can trigger or worsen it. Keratosis pilaris is not caused by poor hygiene, infection, or anything you did wrong, and scrubbing harder will not make it go away.

### What vitamin deficiency causes keratosis pilaris?
No vitamin deficiency causes ordinary keratosis pilaris. This is a common misconception. True keratosis pilaris is a genetic, follicle-plugging condition, not a sign that you are missing a nutrient. There is a separate, rare condition called phrynoderma, linked to vitamin A and other nutritional deficiencies, that can look similar with rough, bumpy skin. Phrynoderma is uncommon in Canada and appears in the setting of significant malnutrition, not in a typical healthy person with bumpy arms. Taking vitamin A or other supplements will not clear standard keratosis pilaris, and high-dose vitamin A can be harmful. If you have widespread rough skin alongside other symptoms, see your family physician to sort out the cause rather than self-treating with supplements.

### What can be mistaken for keratosis pilaris?
Several harmless and a few less harmless conditions can resemble keratosis pilaris. Folliculitis, which is inflammation or infection of hair follicles, can look similar but is often more red, tender, or pus-filled. Acne can appear as bumps on the arms or back. Atopic dermatitis (eczema) frequently overlaps with KP and can coexist. Other look-alikes include milia, small white cysts, and a condition called Darier disease. The bumps of KP are typically small, evenly scattered, painless, and rough to the touch, sitting over individual follicles. Because some conditions look alike, a clinician's exam is the most reliable way to confirm keratosis pilaris. If bumps are painful, rapidly changing, bleeding, or limited to one spot, have them checked in person rather than assuming it is chicken skin.

---

# Basal Cell Carcinoma: Signs, What It Looks Like, and Treatment

URL: https://www.dermadex.ca/blog/basal-cell-carcinoma-signs-treatment
Category: Conditions
Author: Mohsen Khoddami
Published: 2026-02-11

## TL;DR
Basal cell carcinoma (BCC) is the most common cancer in humans and about 80% of all skin cancers (American Academy of Dermatology) | BCC spreads to other organs in far less than 1% of cases (StatPearls, NCBI) | Mohs micrographic surgery cures up to 99% of previously untreated BCCs (American Academy of Dermatology) | Most BCCs appear on sun-exposed skin: the face, nose, ears, scalp, neck, and hands | When found early, BCC is rarely fatal and almost never shortens life expectancy

*As of February 10, 2026.*

Basal cell carcinoma (BCC) is the cancer dermatologists see most often, and it is also one of the most treatable. As a dermatologist and co-founder of [DermaDex](/), I look at spots like these every week, and the same worries come up: Is it dangerous? How fast does it grow? Will I need surgery? This guide covers what BCC looks like, why it develops, how it is diagnosed, and the treatments available in Canada. It is general education, not a diagnosis. If you have a spot that bleeds, crusts, or will not heal, ask a clinician to examine it.

## What is basal cell carcinoma?

**Short answer:** Basal cell carcinoma is a slow-growing skin cancer that begins in the basal cells at the base of the outer skin layer. It is the most common cancer in humans and makes up about 80 percent of all skin cancers, according to the American Academy of Dermatology ([AAD](https://www.aad.org/public/diseases/skin-cancer/types/common/bcc)).

BCC starts when basal cells, which sit in the lowest part of the epidermis, are damaged and begin dividing out of control. Most of that damage comes from ultraviolet (UV) light. Unlike melanoma, BCC very rarely spreads to distant organs. Its real risk is local. Left alone, it can grow wider and deeper into skin, cartilage, and even bone, which makes removal more involved later. The Centers for Disease Control and Prevention ([CDC](https://www.cdc.gov/skin-cancer/)) groups BCC with squamous cell carcinoma as the two main forms of non-melanoma skin cancer.

## What does basal cell carcinoma look like?

**Short answer:** Basal cell carcinoma often shows up as a pearly or waxy bump, a flat scaly patch, or a sore that bleeds, scabs over, seems to heal, and then comes back in the same place. It usually appears on sun-exposed skin: the face, nose, ears, scalp, neck, and the backs of the hands.

There is no single appearance, which is why BCC is missed so often. The classic sign is a small, shiny, skin-coloured or pink bump with fine blood vessels visible across the surface. Other forms include a flat reddish patch, a pale waxy scar-like area with blurry borders, or an open sore that will not close after several weeks. Some BCCs hold brown or black pigment and look like a mole. The [AAD](https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/symptoms) lists a sore that heals and returns as one of the most common warning signs.

| BCC subtype | Typical appearance | Common location |
|---|---|---|
| Nodular (most common) | Pearly, waxy bump with visible vessels and sometimes a central dip | Face, nose, ears |
| Superficial | Flat, scaly pink or red patch that can resemble eczema | Trunk, shoulders, back |
| Morpheaform (sclerosing) | Pale, waxy, scar-like patch with poorly defined edges | Mid-face |
| Pigmented | Brown, blue, or black bump that can mimic a mole | Sun-exposed skin |

If you are trying to tell a harmless growth from something that needs review, our guide on [seborrheic keratosis vs melanoma](/blog/seborrheic-keratosis-vs-melanoma) compares the visual clues.

## What causes basal cell carcinoma and who is most at risk?

**Short answer:** The main cause of basal cell carcinoma is ultraviolet radiation from the sun and from indoor tanning beds. People with fair skin, light eyes, a history of sunburns, and many years of accumulated sun exposure carry the highest risk.

UV light damages the DNA inside skin cells, and that damage adds up over a lifetime. The World Health Organization ([WHO](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation)) classifies solar UV radiation as a proven human carcinogen, and both ultraviolet A (UVA) and ultraviolet B (UVB) wavelengths play a part. Known risk factors, summarized by the [CDC](https://www.cdc.gov/skin-cancer/risk-factors/index.html), include:

- Fair skin that burns rather than tans (Fitzpatrick types I and II)
- Light hair and eye colour
- Frequent sunburns or any indoor tanning
- Older age and a high lifetime sun dose
- A weakened immune system, for example after an organ transplant
- Past radiation treatment or arsenic exposure
- Rare inherited conditions such as basal cell nevus (Gorlin) syndrome

Canadian context matters here. Cold winters do not cancel UV risk. Snow can reflect a large share of UV back at the skin, and across much of the country the summer UV index reaches high or very high levels. [Health Canada](https://www.canada.ca/en/health-canada/services/sun-safety.html) recommends sun protection whenever the UV index is 3 or higher.

## How is basal cell carcinoma diagnosed?

**Short answer:** A clinician diagnoses basal cell carcinoma by examining the skin, often with a dermatoscope, and confirming it with a skin biopsy. The biopsy removes a small sample so a pathologist can study the cells under a microscope, which is the only way to be certain.

The visit usually starts with a close look at the spot and the surrounding skin. Many clinicians use dermoscopy, a handheld magnifier with polarized light that reveals patterns invisible to the naked eye. Our explainer on [dermoscopy](/blog/dermoscopy-explained) describes what those patterns show. If BCC is suspected, the clinician performs a shave or punch biopsy under local anesthetic. Pathology confirms the diagnosis and the subtype, which guides treatment. In Canada, access to a dermatologist can take months in many regions, so primary-care photos and triage tools, including [artificial intelligence (AI) skin checks](/blog/how-ai-skin-checks-work), can help sort which spots need faster review. [StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK482439/) confirms biopsy as the diagnostic standard.

## How is basal cell carcinoma treated?

**Short answer:** Most basal cell carcinomas are cured with a single outpatient procedure that removes the tumour. Options range from surgical excision and Mohs micrographic surgery to curettage, freezing, prescription creams, and, for advanced disease, radiation or targeted medication.

The right choice depends on the subtype, size, location, and whether the BCC has been treated before. Small, low-risk tumours on the trunk or limbs are often handled with simple in-office methods, while tumours on the face or near the eyes, nose, and ears usually call for tissue-sparing surgery.

| Treatment | How it works | Best suited for |
|---|---|---|
| Surgical excision | Cuts out the tumour with a margin of normal skin | Most BCCs |
| Mohs micrographic surgery | Removes thin layers, checking each under a microscope until clear | Face, recurrent, large, or aggressive BCC |
| Curettage and electrodesiccation | Scrapes the tumour, then seals the area with electric current | Small, low-risk BCC on the trunk or limbs |
| Cryotherapy | Freezes the tumour with liquid nitrogen | Small, superficial BCC |
| Topical creams (imiquimod or 5-fluorouracil) | Patient-applied medicine over several weeks | Superficial BCC |
| Radiation therapy | Targeted radiation given in repeated sessions | When surgery is not suitable |
| Targeted drugs or immunotherapy | Block the tumour growth pathway | Advanced or rare metastatic BCC |

The [AAD](https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/treatment) reports that Mohs surgery cures up to 99 percent of basal cell carcinomas that have not been treated before, which is why it is favoured for the face and high-risk tumours. In Canada, medically necessary biopsy and skin-cancer surgery are insured under provincial health plans such as the Ontario Health Insurance Plan (OHIP) when you have a referral, so the out-of-pocket cost for treatment is usually minimal.

## How soon should it be treated, and what about follow-up?

**Short answer:** Basal cell carcinoma is not a same-day emergency, but it should be removed within a few weeks to a few months of diagnosis. Because anyone who has had one BCC has a higher chance of developing another, ongoing skin checks afterward are important.

BCC grows slowly, so a short scheduling delay does not usually change the outcome. The reason not to wait indefinitely is that a larger tumour means a bigger procedure and a larger scar, especially on the face. After treatment, the Canadian Dermatology Association ([CDA](https://dermatology.ca/)) and the AAD both recommend regular full-skin examinations, since a person treated for one BCC has a meaningfully higher chance of developing another within a few years. Daily sun protection lowers that risk: seek shade, cover up, and use a broad-spectrum sunscreen with a Sun Protection Factor (SPF) of 30 or higher. If you notice a new or changing spot, [contact us](/contact) or your own clinician promptly. You can read more about our team and approach on our [about page](/about).

## What else do people ask about basal cell carcinoma?

**Short answer:** The most common questions are about how serious BCC is, how fast it spreads, how quickly it should be removed, and how it affects life expectancy. In short, BCC is highly treatable, spreads very rarely, should be removed within weeks to months, and almost never shortens life when caught early.

### How serious is basal cell skin cancer?

Basal cell carcinoma is the least dangerous of the common skin cancers, but it is still a true cancer that needs treatment. It almost never spreads to other organs, and it is rarely life-threatening. The seriousness is local. If it is ignored for months or years, it can invade nearby skin, cartilage, nerves, and bone, which makes removal more complex and can cause disfigurement, especially on the face. Tumours near the eyes, nose, and ears deserve prompt attention. The good news is that when it is found early, BCC is one of the most curable cancers, with cure rates above 95 percent for small, previously untreated tumours. Take it seriously enough to treat, but it is not a reason to panic. A clinician can confirm whether a spot is BCC.

### How fast does basal cell carcinoma spread?

Basal cell carcinoma usually grows slowly, over months to years rather than days or weeks. Most of that growth is local: the tumour widens and deepens in the skin where it started. Spread to lymph nodes or distant organs, called metastasis, is very rare and is reported in far less than 1 percent of cases in the medical literature summarized by StatPearls. Certain subtypes, such as the morpheaform (sclerosing) and infiltrative types, can extend further under the surface than they appear, which is one reason borders can be hard to judge by eye. Because it grows slowly, BCC is rarely an emergency, but slow growth is not the same as harmless. The longer it is left, the larger the area that must eventually be removed.

### How soon should you get basal cell carcinoma removed?

There is no need to rush to surgery the same week, but most clinicians aim to treat a confirmed BCC within a few weeks to a few months. The timing balances two facts: BCC grows slowly, so a short wait is safe, and it does not stop growing on its own, so indefinite delay only enlarges the eventual procedure and scar. High-risk locations, such as the eyelids, nose, ears, and lips, and aggressive subtypes warrant faster scheduling. In Canada, wait times to see a dermatologist or surgeon can stretch to several months in some regions, so it helps to start the referral promptly and to use photo-based triage where available. If a spot bleeds repeatedly, grows quickly, or changes, tell your clinician so it can be moved up.

### What is the life expectancy of someone with basal cell carcinoma?

For nearly everyone, basal cell carcinoma does not lower life expectancy. It is almost never fatal because it rarely spreads beyond the skin, and the large majority of cases are cured with a single outpatient treatment. Death from BCC is extremely uncommon and is mostly limited to neglected tumours that were allowed to invade deeply over many years, or to the rare advanced cases in people with weakened immune systems. The more realistic long-term issue is recurrence: having one BCC raises the odds of developing another, which is why ongoing skin checks and sun protection matter. With early diagnosis and standard treatment, the outlook is excellent, and people go on to live a normal lifespan. This is general information, not a personal prognosis, so discuss your situation with your own clinician.

## Sources

- American Academy of Dermatology (AAD), "Basal cell carcinoma: Overview." https://www.aad.org/public/diseases/skin-cancer/types/common/bcc
- American Academy of Dermatology (AAD), "Basal cell carcinoma: Signs and symptoms." https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/symptoms
- American Academy of Dermatology (AAD), "Basal cell carcinoma: Diagnosis and treatment." https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/treatment
- Centers for Disease Control and Prevention (CDC), "Skin Cancer." https://www.cdc.gov/skin-cancer/
- Centers for Disease Control and Prevention (CDC), "Risk Factors for Skin Cancer." https://www.cdc.gov/skin-cancer/risk-factors/index.html
- World Health Organization (WHO), "Ultraviolet (UV) radiation." https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation
- Health Canada, "Sun safety." https://www.canada.ca/en/health-canada/services/sun-safety.html
- StatPearls, National Center for Biotechnology Information (NCBI Bookshelf), "Basal Cell Carcinoma." https://www.ncbi.nlm.nih.gov/books/NBK482439/
- Canadian Dermatology Association (CDA). https://dermatology.ca/

## FAQ
### How serious is basal cell skin cancer?
Basal cell carcinoma is the least dangerous of the common skin cancers, but it is still a true cancer that needs treatment. It almost never spreads to other organs, and it is rarely life-threatening. The seriousness is local. If it is ignored for months or years, it can invade nearby skin, cartilage, nerves, and bone, which makes removal more complex and can cause disfigurement, especially on the face. Tumours near the eyes, nose, and ears deserve prompt attention. The good news is that when it is found early, BCC is one of the most curable cancers, with cure rates above 95 percent for small, previously untreated tumours. Take it seriously enough to treat, but it is not a reason to panic. A clinician can confirm whether a spot is BCC.

### How fast does basal cell carcinoma spread?
Basal cell carcinoma usually grows slowly, over months to years rather than days or weeks. Most of that growth is local: the tumour widens and deepens in the skin where it started. Spread to lymph nodes or distant organs, called metastasis, is very rare and is reported in far less than 1 percent of cases in the medical literature summarized by StatPearls. Certain subtypes, such as the morpheaform (sclerosing) and infiltrative types, can extend further under the surface than they appear, which is one reason borders can be hard to judge by eye. Because it grows slowly, BCC is rarely an emergency, but slow growth is not the same as harmless. The longer it is left, the larger the area that must eventually be removed.

### How soon should you get basal cell carcinoma removed?
There is no need to rush to surgery the same week, but most clinicians aim to treat a confirmed BCC within a few weeks to a few months. The timing balances two facts: BCC grows slowly, so a short wait is safe, and it does not stop growing on its own, so indefinite delay only enlarges the eventual procedure and scar. High-risk locations, such as the eyelids, nose, ears, and lips, and aggressive subtypes warrant faster scheduling. In Canada, wait times to see a dermatologist or surgeon can stretch to several months in some regions, so it helps to start the referral promptly and to use photo-based triage where available. If a spot bleeds repeatedly, grows quickly, or changes, tell your clinician so it can be moved up.

### What is the life expectancy of someone with basal cell carcinoma?
For nearly everyone, basal cell carcinoma does not lower life expectancy. It is almost never fatal because it rarely spreads beyond the skin, and the large majority of cases are cured with a single outpatient treatment. Death from BCC is extremely uncommon and is mostly limited to neglected tumours that were allowed to invade deeply over many years, or to the rare advanced cases in people with weakened immune systems. The more realistic long-term issue is recurrence: having one BCC raises the odds of developing another, which is why ongoing skin checks and sun protection matter. With early diagnosis and standard treatment, the outlook is excellent, and people go on to live a normal lifespan. This is general information, not a personal prognosis, so discuss your situation with your own clinician.

---

# How Patient Skin Photos Should Be Stored: Encryption and PHIPA Basics

URL: https://www.dermadex.ca/blog/storing-patient-skin-photos-phipa
Category: Compliance & Security
Author: Elham Hafezi
Published: 2026-01-29

## TL;DR
PHIPA, Ontario's Personal Health Information Protection Act, took effect November 1, 2004 and is enforced by the province's Information and Privacy Commissioner | Encrypt patient skin photos with AES-256 at rest and TLS 1.2 or 1.3 in transit, the baseline cited across health data security guidance | Ontario physicians must keep medical records at least 10 years from the last entry, or 10 years after a minor turns 18 | Identifiable skin images plus EXIF metadata count as personal health information, even with no printed name | DermaDex stores scans encrypted on Canadian servers with role-based access and full audit logging

*As of January 28, 2026.*

Skin photos sit at the center of modern dermatology. A patient snaps a mole, a clinic uploads a lesion to a referral, an artificial intelligence (AI) triage tool reads a rash. Every one of those images is a medical record, and in Canada it has to be handled like one. I lead data and security at [DermaDex](/), and the question I hear most from clinics is simple: where do these photos go, and who is responsible for them? This guide answers that, starting with the law and ending with a checklist you can hand to your team.

## What is the Personal Health Information Protection Act (PHIPA) in Canada?

**Short answer:** The Personal Health Information Protection Act (PHIPA) is Ontario's health privacy law. It took effect on November 1, 2004 and sets the rules for how health information custodians collect, use, store, and disclose personal health information, with oversight from the province's Information and Privacy Commissioner of Ontario.

PHIPA governs Ontario. Other provinces run parallel statutes: Alberta's Health Information Act, plus the Personal Health Information Act in Nova Scotia and Manitoba. Where no provincial health law applies, the federal Personal Information Protection and Electronic Documents Act (PIPEDA) can fill the gap for private-sector custodians. The [Government of Canada privacy overview](https://www.canada.ca/en/treasury-board-secretariat/services/access-information-privacy/privacy.html) and the [Health Canada legislation pages](https://www.canada.ca/en/health-canada/corporate/about-health-canada/legislation-guidelines.html) describe how these layers fit together. A dermatology clinic that stores skin photos is almost always a custodian and carries legal duties for every image it holds.

| Jurisdiction | Health privacy law | Oversight body |
|---|---|---|
| Ontario | Personal Health Information Protection Act (PHIPA), 2004 | Information and Privacy Commissioner of Ontario |
| Alberta | Health Information Act (HIA) | Office of the Information and Privacy Commissioner of Alberta |
| Nova Scotia | Personal Health Information Act (PHIA) | Information and Privacy Commissioner for Nova Scotia |
| Federal / private sector | Personal Information Protection and Electronic Documents Act (PIPEDA) | Office of the Privacy Commissioner of Canada |

## Why are patient skin photos considered personal health information?

**Short answer:** A skin photo is personal health information because it documents an identifiable person's physical condition. Identifiability does not depend on a printed name. A face, a tattoo, a distinctive birthmark, or hidden file metadata can each tie an image back to one patient.

Dermatology images are unusually identifying. Many are close-ups of visible skin, and some include the face. Even a cropped lesion photo carries Exchangeable Image File Format (EXIF) metadata: camera model, timestamp, and sometimes GPS coordinates. That hidden data can re-identify a supposedly anonymous image. Under PHIPA, the moment a custodian collects that photo for care, the full set of privacy duties attaches. The Canadian Dermatology Association (CDA) and teledermatology practice treat clinical images as records, not casual snapshots. Patients who photograph a changing mole at home, as the [American Academy of Dermatology (AAD) recommends for skin cancer monitoring](https://www.aad.org/public/diseases/skin-cancer), are creating the same kind of sensitive record. Strip metadata, store the file securely, and document consent before the image moves anywhere.

## How should patient skin photos be encrypted at rest and in transit?

**Short answer:** Encrypt stored images with Advanced Encryption Standard 256-bit (AES-256) and protect every transfer with Transport Layer Security (TLS) version 1.2 or 1.3. Encryption keys must be managed separately from the data, and access to those keys logged.

Encryption is two jobs. "At rest" protects files sitting on a disk or in a database, where AES-256 is the accepted baseline. "In transit" protects images moving between a phone, a server, and an electronic medical record (EMR) system, where modern TLS does the work. Neither helps if keys are stored next to the data or shared over email. Strong key management, short-lived access tokens, and multi-factor authentication (MFA) close those gaps. The [Canadian Institute for Health Information (CIHI) privacy and security program](https://www.cihi.ca/en/privacy-and-security) and the broader [peer-reviewed literature on medical image security](https://pubmed.ncbi.nlm.nih.gov/?term=medical+image+encryption) describe the same baseline.

| Safeguard | What it protects | Practical baseline |
|---|---|---|
| Encryption at rest | Stored image files and databases | AES-256 |
| Encryption in transit | Uploads and transfers between devices | TLS 1.2 or 1.3 |
| Access control | Who can open an image | Role-based access plus MFA |
| Audit logging | Record of every view and export | Tamper-evident, time-stamped logs |

## Where should patient skin images be stored to satisfy Canadian privacy rules?

**Short answer:** Store patient skin images on servers governed by Canadian privacy law, with a written agreement covering any third-party host. PHIPA does not ban storage outside Canada outright, but custodians must keep the data secure and accountable wherever it lives, and several provinces and hospitals require Canadian data residency.

Where data physically sits matters. Many Ontario hospitals, and provinces such as British Columbia and Quebec, push for storage inside Canada to keep records under domestic legal protection. A clinic using a cloud vendor or an electronic health record (EHR) system stays responsible for that vendor's safeguards through a data processing agreement. Digital health adoption is rising worldwide, and the [World Health Organization (WHO) digital health program](https://www.who.int/health-topics/digital-health) stresses that privacy and security have to scale with it. Ask three questions before signing: Is the data encrypted and stored in Canada? Who else can access it? What happens to the images if the contract ends? DermaDex stores scans encrypted on Canadian servers for exactly these reasons.

## Who should be able to access stored patient photos, and how is access controlled?

**Short answer:** Only people inside the patient's circle of care should reach a stored skin photo, and only to the minimum extent their job requires. Role-based access control, multi-factor authentication, and audit logs enforce that limit and prove who looked at what.

PHIPA builds on a need-to-know principle. A receptionist does not need the same access as a dermatologist. Role-based permissions assign each staff member the narrowest set of rights, MFA blocks stolen-password access, and audit logs create a tamper-evident record of every view, download, and share. Those logs matter twice: they deter snooping, and they let a clinic investigate a suspected breach. PHIPA also requires custodians to notify affected patients and the Information and Privacy Commissioner of Ontario when a breach poses a real risk of harm. Patients are entitled to ask any clinic for its access and breach-notification policy before they upload a single image.

## How long should patient skin photos be retained, and when must they be deleted?

**Short answer:** Keep clinical skin photos as long as provincial record-retention rules require, then delete them securely. In Ontario, physicians must retain medical records for at least 10 years after the last entry, or 10 years after a minor patient turns 18, before secure destruction.

Retention is a balance. Delete too soon and you lose records needed for follow-up or legal defense. Keep them forever and you expand the data a breach could expose. Provincial medical colleges set the floor, and the Ontario standard above is a common reference, though periods differ across provinces and record types. Secure deletion means the file and its backups are cryptographically erased, not just dragged to a trash folder. Patients also hold rights here: under PHIPA they can request access to their own images and ask for corrections to the record. Build a written retention and deletion schedule before the first photo is ever stored.

## What should clinics and patients check before storing skin photos?

**Short answer:** Confirm five things: the image is encrypted at rest and in transit, access is role-based and logged, the data lives under Canadian privacy law, consent is documented, and a retention and deletion schedule exists. If a vendor cannot answer all five in writing, treat that as a warning sign.

This is the practical version of everything above. Patients uploading a photo to any app should ask where the image is stored and who can see it, the same questions we cover in [Is it safe to upload skin photos to an app?](/blog/skin-photo-app-privacy-canada). Clinics evaluating an [AI skin tool](/blog/how-ai-skin-checks-work) should demand the same answers from the vendor. A quick note on scope: secure storage protects the record, it does not replace clinical judgment. Image quality, lighting, and patient history all shape a diagnosis, so confirmed findings should always come from a licensed clinician.

> This article is general information about data security and privacy law, not medical or legal advice, and it is not a diagnosis. For a skin concern, see a physician or dermatologist. For legal duties specific to your clinic, consult a privacy professional. Questions about DermaDex can go through our [contact page](/contact), and our [about page](/about) explains who builds the platform.

## What do patients and clinics most often ask about storing skin photos?

**Short answer:** Four questions come up most: whether you can smile in a health card photo, the four areas PHIPA's purposes cover, whether a photo of an Ontario health card is usable, and what PHIPA actually is. Each answer ties back to one rule: treat any image of health information as a protected record.

### Can you smile in your health card photo?

A relaxed, natural expression is generally fine for an Ontario photo health card, but a wide grin that shows teeth or distorts your features can be rejected, because government identity photos are checked against facial-recognition standards. Rules vary by province and change over time, so confirm current requirements with ServiceOntario or your provincial card issuer before your appointment. The reason this matters for our topic: a health card photo is personal information tied to your identity and your Ontario Health Insurance Plan (OHIP) number, the same class of sensitive data as a clinical skin photo. Treat any image of your health card the way you would a medical image. Store it carefully, share it only through secure channels, and never email it over an unsecured connection.

### What four categories do PHIPA's purposes fall into?

PHIPA's stated purposes are commonly grouped into four areas. First, it sets rules for collecting, using, and disclosing personal health information in a way that protects confidentiality while still letting clinicians provide care. Second, it gives individuals a right to access their own health records. Third, it gives them a right to request corrections to those records. Fourth, it provides independent oversight, including complaint review by the Information and Privacy Commissioner of Ontario and remedies when the Act is broken. For a dermatology clinic, the practical translation is straightforward: protect the image, let patients see and correct their own records, and stay accountable to a regulator. Those four themes shape every storage and access decision a custodian makes.

### Can you use a picture of your health card in Ontario?

Sometimes. For many virtual or phone visits, a clear photo of your health card is accepted so the clinic can read your number and verify coverage, but the provider may still need to validate the card electronically or ask for the physical card at a later visit. The bigger issue is how that photo travels. A health card image is personal information, so never send it through unsecured text or email, and delete it from shared chat threads once the visit is booked. Clinics should accept these images only through encrypted channels and store them under the same safeguards as a clinical photo. When in doubt, ask the clinic how the image will be stored and how long it is kept.

### What is PHIPA in Canada?

PHIPA is the Personal Health Information Protection Act, Ontario's health-specific privacy law, in force since November 1, 2004. It sets the rules for health information custodians, such as doctors, hospitals, and clinics, on how they collect, use, store, disclose, and protect personal health information. It also gives patients the right to see their own records, request corrections, and complain to the Information and Privacy Commissioner of Ontario, who enforces the Act. PHIPA applies only in Ontario. Other provinces have their own health privacy laws, and the federal Personal Information Protection and Electronic Documents Act (PIPEDA) can apply where no provincial law does. For skin photos, PHIPA is the reason a clinic must encrypt, restrict, and account for every clinical image it holds.

## Sources

- Government of Canada, Treasury Board of Canada Secretariat. "Privacy." https://www.canada.ca/en/treasury-board-secretariat/services/access-information-privacy/privacy.html
- Health Canada. "Legislation and Guidelines." https://www.canada.ca/en/health-canada/corporate/about-health-canada/legislation-guidelines.html
- Canadian Institute for Health Information (CIHI). "Privacy and security." https://www.cihi.ca/en/privacy-and-security
- World Health Organization (WHO). "Digital health." https://www.who.int/health-topics/digital-health
- Canadian Dermatology Association (CDA). https://dermatology.ca/
- American Academy of Dermatology (AAD). "Skin cancer." https://www.aad.org/public/diseases/skin-cancer
- U.S. National Library of Medicine, PubMed. "Medical image encryption (literature search)." https://pubmed.ncbi.nlm.nih.gov/?term=medical+image+encryption

## FAQ
### Can you smile in your health card photo?
A relaxed, natural expression is generally fine for an Ontario photo health card, but a wide grin that shows teeth or distorts your features can be rejected, because government identity photos are checked against facial-recognition standards. Rules vary by province and change over time, so confirm current requirements with ServiceOntario or your provincial card issuer before your appointment. The reason this matters for our topic: a health card photo is personal information tied to your identity and your Ontario Health Insurance Plan (OHIP) number, the same class of sensitive data as a clinical skin photo. Treat any image of your health card the way you would a medical image. Store it carefully, share it only through secure channels, and never email it over an unsecured connection.

### What four categories do PHIPA's purposes fall into?
PHIPA's stated purposes are commonly grouped into four areas. First, it sets rules for collecting, using, and disclosing personal health information in a way that protects confidentiality while still letting clinicians provide care. Second, it gives individuals a right to access their own health records. Third, it gives them a right to request corrections to those records. Fourth, it provides independent oversight, including complaint review by the Information and Privacy Commissioner of Ontario and remedies when the Act is broken. For a dermatology clinic, the practical translation is straightforward: protect the image, let patients see and correct their own records, and stay accountable to a regulator. Those four themes shape every storage and access decision a custodian makes.

### Can you use a picture of your health card in Ontario?
Sometimes. For many virtual or phone visits, a clear photo of your health card is accepted so the clinic can read your number and verify coverage, but the provider may still need to validate the card electronically or ask for the physical card at a later visit. The bigger issue is how that photo travels. A health card image is personal information, so never send it through unsecured text or email, and delete it from shared chat threads once the visit is booked. Clinics should accept these images only through encrypted channels and store them under the same safeguards as a clinical photo. When in doubt, ask the clinic how the image will be stored and how long it is kept.

### What is PHIPA in Canada?
PHIPA is the Personal Health Information Protection Act, Ontario's health-specific privacy law, in force since November 1, 2004. It sets the rules for health information custodians, such as doctors, hospitals, and clinics, on how they collect, use, store, disclose, and protect personal health information. It also gives patients the right to see their own records, request corrections, and complain to the Information and Privacy Commissioner of Ontario, who enforces the Act. PHIPA applies only in Ontario. Other provinces have their own health privacy laws, and the federal Personal Information Protection and Electronic Documents Act (PIPEDA) can apply where no provincial law does. For skin photos, PHIPA is the reason a clinic must encrypt, restrict, and account for every clinical image it holds.

---

# Is It Safe to Upload Skin Photos to an App? Privacy in Canada

URL: https://www.dermadex.ca/blog/skin-photo-app-privacy-canada
Category: Compliance & Security
Author: Elham Hafezi
Published: 2026-01-17

## TL;DR
A BMJ 2019 study found 19 of 24 medicines-related apps (79%) shared user data with third parties such as advertisers | A BMJ 2021 study of more than 20,000 mobile health apps found 88% could collect and share user data | In Canada, skin photos are protected by PIPEDA and, in Ontario, the Personal Health Information Protection Act (PHIPA, 2004) | DermaDex encrypts skin photos in transit and at rest, stores them on Canadian servers, and never sells data to advertisers | CIHI reports many Canadians wait months for specialist care, which drives demand for photo-based dermatology tools

*As of January 16, 2026.*

Uploading a photo of a mole, rash, or changing spot to an app feels simple. The privacy question behind it is not. As Chief Information Officer at [DermaDex](/), I spend my days on exactly this problem: how a skin photo is encrypted, where it is stored, who can see it, and what a company is legally allowed to do with it. This guide explains what Canadian privacy law requires, how to tell a secure skin photo app from a risky one, and what to check before you upload anything.

This article is general information about privacy and security, not medical advice. A photo-based tool can help you track a spot or reach a clinician faster, but it does not replace an in-person exam or a diagnosis.

## Is it safe to upload skin photos to an app?

**Short answer:** It can be safe, but only when the app encrypts your photo, stores it on accountable servers, limits who can see it, and does not sell or share it with advertisers. Many free consumer apps do none of these things. A skin photo is sensitive because it can show your face, identifying marks, and a medical concern in a single image. A well-built health app treats that photo as personal health information and protects it. A generic photo or hidden-vault app may store the image without encryption or pass data to advertising partners. The safety difference is not the camera; it is the privacy model behind the upload.

The practical takeaway is that "safe" is not a property of the photo or the phone. It is a property of the service you send the photo to. Two apps can offer the same upload button while one protects a medical image like a clinical record and the other treats it like ad inventory. The rest of this guide shows you how to tell them apart.

## What privacy laws protect your skin photos in Canada?

**Short answer:** In Canada, the Personal Information Protection and Electronic Documents Act (PIPEDA) governs how private companies handle personal data, and provincial health-privacy laws such as Ontario's Personal Health Information Protection Act (PHIPA) cover health information held by clinics and other custodians. Two layers usually apply. PIPEDA is the federal rule for commercial handling of personal information, including consent, access, and safeguards, as set out by the [Government of Canada](https://www.canada.ca/en/treasury-board-secretariat/services/access-information-privacy/privacy.html). When a photo is collected for a health purpose by a clinic, hospital, or regulated provider, provincial legislation often applies on top of it.

Ontario's PHIPA came into force in 2004 and sets rules for "health information custodians," including how records are kept, who may access them, and when you can ask for correction or deletion. Other provinces have comparable health-privacy statutes. A serious skin photo app should tell you plainly which laws it follows and who its custodian is. If a privacy policy never names a Canadian legal framework, that absence is itself a warning.

## Why is a skin photo treated as sensitive health information?

**Short answer:** A skin photo can identify you and reveal a medical condition at the same time, which places it among the most sensitive categories of personal data under Canadian privacy law. Health information gets stronger protection than an ordinary photo because misuse can affect insurance, employment, and dignity. A clear image of a lesion, combined with your account details, can point to a diagnosis in progress. That is why data residency, encryption, and access logging matter for a skin photo in a way they may not for a holiday picture.

The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/skin-cancer/find/check-skin) recommends photographing moles to track change over time, which is good medical practice. It also means people are now creating health records on their phones. Those records deserve the same care a clinic would give a paper chart. If you would not tape that photo to a public noticeboard, you should not hand it to an app that cannot explain how it stores it.

## How do health apps actually use your photos and data?

**Short answer:** Independent research shows that many health and medical apps share user data with third parties, including advertisers and analytics firms, often without clear disclosure. This is not a hypothetical worry. A study in the BMJ examined 24 medicines-related apps and found that 19 of them, about 79 percent, transmitted user data to outside companies such as advertising and analytics providers. A larger analysis reviewed more than 20,000 mobile health apps and found that 88 percent contained code able to collect and potentially share user data.

You can read the primary studies on PubMed: the [2019 data-sharing analysis](https://pubmed.ncbi.nlm.nih.gov/30894349/) and the [2021 mobile health privacy study](https://pubmed.ncbi.nlm.nih.gov/34135009/). The [World Health Organization (WHO)](https://www.who.int/health-topics/digital-health) has called for stronger governance of digital health tools for similar reasons. The lesson is direct: a free app is not always free, and sometimes your data is the payment. Read what an app does with your information before you trust it with a medical image.

## How can you tell if a skin photo app is actually secure?

**Short answer:** Check five things: encryption, data residency, third-party sharing, consent and deletion controls, and whether the app is a regulated medical device. A secure app states all five plainly, while a risky one hides them. Use the checklist below before you upload, and if an app will not answer these questions in its privacy policy, treat that silence as a red flag rather than a detail you can overlook.

| What to check | Secure health app | Generic photo or vault app |
|---|---|---|
| Encryption in transit and at rest | Yes, stated clearly | Often unstated or absent |
| Data residency | Canadian or named servers | Unknown or offshore |
| Third-party data sharing | None for advertising | Common with ad and analytics firms |
| Consent and deletion | You can withdraw and delete | Buried or unavailable |
| Regulatory status | May be a regulated medical device | Not regulated as health software |

Some skin-analysis tools that claim to assess a condition can fall under Health Canada's rules for Software as a Medical Device (SaMD), described on the [Health Canada](https://www.canada.ca/en/health-canada/services/drugs-medical-devices.html) site. Regulation is a useful signal that a tool has been reviewed, though it does not by itself guarantee privacy. Pair the regulatory check with the four other items in the table.

## How does DermaDex protect your skin photos?

**Short answer:** DermaDex encrypts skin photos in transit and at rest, stores them on Canadian servers, restricts access to the people involved in your care, and never sells your data to advertisers. We built [DermaDex](/) so a photo you upload is handled like a clinical record, not marketing data. We align our handling with Canadian privacy law, including PIPEDA and applicable provincial health-privacy statutes, and we do not share your images or metadata with advertising or analytics brokers.

If you want the technical detail on how medical images should be kept, our team wrote a companion guide on [encryption and PHIPA basics for patient photos](/blog/storing-patient-skin-photos-phipa). You can also read how our [Artificial Intelligence (AI) skin checks](/blog/how-ai-skin-checks-work) work and where a human dermatologist stays in the loop. Questions about our data practices can go to our team through the [contact page](/contact), and you can learn more about who we are on our [about page](/about).

## Why does this matter more for Canadians waiting to see a dermatologist?

**Short answer:** Long specialist wait times push many Canadians toward photo-based apps, which makes choosing a privacy-safe option more important, not less. Access is the reason these apps exist. The Canadian Institute for Health Information (CIHI) tracks how long patients wait for specialty and procedural care, and waits of several months are common in many regions. When an in-person dermatology visit can take that long, a photo-based triage tool can help you reach care sooner.

You can review the national figures from [CIHI](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada). In many provinces an insured virtual visit can be billed under plans such as the Ontario Health Insurance Plan (OHIP), so faster access does not have to mean paying out of pocket. The convenience is real, and so is the risk if your photo lands in an insecure app. Choosing a tool that follows Canadian privacy law lets you get quicker access without giving up control of a medical image.

## What should you do before uploading a skin photo anywhere?

**Short answer:** Before you upload, read the privacy policy, confirm encryption and Canadian or named data storage, check for third-party sharing, and make sure you can delete your data. Run through the steps below every time you try a new app, and stop at the first one that fails. A medical image is not the place to give an app the benefit of the doubt.

| Step | What to confirm |
|---|---|
| 1. Read the privacy policy | It names the law it follows and the data it collects |
| 2. Check storage and encryption | Photos are encrypted and stored on accountable servers |
| 3. Look for sharing clauses | No sale or ad-sharing of your images or metadata |
| 4. Confirm deletion rights | You can withdraw consent and delete your account and photos |
| 5. Verify the provider | A real clinic, custodian, or regulated company stands behind it |

A few habits help. Strip location metadata if your camera adds it, avoid public or shared-device galleries for medical images, and prefer apps that connect you to a licensed clinician rather than ones that only store pictures. If a spot is changing, bleeding, or new, do not rely on an app alone. Book a clinician, because a photo tool supports care, it does not replace a diagnosis.

## Frequently asked questions

### What is the best most secure app for intimate photos to stay hidden?

**Short answer:** No single consumer "hidden photo" app is the gold standard, because security depends on how an app encrypts, stores, and shares data, not on a brand name. The most secure approach uses strong encryption at rest and in transit, stores images on accountable servers, shares nothing with advertisers, and lets you delete your data on request. For a medical image such as a skin photo, a hidden-vault app is the wrong tool. A health platform governed by Canadian privacy law, with a named custodian and clear retention rules, protects a sensitive photo far better than an app whose only feature is hiding it from a glance. Read the privacy policy before you trust any app with an image of your body, and prefer one that also connects you to a clinician rather than one that only stores pictures.

### Which app is safe for private photos?

**Short answer:** An app is safe for private photos when it encrypts images, stores them on servers you can identify, shares nothing with third parties, and lets you delete everything on request. The safe choice is the one that proves these claims in writing, not the one with the best marketing. For ordinary private photos, an offline gallery with device encryption can be enough. For medical images such as a mole or rash, choose an app governed by Canadian privacy law, including PIPEDA and applicable provincial health rules, with a clear privacy policy and a real provider behind it. Research has shown that many health apps quietly share data with advertising and analytics firms, so read the policy and confirm there is no third-party sharing of your images or metadata before you upload anything sensitive.

### Is the discreet camera app safe?

**Short answer:** Discreet or secret camera apps are usually not safe for sensitive images, because many lack encryption, request broad permissions, or send data to advertising networks. These apps are built to hide photos from someone glancing at your screen, not to protect health information from a data breach or a third-party broker. Some have been removed from app stores for privacy violations. For a medical skin photo, a discreet camera app is the wrong choice. Use a tool that states its encryption, names where data is stored, and follows Canadian privacy law. If your goal is to track a changing spot or reach care faster, a regulated health app gives you both privacy and a path to a real clinician, which a hidden-camera app cannot offer.

### Which gallery app is most private?

**Short answer:** The most private gallery app is one that encrypts images on your device, does not auto-upload to the cloud without your consent, and limits the permissions it requests. Privacy depends on those settings, not on the app's name. Many gallery apps back photos up to servers in other countries or scan images for features you did not ask for, so review the permissions and cloud settings before trusting one. For skin photos you intend to share with a clinician, a general gallery is not the right place. A purpose-built health app with consent controls, access logs, and Canadian data storage keeps a medical image more private and makes it easier to share securely with your care team when you need to.

## Sources

- Government of Canada. Privacy (Access to Information and Privacy). canada.ca. https://www.canada.ca/en/treasury-board-secretariat/services/access-information-privacy/privacy.html
- Health Canada. Drugs and medical devices (Software as a Medical Device). canada.ca. https://www.canada.ca/en/health-canada/services/drugs-medical-devices.html
- Canadian Institute for Health Information (CIHI). Wait Times for Priority Procedures in Canada. cihi.ca. https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Grundy Q, et al. Data sharing practices of medicines-related apps. BMJ, 2019. PubMed. https://pubmed.ncbi.nlm.nih.gov/30894349/
- Tangari G, et al. Mobile health and privacy: cross sectional study. BMJ, 2021. PubMed. https://pubmed.ncbi.nlm.nih.gov/34135009/
- World Health Organization (WHO). Digital health. who.int. https://www.who.int/health-topics/digital-health
- American Academy of Dermatology (AAD). How to check your skin. aad.org. https://www.aad.org/public/diseases/skin-cancer/find/check-skin

## FAQ
### What is the best most secure app for intimate photos to stay hidden?
No single consumer "hidden photo" app is the gold standard, because security depends on how an app encrypts, stores, and shares data, not on a brand name. The most secure approach uses strong encryption at rest and in transit, stores images on accountable servers, shares nothing with advertisers, and lets you delete your data on request. For a medical image such as a skin photo, a hidden-vault app is the wrong tool. A health platform governed by Canadian privacy law, with a named custodian and clear retention rules, protects a sensitive photo far better than an app whose only feature is hiding it from a glance. Read the privacy policy before you trust any app with an image of your body, and prefer one that also connects you to a clinician rather than one that only stores pictures.

### Which app is safe for private photos?
An app is safe for private photos when it encrypts images, stores them on servers you can identify, shares nothing with third parties, and lets you delete everything on request. The safe choice is the one that proves these claims in writing, not the one with the best marketing. For ordinary private photos, an offline gallery with device encryption can be enough. For medical images such as a mole or rash, choose an app governed by Canadian privacy law, including PIPEDA and applicable provincial health rules, with a clear privacy policy and a real provider behind it. Research has shown that many health apps quietly share data with advertising and analytics firms, so read the policy and confirm there is no third-party sharing of your images or metadata before you upload anything sensitive.

### Is the discreet camera app safe?
Discreet or secret camera apps are usually not safe for sensitive images, because many lack encryption, request broad permissions, or send data to advertising networks. These apps are built to hide photos from someone glancing at your screen, not to protect health information from a data breach or a third-party broker. Some have been removed from app stores for privacy violations. For a medical skin photo, a discreet camera app is the wrong choice. Use a tool that states its encryption, names where data is stored, and follows Canadian privacy law. If your goal is to track a changing spot or reach care faster, a regulated health app gives you both privacy and a path to a real clinician, which a hidden-camera app cannot offer.

### Which gallery app is most private?
The most private gallery app is one that encrypts images on your device, does not auto-upload to the cloud without your consent, and limits the permissions it requests. Privacy depends on those settings, not on the app's name. Many gallery apps back photos up to servers in other countries or scan images for features you did not ask for, so review the permissions and cloud settings before trusting one. For skin photos you intend to share with a clinician, a general gallery is not the right place. A purpose-built health app with consent controls, access logs, and Canadian data storage keeps a medical image more private and makes it easier to share securely with your care team when you need to.

---

# How AI Skin Checks Work and What They Can (and Cannot) Do

URL: https://www.dermadex.ca/blog/how-ai-skin-checks-work
Category: AI & Technology
Author: Elham Sayyah
Published: 2026-01-04

## TL;DR
A 2017 Nature study found a convolutional neural network matched 21 dermatologists at classifying skin cancers | A 2019 Lancet Oncology study found top algorithms outperformed most of 139 human readers on a test set | An AI skin check is a triage and education aid, not a diagnosis; only a licensed clinician can diagnose | In Canada, software that claims to detect skin cancer must be licensed by Health Canada as a medical device | DermaDex uses AI to triage, then a certified dermatologist reviews every flagged case

*As of January 3, 2026.*

Artificial Intelligence (AI) skin tools have moved from research labs onto phones. As the computer engineer who builds these models at DermaDex, I want to explain in plain terms what an AI skin check measures, how close it gets to a dermatologist, and the line it cannot cross. [DermaDex](/) builds AI-assisted dermatology tools and connects patients across Canada to certified dermatologists, so this is the question I answer most.

## What is an AI skin check?

**Short answer:** An AI skin check is software that analyzes a photo of your skin and estimates whether a spot, mole, or rash looks concerning, then suggests whether to see a clinician. It is a triage and education aid, not a diagnosis. You point a camera at a lesion, and the tool returns a score or a short list of possible matches with advice such as "monitor" or "see a clinician soon." It helps you decide whether and how quickly to seek care, which matters most for people far from a dermatology clinic. It does not write a diagnosis into your chart, and it does not prescribe.

The output is a probability, not a verdict. Good tools say so plainly. The value is in pointing you toward the right next step before a changing spot has months to grow.

## How does an AI skin check actually work?

**Short answer:** Most AI skin checks run a convolutional neural network (CNN), a type of machine learning (ML) model trained on hundreds of thousands of labeled skin images, to score how closely your photo matches patterns linked to specific conditions. The app first crops and lighting-corrects the image. The CNN then extracts visual features such as color variation, border shape, and texture, layer by layer. Finally it outputs a probability for each condition it was trained to recognize. The model does not see the way a person does; it matches statistical patterns learned from its training set.

The 2017 [Nature study by Esteva and colleagues](https://www.nature.com/articles/nature21056) showed a CNN trained on roughly 130,000 images could classify skin cancers at a level comparable to dermatologists, which set the template most tools still follow. The quality of those training images matters as much as the model. To see how clinicians capture the high-magnification images these systems learn from, read our explainer on [dermoscopy](/blog/dermoscopy-explained).

## How accurate are AI skin checks compared with dermatologists?

**Short answer:** In controlled studies the best AI models match or slightly beat dermatologists at classifying single lesion images, but accuracy falls in everyday use with varied lighting, skin tones, and camera quality. Treat any result as a prompt to act, not proof. Laboratory performance on clean, curated images is the best case. On a phone photo taken in dim light, or for a condition or skin tone the model rarely saw in training, the same tool is far less reliable. That gap between published numbers and field results is the single most important thing to understand about these tools.

Two studies anchor the evidence, and a [2019 Lancet Oncology study](https://pubmed.ncbi.nlm.nih.gov/31201137/) is one of the largest comparisons to date.

| Study | Year | What it tested | Result |
|-------|------|----------------|--------|
| Esteva et al., Nature | 2017 | CNN vs 21 dermatologists on biopsy-proven images | AI reached dermatologist-level classification |
| Tschandl et al., Lancet Oncology | 2019 | 139 human readers vs algorithms on dermoscopy images | Top algorithms outperformed most human readers on the test set |
| Consumer smartphone apps | Varies | Everyday photos across skin types | Real-world accuracy is lower and varies widely by app |

Independent reviews keep finding the same gap: lab numbers look strong, but field performance depends on image quality and on which conditions and skin tones were in the training data.

## What can an AI skin check do well?

**Short answer:** AI skin checks are good at flagging spots that deserve a closer look, teaching the [ABCDE warning signs](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) of melanoma (Asymmetry, Border, Color, Diameter, Evolving), and helping people in high-wait regions decide when to seek care sooner. They sort routine-looking spots from ones worth checking, so a changing mole does not get ignored for months. They can track the same spot across dated photos to reveal change over time, which is one of the strongest warning signs. In rural and northern communities, a phone check is available the same day, while a specialist visit often is not.

Where these tools earn their place:

- Triage. They help you decide whether to watch a spot or have it examined.
- Education. They teach the self-exam signs the American Academy of Dermatology (AAD) recommends.
- Monitoring. Dated, repeated photos make change easy to see.
- Access. A same-day check reaches people who cannot quickly book a specialist.

## What can an AI skin check not do?

**Short answer:** An AI skin check cannot diagnose, cannot order a biopsy, and cannot replace a clinician's judgment. It will sometimes miss real cancers (false negatives) and flag harmless spots (false positives). A model only knows what its training data taught it, so accuracy drops for conditions or skin tones that were rare in that data, and many public image sets underrepresent darker skin. A single flat photo also loses information a clinician gathers by touch, patient history, and a magnified dermatoscope view. A reassuring score on a spot that is bleeding, growing, or new is not a green light.

This is why a careful tool routes uncertain or high-risk results to a human instead of closing the loop on its own. The model narrows the question. A clinician answers it.

## Can an AI skin check replace seeing a dermatologist in Canada?

**Short answer:** No. In Canada an AI skin check is a first step that helps you decide whether and how urgently to seek care; only a licensed clinician can diagnose and treat. Access is the real problem the technology helps with, because waits for specialty care are long and the Canadian Institute for Health Information (CIHI) tracks how many patients fall outside benchmark waits. Services covered by the Ontario Health Insurance Plan (OHIP) and other provincial plans still require a licensed physician's assessment for diagnosis. A same-day AI check plus a clear referral path beats an app that pretends to be a doctor.

The [CIHI wait-time data](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) explains why patients reach for a phone tool first. The Canadian Dermatology Association (CDA) lists certified specialists, and you can confirm a dermatologist's standing through the [CDA](https://dermatology.ca). At DermaDex the model triages, then a certified dermatologist reviews flagged cases. You can reach our team through [contact](/contact).

## Is AI skin analysis regulated in Canada?

**Short answer:** Software that claims to diagnose or screen for disease is regulated as a medical device. In Canada, Health Canada (HC) oversees Software as a Medical Device (SaMD); in the United States the Food and Drug Administration (FDA) plays a similar role. This is why the wording on an app store matters: a tool that says it "detects skin cancer" is making a medical claim and should be licensed. Many consumer "skin analysis" apps call themselves wellness or education products to stay outside device rules, which also means no regulator has checked their accuracy against real cases.

Health Canada publishes guidance on how [medical devices](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices.html), including software, are reviewed and licensed. Privacy is the second question. Your photos are health data, and in Ontario they fall under the Personal Health Information Protection Act (PHIPA). Before you upload, read how the app stores and shares images; our guide on [skin photo privacy in Canada](/blog/skin-photo-app-privacy-canada) walks through what to check.

## How should you use an AI skin check safely?

**Short answer:** Use it as a prompt to act, not as a verdict. Photograph spots in good light, recheck monthly, and book a clinician for anything new, changing, bleeding, or flagged, no matter what the app says. Shoot in bright, even light with the spot in focus and the camera steady. Keep dated photos so you can compare the same spot over months. Act on the ABCDE signs and on your own instinct, not only the score. See a clinician for any sore that will not heal, or a spot that itches, bleeds, or changes shape, size, or color.

For a simple routine, follow the AAD steps on [how to check your own skin](https://www.aad.org/public/diseases/skin-cancer/find/check-skin) once a month and after any new spot appears. This article is general information, not a diagnosis. If you are worried about a specific spot, talk to a clinician. To learn how we work, see [about DermaDex](/about). For background on a common skin cancer these tools screen for, read our piece on [basal cell carcinoma](/blog/basal-cell-carcinoma-signs-treatment).

## What else do people ask about AI skin checks?

### Are AI skin checks accurate?

AI skin checks can be accurate in controlled tests and much less so in everyday use. In a 2017 Nature study, a convolutional neural network classified skin cancers at a level comparable to 21 dermatologists, and a 2019 Lancet Oncology study found the best algorithms beat most of 139 human readers on a fixed image set. Those results came from clean, high-quality images. On a phone photo with poor light, an unusual skin tone, or a condition the model rarely saw in training, accuracy drops, and the tool can both miss cancers and flag harmless spots. Read any "accuracy" claim as a best case, and treat a result as a reason to get a real exam, not as a diagnosis.

### Can AI analyze my skin?

Yes, AI can analyze a photo of your skin and describe visual features such as color, border shape, asymmetry, and texture, then estimate how closely a spot matches patterns it learned during training. That is what powers most skin analysis apps and the triage step at DermaDex. What it produces is a probability and a recommendation, not a medical finding. It cannot feel the lesion, take your history, or use a dermatoscope, so it works best as a first filter that tells you whether to watch a spot or get it checked. Choose a tool that routes uncertain results to a licensed clinician rather than one that delivers a confident answer with no human review.

### Can AI check for skin cancer?

AI can screen images for signs that a spot may be [skin cancer](https://www.aad.org/public/diseases/skin-cancer), but it cannot confirm it. Only a biopsy, read by a pathologist, can do that. A well-trained model can flag features linked to melanoma and other skin cancers, such as the ABCDE warning signs, and prompt you to seek care sooner. It will still produce false negatives, where a real cancer looks reassuring, and false positives, where a harmless mole looks worrying. In Canada, software that claims to detect cancer should be licensed by Health Canada as a medical device. If a spot is new, changing, bleeding, or will not heal, see a clinician regardless of what an app reports.

### Is there an AI that can diagnose skin conditions?

No consumer AI can legally diagnose skin conditions on its own. Diagnosis is a regulated medical act that requires a licensed clinician, and in Canada a tool that claims to diagnose disease must be cleared by Health Canada as Software as a Medical Device. Research models can classify many conditions from images with high accuracy in studies, and clinics use AI as a decision-support aid, but the clinician makes and owns the diagnosis. Consumer apps that suggest a condition are giving you an educated guess to discuss with a professional, not a diagnosis. The safe pattern, and the one we use at DermaDex, is AI for triage and a certified dermatologist for the actual diagnosis and treatment plan.

## Sources

- Esteva, A. et al. "Dermatologist-level classification of skin cancer with deep neural networks." Nature, 2017. https://www.nature.com/articles/nature21056
- Tschandl, P. et al. "Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification." Lancet Oncology, 2019. https://pubmed.ncbi.nlm.nih.gov/31201137/
- American Academy of Dermatology. "Skin cancer." https://www.aad.org/public/diseases/skin-cancer
- American Academy of Dermatology. "Melanoma (ABCDE warning signs)." https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma
- American Academy of Dermatology. "How to check your skin." https://www.aad.org/public/diseases/skin-cancer/find/check-skin
- Canadian Institute for Health Information. "Wait times for priority procedures in Canada." https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Health Canada. "Medical devices." https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices.html
- Canadian Dermatology Association. https://dermatology.ca

## FAQ
### Are AI skin checks accurate?
AI skin checks can be accurate in controlled tests and much less so in everyday use. In a 2017 Nature study, a convolutional neural network classified skin cancers at a level comparable to 21 dermatologists, and a 2019 Lancet Oncology study found the best algorithms beat most of 139 human readers on a fixed image set. Those results came from clean, high-quality images. On a phone photo with poor light, an unusual skin tone, or a condition the model rarely saw in training, accuracy drops, and the tool can both miss cancers and flag harmless spots. Read any "accuracy" claim as a best case, and treat a result as a reason to get a real exam, not as a diagnosis.

### Can AI analyze my skin?
Yes, AI can analyze a photo of your skin and describe visual features such as color, border shape, asymmetry, and texture, then estimate how closely a spot matches patterns it learned during training. That is what powers most skin analysis apps and the triage step at DermaDex. What it produces is a probability and a recommendation, not a medical finding. It cannot feel the lesion, take your history, or use a dermatoscope, so it works best as a first filter that tells you whether to watch a spot or get it checked. Choose a tool that routes uncertain results to a licensed clinician rather than one that delivers a confident answer with no human review.

### Can AI check for skin cancer?
AI can screen images for signs that a spot may be skin cancer, but it cannot confirm it. Only a biopsy, read by a pathologist, can do that. A well-trained model can flag features linked to melanoma and other skin cancers, such as the ABCDE warning signs, and prompt you to seek care sooner. It will still produce false negatives, where a real cancer looks reassuring, and false positives, where a harmless mole looks worrying. In Canada, software that claims to detect cancer should be licensed by Health Canada as a medical device. If a spot is new, changing, bleeding, or will not heal, see a clinician regardless of what an app reports.

### Is there an AI that can diagnose skin conditions?
No consumer AI can legally diagnose skin conditions on its own. Diagnosis is a regulated medical act that requires a licensed clinician, and in Canada a tool that claims to diagnose disease must be cleared by Health Canada as Software as a Medical Device. Research models can classify many conditions from images with high accuracy in studies, and clinics use AI as a decision-support aid, but the clinician makes and owns the diagnosis. Consumer apps that suggest a condition are giving you an educated guess to discuss with a professional, not a diagnosis. The safe pattern, and the one we use at DermaDex, is AI for triage and a certified dermatologist for the actual diagnosis and treatment plan.

---

# Dermoscopy Explained: How Dermatologists See Below the Surface

URL: https://www.dermadex.ca/blog/dermoscopy-explained
Category: AI & Technology
Author: Elham Sayyah
Published: 2025-12-23

## TL;DR
A dermatoscope magnifies skin about 10 times and uses polarized light to reveal pigment and blood vessels invisible to the naked eye | A 2008 British Journal of Dermatology meta-analysis found dermoscopy improved melanoma detection versus naked-eye exam (Vestergaard, PMID 18616769) | Dermoscopy is painless and non-invasive; only a biopsy confirms a skin cancer diagnosis | The Canadian Institute for Health Information (CIHI) tracks specialist wait times that can run months for dermatology | At DermaDex, skin scans are handled under PHIPA and stored on Canadian servers

*As of December 22, 2025.*

When a dermatologist looks at a mole with the unaided eye, they see roughly what you see: a coloured spot with a shape and a border. Place a dermatoscope against that same mole and a hidden layer appears, with pigment networks, dots, and small blood vessels that sit just under the surface. That extra detail is the difference between a quick guess and a structured assessment. As the person who builds the image analysis tools that learn from these pictures at [DermaDex](/), I spend a lot of time looking at dermoscopy images. This guide explains what they show, how the technique works, and what a real appointment looks like in Canada.

## What is dermoscopy?

**Short answer:** Dermoscopy is a non-invasive examination that uses a handheld magnifier, called a dermatoscope, to view skin structures below the surface that the naked eye cannot see. Clinicians use it to assess moles, growths, and rashes, and to decide whether a spot needs a biopsy.

A dermatoscope (sometimes called a dermascope or skin surface microscope) pairs a magnifying lens, usually around 10 times magnification, with a built-in light. Looking through it, a clinician can study colours and patterns inside the upper layers of skin, the epidermis and the top of the dermis, that simply are not visible otherwise. The technique is used most often to evaluate pigmented lesions. The American Academy of Dermatology (AAD) describes [melanoma and other skin cancers](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) that early detection can catch, and dermoscopy adds structure to that exam by giving the clinician a closer, glare-free look.

## How does dermoscopy work?

**Short answer:** Dermoscopy works by combining magnification with controlled lighting that removes surface glare, so structures inside the top layers of skin become visible. Most modern devices use polarized light, which cancels reflections and reveals colour and vessel patterns in seconds.

Skin reflects a lot of light at its surface, which hides what lies beneath. Dermatoscopes solve this in two ways. Older contact devices press a glass plate against the skin with a thin layer of fluid, such as alcohol gel, to reduce scatter. Newer devices use cross polarized filters that block reflected glare without touching the skin. Many tools now switch between both modes in one body. The table below sums up how each approach is used.

| Imaging mode | How it cuts glare | Best for |
| --- | --- | --- |
| Polarized, no contact | Cross polarized filters cancel surface reflection | Fast scanning and blood vessel patterns |
| Contact with fluid | Gel or alcohol plus a glass plate reduce scatter | Surface scale and milia-like cysts |
| Hybrid device | Switches between polarized and contact modes | Full structural detail in one tool |

## Can dermoscopy detect melanoma and other skin cancers?

**Short answer:** Yes. In trained hands, dermoscopy improves detection of melanoma compared with naked-eye examination, and it also helps identify basal cell and squamous cell carcinomas. It guides the decision to biopsy, but it does not confirm a diagnosis on its own.

A 2008 meta-analysis in the British Journal of Dermatology found that dermoscopy performed by trained examiners improved sensitivity for melanoma without a meaningful loss of specificity, compared with inspection by eye alone ([Vestergaard et al.](https://pubmed.ncbi.nlm.nih.gov/18616769/)). A later 2018 Cochrane review reached a similar conclusion: dermoscopy in person was more accurate than visual inspection alone for diagnosing melanoma in adults ([Dinnes et al.](https://pubmed.ncbi.nlm.nih.gov/30521682/)). Dermoscopy also helps separate harmless spots from cancers such as [basal cell carcinoma](/blog/basal-cell-carcinoma-signs-treatment), and it is one of the main tools for telling a [seborrheic keratosis from a melanoma](/blog/seborrheic-keratosis-vs-melanoma). The catch is training: the benefit shows up with practice, not with the device alone.

## How is dermoscopy different from a biopsy?

**Short answer:** Dermoscopy only looks; a biopsy removes tissue. Dermoscopy is a painless, non-invasive way to inspect a lesion in seconds, while a biopsy takes a small skin sample for a pathologist to examine under a microscope, which is the only way to confirm whether a spot is cancer.

Think of dermoscopy as a high-detail preview and a biopsy as the confirmed answer. A clinician may use the dermatoscope on dozens of spots in one visit, then recommend a biopsy for only the few that look concerning. The biopsy is a minor procedure done with local anaesthetic, and the sample goes to a laboratory. This is why the two steps are not interchangeable: one narrows the field, the other settles it. The table below compares the three stages a single spot can pass through.

| Method | What it does | Invasive? | Confirms cancer? | Typical setting |
| --- | --- | --- | --- | --- |
| Naked-eye exam | Checks size, colour, and shape | No | No | Any clinic visit |
| Dermoscopy | Magnified view of sub-surface structures | No | No | Dermatology or primary care |
| Skin biopsy | Removes tissue for lab analysis | Yes, minor | Yes | Clinic, with local anaesthetic |

## What happens at a dermoscopy appointment in Canada?

**Short answer:** At a dermoscopy appointment, a clinician rests the dermatoscope gently on your skin and studies each spot for a minute or two. There is no preparation, no needles, and no pain, and the exam is usually covered by provincial health plans when it is medically necessary.

A typical visit starts with a referral from your family doctor for a suspicious or changing mole. The dermatologist examines the area with the dermatoscope, sometimes photographs spots for follow-up, and decides whether a biopsy is needed. In Ontario, an in-office skin exam is generally covered by the Ontario Health Insurance Plan (OHIP) when ordered for a medical reason. The barrier is usually time, not cost. The Canadian Institute for Health Information (CIHI) tracks specialist [wait times across Canada](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada), and dermatology waits can run for months in many regions. The Canadian Dermatology Association (CDA) offers [patient guidance](https://dermatology.ca/public-patients/) on skin health while you wait. [DermaDex](/about) was built to shorten that gap by triaging cases first and routing urgent ones faster.

## How do AI tools use dermoscopy images?

**Short answer:** Artificial intelligence (AI) tools learn from large sets of labelled dermoscopy images to flag patterns linked to melanoma and other lesions. They help clinicians prioritize suspicious cases, but they do not replace a dermatologist's judgement or a biopsy.

The kind of model used here is usually a convolutional neural network (CNN), a form of machine learning (ML) that learns visual features directly from images. Trained on thousands of dermoscopic pictures, it can rank how concerning a spot looks and push higher-risk cases to the front of the queue. These tools are aids, not decision-makers. Software that claims to diagnose disease is regulated as a medical device by Health Canada (HC) and, in the United States, by the U.S. Food and Drug Administration (FDA). At DermaDex, scans are handled under the Personal Health Information Protection Act (PHIPA) and stored on Canadian servers. If you want the detail on accuracy and limits, see our guide on [how AI skin checks work](/blog/how-ai-skin-checks-work).

## When should you ask for a skin check?

**Short answer:** Ask for a professional skin check if a mole changes in size, shape, or colour, if it bleeds or itches, or if it looks different from your other spots. The ABCDE rule (Asymmetry, Border, Colour, Diameter, Evolving) is a simple way to catch warning signs between visits.

Most spots on your body are harmless, but a few are worth a closer look. The AAD recommends the [ABCDE checklist](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes) for self-checks, summarized below. Sun exposure is the main modifiable risk for skin cancer. The World Health Organization (WHO) links ultraviolet (UV) radiation to most skin cancers ([WHO fact sheet](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation)), the U.S. Centers for Disease Control and Prevention (CDC) describes the [main skin cancer types](https://www.cdc.gov/skin-cancer/about/index.html), and the Government of Canada offers practical [sun safety guidance](https://www.canada.ca/en/public-health/services/sun-safety.html).

| Letter | Stands for | Warning sign |
| --- | --- | --- |
| A | Asymmetry | One half does not match the other |
| B | Border | Edges are ragged, notched, or blurred |
| C | Colour | More than one shade, or uneven colour |
| D | Diameter | Larger than 6 mm, about a pencil eraser |
| E | Evolving | Changing in size, shape, or symptoms |

This article is educational and is not a diagnosis. If a spot worries you, talk to a clinician. You can reach our team through the [DermaDex contact page](/contact).

## Sources

- American Academy of Dermatology (AAD), "Melanoma overview": https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma
- American Academy of Dermatology (AAD), "What to look for: ABCDEs of melanoma": https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes
- Vestergaard ME et al., British Journal of Dermatology (2008), "Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma": https://pubmed.ncbi.nlm.nih.gov/18616769/
- Dinnes J et al., Cochrane Database of Systematic Reviews (2018), "Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults": https://pubmed.ncbi.nlm.nih.gov/30521682/
- Canadian Institute for Health Information (CIHI), "Wait times for priority procedures in Canada": https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Canadian Dermatology Association (CDA), "Public and patients": https://dermatology.ca/public-patients/
- World Health Organization (WHO), "Ultraviolet radiation": https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation
- Centers for Disease Control and Prevention (CDC), "About skin cancer": https://www.cdc.gov/skin-cancer/about/index.html
- Government of Canada, "Sun safety": https://www.canada.ca/en/public-health/services/sun-safety.html

## FAQ
### Can dermoscopy detect cancer?
Yes, dermoscopy helps detect skin cancer, but it does not confirm it. By magnifying a lesion and removing surface glare, a dermatoscope reveals pigment patterns and blood vessels that point toward melanoma, basal cell carcinoma, or squamous cell carcinoma. A 2008 meta-analysis in the British Journal of Dermatology found that dermoscopy used by trained clinicians improved melanoma detection compared with the naked eye. The technique works best in experienced hands, and it is most useful for deciding which spots need a biopsy. Dermoscopy cannot give a final answer on its own. Only a biopsy, where a small sample of skin is examined under a microscope by a pathologist, confirms whether a lesion is cancer. If a spot is changing, ask a clinician for an assessment.

### What is the purpose of a dermoscopy?
The purpose of dermoscopy is to look below the surface of the skin so a clinician can assess a mole, growth, or rash more accurately than with the naked eye. A dermatoscope magnifies the area, usually around 10 times, and uses polarized or contact lighting to reveal colours, pigment networks, and tiny blood vessels. This extra detail helps a clinician decide whether a spot is harmless or needs a biopsy, and it can reduce unnecessary removals of benign lesions. Dermatologists also use dermoscopy to monitor moles over time by comparing photographs, and to support diagnoses of conditions beyond cancer, including some hair and nail problems. The goal is sharper, faster, non-invasive assessment, not a final diagnosis.

### How is dermoscopy different from a biopsy?
Dermoscopy and a biopsy answer different questions. Dermoscopy is a non-invasive look: the clinician places a dermatoscope on the skin and examines the lesion in seconds, with no cutting and no pain. It guides the decision about what to do next. A biopsy is a minor procedure that removes a small piece of skin, done with local anaesthetic, and sends the tissue to a laboratory. A pathologist then examines it under a microscope. That lab result is the only way to confirm whether a lesion is cancer and what type it is. In practice the two work together: a clinician uses dermoscopy on many spots, then recommends a biopsy for the few that look concerning. One looks, the other confirms.

### What happens at a dermoscopy appointment?
At a dermoscopy appointment, you usually do not need any preparation. The clinician asks about the spot that concerns you, then rests a dermatoscope gently against your skin and studies each lesion for a minute or two. The exam is painless and takes only seconds per spot. The clinician may photograph some lesions so they can be compared at a later visit, which is common for people with many moles. After the exam, you will hear one of three things: the spot looks benign and needs no action, it should be watched and rephotographed later, or it needs a biopsy to be sure. In Canada, an in-office skin exam is generally covered by provincial health plans when it is medically necessary. Bring a list of any spots you have noticed changing.

---

# Year in Review: Canadian Dermatology AI in 2025

URL: https://www.dermadex.ca/blog/year-in-review-dermadex-2025
Category: AI & Technology
Author: Mohsen Khoddami
Published: 2025-12-16

## TL;DR
AI-assisted dermatology tools moved from pilot research toward clinical deployment in Canada during 2025 | Health Canada published updated guidance on Software as a Medical Device (SaMD), clarifying the regulatory path for AI diagnostic tools | Average specialist wait time for dermatology exceeded 26 weeks in some provinces in 2024 (CIHI), a structural gap driving industry investment | Federated learning emerged as the preferred privacy-preserving approach for multi-clinic AI research under PHIPA (Ontario) and PIPEDA (federal) — data stays at each clinic | DermaDex works in this space, building toward clinical deployment in Canada

*As of December 16, 2025.*

Canadian dermatology care ran into a familiar bottleneck in 2025: too few specialists, too many patients, and wait times that stretched well past six months in several provinces. Across the industry, healthtech companies and academic research groups spent the year building tools designed to close that gap — not by replacing dermatologists, but by giving clinicians better information sooner. This article looks at what happened in Canadian dermatology artificial intelligence (AI) broadly in 2025, what regulators and professional bodies published, and where the field is heading.

## What is the trend in dermatology in 2025?

<b>Short answer:</b> The dominant trend in dermatology in 2025 was artificial intelligence (AI) moving from research settings into early clinical workflows. Canadian clinics began evaluating AI-assisted triage tools, teledermatology platforms expanded coverage into rural communities, and regulatory bodies like Health Canada published clearer guidance on software as a medical device (SaMD). Professional conferences began treating AI not as a theoretical concept but as a practical clinical tool under active evaluation, and federal working groups turned attention toward defining performance benchmarks for AI-assisted dermatology in a Canadian context.

At the Canadian Dermatology Association (CDA) annual meeting in June 2025, multiple presentations highlighted machine learning (ML) models for lesion classification — a shift from prior years, when AI in dermatology was still largely theoretical at Canadian conferences. The [Canadian Institute for Health Information (CIHI)'s specialist wait-time data](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) has documented specialist shortages in every province, and AI triage is now part of the mitigation conversation at a federal level.

The table below summarizes specialist wait-time data from CIHI's most recent reporting, which covers the 2024 reference period and provides the access-gap context motivating AI investment across Canadian healthtech.

| Province | Median specialist wait (weeks) | Context |
|----------|-------------------------------|----------|
| Prince Edward Island | 40+ weeks | Highest reported median in CIHI data |
| New Brunswick | 35+ weeks | Limited specialist density outside Fredericton/Moncton |
| Nova Scotia | 26–30 weeks | Rural communities face longest waits |
| Manitoba | 24–28 weeks | Northern communities severely underserved |
| Ontario | 18–24 weeks | Urban centres shorter; Northern Ontario significantly longer |
| British Columbia | 20–26 weeks | Interior and Northern BC longest |
| Alberta | 18–22 weeks | Rural-urban gap documented |

*Source: CIHI Wait Times for Priority Procedures in Canada. Figures are approximate ranges based on CIHI's reported provincial medians for specialist (non-emergency) referrals. Dermatology-specific data varies; these figures reflect specialist care broadly.*

## What's new in dermatology in 2025?

<b>Short answer:</b> In 2025, the notable advances in dermatology technology included multimodal AI classifiers combining dermoscopy images with patient history, federated learning research protecting patient privacy across multi-clinic networks, and deeper integrations between AI tools and electronic medical record (EMR) systems. Health Canada's updated Software as a Medical Device (SaMD) framework gave industry a clearer regulatory path. Research in journals including JAMA Dermatology continued to validate AI classifier performance on common lesion types, and the field moved toward explicit calibration across Fitzpatrick skin tone diversity as a publication standard.

Health Canada's updated [Software as a Medical Device guidance](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/software-medical-device-guidance-document.html) provided a clearer regulatory framework for AI diagnostic tools in Canada, which accelerated serious development work across the industry. Research published in journals like JAMA Dermatology and Nature continued to validate AI classifier performance on common conditions including basal cell carcinoma and melanocytic lesions, with particular attention to ensuring calibration across diverse skin tones — a documented gap in earlier training datasets.

Federated learning emerged as the preferred technical architecture for multi-clinic AI research under Canadian privacy law — PHIPA (Personal Health Information Protection Act) in Ontario and PIPEDA (Personal Information Protection and Electronic Documents Act) at the federal level — allowing model improvement across clinic networks without raw patient data leaving each site. This is an area of active research and early-stage work across Canadian healthtech, including by DermaDex as the company works toward production readiness.

## How will technology change dermatology in the future?

<b>Short answer:</b> Technology will change dermatology by compressing the time between a patient's first concern and a qualified clinical assessment. AI triage allows primary care physicians to independently manage a larger share of dermatology presentations, routing only the most complex and ambiguous cases to specialist review. Asynchronous teledermatology extends specialist reach into rural and remote communities where in-person access is limited. The next major technical frontier is multimodal AI — combining imaging data with patient history, medications, and prior diagnoses from electronic health record (EHR) systems to improve classifier accuracy and reduce false-positive referrals.

The [Canadian Institute for Health Information (CIHI)](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) reported that specialist wait times for dermatology exceeded 26 weeks in some provinces in 2024, a figure the Canadian Medical Association (CMA) has cited as a patient safety concern. AI-assisted triage does not shorten that wait for patients who need a specialist appointment, but it does allow primary care physicians to confidently manage a larger share of cases independently. The cases that do require specialist review arrive with more context, which makes those appointments more efficient.

Research published in 2025 continued to show strong sensitivity and specificity for AI classifiers on common conditions, particularly basal cell carcinoma and melanocytic lesions. The integration of EHR data with imaging AI is broadly viewed as the next technical frontier. DermaDex is among the companies building toward this capability.

## Is AI going to replace dermatologists?

<b>Short answer:</b> No. AI tools in dermatology are designed to help dermatologists and primary care physicians work more effectively, not to replace specialist judgment. AI classifiers can flag lesions that warrant closer inspection and prioritize cases by urgency, but the clinical decision — including biopsy, treatment selection, and patient communication — stays with the physician. The evidence base for AI-assisted dermatology consistently frames these tools as a triage and decision-support layer. Canada's dermatologist shortage is a workforce distribution problem; AI helps extend the reach of the specialists who do exist, particularly into rural and remote communities.

Per [Statistics Canada](https://www.statcan.gc.ca) data on health workforce distribution, rural and remote communities have the fewest specialists and the longest waits. AI tools help extend the reach of the specialists who do exist. A family physician using an AI-assisted tool can assess a lesion with confidence scoring, document it in their EMR, and make a more informed referral decision — or choose to monitor and reassess — without requiring an immediate specialist consult.

Dermatologists bring pattern recognition built over years of clinical exposure, the ability to ask follow-up questions, and the judgment to weigh factors that do not appear in an image. AI contributes speed and consistency at scale. The two work better together than either does alone. Responsible AI tools in this space should include confidence scores and explicit recommendations to consult a physician for any ambiguous or high-risk result.

## Sources

- Canadian Institute for Health Information (CIHI). *Wait Times for Priority Procedures in Canada.* https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada
- Canadian Medical Association (CMA). *CMA Health Care Access Reports.* https://www.cma.ca
- Statistics Canada. *Health Workforce Distribution in Canada.* https://www.statcan.gc.ca
- Health Canada. *Software as a Medical Device Guidance.* https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/software-medical-device-guidance-document.html
- Esteva A et al. *Dermatologist-level classification of skin cancer with deep neural networks.* Nature, 2017. https://pubmed.ncbi.nlm.nih.gov/28117445/

## FAQ
### What is the trend in dermatology in 2025?
The defining trend in dermatology in 2025 was AI moving from academic research into early clinical consideration. Clinics across Canada began evaluating AI-assisted triage tools, teledermatology expanded into underserved communities, and Health Canada published clearer frameworks for AI as a medical device. The Canadian Dermatology Association highlighted AI-assisted lesion classification at its 2025 annual meeting, signalling that the field now treats AI as a practical clinical tool rather than a future prospect. DermaDex is among the companies working in this space, building toward production deployment in Canada.

### How will technology change dermatology in the future?
Technology will change dermatology primarily by improving how fast a patient reaches the right level of care. AI triage allows primary care physicians to confidently handle more dermatology cases independently, reserving specialist time for complex presentations. Federated learning lets AI models improve across clinic networks without moving raw patient data, which matters under Canadian privacy law — PHIPA (Ontario) and PIPEDA (federal). The next major shift will likely be multimodal AI that combines imaging data with patient history from EHR systems. The CIHI has documented wait times exceeding 26 weeks for dermatology in some provinces — that structural problem is what drives development work across the Canadian healthtech industry.

### What's new in dermatology in 2025?
In 2025, the notable developments in dermatology technology included AI classifiers trained across diverse skin tones to address documented gaps in historical datasets, federated learning research protecting patient privacy across multi-clinic networks, and tighter integrations between AI diagnostic tools and existing EMR platforms. Health Canada published updated Software as a Medical Device (SaMD) guidance that created a clearer regulatory path for AI tools in Canada. Research published in journals like JAMA Dermatology continued to validate AI classifier performance, particularly for basal cell carcinoma and melanocytic lesions.

### Is AI going to replace dermatologists?
No. AI tools are designed to support dermatologists and primary care physicians, not replace them. AI classifiers can flag lesions, assign confidence scores, and prioritize cases by urgency, but all clinical decisions — biopsy, treatment, patient communication — remain with the physician. Canada's dermatologist shortage is a workforce distribution problem documented by CIHI and Statistics Canada. AI helps primary care physicians handle more dermatology cases confidently and makes specialist referrals more efficient. Responsible AI tools in this space should always include confidence scores and explicit recommendations to consult a physician for any ambiguous result.

---

# Federated Learning for Multi-Clinic Dermatology AI: How It Works and Why It Matters

URL: https://www.dermadex.ca/blog/why-we-chose-federated-learning-for-multi-clinic-ai
Category: AI & Technology
Author: Elham Sayyah
Published: 2025-11-18

## TL;DR
Federated Learning (FL) trains a shared AI model across clinics without copying patient data to a central server | The Rieke et al. 2020 Nature Digital Medicine paper (3,700+ citations) established FL as the standard for privacy-preserving medical AI | In a typical FL setup each clinic runs local training rounds; only weight gradients leave the server | FL compliance with Ontario's PHIPA (Personal Health Information Protection Act) and federal PIPEDA (Personal Information Protection and Electronic Documents Act) is built in by design, not bolted on after | A differential privacy (DP) budget can cap information leakage from any single clinic's gradient updates

*As of November 18, 2025.*

At [DermaDex](/) we connect Canadian patients to certified dermatologists and build the AI tools those dermatologists trust. When multi-clinic networks evaluate AI tools, the first question is almost always the same: "Our patients' images stay on our servers, right?"

Federated Learning (FL) is the architectural approach designed to make that answer yes. This post explains how FL works, why it is the leading framework for privacy-preserving medical AI, and what the trade-offs are for any organization considering it.

## What is federated learning in healthcare?

<b>Short answer:</b> Federated Learning (FL) trains a shared artificial intelligence (AI) model across multiple hospitals or clinics without moving patient data to a central server. Each clinic trains a local copy of the model on its own data. Only model weight updates, not images or records, travel to a central aggregator. The result is a model that has seen diverse patient populations without any single patient's data ever leaving the clinic network. Rieke et al. (2020) describe this as [the future of digital health with federated learning](https://pubmed.ncbi.nlm.nih.gov/33015372/), citing FL's ability to satisfy data governance requirements that block conventional centralized training.

For dermatology specifically, this matters because skin images are among the most sensitive categories of personal health data under the Personal Health Information Protection Act (PHIPA) in Ontario and equivalent provincial statutes across Canada.

## What is federated learning in simple terms?

<b>Short answer:</b> Think of it like a book club where no one shares their copy of the book. Each clinic reads the book locally and writes down notes about what they learned. Those notes go to a coordinator, who merges everyone's notes into a smarter summary and sends the updated summary back. No one ever sees another clinic's copy. In machine learning (ML) terms: the "book" is patient data, the "notes" are gradient updates to the model weights, and the "coordinator" is a central aggregation server that runs FedAvg or a similar algorithm to merge weight updates.

This framing helps clinical operators explain FL to their privacy officers without requiring a background in distributed systems.

## What are the three types of federated learning?

<b>Short answer:</b> The three main types are horizontal FL, vertical FL, and federated transfer learning. Horizontal FL is the most common in healthcare: all clinics hold the same data schema (patient images, labels, demographics) but different patients. Vertical FL applies when two organizations hold different features about the same patients, such as a lab and an insurer. Federated transfer learning handles cases where data schemas and patient populations both differ. For a multi-clinic dermatology tool, horizontal FL is the natural fit because every participating clinic captures the same structured image data under the same diagnostic workflow.

| Type | Data overlap | Common healthcare use case |
|---|---|---|
| Horizontal FL | Same features, different patients | Multi-clinic image classifiers |
| Vertical FL | Different features, same patients | Lab + EHR data fusion |
| Federated transfer learning | Neither features nor patients overlap | Cross-country research consortia |

## Why not just centralize the data?

<b>Short answer:</b> Centralizing skin image datasets from multiple Canadian clinics creates serious legal exposure under PHIPA (Personal Health Information Protection Act) in Ontario and PIPEDA (Personal Information Protection and Electronic Documents Act) federally, requires patient re-consent at each site, and introduces a single breach target for attackers. Beyond compliance, clinics are generally reluctant to transfer sensitive patient data to a shared repository controlled by a third party. FL sidesteps all three objections: no re-consent required, no central breach surface, no data custody transfer.

The three architectures typically evaluated are:

1. **Central pooling** — all images sent to one cloud bucket, one training run. Fastest to prototype, but creates legal and custody problems for regulated Canadian clinics.
2. **Federated learning** — local training, gradient aggregation. Privacy-compliant by design.
3. **Split learning** — the convolutional neural network (CNN) is split across the clinic and server; activations travel instead of gradients. Lower communication cost in some configurations, but the server sees intermediate activations that can partially reconstruct inputs.

FL offers the best balance of data privacy, model quality, and integration effort for most multi-clinic use cases.

## How does federated learning protect against gradient leakage?

<b>Short answer:</b> Raw gradient updates can theoretically be inverted to reconstruct training images, a class of attacks studied since Zhu et al. (2019). The two practical defenses are differential privacy (DP) and secure aggregation. Differential Privacy adds calibrated noise to each clinic's gradient update before it leaves the local server. The noise budget is set so that no single training example can be identified from the gradient, but the aggregate signal across thousands of examples still improves the model. Secure aggregation uses cryptographic protocols so the central server only ever sees the sum of all clinic gradients, never any individual clinic's update.

Applying both a per-clinic DP epsilon budget and a secure aggregation protocol at the aggregator is the approach recommended in the FL healthcare literature. The privacy cost is a small reduction in convergence speed rather than a meaningful loss of model accuracy at production scale.

## How does federated learning compare to centralized ML in practice?

<b>Short answer:</b> Federated models reach comparable accuracy to centralized models when the data is independently and identically distributed (IID) across sites. In real multi-clinic deployments the data is non-IID: one clinic may see more Fitzpatrick Type VI patients, another more pediatric cases. Standard FedAvg can struggle with high non-IID skew. FedProx, a variant that adds a proximal regularization term to local objectives, keeps local models from drifting too far from the global model during each communication round and is widely used to address this.

A 2024 [systematic review of federated machine learning in healthcare](https://pubmed.ncbi.nlm.nih.gov/38340728/) covering 612 studies found that non-IID data distributions are the most commonly reported barrier to FL deployment in clinical settings. For a detailed look at how model architecture can address skin tone diversity, see [Why Skin Tone Matters in AI Dermatology Models](/blog/why-skin-tone-matters-in-ai-dermatology-models).

| Aspect | Centralized ML | Federated Learning |
|---|---|---|
| Data location | Central cloud server | Stays at each clinic |
| Privacy risk | Single breach exposes all | Breach at one clinic affects only that clinic |
| PHIPA compliance | Requires explicit data-sharing agreements | Compliant by architecture |
| Model accuracy (IID data) | Slightly higher | Comparable |
| Model accuracy (non-IID data) | N/A | Requires FedProx or similar |
| Setup complexity | Low | Medium |
| Communication cost | None after data transfer | Per-round gradient sync |
| Regulatory overhead | High (data transfer agreements) | Low |

## What are the downsides of federated learning?

<b>Short answer:</b> The three main downsides are communication overhead, debugging difficulty, and slower iteration cycles. Each training round requires synchronized gradient uploads from all participating clinics; a single clinic with a slow connection delays the round for everyone. Debugging a model trained across many clinics is harder than debugging a central training job: you cannot inspect intermediate activations or training curves from individual clinics without additional tooling. Iteration speed is slower because you cannot re-run a training experiment on centralized data in minutes. In a typical multi-clinic FL deployment, a full federated round can take several hours overnight depending on clinic count and data volume.

None of these trade-offs eliminate FL as the right choice when regulatory compliance or patient data sensitivity makes centralization impossible. Building a round-monitoring dashboard and an asynchronous aggregation fallback for slow clinics are standard mitigations in production FL systems. For an overview of how the base model is designed and tested before federation, see [Building Our Skin Lesion Classifier: Architecture and Training](/blog/building-our-skin-lesion-classifier-architecture-and-training).

## What does a federated training round look like in practice?

<b>Short answer:</b> In a typical FL setup, participating clinics receive an updated global model checkpoint on a recurring schedule. Each clinic's local training job runs for a fixed number of epochs on recently added cases. The resulting gradient delta is clipped, noise-injected under the DP budget, and uploaded to the aggregation server over mutual TLS. The aggregator runs weighted FedAvg (weighted by clinic case volume), publishes the new global checkpoint, and triggers validation against a held-out multi-site test set. If the new checkpoint scores below the previous round on sensitivity for high-risk lesions, the round is rolled back automatically.

This architecture can be implemented so that clinics do not require GPU (graphics processing unit) hardware beyond what runs standard clinical software. A containerized training job that runs on CPU is feasible for most clinic dataset sizes at typical update frequencies.

## Sources

- Rieke, N. et al. (2020). [The future of digital health with federated learning](https://pubmed.ncbi.nlm.nih.gov/33015372/). *npj Digital Medicine*, 3(119). PubMed PMID 33015372.
- Teo, Z.L. et al. (2024). [Federated machine learning in healthcare systematic review](https://pubmed.ncbi.nlm.nih.gov/38340728/). *Cell Reports Medicine*. PubMed PMID 38340728.

## FAQ
### What is federated learning in healthcare?
Federated Learning (FL) trains a shared AI model across multiple hospitals or clinics without moving patient data to a central server. Each site trains a local model copy on its own records. Only weight updates travel to a central aggregator, which merges them into an improved global model and redistributes it. Patient images and records never leave the originating institution. This satisfies data governance laws like PHIPA (Ontario) and PIPEDA (federal) in Canada and HIPAA in the US, making FL the standard architecture for privacy-preserving medical AI.

### What is federated learning in simple terms?
Federated learning is a method where many computers train the same AI model without sharing the underlying data. Each participant trains a local copy, sends only a summary of what it learned (called gradient updates) to a coordinator, and the coordinator builds a smarter shared model from those summaries. In healthcare, the 'data' is patient records and images. Because only summaries travel, patients' data stays inside the clinic's own network. The end result is an AI model trained on diverse patient populations without anyone handing over sensitive files.

### What are the three types of federated learning?
The three main types are: (1) Horizontal FL, where all participants hold the same data features but different patients, the most common setup in healthcare; (2) Vertical FL, where different organizations hold different features about the same patients, such as a hospital and an insurance company; and (3) Federated transfer learning, used when both the patient populations and the feature schemas differ across sites. For a multi-clinic dermatology tool, horizontal FL is the standard choice because all participating clinics capture the same structured image data under the same diagnostic workflow.

### What are the downsides of federated learning?
The main downsides are communication overhead, debugging complexity, and slower iteration. Every training round requires all participating clinics to upload gradient updates; a slow clinic delays the whole round. Debugging is harder because you cannot inspect training data or intermediate outputs across sites without special tooling. Iteration cycles are slower than centralized training since experiments cannot be re-run on a single dataset in minutes. Additional engineering is needed when data is unevenly distributed across sites, requiring algorithms like FedProx to prevent model drift. These costs are worthwhile when regulatory compliance or patient data sensitivity makes centralization impossible.

---

# Rosacea Triggers and Treatments: 2025 Update

URL: https://www.dermadex.ca/blog/rosacea-triggers-and-treatments-2025-update
Category: Conditions
Author: Mohsen Khoddami
Published: 2025-10-14

## TL;DR
Sun exposure triggers rosacea in up to 81% of patients (National Rosacea Society, 2024) | Azelaic acid and topical metronidazole are first-line AAD (American Academy of Dermatology)-recommended treatments for rosacea subtypes 1 and 2 | A 14-day trigger diary reduces flare frequency by roughly 50% in most patients | Canadian Dermatology Association guidelines recommend SPF 30+ daily for all rosacea patients | Oral low-dose doxycycline (40 mg modified-release) is FDA-approved and Health Canada-listed for papulopustular rosacea

*As of October 14, 2025.*

Rosacea is a chronic inflammatory skin condition that affects an estimated 3% of Canadians. It causes facial redness, visible blood vessels, and in some cases acne-like bumps that come and go in cycles of flares and remission. There is no cure, but with the right rosacea triggers treatment strategy, most people reduce flare frequency significantly. This guide explains what drives flare-ups, compares current topical and oral options, and outlines practical steps you can take this week.

For a broader view of where rosacea fits among the most prevalent inflammatory skin diseases, see our overview of [common skin conditions in Canadian adults](/blog/5-common-skin-conditions-in-canadian-adults).

## What is the number one trigger for rosacea?

<b>Short answer:</b> Sun exposure is the most frequently reported rosacea trigger, affecting up to 81% of patients according to survey data from the National Rosacea Society. UV radiation dilates facial blood vessels and activates toll-like receptor pathways in rosacea-prone skin, intensifying both redness and papule formation. Wearing a broad-spectrum SPF 30 or higher sunscreen every day is the single highest-impact habit a rosacea patient can build. Other top triggers include heat, hot beverages, alcohol, spicy food, and emotional stress.

Triggers vary considerably between individuals, which is why identifying your personal pattern matters as much as knowing the population averages. A 14-day trigger diary, where you log food, environment, and skin response each day, gives you actionable data that general trigger lists cannot.

### Common rosacea flare-up triggers by frequency

| Trigger | % of patients affected | Avoidance tip |
|---|---|---|
| Sun exposure | 81% | SPF 30+ daily, wide-brim hat outdoors |
| Emotional stress | 79% | Mindfulness, sleep hygiene, stress journalling |
| Hot weather / heat | 75% | Stay cool, use a facial mist, avoid saunas |
| Wind / cold air | 57% | Physical barrier (scarf), fragrance-free moisturiser |
| Strenuous exercise | 56% | Exercise in cool environments, cool down with cold water |
| Alcohol (red wine) | 52% | Limit or eliminate; note which types are worst |
| Hot beverages | 44% | Switch to iced drinks or let coffee cool |
| Spicy food | 45% | Reduce capsaicin; track individual foods in diary |
| Certain skincare products | 41% | Patch-test new products; avoid alcohol-based toners |

*Source: National Rosacea Society patient survey data, adapted for educational use.*

## How do you avoid triggering rosacea?

<b>Short answer:</b> Avoiding rosacea flare-ups depends on building habits around your personal trigger list, not a universal one. Start a 14-day diary recording what you eat, drink, the weather, your stress level, and your skin's response. After two weeks, patterns emerge. Sun protection is non-negotiable for everyone with rosacea: the Canadian Dermatology Association (CDA) recommends SPF 30 or higher every morning, even on cloudy days, because up to 40% of UV reaches skin through overcast skies. Physical sunscreens containing zinc oxide or titanium dioxide tend to suit rosacea skin better than chemical filters.

Beyond sun protection, reduce alcohol (especially red wine), choose lukewarm over hot beverages, and switch to fragrance-free, pH-balanced cleansers. During the Canadian winter, wind and cold air rank among the most common rosacea flare-up causes, so a physical barrier outdoors helps. Learn more about how our climate affects barrier function in [sunscreen science and the Canadian climate](/blog/sunscreen-science-spf-uva-uvb-and-the-canadian-climate).

## How do you relieve a rosacea flare-up?

<b>Short answer:</b> To calm an active flare, move to a cool environment immediately, apply a cool (not cold) damp cloth for 10 minutes, then use a plain, fragrance-free moisturiser to restore barrier function. Avoid any active ingredients like retinoids, exfoliating acids, or benzoyl peroxide during a flare. Over-the-counter products containing niacinamide (4-5%) can reduce transient redness without irritating inflamed skin. For flares driven by papulopustular rosacea, your prescribed topical treatment should continue. If a flare lasts more than a week, contact a dermatologist. In Canada, telemedicine platforms like [DermaDex](/) let you get an assessment and prescription refill without waiting months for a specialist appointment.

Short-term, brief application of a topical vasoconstrictor (brimonidine 0.33% gel, sold as Mirvaso) reduces redness within 30 minutes for many patients, though rebound flushing can occur with daily use. Discuss frequency limits with your prescribing physician.

## What autoimmune condition is linked to rosacea?

<b>Short answer:</b> Rosacea shares immunological pathways with several autoimmune conditions. Research published in the Journal of the American Medical Association (JAMA) has identified associations between rosacea and inflammatory bowel disease, particularly Crohn's disease and celiac disease. A large 2015 Danish cohort study (over 5 million participants) found that rosacea patients had significantly higher odds of rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and celiac disease than matched controls. The mechanistic overlap involves toll-like receptor activation, cathelicidin dysregulation, and shared genetic susceptibility loci. This does not mean rosacea causes these conditions; it means the underlying inflammatory environment can be common to both. Patients with rosacea who also experience gastrointestinal symptoms, joint pain, or unexplained fatigue should raise this with their GP.

## What are the main rosacea treatment options in 2025?

<b>Short answer:</b> The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/rosacea) classifies rosacea treatment by subtype. For erythematotelangiectatic rosacea (ETR, persistent redness and flushing), brimonidine gel and oxymetazoline cream are approved vasoconstrictors. For papulopustular rosacea (PPR, red bumps), topical azelaic acid 15% gel, metronidazole 0.75-1% gel or cream, and ivermectin 1% cream are first-line choices. Oral low-dose doxycycline 40 mg (modified-release), approved by the FDA and listed by Health Canada, remains the most studied systemic option for moderate-to-severe PPR.

### Rosacea subtype comparison

| Subtype | Key features | First-line treatment |
|---|---|---|
| Erythematotelangiectatic (ETR) | Flushing, persistent central redness, telangiectasias | Brimonidine gel, oxymetazoline cream, laser/IPL |
| Papulopustular (PPR) | Red papules and pustules, central redness | Topical azelaic acid, metronidazole, ivermectin; oral doxycycline 40 mg |
| Phymatous | Skin thickening, rhinophyma (nose), sebaceous hyperplasia | Oral isotretinoin (low-dose), surgical debulking, laser |
| Ocular | Red, irritated eyes; blepharitis; corneal involvement | Lid hygiene, artificial tears, oral omega-3, doxycycline |

*Based on AAD and National Institutes of Health (NIH) clinical guidance, 2024-2025.*

For topical rosacea treatment, ivermectin 1% cream (Soolantra) has shown superiority over metronidazole 0.75% in reducing inflammatory lesion counts in two large randomised controlled trials. Azelaic acid 15% gel (Finacea) addresses both redness and papules and is well-tolerated on sensitive skin. Patients often rotate or combine agents under dermatologist supervision.

## Does rosacea diet management actually work?

<b>Short answer:</b> The evidence for rosacea diet modification is indirect but consistent: foods that cause vasodilation and inflammatory signalling worsen flares in susceptible individuals. The main dietary culprits are alcohol (especially red wine and beer), hot beverages above about 60°C, capsaicin in spicy foods, and histamine-rich foods like aged cheese and cured meats. No randomised controlled trial has proven a specific rosacea diet prevents flares, but observational data and patient-reported outcomes strongly support avoidance of personal food triggers. An anti-inflammatory dietary pattern (high in omega-3 fatty acids from fish, colourful vegetables, and low glycaemic carbohydrates) may reduce baseline systemic inflammation. Probiotic supplementation is under study, with preliminary data suggesting gut microbiome dysbiosis correlates with rosacea severity.

The practical approach: keep a food-symptom diary for 2-4 weeks, eliminate the top 3 suspects one at a time, and reassess skin response after 4 weeks. This is more evidence-guided than following a fixed elimination diet.

## Sources

- American Academy of Dermatology (AAD). *Rosacea: Overview.* [https://www.aad.org/public/diseases/rosacea](https://www.aad.org/public/diseases/rosacea)
- National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases. *Rosacea: Diagnosis, Treatment, and Steps to Take.* May 2024. [https://www.niams.nih.gov/health-topics/rosacea](https://www.niams.nih.gov/health-topics/rosacea)
- Egeberg A, et al. *Rosacea and risk of autoimmune disease.* JAMA Dermatology. Published on PubMed. [https://pubmed.ncbi.nlm.nih.gov/26043855/](https://pubmed.ncbi.nlm.nih.gov/26043855/)
- Canadian Dermatology Association (CDA). *Rosacea.* [https://dermatology.ca/public-patients/skin/rosacea/](https://dermatology.ca/public-patients/skin/rosacea/)
- AAD. *How to prevent rosacea flare-ups.* [https://www.aad.org/public/diseases/rosacea/triggers/prevent](https://www.aad.org/public/diseases/rosacea/triggers/prevent)

## FAQ
### How to relieve a rosacea flare-up?
Move to a cool environment and apply a cool damp cloth to the face for 10 minutes. Avoid any active skincare ingredients such as retinoids or acids during the flare. Apply a fragrance-free, ceramide-based moisturiser to restore barrier function. Niacinamide 4-5% serum can reduce transient redness without irritating inflamed skin. If your dermatologist has prescribed brimonidine gel (Mirvaso), a single application reduces visible redness within 30 minutes, but limit use to avoid rebound flushing. For papulopustular flares, continue your prescribed topical antiparasitic or antibiotic. If the flare persists beyond 7 days or is unusually severe, contact a dermatologist. Telemedicine services like DermaDex allow same-week assessment without a long specialist wait.

### How to avoid triggering rosacea?
The most effective strategy is a personal trigger diary kept for 14 days, logging food, weather, stress, and skin response daily. Population data show sun exposure, heat, stress, alcohol, hot beverages, and spicy food rank as the top triggers, but each person's hierarchy differs. Apply SPF 30+ sunscreen daily, including on cloudy days; physical filters (zinc oxide, titanium dioxide) are better tolerated than chemical ones. Reduce or eliminate alcohol, let coffee cool before drinking, wear a scarf outdoors in cold or windy weather, and switch to fragrance-free cleansers. Avoid high-heat activities like saunas and hot yoga. Review all skincare products for alcohol, witch hazel, and synthetic fragrance, which commonly provoke flares.

### What autoimmune is linked to rosacea?
Research shows rosacea correlates with several autoimmune and inflammatory diseases. A major Danish cohort study of over 5 million individuals found rosacea patients have higher rates of celiac disease, Crohn's disease, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis compared to the general population. The shared mechanism appears to involve toll-like receptor pathway dysregulation and elevated cathelicidin peptides, which drive both skin inflammation in rosacea and systemic autoimmunity. This association does not mean rosacea causes these conditions. If you have rosacea and also experience persistent digestive symptoms, joint pain, or fatigue, discuss autoimmune screening with your family doctor, as early detection changes outcomes for most of these conditions.

### What is the number one trigger for rosacea?
Sun exposure is the most commonly reported rosacea trigger, cited by up to 81% of patients in National Rosacea Society survey data. UV radiation activates inflammatory signalling in rosacea-prone skin, dilates blood vessels, and can worsen both erythematotelangiectatic and papulopustular subtypes. Broad-spectrum SPF 30 or higher applied every morning is the single most impactful prevention habit. Emotional stress ranks a close second at 79%, followed by heat at 75%. Because triggers are cumulative, a day with moderate sun plus exercise plus a glass of wine can produce a flare even when each factor alone would not. Identifying and controlling your top three personal triggers through a diary approach reduces flare frequency substantially for most patients.

---

# Audit Logging in Healthcare Apps: What PHIPA Requires

URL: https://www.dermadex.ca/blog/audit-logging-in-healthcare-apps-what-phipa-requires
Category: Compliance & Security
Author: Elham Hafezi
Published: 2025-09-09

## TL;DR
PHIPA requires an electronic audit log for every EHR access — user ID, timestamp, record, and action | Logs must be produced to Ontario's Information and Privacy Commissioner (IPC) on request under s. 55.3(4)(i) | Minimum retention is seven years for most health records under Ontario's regulations | PHIPA's audit log rules became mandatory with Bill 188 amendments in 2020 | Non-compliance can trigger IPC investigations and fines up to $100,000 CAD

*As of September 9, 2025.*

The Personal Health Information Protection Act (PHIPA) is Ontario's primary law governing how health information custodians collect, use, and disclose personal health information (PHI). When your app touches an electronic health record (EHR), PHIPA does not just regulate what you store — it requires you to keep a detailed, tamper-evident log of every access. Getting audit logging right protects your patients, satisfies the Information and Privacy Commissioner (IPC), and keeps your organization out of enforcement proceedings.

This article covers what PHIPA's audit log requirements are, how they compare to the Personal Information Protection and Electronic Documents Act (PIPEDA) and the American Health Insurance Portability and Accountability Act (HIPAA), and what a compliant implementation looks like for a Canadian healthtech product. For the broader data protection picture, see our guide on [PHIPA, PIPEDA, and skin health data](/blog/phipa-pipeda-and-skin-health-data-what-patients-should-know).

## What does PHIPA require for audit logs?

<b>Short answer:</b> PHIPA requires Ontario health information custodians who operate electronic health records to log every instance where PHI is viewed, modified, or disclosed. Under section 55.3(4)(i), Ontario Health and custodians using provincial EHR systems must record who accessed which records, at what time, and what action was taken. The IPC can demand a copy of these logs at any time, and custodians must be able to produce them on request from a patient whose record was accessed.

The 2020 amendments introduced by Bill 188 (the *Connecting People to Home and Community Care Act*) made the audit log obligation explicit in the statute. Before that, the duty was inferred from the general obligation to have administrative safeguards. The amendment removed ambiguity: if you run an electronic health record system in Ontario, a functioning audit log is not optional.

The IPC's guidance document *Digital Health under PHIPA* sets out the expectation that logs capture at minimum: the identity of the user who accessed the record, the date and time of access, the specific record or data element accessed, and the type of action (view, edit, delete, export, print). Organizations that use [DermaDex](/) for artificial intelligence (AI)-assisted dermatology assessments should ensure their integration with any connected EHR satisfies these four fields for every transaction.

## What fields must a PHIPA-compliant audit log capture?

<b>Short answer:</b> At minimum, a compliant audit log must record the user identity, timestamp, the specific PHI record touched, and the action performed. Ontario's IPC guidance and PHIPA section 55.3 together require these four data points. Most mature implementations also capture the patient's identifier, the workstation or IP address, and the application module initiating the transaction, which helps with breach investigation.

The table below maps required fields across PHIPA, PIPEDA, and HIPAA so Canadian teams building cross-border or federated systems know where the obligations converge and where they differ.

| Field | PHIPA (Ontario) | PIPEDA (Federal) | HIPAA (US) |
|---|---|---|---|
| User / accessor identity | Required (s. 55.3) | Recommended (Principle 7) | Required (§ 164.312(b)) |
| Timestamp (date + time) | Required | Recommended | Required |
| Record / data element accessed | Required | Recommended | Required |
| Action type (view / edit / delete) | Required | Recommended | Required |
| Patient / subject identifier | Strongly implied | Not specified | Required |
| Workstation or IP address | Recommended by IPC | Not specified | Addressable |
| Reason / purpose of access | Required for disclosures | Not specified | Addressable |
| Export or print events | Required | Not specified | Addressable |

PIPEDA does not prescribe audit log fields with the same precision as PHIPA or HIPAA, but organizations subject to both laws — for example, a Canadian telehealth platform that also serves patients in the US — must satisfy the stricter standard on each field. If you store or transmit patient images, our article on [encrypting patient images at rest and in transit](/blog/encrypting-patient-images-at-rest-and-in-transit) covers the complementary technical controls PHIPA expects alongside audit logging.

## How long must healthcare organizations retain audit logs?

<b>Short answer:</b> Ontario health regulations require health records to be retained for at least ten years from the date of the last entry, or until the patient turns 18, whichever is longer. Audit logs are part of the health record under PHIPA and inherit that retention schedule. In practice, most Ontario health information custodians apply a seven-to-ten year retention window for audit log data specifically, consistent with guidance from the Ontario Ministry of Health.

Log retention is a common gap in healthcare app compliance programs. Development teams often set database purge jobs that trim logs after 90 days for storage cost reasons, not realizing that audit trail data is subject to the same retention rules as the clinical record itself. A short-retention audit log does not just create a regulatory risk — it also eliminates your organization's ability to investigate a privacy breach that surfaces years after the fact.

For cloud-hosted systems, immutable log storage services (append-only buckets, write-once object storage) satisfy both the retention and the tamper-evidence expectations in the IPC guidance. The IPC has noted in enforcement decisions that mutable logs — where records can be altered or deleted by administrators — do not meet the spirit of the audit log requirement even if the raw retention period is met.

## What is an EHR audit trail?

<b>Short answer:</b> An EHR (electronic health record) audit trail is a time-stamped, sequential record of every interaction with a patient's digital health record. It captures who did what, when, and from where. The audit trail serves three purposes: detecting unauthorized access, supporting breach investigations, and giving patients a verifiable account of who has seen their information.

EHR audit trails differ from application logs in one critical way: they are patient-centric rather than system-centric. A system log might record that a database query ran at a given timestamp. An EHR audit trail maps that query to a specific patient record, a specific clinician credential, and a specific clinical purpose. Research published in *JAMIA* by Kannampallil et al. (2022) documents how EHR audit log data has become a significant research resource for understanding clinical workflows — precisely because of this patient-record linkage.

For healthcare apps built on top of an existing EHR (such as Oscar Electronic Medical Record (EMR) or TELUS PS Suite), the audit trail responsibility may be split: the EHR vendor logs access within their system, but your application must log the actions it takes via the EHR's API. Both layers are required.

## What is an audit trail for electronic records?

<b>Short answer:</b> An audit trail for electronic records is a mechanism that automatically records every create, read, update, and delete operation applied to a record, along with the actor and time. In healthcare, this typically means a separate, append-only log table or log service that cannot be modified by the same user roles that access the clinical data.

From a software architecture standpoint, audit trails are most reliably implemented at the database or middleware layer rather than in application code. Application-layer logging can be bypassed by direct database access, batch jobs, or administrative tools. A trigger-based or change-data-capture approach at the data layer ensures that every write to a PHI table generates a corresponding audit entry regardless of which application component initiated the change.

For healthcare apps in Ontario, the IPC expects audit trails to be accessible to privacy officers without requiring the same administrative privileges used for clinical operations. Separating the audit log read path from the EHR admin path is both a security control and a governance requirement under PHIPA.

## What should be included in an audit trail?

<b>Short answer:</b> A complete healthcare audit trail should include: user or system identity, timestamp (with timezone), the specific record or dataset affected, the action type, the patient identifier, the application module or API endpoint, the IP address or workstation identifier, and — for disclosures to third parties — the recipient and stated purpose. This set satisfies PHIPA, aligns with HIPAA addressable requirements, and gives privacy officers the information needed to answer a patient's access request.

Optional but valuable fields include the session ID (to link events in a single login session), the EHR version or schema version (useful when investigating historical access after a system upgrade), and a hash of the accessed record (to prove the record has not changed since it was accessed). These fields add storage overhead but significantly reduce the time to close a privacy breach investigation.

## What are the four different types of audit trails?

<b>Short answer:</b> In healthcare IT, audit trails are commonly categorized as: (1) access audit trails, which log who viewed a record; (2) change audit trails, which log modifications including edits and deletions; (3) disclosure audit trails, which log when PHI was sent to an external party; and (4) system audit trails, which log administrative and configuration actions. PHIPA's audit log requirement primarily covers the first three; the fourth is a security best practice rather than a statutory requirement.

Each type serves a different compliance function. Access audit trails respond to patient requests ('who has seen my file?'). Change audit trails support clinical integrity investigations and malpractice defense. Disclosure audit trails document the chain of custody for PHI shared with insurers, researchers, or other custodians. System audit trails detect privilege escalation and unauthorized configuration changes.

Mature healthcare apps implement all four, with access and change trails stored in the same patient-centric audit table and disclosure trails recorded in a separate consent-and-disclosure register. The IPC's enforcement decisions suggest that access and disclosure trails are the most frequently requested during investigations.

## Sources

- Ontario. *Personal Health Information Protection Act, 2004*, SO 2004, c 3, Sch A, s 55.3(4)(i). [https://www.ontario.ca/laws/statute/04p03](https://www.ontario.ca/laws/statute/04p03)
- Information and Privacy Commissioner of Ontario. *Digital Health under PHIPA: Selected Overview*. [https://www.ipc.on.ca](https://www.ipc.on.ca)
- Kannampallil T, et al. 'Using electronic health record audit log data for research.' *J Am Med Inform Assoc*, 2022. [https://pubmed.ncbi.nlm.nih.gov/35390822/](https://pubmed.ncbi.nlm.nih.gov/35390822/)
- Government of Canada. *Personal Information Protection and Electronic Documents Act* (PIPEDA), SC 2000, c 5. [https://laws-lois.justice.gc.ca/eng/acts/P-8.6/](https://laws-lois.justice.gc.ca/eng/acts/P-8.6/)
- Office of the Privacy Commissioner of Canada. *PIPEDA in Brief*. [https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/pipeda_brief/](https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/pipeda_brief/)
- US Department of Health and Human Services. *HIPAA Administrative Simplification — Security Rule* (45 CFR § 164.312). [https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html](https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html)
- Meingast M, et al. 'Security and privacy issues with health care information technology.' *Conf Proc IEEE Eng Med Biol Soc*, 2006. [https://pubmed.ncbi.nlm.nih.gov/17946847/](https://pubmed.ncbi.nlm.nih.gov/17946847/)
- Adler-Milstein J, et al. 'EHR audit logs: A new goldmine for health services research.' *J Am Med Inform Assoc*, 2020. [https://pubmed.ncbi.nlm.nih.gov/32363392/](https://pubmed.ncbi.nlm.nih.gov/32363392/)

## FAQ
### What is an EHR audit trail?
An EHR (electronic health record) audit trail is a time-stamped, sequential record of every interaction with a patient's digital health record. It captures who accessed the record, what action was taken, when, and from which system or workstation. In Ontario, PHIPA section 55.3(4)(i) requires health information custodians to maintain this trail for every EHR transaction and to produce it to the IPC on request. Patients can also request a copy to see who has viewed their information. A complete EHR audit trail differs from a generic application log in that every entry is linked to a specific patient record and a specific user credential, not just a system event.

### What is an audit trail for electronic records?
An audit trail for electronic records is an automatic, append-only record of every create, read, update, and delete operation applied to a digital record, along with the actor, timestamp, and record identifier. In healthcare, this mechanism is required by law in Ontario under PHIPA and in the US under HIPAA. The trail must be tamper-evident — typically implemented at the database layer using triggers or change-data-capture so that application-layer bypasses cannot suppress entries. For health records, the audit trail is itself part of the patient record and inherits the same multi-year retention obligations.

### What should be included in an audit trail?
A complete healthcare audit trail should include: the identity of the user or system that performed the action, the date and time with timezone, the specific record or dataset affected, the action type (view, create, edit, delete, export), the patient identifier, the application module or API endpoint, and the IP address or workstation identifier. For disclosures to third parties, the recipient identity and stated purpose are also required under PHIPA. Optional but valuable fields include session ID, the EHR schema version at the time of access, and a cryptographic hash of the accessed record. Together, these fields allow a privacy officer to reconstruct the full context of any access event during a breach investigation.

### What are the four different types of audit trails?
In healthcare IT, audit trails fall into four categories: (1) access audit trails, which log every instance of a record being viewed; (2) change audit trails, which log edits, additions, and deletions; (3) disclosure audit trails, which record when PHI was transmitted to an external party such as an insurer or researcher; and (4) system audit trails, which capture administrative actions like permission changes and configuration updates. PHIPA's explicit audit log requirement under section 55.3 focuses on access and change trails. Disclosure trails are required under PHIPA's consent and accountability provisions. System audit trails are a security best practice expected by the IPC but are not specified in the statute.

---

# Photo Quality Guide: Take Better Skin Photos at Home

URL: https://www.dermadex.ca/blog/photo-quality-guide-take-better-skin-photos-at-home
Category: Patient Education
Author: Maryam Sobhkhiz Sabet
Published: 2025-08-05

## TL;DR
Natural daylight within 60 cm gives the sharpest, most colour-accurate skin photos | Three shots per lesion (close-up, mid-range, body-area) is standard teledermatology protocol (AAD, 2023) | A 1-cent coin in frame provides the scale a dermatologist needs to gauge lesion size | Flash reflects off skin and hides texture so always disable it | DermaDex connects Canadian patients to certified dermatologists at dermadex.ca

*As of August 5, 2025.*

A blurry, poorly lit photo of a skin lesion tells your dermatologist almost nothing. A sharp, well-framed image taken in natural daylight can shorten your assessment time and sometimes replace an in-person triage visit entirely. This guide gives you the exact steps to photograph any skin condition — a new mole, a spreading rash, or a patch of discoloured skin — so the image is clinically useful. Before you send anything, review [how to do a monthly self-skin check](/blog/how-to-perform-a-monthly-self-skin-check-step-by-step) so you know what to look for first.

## What lighting works best for skin photos?

<b>Short answer:</b> Indirect natural daylight is the best light source for skin photography. Stand near a window on an overcast day or in open shade outdoors. Overcast light scatters evenly across the skin, so you get true colour and visible texture without highlights that wash out lesion detail. Avoid direct sunlight (harsh shadows), indoor incandescent bulbs (yellow cast), and above all your phone's built-in flash, which creates a specular reflection that flattens texture and disguises the border irregularity a dermatologist needs to assess.

## How do you photograph a mole for your doctor?

<b>Short answer:</b> Use natural daylight, hold your camera 15 to 30 cm from the lesion, tap the screen to lock focus directly on the mole, and place a coin or ruler beside it for scale. Disable flash. Take three shots: a close-up of the mole alone, a mid-range view showing 5 cm of surrounding skin, and a wider body-area shot showing location (shoulder, back, shin). This three-shot sequence is the standard protocol recommended by the American Academy of Dermatology (AAD) for teledermatology submissions.

A coin is not decorative. Dermatologists use it to estimate diameter: a Canadian 1-cent coin is 19.1 mm across, which gives an immediate size reference. Without a scale object, a 4 mm lesion and a 14 mm lesion can look identical in a photo.

## Does camera resolution affect whether a dermatologist can read your photo?

<b>Short answer:</b> Any smartphone made after 2018 has sufficient resolution for teledermatology. Blur, poor lighting, and missed focus are the real problems. A 12-megapixel photo taken in focus in daylight outperforms a 50-megapixel photo taken in a dim bathroom with flash. If your phone has a portrait or macro mode, macro is preferable for close-up shots; portrait mode adds artificial background blur that can obscure lesion edges. Shoot in standard photo mode and let the lighting and distance do the work.

A 2024 study published in *Telemedicine and e-Health* found that image quality control is a key factor in teledermatology outcomes. See the [teledermatology image quality study](https://pubmed.ncbi.nlm.nih.gov/38150704/) for the full data.

## What is a teledermatology photo guide you can follow before every upload?

<b>Short answer:</b> Run through this five-point checklist before you send any skin image. Remove makeup, nail polish, or covering dressings from the area first. Set up near a window for natural light. Hold your camera 15 to 30 cm away, tap to focus, and shoot with flash off. Include a coin for scale. Take close-up, mid-range, and location shots. Check the preview: if the lesion looks blurry or the colour looks orange or green, move to better light and reshoot. The 60 seconds you spend on this saves your clinician from requesting a repeat submission.

For a deeper comparison of what visit types are best handled by photo versus in-person assessment, see [teledermatology vs in-person visits: when to choose which](/blog/teledermatology-vs-in-person-visits-when-to-choose-which).

| Element | Recommended | Avoid |
|---|---|---|
| Light source | Indirect natural daylight, window light on overcast day | Flash, direct sunlight, incandescent bulbs |
| Camera distance | 15-30 cm for close-up; 50-80 cm for mid-range | Less than 10 cm (blurs), more than 1 m (too small) |
| Background | Plain, contrasting fabric (white towel, dark cloth) | Patterned clothing, carpet, busy backgrounds |
| Scale object | Coin (19 mm) or ruler placed beside lesion | No scale object, makes size impossible to judge |
| Focus | Tap screen to focus on lesion; confirm in preview | Auto-focus locked on background or surrounding skin |
| Camera mode | Standard photo mode; macro if available | Portrait mode, beauty filter, digital zoom |
| Makeup/coverings | Remove before shooting | Foundation, nail polish, bandages over lesion |

## Can I take a picture of a rash to see what it is?

<b>Short answer:</b> A photo of a rash can support a clinical assessment, but it cannot replace one. A well-taken image lets a dermatologist or AI (Artificial Intelligence)-assisted screening tool evaluate colour, distribution, border, and texture enough to triage urgency and suggest likely differentials. What a photo cannot show is texture you feel with a finger, skin temperature, or whether the rash blanches under pressure (the glass test for meningococcal disease). If your rash spreads rapidly, involves mucous membranes, or is accompanied by fever or difficulty breathing, seek emergency care rather than sending a photo.

## Is there an app to scan skin conditions?

<b>Short answer:</b> Several applications offer AI-assisted skin screening, including [DermaDex](https://dermadex.ca), which connects patients across Canada to certified dermatologists with AI-assisted triage. Consumer AI apps vary widely in validation quality, so check whether the tool has been evaluated against clinical datasets before relying on results. Health Canada does not currently regulate standalone consumer skin-scanning apps as medical devices in all categories, so user discretion matters. A validated tool used alongside, not instead of, a clinician review gives you the most reliable pathway.

## How to take dermatology pictures?

<b>Short answer:</b> The steps are: prepare the area (remove coverings and clean the skin), find indirect natural light, set your phone to standard photo mode with flash off, position yourself 15 to 30 cm from the lesion, place a coin beside it, tap to focus, and shoot three frames. Review the preview immediately: zoom in to confirm the lesion centre is sharp, not the surrounding skin. If the image passes review, label it with body location and date before uploading to your clinic or telehealth platform. Consistent labelling such as left forearm mole Aug 2025 is especially useful for tracking changes over time.

The AAD's patient photography guidance, available at [aad.org](https://www.aad.org), outlines the same approach for home documentation.

## Sources

- American Academy of Dermatology (AAD). "How to take pictures of your skin for your dermatologist." Updated July 20, 2023. https://www.aad.org
- Marin-Gomez FX, et al. "Accuracy of a smartphone-based dermatological diagnosis." PubMed/NCBI, 2020. https://pubmed.ncbi.nlm.nih.gov/38150704/
- Canadian Dermatology Association (CDA). Teledermatology resources. https://dermatology.ca
- National Institutes of Health (NIH) / National Library of Medicine. Dermatology imaging. https://www.ncbi.nlm.nih.gov

## FAQ
### Can I take a picture of a rash to see what it is?
A photo of a rash can support a clinical assessment but cannot replace one. A well-taken image lets a dermatologist or AI-assisted screening tool evaluate colour, distribution, border, and texture enough to triage urgency and suggest likely diagnoses. What a photo cannot show is temperature, how the rash feels to the touch, or whether it blanches under pressure. If your rash spreads rapidly, involves your mouth or eyes, or comes with fever or breathing difficulty, seek emergency care instead of sending a photo. For anything else, a clear image taken in natural light at 15 to 30 cm with flash off gives a clinician enough to advise next steps.

### Is there an app to scan skin conditions?
Several applications offer AI-assisted skin screening. DermaDex (dermadex.ca) is a Canadian platform that combines AI-assisted triage with access to certified dermatologists, built to meet Canadian privacy standards. Consumer AI apps vary widely in clinical validation, so check the evidence before relying on results. Health Canada does not currently regulate all standalone consumer skin-scanning apps as medical devices, which means quality controls differ between products. A validated tool used alongside clinician review gives the most reliable pathway. An app result is a starting point, not a diagnosis.

### How to take dermatology pictures?
Prepare the area by removing makeup, nail polish, or bandages. Find indirect natural daylight near a window. Set your phone to standard photo mode with flash disabled. Hold the camera 15 to 30 cm from the lesion, place a coin beside it for scale, tap the screen to lock focus directly on the lesion, then shoot. Take three frames: close-up, mid-range showing surrounding skin, and a wider body-location shot. Review the preview immediately so the lesion centre is sharp. Label the file with body location and date before uploading to your clinic or teledermatology platform.

### What are the 10 most common skin disorders?
The most common skin conditions seen in Canadian adults include acne, eczema (atopic dermatitis), psoriasis, rosacea, seborrheic dermatitis, contact dermatitis, tinea (fungal infections), warts, basal cell carcinoma, and melanoma. Acne and eczema together account for the largest share of dermatology referrals in Canada. If you have a spot or lesion you are uncertain about, a clear photograph taken following the steps in this guide gives a dermatologist or teledermatology platform enough information to advise whether an in-person visit is needed.

---

# Rural Healthcare in Canada: How Telehealth Closes the Gap

URL: https://www.dermadex.ca/blog/rural-healthcare-in-canada-how-telehealth-closes-the-gap
Category: Telemedicine
Author: Mohsen Khoddami
Published: 2025-07-01

## TL;DR
Rural Canadians are 3x more likely to have no specialist within 50 km (CIHI, 2023) | Indigenous communities in Nunavut have used telehealth equipment in every health centre for over a decade (CIHI, 2022) | Virtual visits grew from 1% to over 20% of primary care contacts between 2019 and 2021 (CIHI, 2022) | BC's Real-Time Virtual Support network served rural, First Nations, and remote communities province-wide (CMAJ, 2025) | Dr. Mohsen Khoddami, MD, has practiced dermatology for 30+ years and considers geography the single largest equity gap in Canadian skin care

*As of July 1, 2025.*

Over 6.3 million Canadians, roughly one in six, live in rural or remote communities. They pay the same taxes and carry the same health risks as city residents, yet they face specialist wait times that can stretch months longer, travel distances measured in hours rather than minutes, and a narrower range of services available locally. The Canadian Institute for Health Information (CIHI) has documented this divide consistently: rural residents have direct access to far fewer health services and providers than urban residents do.

Telehealth, the delivery of health services by video, phone, or asynchronous digital tools, does not solve every rural health problem. It cannot perform surgery or replace a community hospital. But for a broad range of consultations, follow-ups, and specialist referrals, it works. For dermatology specifically, where the vast majority of assessments are visual, the case for virtual care is strong. [DermaDex](/) connects patients across Canada to certified dermatologists, including patients who would otherwise wait months for an in-person appointment.

## What makes rural healthcare access so difficult in Canada?
Short answer: Rural Canadians face a structural shortage of family doctors and specialists, much longer distances to health facilities, and persistent difficulty recruiting clinicians outside major cities. These gaps have held for decades despite federal and provincial policy efforts, and avoidable hospitalisation rates remain consistently higher in rural areas than in urban ones.

The Canadian Medical Association (CMA) notes that rural communities often depend on community health centres staffed by temporary or travelling physicians. When those positions go unfilled, residents may drive two to four hours each way for care that a city resident accesses in 30 minutes. CIHI data shows that rates of avoidable hospitalisations, conditions that should be managed before they require a hospital stay, are higher in rural areas, a signal that primary and specialty care is reaching people too late.

Physician recruitment is part of the problem. Medical graduates cluster in urban centres where income is higher, professional networks are denser, and personal amenities are greater. Incentive programs exist at the provincial level, but vacancy rates in rural general practice remain elevated. Specialist shortages are worse: rural Canadians are far less likely to have a cardiologist, dermatologist, or mental health specialist within reasonable distance.

## How does telehealth reduce wait times for rural Canadians?
Short answer: Telehealth connects patients to remote specialists by video or store-and-forward digital tools, removing the travel barrier and letting urban-based clinicians serve underserved regions. For the consults it handles well, it cuts median wait times significantly, from weeks to days in multiple Canadian and international trials.

A 2019 study published in PMC ([pmc.ncbi.nlm.nih.gov/articles/PMC6508037](https://pmc.ncbi.nlm.nih.gov/articles/PMC6508037/)) examined telehealth delivery in northern Canada and found it enabled cost-effective, accessible care closer to patients' homes. For dermatology, store-and-forward teledermatology, where images and clinical notes are submitted asynchronously for specialist review, reduces median consult wait times from weeks to days. Roughly 70 to 80 percent of common dermatology presentations can be assessed accurately from high-quality photographs with a structured clinical history.

Nunavut offers a useful example. CIHI's 2022 report on virtual care expansion documented that Nunavut deployed telehealth equipment to all 25 communities more than a decade ago. Every health centre has the infrastructure to connect patients with specialists in the south without air travel. This matters in a territory where flying to Iqaluit for a consult can cost thousands of dollars and disrupt a patient's work and family life for days. [Teledermatology versus in-person visits: when to choose which](/blog/teledermatology-vs-in-person-visits-when-to-choose-which) explores these trade-offs in more depth.

## What telehealth programs exist specifically for rural and Indigenous communities in Canada?
Short answer: Provinces and territories run publicly funded telehealth networks, and Indigenous Services Canada (ISC) funds dedicated virtual care programs for First Nations and Inuit communities. BC's Real-Time Virtual Support network is among the most developed provincial examples, while Nunavut's decade-long investment shows what sustained infrastructure commitment can achieve for remote populations.

BC's Real-Time Virtual Support (RTVS) network, described in a 2025 *CMAJ* paper by Ho et al. ([cmaj.ca/content/197/15/E414](https://www.cmaj.ca/content/197/15/E414)), connects rural, remote, First Nations, and pan-provincial communities to specialist advice in real time. The network supports frontline clinicians, not just patients: a nurse or community health worker in a remote setting can reach a physician or specialist within minutes for guidance on a complex case.

ISC funds the First Nations and Inuit Home and Community Care program, which includes telehealth components for communities that lack on-site nurses or physicians. Federal broadband investments are a necessary precondition: telehealth only works where internet connectivity is reliable. The table below summarises key differences in healthcare access between urban and rural Canadians.

| Metric | Urban | Rural | Source |
|---|---|---|---|
| Average distance to nearest specialist | Under 10 km | 80-200+ km | CIHI, 2023 |
| Specialist-to-population ratio | ~200 per 100,000 | ~30 per 100,000 | CMA, 2022 |
| Avoidable hospitalisation rate (per 100,000) | ~220 | ~370 | CIHI, 2023 |
| Households with 25/5 Mbps broadband | ~97% | ~46% | CRTC, 2023 |
| Virtual primary care contacts (2021) | ~22% | ~18% | CIHI, 2022 |

## Is telehealth covered by provincial health insurance in Canada?
Short answer: Most provinces now cover physician-led virtual visits under provincial health plans. Ontario's Ontario Health Insurance Plan (OHIP) added billing codes for telephone and video visits in 2020, and most provinces have retained them. Coverage for allied health, mental health, and specialist telehealth is far less consistent, and gaps fall hardest on rural and low-income Canadians.

During the COVID-19 pandemic, provinces moved quickly to add billing codes for virtual care. Most of these codes were retained post-pandemic, though some provinces reduced fees during budget negotiations with physician associations. For dermatology, publicly funded teledermatology is available in some provinces, notably BC through its DermCafe program, but is not universally available. Patients in provinces without funded programs pay out of pocket or through private insurance. This creates a two-tier dynamic that disproportionately affects rural and low-income Canadians, who are less likely to hold supplemental coverage.

Patients interested in where [DermaDex](/) fits within this landscape, including which consultations may be reimbursable and which fall outside public coverage, can review our [state of dermatology access in Canada](/blog/the-state-of-dermatology-access-in-canada-in-2024) overview for context.

## How does telehealth serve Indigenous communities in Canada?
Short answer: Telehealth reduces the burden of medical travel for First Nations and Inuit patients, supports on-site community health workers with specialist backup, and when properly resourced, is culturally safer than requiring patients to travel to distant urban hospitals far from their families and communities.

For many First Nations and Inuit communities, medical travel is a significant hardship. Patients may need to fly to regional hospitals for specialist consultations, stay away from home for days or weeks, and navigate health systems where staff are unfamiliar with their language or cultural context. This documented reluctance to seek care has real consequences for outcomes. ISC has funded telehealth infrastructure as part of its broader First Nations and Inuit Health Branch mandate. A CIHI analysis of virtual care expansion noted that Nunavut's decade-long investment provides a model for other remote regions, with key lessons: equipment alone is insufficient, community health workers need training and ongoing technical support, and bandwidth must be reliable.

Cultural safety in virtual care requires the same attention it demands in person. Offering language interpretation, involving community health representatives, and building trust with Indigenous health governance bodies are all prerequisites for telehealth programs that communities will actually use. For skin conditions, dermatology is a field where virtual care is especially valuable: many conditions common in remote northern communities, including infections, inflammatory conditions, and skin cancer screening, can be assessed from photographs. Early detection of melanoma, as the ABCDE (Asymmetry, Border, Colour, Diameter, Evolving) framework shows, depends on access to screening, and teledermatology extends that access to communities that have lacked it.

## Sources

- CIHI. *Virtual Care in Canada.* 2022. [https://www.cihi.ca/en/virtual-care-in-canada](https://www.cihi.ca/en/virtual-care-in-canada)
- Health Canada. *Canada's Health Care System.* canada.ca. [https://www.canada.ca/en/health-canada/services/health-care-system.html](https://www.canada.ca/en/health-canada/services/health-care-system.html)
- Jong M et al. *Enhancing access to care in northern rural communities via telehealth.* PMC, 2019. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6508037/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6508037/)
- Jong M et al. PubMed abstract. [https://pubmed.ncbi.nlm.nih.gov/31070593/](https://pubmed.ncbi.nlm.nih.gov/31070593/)
- Ho K et al. *Real-Time Virtual Support: a network of virtual care for rural, remote, First Nations, and pan-provincial communities in BC.* CMAJ, 2025. [https://www.cmaj.ca/content/197/15/E414](https://www.cmaj.ca/content/197/15/E414)

## FAQ
### What makes rural healthcare access so difficult in Canada?
Rural Canadians face a structural shortage of family doctors and specialists, much longer distances to health facilities, and persistent difficulty recruiting clinicians outside major cities. The Canadian Medical Association (CMA) notes that rural communities often rely on temporary or travelling physicians to staff community health centres. CIHI data shows avoidable hospitalisation rates are consistently higher in rural areas, meaning preventable conditions are reaching a crisis point before care arrives. Specialist access is especially limited: a rural patient may wait months longer than an urban patient for the same dermatology or cardiology consult.

### Does telehealth actually work for rural patients in Canada?
Yes, for the consults it can handle. A 2019 study in PMC examined telehealth in northern Canada and found it delivered cost-effective, accessible care closer to patients' homes. CIHI's 2022 virtual care report documented that Nunavut, which equipped every community health centre with telehealth infrastructure over a decade ago, achieved meaningful specialist access without requiring patients to fly south. For dermatology, store-and-forward teledermatology, where photographs and clinical notes are submitted for asynchronous specialist review, has been shown to reduce median wait times from weeks to days in multiple trials.

### Is virtual care covered by provincial health insurance in Canada?
Most provinces cover physician-led virtual visits under public health insurance. Ontario's OHIP introduced billing codes for video and phone consultations in 2020 and retained most of them post-pandemic. Coverage for specialist telehealth, allied health, and mental health services is less consistent and varies by province. Publicly funded teledermatology exists in BC through programs like DermCafe but is not available everywhere. Rural and low-income Canadians, who are less likely to hold supplemental insurance, face the steepest gaps when publicly funded coverage does not extend to their needed service.

### How does telehealth help Indigenous communities in Canada?
Telehealth reduces the burden of medical travel for First Nations and Inuit patients, who often must fly to regional hospitals for specialist consults, staying away from family and community for days. Indigenous Services Canada (ISC) funds telehealth infrastructure as part of its First Nations and Inuit Health Branch mandate. CIHI's analysis of virtual care expansion highlights Nunavut's model, with equipment in every community health centre, as a template for remote regions. Cultural safety remains essential: programs that include language interpretation, community health worker involvement, and Indigenous governance input achieve higher uptake than those that do not.

---

# How Skin Lesion Classifiers Are Built: Architecture & Training

URL: https://www.dermadex.ca/blog/building-our-skin-lesion-classifier-architecture-and-training
Category: AI & Technology
Author: Elham Sayyah
Published: 2025-06-10

## TL;DR
HAM10000 contains 10,015 labelled dermoscopy images across 7 lesion classes, published by Tschandl et al. in Nature Scientific Data (2018) | Published CNNs have reached dermatologist-level accuracy on ISIC benchmarks per Esteva et al. (Nature, 2017) | Class imbalance is the central practical challenge: 67% of HAM10000 images are benign nevi | EfficientNet and ResNet architectures are widely used in published skin lesion classification research | AI-assisted tools are designed to support, not replace, certified dermatologist review

*As of June 10, 2025.*

AI-assisted dermatology tools help patients get faster, more consistent access to specialist review. A core component of these tools is a skin lesion classifier: a CNN (Convolutional Neural Network) that takes a dermoscopy image as input and outputs a probability distribution across lesion categories. This article explains how such classifiers are typically built, covering data, architecture, training decisions, and validation — drawing on published research.

## What is the HAM10000 dataset?
HAM10000 (Human Against Machine with 10,000 training images) is a publicly available benchmark of 10,015 dermoscopy images spanning seven skin lesion categories, assembled by Tschandl et al. and published in *Nature Scientific Data* in 2018. It remains the most widely used training corpus for skin lesion classification research as of mid-2025.

The seven classes are: melanocytic nevi (nv), melanoma (mel), benign keratosis (bkl), basal cell carcinoma (bcc), actinic keratosis (akiec), vascular lesions (vasc), and dermatofibroma (df). Images were collected across two decades from the Medical University of Vienna and Melanoma Institute Australia, covering a range of acquisition devices. The class distribution is heavily skewed, with approximately 67% of images being benign nevi — a well-known challenge for any team training a classifier on this data. The dataset is available through the [ISIC (International Skin Imaging Collaboration) archive](https://www.nature.com/articles/sdata2018161).

## Why do researchers use CNN instead of a standard neural network?
A CNN (Convolutional Neural Network) applies learned spatial filters that slide across an image, detecting texture, colour gradient, and structural features like asymmetric borders regardless of where they appear in the frame. A fully connected network would need to learn these spatial relationships separately for every pixel position, requiring far more parameters and training data to achieve comparable results.

For dermoscopy images, this matters in practice. A suspicious pigment network pattern in the upper-left corner of a 450x600 image should produce the same feature activations as the same pattern centred in the frame. Convolution provides that translation invariance by design. It also means the same trained weights apply to images of different resolutions by adjusting the final pooling layer — useful when input images come from different dermatoscope models.

Published comparisons consistently show that CNN backbones outperform simple fully connected networks on HAM10000 and similar dermoscopy datasets by a substantial margin on weighted F1 before any hyperparameter tuning.

A deeper primer on how computer vision models process skin images is available in our article on [how computer vision models detect skin conditions](/blog/how-computer-vision-models-detect-skin-conditions-a-technical-primer).

## Which architectures are used in published skin lesion classification research?
Research teams have evaluated a range of CNN architectures pretrained on ImageNet and fine-tuned on HAM10000. Published results show EfficientNet variants and ResNet-based models among the best-performing options on the ISIC benchmarks, balancing accuracy with parameter efficiency.

Architectures commonly reported in the literature include:

| Model | Year | Params (M) | Notes |
|---|---|---|---|
| ResNet-50 | 2015 | 25.6 | Strong baseline, widely cited in dermatology ML research |
| Inception-V3 | 2016 | 23.8 | Good at multi-scale features |
| EfficientNet-B3 | 2019 | 12.2 | Favourable accuracy-to-size ratio in published results |
| ViT-B/16 | 2020 | 86.6 | High accuracy on large datasets; parameter-heavy relative to HAM10000 scale |

The Vision Transformer (ViT-B/16) typically requires more training data to generalise well. HAM10000's 10,015 images is modest by computer vision standards, which is why CNN architectures with compound scaling — like EfficientNet — appear frequently in published skin lesion classification work. The ISIC annual challenge leaderboard provides a public record of model performance across these architectures.

For context on how architecture choices interact with Fitzpatrick skin tone generalisation, see our article on [training AI on diverse skin tones](/blog/training-ai-on-diverse-skin-tones-fitzpatrick-i-vi).

## How do researchers handle class imbalance during training?
Class imbalance is the central practical challenge in skin lesion classification CNN work. When approximately 67% of training images belong to a single class (benign nevi), a naive model learns to predict that class most of the time and still achieves a passable accuracy number — while failing badly on the clinically critical minority classes like melanoma.

Two complementary techniques are widely reported in the literature: weighted cross-entropy loss (giving rare classes proportionally higher gradient signal during backpropagation) and augmentation-based oversampling for minority classes. Augmentation typically includes random flip, rotation, colour jitter, and random crop with resize to generate synthetic variants, bringing minority classes to a higher effective training count per epoch.

Published results consistently show that these adjustments improve both overall weighted F1 and per-class recall for melanoma — reducing false-negative rates meaningfully compared to training on raw class proportions. In a clinical context, missing a melanoma is far more consequential than a false-positive that prompts a follow-up, which is why recall on the melanoma class is treated as the primary optimisation target in most published work.

## What training setups are typical in published research?
Published skin lesion classification papers typically use PyTorch or TensorFlow with pretrained ImageNet weights, AdamW or SGD optimisers, cosine learning rate schedules, and batch sizes between 16 and 64. Input images are commonly resized to between 224x224 and 300x300 pixels and normalised to ImageNet mean and standard deviation.

A standard data split is 80% train, 10% validation, and 10% test, stratified by class. Early stopping on validation weighted-F1 is common, and ensemble averaging across multiple training seeds is a well-established technique for reducing variance on small medical imaging datasets — consistent with findings in the [dermatologist-level classification paper by Esteva et al.](https://pubmed.ncbi.nlm.nih.gov/28117445/). FP16 mixed-precision training is now standard practice for reducing GPU memory consumption without degrading accuracy.

## What does a CNN's feature maps reveal about skin lesion patterns?
In early convolutional layers, a CNN responds to low-level edge contrasts and colour boundaries. Deeper layers activate on lesion-specific patterns: irregular pigment networks, atypical vascular structures, and asymmetric colour distributions that correlate with malignancy in clinical dermoscopy criteria.

Grad-CAM (Gradient-weighted Class Activation Mapping) is a widely used interpretability technique that generates heatmaps showing which image regions most influenced each classification decision. For melanoma predictions, activation typically concentrates on areas of irregular pigment network and blue-white veil — consistent with the dermoscopic criteria described in American Academy of Dermatology (AAD) clinical guidelines at [aad.org](https://www.aad.org). Surfacing these heatmaps alongside confidence scores in clinical review interfaces allows dermatologists to verify which features the model weighted most heavily before confirming or overriding the classification.

The foundational work showing CNN accuracy at dermatologist level was published by Esteva et al. in *Nature* in 2017 at [nature.com](https://www.nature.com/articles/nature21056), and remains a key benchmark for dermatology ML (Machine Learning) research.

## How are skin lesion classifiers validated against clinical benchmarks?
The ISIC challenge test sets provide consistent, blinded evaluation that prevents overfitting to a single institution's data distribution. Published ISIC 2019 results (25,331 images, 8 classes) show normalised multi-class accuracy scores ranging across participating teams, with top academic groups reporting results in the 0.60–0.65 range on normalised accuracy — a publicly accessible leaderboard that researchers use to compare approaches.

Dermatologist-to-dermatologist agreement on dermoscopy classification studies typically falls between 70% and 85% depending on lesion type and image quality, consistent with findings reported in the [HAM10000 dataset paper](https://www.nature.com/articles/sdata2018161). This inter-rater variability provides important context for evaluating AI model agreement rates.

AI-assisted skin lesion tools are not diagnostic devices and are not designed to replace clinician judgment. The clinical value lies in prioritisation and pre-classification — helping certified dermatologists allocate review time to the cases most likely to require urgent attention. Health Canada's regulatory position on AI-assisted medical devices is evolving; any deployed tool must operate within applicable Canadian federal guidelines at [canada.ca](https://www.canada.ca/en/health-canada.html).

## Sources

- Tschandl, P., Rosendahl, C. & Kittler, H. (2018). The HAM10000 dataset, a large collection of multi-source dermatoscopic images of common pigmented skin lesions. *Scientific Data* 5, 180161. https://www.nature.com/articles/sdata2018161
- Esteva, A. et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature* 542, 115-118. https://www.nature.com/articles/nature21056
- Esteva, A. et al. (2017). [PubMed record] https://pubmed.ncbi.nlm.nih.gov/28117445/
- American Academy of Dermatology (AAD). Dermoscopy: Overview and clinical use. https://www.aad.org
- Health Canada. Digital health and artificial intelligence in health care. https://www.canada.ca/en/health-canada.html

## FAQ
### Why do researchers use CNN instead of a standard neural network for skin lesion classification?
A CNN (Convolutional Neural Network) applies learned spatial filters that slide across an image, detecting features like edges, textures, and patterns regardless of where they appear in the frame. A standard ANN (Artificial Neural Network) treats each pixel as an independent input, which means it must learn spatial relationships separately for every pixel position. This requires far more parameters and training data to achieve comparable accuracy. For dermoscopy images specifically, a suspicious pigment pattern in the corner of the image should trigger the same response as the same pattern in the centre. CNNs provide that translation invariance automatically. Every published skin lesion classification benchmark uses a CNN or transformer backbone rather than a plain fully connected network for this reason.

### What is 90% of melanoma cancer caused by?
Approximately 90% of melanoma cases are attributed to ultraviolet (UV) radiation exposure, primarily from sunlight and artificial tanning devices. UV radiation damages the DNA of melanocytes, the pigment-producing skin cells, and repeated damage over time leads to mutations that can trigger uncontrolled cell growth. The American Academy of Dermatology identifies UV exposure as the most significant modifiable risk factor for melanoma. Genetic predisposition, fair skin type, a history of sunburn, and a large number of atypical moles also increase risk, but UV exposure remains the dominant environmental cause across the published epidemiological literature. Avoiding tanning beds and using broad-spectrum SPF 30 or higher sunscreen are the two highest-impact prevention steps.

### What does the beginning of skin cancer look like?
Early skin cancer often appears as a new or changing spot that does not look like surrounding moles. The ABCDE criteria cover Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, and Evolution. A lesion that is asymmetric, has a ragged or notched border, shows multiple shades of brown, tan, black, red, or blue, measures more than 6 mm across, or has changed recently warrants prompt dermatologist review. Basal cell carcinoma often starts as a pearly or waxy bump. Squamous cell carcinoma can begin as a firm red nodule or flat scaly crust. If in doubt, a dermatologist can assess the lesion with a dermatoscope and, where available, an AI-assisted triage tool to prioritise urgent cases.

---

# Sunscreen Science: SPF, UVA, UVB, and the Canadian Climate

URL: https://www.dermadex.ca/blog/sunscreen-science-spf-uva-uvb-and-the-canadian-climate
Category: Prevention
Author: Mohsen Khoddami
Published: 2025-05-20

## TL;DR
SPF 30 blocks 97% of UVB rays; SPF 50 blocks 98% — a 1% gap that matters most for fair skin types | Health Canada classifies sunscreen as a drug, requiring DIN registration before sale | The Canadian Dermatology Association (CDA) recommends SPF 30 or higher, broad-spectrum, water-resistant sunscreen year-round | UV index in Canada can reach 10 or higher in southern cities during summer — equal to tropical destinations | Reapplication every 2 hours is required to maintain the rated SPF protection level

*As of May 20, 2025.*

Canadians often treat sunscreen as a summer-only habit. But ultraviolet radiation hits your skin in January as well as July, and the UV index in Toronto, Vancouver, or Calgary can match Florida on a clear midsummer day. This guide unpacks the science of Sun Protection Factor (SPF), ultraviolet A (UVA), and ultraviolet B (UVB) radiation, and explains how Canada's climate shapes what your skin actually needs.

## What do SPF numbers actually mean?

SPF numbers measure how much UVB radiation reaches your skin relative to no sunscreen at all. **Short answer:** SPF 30 blocks roughly 97% of UVB rays; SPF 50 blocks roughly 98%. The gap is smaller than the marketing implies, but both levels offer meaningful protection when you apply the right amount. The number comes from a standardized laboratory test: a researcher compares the dose of UVB that causes a minimal sunburn on protected skin to the dose on bare skin. SPF 30 means the body needs 30 times more UV energy to burn. In practice, people apply far less product than the test quantity, which cuts real-world protection substantially.

Health Canada classifies sunscreen as a drug, requiring every product sold in Canada to carry a Drug Identification Number (DIN) before reaching pharmacy shelves. For most people, dermatologists recommend SPF 30 as a daily minimum and SPF 50 if you have fair skin, a history of skin cancer, or spend extended time outdoors.

| SPF Level | % UVB Blocked | Recommended For | Reapply Every |
|-----------|--------------|-----------------|---------------|
| SPF 15 | ~93% | Incidental sun exposure, darker skin types | 2 hours |
| SPF 30 | ~97% | Daily use, most skin types, Canadian summer | 2 hours |
| SPF 50 | ~98% | Fair skin, prolonged outdoor activity, high UV index days | 2 hours |
| SPF 50+ | ~98-99% | Post-procedure skin, history of skin cancer, snow or mountain environments | 2 hours |

## What is the difference between UVA and UVB radiation?

Broad-spectrum sunscreen protects against two distinct types of UV rays, each causing different damage. **Short answer:** UVB rays cause sunburn and drive most skin cancers; UVA rays penetrate deeper, trigger photoaging, and also contribute to melanoma. You need protection from both. UVB radiation (wavelengths 280-315 nm) carries enough energy to directly damage DNA in skin cells, producing the red painful burn visible within hours. UVA radiation (315-400 nm) accounts for about 95% of UV reaching the earth's surface and passes through glass and clouds. It degrades collagen, produces wrinkles and brown spots, and contributes to melanoma over decades of exposure.

When a Canadian sunscreen label reads "broad-spectrum," it means the product passed Health Canada's critical wavelength test confirming UVA coverage alongside UVB. A product that shows only an SPF number without a broad-spectrum claim protects against burning but leaves you exposed to long-wave damage that accumulates silently. The [Sunscreen FAQs](https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/sunscreen-faqs) published by the American Academy of Dermatology (AAD) recommend broad-spectrum SPF 30 or higher for everyone, every day.

## How does the UV index in Canada compare to other countries?

Canada's UV index reaches levels most Canadians associate with tropical destinations. **Short answer:** Southern Canadian cities regularly record UV index values of 9-10 during summer, matching many Caribbean or Mediterranean locations. Snow, altitude, and clear skies push the index higher still. The UV index is a linear scale developed by the World Health Organization (WHO) and Environment and Climate Change Canada. A WHO fact sheet on [ultraviolet radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) explains the health risks in detail. A reading of 3 signals moderate risk; 8-10 is very high; 11 and above is extreme. Cities such as Windsor, Toronto, and Vancouver hit indices of 9-10 between May and August. At altitude, including Banff, Whistler, or Jasper, thinner atmosphere filters less radiation, raising the index further.

Snow reflects up to 80% of UV, effectively doubling exposure on a February ski day. Cloud cover provides only partial protection; up to 80% of UV passes through light cloud. You can check the daily UV index forecast at [canada.ca](https://www.canada.ca/en/health-canada/services/sun-safety.html) before heading outside. Year-round sun protection is therefore not optional in Canada for fair-skinned Canadians or anyone with a history of abnormal moles.

AI-assisted triage tools, including platforms like [DermaDex](/), aim to flag patients who report chronic high UV exposure as higher priority for dermatologist review, particularly when combined with fair skin or a family history of melanoma.

## Does SPF in makeup or moisturizer count as real protection?

Cosmetics with SPF ratings are regulated the same way as dedicated sunscreens in Canada, but application quantity is where most people fall short. **Short answer:** SPF in foundation or tinted moisturizer works, but only if you apply the same quantity used in the lab test, roughly a quarter teaspoon for the face and neck. Most people apply a fraction of that amount, which drops an SPF 30 product's real-world protection significantly. The [Sunscreen FAQ](https://dermatology.ca/public-patients/sun-protection/sunscreen-faq/) published by the Canadian Dermatology Association (CDA) recommends applying a dedicated broad-spectrum sunscreen as a base layer, letting it absorb fully, then adding makeup on top. This ensures the sunscreen layer receives the full application amount and the cosmetic functions as a cosmetic only.

For a daily commute or brief outdoor exposure, SPF-containing moisturizer may be adequate. For any activity lasting more than 20 minutes outside, a dedicated water-resistant sunscreen with an SPF of at least 30 is the better choice. The CDA Sun Protection Program publishes a list of recognized sunscreen products that meet essential criteria for Canadian conditions.

## How should Canadians apply sunscreen for maximum protection?

Application technique affects protection as much as SPF number, and most Canadians make at least one of three common errors: too little product, missed skin areas, or no reapplication. **Short answer:** Apply one ounce for the full body at least 15-30 minutes before outdoor exposure, cover ears, neck, and the tops of feet, and reapply every two hours or after swimming or heavy sweating. Chemical sunscreens containing avobenzone or octinoxate need time to bind to skin before exposure, making the 30-minute lead time meaningful. Mineral sunscreens based on zinc oxide or titanium dioxide work immediately on application and are generally better tolerated by sensitive or reactive skin.

Water-resistant formulas maintain their rated protection for 40 or 80 minutes of water exposure, as stated on the label, after which reapplication is needed. The term "water-resistant" does not mean "waterproof." For children under six months, Health Canada advises avoiding sunscreen in favour of physical sun protection such as shade, UV-protective clothing, and wide-brimmed hats. For older children, SPF 30 broad-spectrum sunscreen applies equally.

If you notice a new or changing lesion after sun exposure, [our step-by-step guide to monthly self-skin checks](/blog/how-to-perform-a-monthly-self-skin-check-step-by-step) walks you through a systematic method. For spots that evolve over weeks, [understanding the ABCDE criteria for melanoma detection](/blog/understanding-melanoma-the-abcdes-of-skin-cancer-detection) gives you the clinical framework dermatologists use.

## Sources

- Health Canada. "Sun Safety." canada.ca. https://www.canada.ca/en/health-canada/services/sun-safety.html (accessed May 2025).
- Canadian Dermatology Association. [Sunscreen FAQ](https://dermatology.ca/public-patients/sun-protection/sunscreen-faq/). dermatology.ca (accessed May 2025).
- American Academy of Dermatology. [Sunscreen FAQs](https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/sunscreen-faqs). aad.org (accessed May 2025).
- World Health Organization. [Ultraviolet radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation). who.int, June 2022.
- Centers for Disease Control and Prevention. [Reducing Risk for Skin Cancer](https://www.cdc.gov/skin-cancer/prevention/index.html). cdc.gov (accessed May 2025).

## FAQ
### Is it better to buy SPF 30 or 50?
For most Canadians, SPF 30 is the minimum recommended by the Canadian Dermatology Association (CDA) and provides 97% UVB protection when applied correctly. SPF 50 raises that to 98% — a one percentage point difference that sounds small but means roughly one-third fewer UVB photons reach the skin. Dermatologists generally recommend SPF 50 for people with fair skin (Fitzpatrick type I-II), a personal or family history of skin cancer, extended outdoor activity, or environments with a high UV index such as mountains or snow. For daily indoor workers who spend fewer than 20 minutes outside, SPF 30 applied generously is sufficient. Both levels require reapplication every two hours.

### Why do I burn with SPF 50 but not 30?
Burning despite higher SPF is almost always caused by inadequate application amount or skipped reapplication, not a product defect. SPF ratings are calculated using 2 mg per cm squared of skin — roughly one ounce for the full body. Most people apply 25-50% of that quantity, which drops an SPF 50 product's real-world protection to the equivalent of SPF 10-15. People who switch from SPF 30 to SPF 50 may also stay outside longer, assuming greater safety. Additionally, SPF measures only UVB protection; a product without a broad-spectrum label allows significant UVA exposure. Check that your SPF 50 product is labeled broad-spectrum and water-resistant, apply generously, and reapply every two hours.

### Is SPF 50 too much for your face?
No. SPF 50 is not too much for facial skin, and dermatologists frequently recommend it for the face specifically because facial skin sees chronic daily UV exposure and cannot easily be covered with clothing. Modern SPF 50 formulations, particularly mineral-based products with zinc oxide, are non-comedogenic and designed for daily facial use. Any concern about pore clogging or breakouts is formulation-specific, not SPF-level-specific. If you have acne-prone or sensitive skin, look for oil-free, non-comedogenic SPF 50 products or mineral formulas. Very high SPF numbers (SPF 100+) show diminishing returns and are unnecessary for routine daily use in Canada.

### Which sunscreen is best for rosacea?
For rosacea-prone skin, dermatologists recommend mineral sunscreens containing zinc oxide or titanium dioxide as the sole active ingredients. These physical blockers sit on top of the skin rather than absorbing into it, reducing the risk of irritation or flushing that some patients experience with chemical UV filters such as oxybenzone or avobenzone. Look for fragrance-free, alcohol-free formulas with a simple ingredient list. Tinted mineral sunscreens offer an added benefit: iron oxide pigment in tinted versions provides partial protection against visible light, which can trigger rosacea flares in some patients. The Canadian Dermatology Association publishes a recognized sunscreen list that includes products tested for sensitive skin.

### What sunscreen is best for melasma?
Melasma is worsened by UV radiation and visible light, particularly high-energy visible blue light, meaning standard broad-spectrum sunscreen alone is often insufficient. Dermatologists treating melasma recommend tinted mineral sunscreens containing iron oxides, which block visible light wavelengths that transparent sunscreens do not cover. SPF 50 or higher is advisable, given that even small UV doses can trigger pigment production. Physical protection through wide-brimmed hats and seeking shade between 10 a.m. and 4 p.m. significantly reduces melasma triggers. Sunscreen must be reapplied every two hours during outdoor exposure. Patients with melasma should consult a dermatologist for a complete treatment plan, as topical treatments such as azelaic acid may also be indicated.

---

# Reducing Dermatology Wait Times: Ontario Pilot Findings

URL: https://www.dermadex.ca/blog/reducing-dermatology-wait-times-ontario-pilot-findings
Category: Healthcare Access
Author: Maryam Sobhkhiz Sabet
Published: 2025-04-29

## TL;DR
Ontario dermatology wait times average 78–130 days from referral to appointment, depending on region (CIHI, 2024) | eConsult pilots in Ontario resolved 40–60% of dermatology cases without a specialist visit (Ontario Health, 2023) | Urgent referrals for suspected skin cancer should reach a dermatologist within 14 days under Ontario Health Insurance Plan (OHIP) triage guidelines | Asynchronous teledermatology triage cut median time to clinical advice from 78 days to under 5 business days in Ontario pilots (Ontario Health, 2023) | Rural Ontario patients wait a median 130 days vs. 78 days in urban centres for a non-urgent dermatology appointment

*As of April 29, 2025.*

Ontario patients with skin concerns face some of the longest specialist waits in the country. Over the past five years, several regional and provincial programs have tested whether electronic consultations and asynchronous teledermatology can reduce the backlog without adding dermatologist capacity. This article examines what those pilots found, what the numbers looked like before and after, and what they mean for patients still waiting today.

## What was the baseline dermatology wait time in Ontario before the pilots?
Before Ontario's pilot programs launched, the median wait from a family physician referral to a first dermatology appointment ranged from 78 days in urban centres to 130 days in rural and northern regions. Urgent referrals for suspected melanoma frequently missed the 14-day target outside major cancer centres. The Canadian Institute for Health Information (CIHI) tracks these waits nationally, and Ontario consistently ranks among the longest for non-surgical specialist access.

The [Canadian Institute for Health Information (CIHI)](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) has tracked specialist wait times since 2008, and dermatology has consistently ranked among the longest waits in Ontario. The Ontario Ministry of Health (MOH) does not publish specialty-specific wait time data at the same granularity as surgical queues, but CIHI's pan-Canadian data and the [Canadian Medical Association (CMA)](https://www.cma.ca/) physician workforce reports fill part of that gap. Ontario holds more than 14 million residents but approximately 450 of Canada's 600 practicing dermatologists. For patients outside Toronto, Ottawa, or Hamilton, routine access is a 4-to-6-month problem.

| Region | Avg. referral-to-appt wait (routine) | Urgent referral wait | Triage method |
|---|---|---|---|
| Toronto (urban core) | 78 days | 10–21 days | Electronic Medical Record (EMR) referral |
| Ottawa / Hamilton | 90 days | 14–28 days | EMR e-referral |
| Rural Southern Ontario | 110 days | 21–45 days | Fax referral |
| Northern Ontario | 130 days | 30–60 days | Fax or telephone |
| Provincial MOH target | Not formally set | 14 days | Varies |

*Sources: CIHI Health System Performance, 2024; CMA Physician Data Centre, 2023.*

## How did Ontario's eConsult pilots change specialist access?
The Ontario eConsult Service, funded through the Ontario Health Insurance Plan (OHIP) and modelled on the Champlain BASE eConsultation program, resolved 40–60% of dermatology cases without a face-to-face specialist appointment. Median time to clinical advice dropped from 78 days to under 5 business days for those cases, cutting appointment demand substantially and freeing in-person slots for cases that genuinely needed them.

The eConsult model allows a family physician or nurse practitioner to submit a patient's case including photos, history, and lab results to a dermatologist through a secure digital platform. The dermatologist reviews the case asynchronously and responds within days rather than scheduling an in-person visit. For patients with eczema, psoriasis, acne, or benign seborrheic keratoses, a management plan arrives in under a week. Cases that did require in-person follow-up were triaged faster because the dermatologist already had a clinical summary. For context on how teledermatology compares to in-person visits, see [DermaDex's comparison of teledermatology and in-person care](/blog/teledermatology-vs-in-person-visits-when-to-choose-which).

## What did the teledermatology triage pilots find specifically?
Asynchronous teledermatology triage outperformed synchronous video models on throughput. Ontario pilot sites reviewed 3–4 times as many cases per dermatologist hour while maintaining diagnostic agreement above 85% compared to in-person review. Several academic health centre pilots running from 2019 to 2023 measured diagnostic concordance, patient satisfaction, and time-to-treatment across both delivery models.

A key finding was that store-and-forward models scaled better than live video: a single dermatologist could review 20–30 cases per half-day session compared to 8–12 live video appointments. Diagnostic concordance for common inflammatory skin conditions ran above 85%. For suspected skin cancers, concordance was slightly lower (78–82%) on photo review alone, which is why these cases were flagged for priority in-person appointments. These findings align with [PubMed literature on store-and-forward teledermatology](https://pubmed.ncbi.nlm.nih.gov/), which consistently shows concordance rates of 80–90% for inflammatory dermatoses. For the broader access picture, see [the state of dermatology access in Canada in 2024](/blog/the-state-of-dermatology-access-in-canada-in-2024).

## Which pilot interventions reduced wait times the most?
The three highest-impact Ontario interventions were: eConsult integrated directly into EMR referral workflows, which cut routine referral volume by roughly half; structured photo triage for new referrals, which eliminated the in-office triage appointment; and a single-point-of-entry intake model that pooled referrals across a dermatology group and assigned them by urgency rather than by individual physician queue.

Not all pilots succeeded equally. Programs that added teledermatology as a parallel option without changing the underlying referral pathway saw modest uptake and minimal wait time reduction. The highest-impact programs changed the default: structured photo triage with eConsult became the first step, and in-person booking was triggered only when clinically needed.

| Intervention | Pre-pilot wait | Post-pilot wait | Referral reduction |
|---|---|---|---|
| eConsult integrated into EMR | 90 days | 5 days for advice | 40–60% of referrals resolved |
| Asynchronous photo triage | 90 days | 14 days to triage decision | 35% fewer in-person bookings |
| Pooled intake and urgency sorting | 78 days | 55 days | 30% faster first appointment |
| Video teledermatology (standalone) | 90 days | 75 days | Minimal change |
| Standard referral (no intervention) | 90 days | 88 days | Baseline |

*Sources: Ontario eConsult Service outcome reports, Ontario Health, 2023; CIHI, 2024.*

## Can a patient in Ontario still see a dermatologist without a referral?
Yes. Ontario patients can book directly at private dermatology clinics, though those visits are not covered under OHIP. For OHIP-covered care, a referring physician's letter is required, but eConsult and teledermatology platforms now offer faster pathways to clinical advice and, when necessary, specialist triage that feeds the OHIP referral queue more efficiently than a standard fax-based referral.

OHIP covers dermatology visits only when initiated through a referring physician, which remains the system's structural bottleneck. Patients who cannot wait, or who lack a family physician (roughly 1 in 5 Ontario adults), can access private clinics directly at approximately $150–$350 for an initial consultation. A growing number of platforms, including [DermaDex](/), allow patients to submit clinical photos and history for AI-assisted triage reviewed by a certified dermatologist. The Personal Health Information Protection Act (PHIPA) governs how health data is stored and shared in Ontario; any platform handling patient photos must be PHIPA-compliant. For patients with OHIP coverage, the most efficient current route is to ask a primary care provider or walk-in clinic physician to submit an eConsult before booking a standard in-person referral.

## What do the pilot findings mean for Ontario's dermatology system going forward?
The pilot evidence shows the Ontario dermatology access problem is solvable with existing physician capacity, provided referral workflows shift from defaulting to in-person queues toward triage-first digital models. Province-wide scaling requires MOH funding commitments and EMR integration work that the Ministry has not yet formally announced, but the proof of concept is established across multiple regional sites.

The pilots demonstrated that digital-first triage does not require more dermatologists to dramatically reduce wait times. It requires a change in how referrals are routed. The limitation is that pilots ran in well-resourced academic sites with motivated physician champions. Scaling to rural Northern Ontario or to family physicians using older practice management software requires infrastructure investment. The [Statistics Canada 2024 specialist wait time report](https://www150.statcan.gc.ca/n1/pub/82-625-x/2024001/article/00001-eng.htm) identified administrative friction as the second-largest driver of specialist wait times after raw capacity shortages. Fixing that friction is a systems problem, and the Ontario pilots show it is fixable.

## What are the most common questions Ontario patients ask about dermatology wait times?
Ontario patients most often ask about how long they will wait, what constitutes a clinical red flag requiring urgent care, whether they can self-refer, and which route gets them to a dermatologist fastest. The answers below draw on current OHIP guidelines, CIHI wait time data, and Canadian clinical standards for dermatology triage.

### How long will I wait for a dermatology appointment?

Wait times for a dermatology appointment in Ontario depend on where you live, how your referral is classified, and whether your primary care provider uses eConsult or standard paper referral. For a routine non-urgent concern in Toronto or Ottawa, expect 8–16 weeks from referral. In rural or Northern Ontario, waits of 4–6 months are common. If your referring physician classifies the case as urgent, the target under OHIP guidelines is 14 days, though capacity constraints mean this target is missed in many regions. If your concern is time-sensitive, an asynchronous teledermatology service or eConsult can provide clinical advice within days.

### What is a red flag in dermatology?

Red flags in dermatology are clinical findings that require prompt specialist assessment rather than routine monitoring. These include a mole or pigmented lesion that has changed shape, color, or size within weeks; a sore or ulcer that has not healed after 6 weeks; a rapidly growing nodule; and a rash accompanied by fever, joint pain, or systemic symptoms. The ABCDE rule (Asymmetry, Border, Color, Diameter, Evolution) is the standard screening checklist for suspicious pigmented lesions. The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) also lists satellite lesions and lymph node changes as warning signs. Any red flag finding should trigger an urgent referral.

### Can I see a dermatologist in Ontario without a referral?

Yes, you can see a dermatologist in Ontario without a referral, but OHIP will not cover the visit unless a physician has referred you. Private direct-access dermatology clinics operate across Ontario and accept self-booked appointments, typically at $150–$350 for an initial consultation. For OHIP-covered care, you need a referral from any licensed physician or nurse practitioner. Alternatively, teledermatology platforms can review your case asynchronously and, when clinical findings warrant it, connect you with the OHIP-covered referral queue faster than waiting for a routine appointment.

### What is the fastest way to see a dermatologist?

The fastest route to a dermatologist in Ontario, from quickest to slowest: first, a teledermatology or eConsult platform where a certified dermatologist reviews photos of your concern within 1–5 business days; second, a direct-access private clinic that accepts self-referrals (no OHIP coverage); third, an urgent referral from a family physician or walk-in clinic physician if your case meets clinical criteria; and fourth, the standard non-urgent referral pathway, which takes 8–16 weeks in urban Ontario. AI-assisted triage can flag urgency and connect your case to a certified dermatologist faster than a fax-based referral.

## Sources

- [CIHI — Wait Times for Priority Procedures in Canada](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada). Canadian Institute for Health Information, 2024.
- [CMA Physician Data Centre](https://www.cma.ca/). Canadian Medical Association, 2023.
- [Statistics Canada — Health characteristics, annual estimates](https://www150.statcan.gc.ca/n1/pub/82-625-x/2024001/article/00001-eng.htm). Statistics Canada, 2024.
- [AAD — Melanoma: Signs and Symptoms](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma). American Academy of Dermatology, 2025.
- [PubMed — Teledermatology diagnostic concordance studies](https://pubmed.ncbi.nlm.nih.gov/). National Library of Medicine, multiple studies.

## FAQ
### How long will I wait for a dermatology appointment?
Wait times for a dermatology appointment in Ontario depend on where you live, how your referral is classified, and whether your primary care provider uses eConsult or standard paper referral. For a routine non-urgent concern in Toronto or Ottawa, expect 8–16 weeks from referral. In rural or Northern Ontario, waits of 4–6 months are common. If your referring physician classifies the case as urgent, the target under OHIP guidelines is 14 days, though capacity constraints mean this target is missed in many regions. If your concern is time-sensitive, an asynchronous teledermatology service or eConsult can provide clinical advice within days.

### What is a red flag in dermatology?
Red flags in dermatology are clinical findings that require prompt specialist assessment rather than routine monitoring. These include a mole or pigmented lesion that has changed shape, color, or size within weeks; a sore or ulcer that has not healed after 6 weeks; a rapidly growing nodule; and a rash accompanied by fever, joint pain, or systemic symptoms. The ABCDE rule is the standard screening checklist for suspicious pigmented lesions. The AAD also lists satellite lesions and lymph node changes as warning signs in advanced melanoma. Any red flag finding should trigger an urgent referral, not a routine one.

### Can I see a dermatologist in Ontario without a referral?
Yes, you can see a dermatologist in Ontario without a referral, but OHIP will not cover the visit unless a physician has referred you. Private direct-access dermatology clinics operate across Ontario and accept self-booked appointments, typically at $150–$350 for an initial consultation. For OHIP-covered care, you need a referral from any licensed physician or nurse practitioner. Alternatively, teledermatology platforms can review your case asynchronously and, when clinical findings warrant it, connect you with the OHIP-covered referral queue faster than waiting for a routine appointment.

### What is the fastest way to see a dermatologist?
The fastest route to a dermatologist in Ontario, from quickest to slowest: first, a teledermatology or eConsult platform where a certified dermatologist reviews photos of your concern within 1–5 business days; second, a direct-access private clinic that accepts self-referrals (no OHIP coverage); third, an urgent referral from a family physician or walk-in clinic physician if your case meets clinical criteria; and fourth, the standard non-urgent referral pathway, which takes 8–16 weeks in urban Ontario. AI-assisted triage can flag urgency and connect your case to a certified dermatologist faster than a fax-based referral.

---

# What Confidence Scores Mean in AI Skin Diagnosis

URL: https://www.dermadex.ca/blog/what-confidence-scores-mean-in-ai-skin-diagnosis
Category: AI & Technology
Author: Elham Sayyah
Published: 2025-04-08

## TL;DR
A 0.85 ML confidence score means the model assigns 85% probability to its top prediction, not that it is correct 85% of the time across all cases | Neural network calibration research (Guo et al., ICML 2017) shows modern deep networks are systematically overconfident without post-processing | Threshold settings directly trade false-positive rate against false-negative rate: a 0.90 cutoff catches fewer benign lesions but may miss more early cancers | Best-practice AI dermatology workflows route sub-threshold scans to a certified dermatologist for human review rather than acting on the AI output alone | Confidence score interpretation should always account for the patient's Fitzpatrick skin tone and lesion type

*As of April 8, 2025.*

When an AI dermatology tool returns a confidence score alongside a skin-condition flag, patients and clinicians sometimes treat that number as a simple pass/fail grade. It is not. A confidence score is a calibrated probability estimate produced by a machine learning (ML) model, and reading it correctly changes how you act on the result.

This article explains what those numbers actually represent, where they break down, and how threshold choices affect the tradeoff between catching serious conditions and avoiding unnecessary referrals.

## What is an AI confidence score?

<b>Short answer:</b> A confidence score is the model's estimated probability that its top-ranked prediction is correct for a given input image. A score of 0.87 means the model assigns 87% probability to its first-choice label, based on patterns learned during training. That estimate is only as reliable as the model's calibration, specifically how well its stated probabilities match actual outcomes in the real world.

In a convolutional neural network (CNN) used for skin image classification, the final layer applies a softmax function to convert raw logit values into a probability distribution across all possible output classes. The highest value in that distribution becomes the confidence score reported to the user. A model trained to distinguish eczema, psoriasis, and contact dermatitis outputs three probabilities that sum to 1.0; the top value is the confidence score. This is distinct from accuracy: accuracy measures performance across many cases, while a single confidence score describes the model's certainty about one specific image. The two numbers converge only when the model is well-calibrated across a large and representative test set.

## What is a good confidence score?

<b>Short answer:</b> There is no universal threshold that qualifies as good. The appropriate cutoff depends on what you are screening for, the cost of a missed diagnosis versus a false alarm, and how well the model is calibrated on populations similar to the patient in front of you. For low-risk conditions a 0.75 threshold may be acceptable; for suspected melanoma, many clinicians prefer to flag anything below 0.90 for human review regardless of the computational cost.

Context matters more than the raw number. A 0.82 score for a clearly benign sebaceous cyst carries different clinical weight than a 0.82 score for a suspicious pigmented lesion. The artificial intelligence (AI) model does not know which question is more consequential; that judgment stays with the clinician. Research published in *JAMA Dermatology* has shown that AI diagnostic accuracy (Area Under the Curve, or AUC, values above 0.90) for melanoma detection is achievable, but AUC is a population-level metric. At the individual scan level, confidence scores can still mislead, particularly on skin tones underrepresented in training data. Our [technical primer on computer vision models](/blog/how-computer-vision-models-detect-skin-conditions-a-technical-primer) covers how training data composition shapes output distributions.

## Are AI models well-calibrated for medical use?

<b>Short answer:</b> Modern deep learning models are often poorly calibrated out of the box. A widely cited 2017 paper by Guo et al. demonstrated that deep neural networks tend to be overconfident: a model reporting 0.95 confidence may be correct only around 80% of the time on held-out data. Post-hoc calibration methods such as temperature scaling reduce this gap, but calibration degrades whenever the deployment population differs from the training population.

For skin diagnosis, calibration drift is a consistent practical concern. A model trained predominantly on lighter Fitzpatrick skin types (I through III) may output high confidence scores on darker skin tones (IV through VI) while making more errors, because the softmax output reflects pattern similarity to training examples regardless of whether those examples were representative. This is one reason [why skin tone diversity in training data matters](/blog/why-skin-tone-matters-in-ai-dermatology-models). A 2018 study by Haenssle et al. comparing a CNN against 58 dermatologists on melanoma detection found that the algorithm's stated confidence scores consistently outperformed most dermatologists in specificity, but that the gap narrowed significantly when dermatologists could see the AI output alongside their own judgment. Health Canada has not yet issued specific calibration standards for AI-assisted dermatology tools, but the FDA's guidance on Software as a Medical Device (SaMD) references performance across demographic subgroups as a pre-market evaluation requirement.

## How do confidence thresholds affect false positives and false negatives?

<b>Short answer:</b> Setting a higher confidence threshold, for example 0.90 instead of 0.75, reduces the number of low-probability cases the model accepts as definitive. This lowers the false-positive rate but raises the false-negative rate. Every threshold choice is a tradeoff, and the right setting depends on the clinical consequence of each error type in your specific workflow.

The Receiver Operating Characteristic (ROC) curve visualizes this tradeoff across all possible thresholds. For a screening tool the goal is high sensitivity (catching most true positives), which usually means accepting a higher false-positive rate. For a tool used to confirm a diagnosis before a procedure, high specificity matters more. The table below maps common threshold ranges to recommended actions and expected error profiles for a general-purpose skin lesion classifier:

| Confidence threshold | Recommended clinical action | False-positive risk | False-negative risk |
|---|---|---|---|
| < 0.60 | Flag for mandatory human review; do not act on AI output | Low | High |
| 0.60 to 0.74 | Present to clinician alongside differential; treat as suggestive only | Moderate | Moderate-high |
| 0.75 to 0.84 | Use as supporting evidence; document in chart; consider follow-up | Moderate | Moderate |
| 0.85 to 0.89 | Provisionally act on finding; schedule follow-up to confirm | Moderate-low | Moderate-low |
| 0.90 and above | High confidence; suitable as primary factor in triage decision | Low | Low |

These ranges assume a well-calibrated model evaluated on a demographically diverse dataset. Adjust cutoffs downward for any subpopulation underrepresented in the model's training set, and revisit thresholds whenever a new model version is deployed.

## How should a probability score change patient or clinician behaviour?

<b>Short answer:</b> A high confidence score should increase the prior probability you assign to a diagnosis, not replace clinical judgment. Treat it as one structured input among several, alongside symptom history, lesion morphology, and patient context. A score below your threshold for unilateral action should trigger a referral or second look, not dismissal of the AI output entirely.

In practice this means documenting the score alongside the clinical note. If a CNN's output was 0.78 for atopic dermatitis and the clinician agreed with that read, the chart should record both. If the score was 0.91 for a benign seborrheic keratosis but the lesion has an atypical border, the clinician's physical finding overrides the probability estimate. This is consistent with how the Canadian Medical Association (CMA) frames physician responsibility for AI-assisted decisions: the physician remains accountable for the final decision regardless of what the algorithm outputs. The Personal Health Information Protection Act (PHIPA) in Ontario similarly places data stewardship and care accountability on the regulated health professional, not the software vendor.

For patients, the score is less useful as a standalone figure. A plain-language statement such as "the scan strongly suggests eczema and a dermatologist will review" communicates more than a raw percentage and prevents over-reliance on a number that carries technical assumptions most patients cannot evaluate on their own. Clinicians who explain confidence scores in plain terms typically see higher patient engagement with recommended follow-up steps.

## Sources

- Esteva, A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, 542, 115-118. [Esteva et al., PubMed 2017](https://pubmed.ncbi.nlm.nih.gov/28117445/)
- Haenssle, H.A., et al. (2018). Man against machine: deep learning convolutional neural network for dermoscopic melanoma recognition versus 58 dermatologists. *Annals of Oncology*. [Haenssle et al., PubMed 2018](https://pubmed.ncbi.nlm.nih.gov/29846502/)
- National Institutes of Health (NIH). Artificial intelligence in health and biomedical research. [National Institutes of Health (NIH)](https://www.nih.gov)

## FAQ
### What is an AI confidence score?
An AI confidence score is the probability value a machine learning model assigns to its top prediction for a given input. In skin diagnosis, a score of 0.87 means the model places 87% probability on its first-choice diagnosis based on patterns in the image. The score comes from the final softmax layer of a convolutional neural network (CNN), which converts raw output values into a probability distribution. A higher score indicates the model found strong visual evidence matching a known pattern, but it does not guarantee correctness. Calibration, meaning how well stated probabilities match real-world accuracy, determines whether the number is trustworthy. Well-calibrated models produce roughly 87% accuracy at the 0.87 confidence level; poorly calibrated ones may be systematically over- or underconfident.

### What is a good AI GPT score?
This question refers to language model confidence scoring, which works differently from image-based diagnostic AI. Large language models like GPT do not output traditional confidence scores alongside responses; instead they generate token probabilities that some interfaces surface as a proxy for certainty. In a medical context, these token-level probabilities are not calibrated for clinical use and should not be treated as equivalent to validated diagnostic confidence scores from purpose-built medical AI tools. For skin diagnosis, rely on tools that report AUC (Area Under the Curve) values and calibration metrics measured on demographically diverse dermatology datasets, rather than general-purpose language model outputs.

### What is a good confidence score?
A good confidence score is one that is high relative to the model's own calibrated performance on cases similar to the one in question. There is no single universal cutoff. For general-purpose skin screening, many clinical workflows treat scores at or above 0.85 as reliable enough to inform triage decisions, while routing anything below 0.75 to mandatory human review. The appropriate threshold shifts based on clinical stakes: suspected melanoma warrants a higher bar than a suspected benign sebaceous cyst. The most useful question is not whether the score exceeds a fixed number but whether the model was calibrated on data that includes patients like the one being assessed, covering skin tone, age range, and lesion type.

### Is Gemini or ChatGPT better for medical questions?
Neither Gemini nor ChatGPT is a validated medical diagnostic tool. Both are general-purpose language models that can summarize medical literature and describe conditions, but neither produces clinically calibrated diagnostic confidence scores for skin conditions. They lack access to patient images, are not trained on labeled dermatology datasets, and have not been evaluated under Health Canada or FDA frameworks for Software as a Medical Device (SaMD). For AI-assisted skin diagnosis, purpose-built tools trained and evaluated on dermatology image datasets with known sensitivity and specificity metrics are the appropriate choice. Always consult a certified dermatologist for any diagnosis or treatment decision.

---

# Psoriasis Treatment Options: A 2025 Patient Guide

URL: https://www.dermadex.ca/blog/psoriasis-treatment-options-a-2025-patient-guide
Category: Conditions
Author: Mohsen Khoddami
Published: 2025-03-18

## TL;DR
Psoriasis affects roughly 1 million Canadians, or about 2.5% of the population (CDA, 2024) | Mild-to-moderate cases are managed with topical corticosteroids; moderate-to-severe cases require biologics that target IL-17 or IL-23 pathways | Biologics such as secukinumab and risankizumab are covered by most provincial drug plans after step therapy | The Psoriasis Area and Severity Index (PASI) score guides treatment escalation from topicals to systemic agents | Teledermatology services can provide clinical advice and prescription renewals without the typical 78-day specialist wait (CIHI, 2024)

*As of March 18, 2025.*

Psoriasis is a chronic immune-mediated skin disease that affects roughly 1 million Canadians, according to the [Canadian Dermatology Association](https://dermatology.ca) (CDA). Itchy, scaly plaques most often appear on the scalp, elbows, knees, and lower back, but the condition can affect any body surface. This guide walks through every treatment tier available in Canada as of early 2025, from over-the-counter moisturisers to the latest biologics, so you can have a more informed conversation with your dermatologist.

If you are waiting on a specialist referral or want a faster path to diagnosis, [DermaDex](/) connects you to a certified Canadian dermatologist within minutes.

## What is psoriasis and how is it diagnosed?

Diagnosis is usually clinical, based on skin and nail findings, and severity is scored with the Psoriasis Area and Severity Index (PASI). **Short answer:** Psoriasis is a chronic autoimmune condition in which the immune system accelerates skin-cell turnover, producing thick, scaly plaques. A dermatologist examines your skin, scalp, and nails; in uncertain cases, a punch biopsy confirms the finding. PASI runs from 0 to 72 — below 10 indicates mild disease, 10 or above signals moderate-to-severe disease requiring systemic therapy. About 30% of people with psoriasis also develop psoriatic arthritis, making early accurate diagnosis especially important.

The National Institutes of Health (NIH) classifies psoriasis as an immune-mediated inflammatory disease. T-cells mistakenly trigger keratinocyte proliferation at roughly 10 times the normal rate, which is why plaques form. Your dermatologist may also assess the Dermatology Life Quality Index (DLQI) alongside PASI to capture how the condition affects sleep, work, and social activity.

## What is the new treatment for psoriasis 2025?

Several biologics and one novel topical have expanded the Canadian treatment menu by early 2025. **Short answer:** The most notable advances include roflumilast foam for difficult-to-treat areas (scalp, genitals, skin folds) and next-generation interleukin (IL) inhibitors with longer dosing intervals. Bimekizumab, which blocks both IL-17A and IL-17F, received Health Canada approval and offers high PASI-90 response rates. Vunakizumab, an IL-17A antibody with quarterly dosing after induction, showed strong Phase 3 results published in January 2025. These agents build on established biologic science rather than replacing it.

For patients who cannot access biologics, topical roflumilast (a phosphodiesterase-4 inhibitor) is a meaningful addition. Earlier steroid-free topical options were limited to calcineurin inhibitors, which carry a black-box warning; roflumilast foam lacks that restriction. Research indexed on [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=psoriasis+biologics) has also outlined longer-term remission approaches targeting T-regulatory cells, though those remain experimental. The treatment ladder described below reflects what dermatologists in Canada are actually prescribing today.

## How is psoriasis treated in Canada?

Canadian dermatologists follow a step-therapy model anchored to disease severity. **Short answer:** Mild psoriasis starts with topical corticosteroids, vitamin D analogues, or combination products. Moderate-to-severe psoriasis escalates to phototherapy (narrowband UVB) or conventional systemic agents (methotrexate, cyclosporine, acitretin), and then to biologics if systemic therapy fails or causes adverse effects. Most provincial drug plans require documented failure of at least one conventional systemic agent before covering biologics, though exceptions exist for severe disease or contraindications.

The table below summarises the standard Canadian treatment ladder based on CDA and [AAD (American Academy of Dermatology) psoriasis guidelines](https://www.aad.org/member/clinical-quality/guidelines/psoriasis):

| Severity | Body surface area (BSA) | First-line | Step-up | Notes |
|---|---|---|---|---|
| Mild | Less than 3% BSA | Topical corticosteroids (mid-to-high potency), vitamin D analogues (calcipotriol) | Combination betamethasone/calcipotriol foam | OTC moisturisers as adjuncts; avoid prolonged high-potency steroids on face or folds |
| Moderate | 3 to 10% BSA | Narrowband UVB phototherapy, topical combination agents | Methotrexate or acitretin | Phototherapy requires 2 to 3 clinic visits per week; teleconsult can reduce travel burden |
| Severe | Over 10% BSA or PASI 10 or above | Methotrexate, cyclosporine (short-term) | IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (risankizumab, guselkumab) | Biologic access requires prior-auth on most provincial formularies |
| Special sites | Scalp, genitals, nails | Roflumilast foam, calcipotriol/betamethasone solution | Biologics for nail disease unresponsive to topicals | Nail psoriasis predicts psoriatic arthritis risk |

For more on how Canadian patients access specialty dermatology care, see [The State of Dermatology Access in Canada in 2024](/blog/the-state-of-dermatology-access-in-canada-in-2024).

## What are psoriasis biologics and who qualifies?

Biologics are the standard of care for moderate-to-severe psoriasis that has not responded to topicals or phototherapy. **Short answer:** Biologics are injectable proteins that block specific inflammatory cytokines driving psoriasis. The two main classes target IL-17 (secukinumab, ixekizumab, bimekizumab) or IL-23 (risankizumab, guselkumab; ustekinumab targets IL-12/23). In clinical trials, IL-23 inhibitors typically achieve PASI-90 in 70 to 80% of patients at 16 weeks. Most provincial drug plans in Canada cover at least one biologic after failure of methotrexate or phototherapy, and your dermatologist must submit a prior-authorisation form documenting disease severity and prior treatments.

The following comparison covers the biologics most commonly prescribed in Canada as of 2025:

| Biologic | Target | Dosing after induction | Typical PASI-90 at 16 weeks | Provincial coverage note |
|---|---|---|---|---|
| Secukinumab (Cosentyx) | IL-17A | Every 4 weeks | ~70% | Listed on most provincial formularies |
| Ixekizumab (Taltz) | IL-17A | Every 4 weeks | ~75% | Requires prior-auth; listed in most provinces |
| Bimekizumab (Bimzelx) | IL-17A and IL-17F | Every 4 weeks (may extend to 8 weeks) | ~85% | Health Canada approved 2024; coverage expanding |
| Risankizumab (Skyrizi) | IL-23p19 | Every 12 weeks | ~75% | Strong formulary coverage; once-quarterly convenience |
| Guselkumab (Tremfya) | IL-23p19 | Every 8 weeks | ~73% | Listed; option if risankizumab unavailable |
| Ustekinumab (Stelara) | IL-12/23p40 | Every 12 weeks | ~60% | Biosimilars entering market; cost-effective option |

Patients with psoriatic arthritis should discuss options with both a dermatologist and a rheumatologist, as some biologics carry rheumatology indications as well.

## What vitamin am I lacking if I have psoriasis?

Vitamin D is the micronutrient most consistently linked to psoriasis in published research. **Short answer:** Research most consistently shows low vitamin D levels in people with psoriasis. Serum 25-hydroxyvitamin D often falls below 30 nmol/L in affected patients, and topical vitamin D analogues (calcipotriol) are a standard first-line treatment that slows keratinocyte proliferation. Oral vitamin D supplements do not treat active plaques on their own. The relationship is likely bidirectional: chronic inflammation may reduce vitamin D synthesis, and low vitamin D may amplify immune dysregulation. Talk to your physician before starting high-dose supplementation.

A [2020 meta-analysis indexed in PubMed](https://pubmed.ncbi.nlm.nih.gov/32145944/) found significantly lower serum vitamin D in psoriasis patients compared to healthy controls. Some patients also show lower omega-3 fatty acid and zinc levels, though the clinical evidence for supplementing those is weaker. Focus on prescription treatments first; supplements are adjuncts at best.

## What topical treatments are available for psoriasis?

Topicals are the first stop for any patient with mild or localised psoriasis, and they remain useful as adjuncts even in severe disease. **Short answer:** Topical psoriasis treatment options include corticosteroids (mild to super-potent, depending on body site), vitamin D analogues (calcipotriol), combination products (betamethasone dipropionate plus calcipotriol), coal tar, salicylic acid for scale removal, calcineurin inhibitors (tacrolimus, pimecrolimus) for sensitive areas, and the newer phosphodiesterase-4 inhibitor roflumilast foam. Most patients use a corticosteroid as the backbone, rotating off periodically to prevent skin thinning. Canadian pharmacists can dispense some of these without a prescription, but a dermatologist's guidance on potency and site selection matters significantly.

Corticosteroid potency runs from Class I (mildest) to Class VII (super-potent) in the Canadian classification. Apply super-potent agents like clobetasol propionate only to thick plaques on palms or soles, for no more than two consecutive weeks. For the scalp, a shampoo or foam vehicle improves adherence. For the face and genitals, use Class I or II corticosteroids or calcineurin inhibitors only, as stronger agents cause atrophy. The [AAD guidelines](https://www.aad.org/member/clinical-quality/guidelines/psoriasis) provide detailed site-specific recommendations. See also [5 Common Skin Conditions in Canadian Adults](/blog/5-common-skin-conditions-in-canadian-adults) for context on how psoriasis compares to other chronic skin conditions.

## How does psoriasis care in Canada differ from other countries?

Geography, climate, and provincial funding structures all shape the patient experience in Canada. **Short answer:** Canadian patients face longer specialist wait times than patients in many European countries. Dermatologist wait times average 78 days nationally according to [CIHI](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada), meaning many Canadians manage psoriasis through primary care for months before reaching a specialist. Provincial drug plan criteria for biologic access vary: Ontario's ODB, Alberta Blue Cross, and BC PharmaCare each maintain their own prior-authorisation requirements, so coverage for the same drug can differ across provinces. Canada's cold, low-UV climate also limits natural UVB exposure for six months of the year, worsening phototherapy access for rural patients.

Patients in northern and rural communities face particular challenges because narrowband UVB phototherapy requires clinic-based equipment. Home phototherapy units are available but rarely covered by provincial plans. Teledermatology services can reduce unnecessary travel for diagnostic consultations and prescription renewals.

## Sources

- Canadian Dermatology Association (CDA). Psoriasis. [https://dermatology.ca/public-patients/skin/psoriasis/](https://dermatology.ca/public-patients/skin/psoriasis/) Accessed March 2025.
- American Academy of Dermatology (AAD). Guidelines of care for the management of psoriasis and psoriatic arthritis. [https://www.aad.org/member/clinical-quality/guidelines/psoriasis](https://www.aad.org/member/clinical-quality/guidelines/psoriasis) Accessed March 2025.
- National Institutes of Health (NIH). Psoriasis overview. National Institute of Arthritis and Musculoskeletal and Skin Diseases. [https://www.niams.nih.gov/health-topics/psoriasis](https://www.niams.nih.gov/health-topics/psoriasis) Accessed March 2025.
- Dopytalska K et al. Vitamin D in dermatological practice. PubMed / NCBI. [https://pubmed.ncbi.nlm.nih.gov/32145944/](https://pubmed.ncbi.nlm.nih.gov/32145944/) Published 2020.
- Canadian Institute for Health Information (CIHI). Wait Times for Priority Procedures in Canada. [https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) Accessed March 2025.
- PubMed / NCBI. Psoriasis biologics research index. [https://pubmed.ncbi.nlm.nih.gov/?term=psoriasis+biologics](https://pubmed.ncbi.nlm.nih.gov/?term=psoriasis+biologics) Accessed March 2025.

## FAQ
### What is the new treatment for psoriasis 2025?
By early 2025, the most significant additions to the Canadian psoriasis treatment landscape are bimekizumab (Bimzelx), which targets both IL-17A and IL-17F for higher clearance rates, and roflumilast foam for difficult-to-treat areas like the scalp and genitals. Vunakizumab, an IL-17A antibody with quarterly dosing after induction, published strong Phase 3 results in January 2025. These join an established biologic toolkit of IL-23 inhibitors (risankizumab, guselkumab) that achieve PASI-90 clearance in roughly 75% of patients. None replaces existing options; they expand choice for patients who did not respond adequately to earlier biologics.

### What vitamin am I lacking if I have psoriasis?
Vitamin D is the micronutrient most consistently associated with psoriasis. Multiple studies show that people with psoriasis tend to have lower serum 25-hydroxyvitamin D than matched controls. Topical vitamin D analogues like calcipotriol are a standard first-line treatment because they slow keratinocyte proliferation and modulate immune responses. However, oral vitamin D supplementation alone does not clear plaques. Some patients also have low zinc or omega-3 fatty acid levels, but the evidence for supplementing those is weaker. Ask your physician to check your vitamin D level as part of a routine blood panel, and prioritise prescription treatments first.

### What is the new treatment for psoriasis in 2026?
As of early 2025, the most anticipated agents for 2026 include several oral tyrosine kinase 2 (TYK2) inhibitors following the success of deucravacitinib (Sotyktu), which received Health Canada approval in 2023. Oral options are attractive because they avoid injections and may suit patients with needle anxiety or limited clinic access. Researchers are also investigating cell-therapy and regulatory T-cell approaches that aim at long-term remission rather than ongoing suppression. These remain in Phase 2 trials; approval timelines are uncertain. Speak with a dermatologist for the most current access information when 2026 arrives.

### How do Japanese treat psoriasis?
Japan follows international biologic guidelines similar to Canada and the European Union, and has been an early adopter of IL-23 inhibitors including risankizumab, which was first approved in Japan in 2019. Japanese dermatology guidelines from the Japanese Dermatological Association closely mirror AAD and European Academy of Dermatology and Venereology recommendations: topicals first, then phototherapy or methotrexate for moderate disease, then biologics for severe or refractory cases. Japan also has a tradition of balneotherapy (medicated baths) in some spa regions, though this is a complementary measure rather than a clinical standard. Overall, the pharmacological approach is very similar to Canadian practice.

---

# Integrating an AI Dermatology Tool with OSCAR EMR and Telus PS Suite

URL: https://www.dermadex.ca/blog/integrating-dermadex-with-oscar-emr-and-telus-ps-suite
Category: Operations
Author: Elham Hafezi
Published: 2025-02-25

## TL;DR
OSCAR (Open Source Clinical Application Resource) EMR holds roughly 14,000 Canadian physician users as of 2024 (CIHI) | Telus PS Suite is the leading proprietary EMR in Canada with over 20,000 users | AI dermatology tools typically use HL7 FHIR (Fast Healthcare Interoperability Resources) messaging to exchange data with EMR platforms | Patient data transfers in Ontario must comply with PHIPA (Personal Health Information Protection Act); federally and in other provinces, PIPEDA (Personal Information Protection and Electronic Documents Act) applies — all transfers must be encrypted in transit | Setup typically takes one to three business days for most clinics once credentials and data-sharing agreements are in place

*As of February 25, 2025.*

Canadian primary-care and dermatology clinics rarely run on a single software platform. The average family physician uses one electronic medical record (EMR) system while the dermatologist they refer to uses another, and neither system was designed to talk to each other out of the box. Integrating any AI-assisted dermatology tool with a referring physician's EMR — whether OSCAR or Telus PS Suite — involves a predictable set of technical, administrative, and compliance steps.

This article explains how those integrations work in general, what data moves across them, and what your IT team or clinic manager needs to know before going live.

## What is OSCAR EMR and who uses it in Canada?

OSCAR (Open Source Clinical Application Resource) is a free, open-source electronic medical record (EMR) built at McMaster University and used by approximately 14,000 Canadian physicians. It is most prevalent in British Columbia, Ontario, and Alberta, particularly in community health centres and academic family medicine clinics. Because OSCAR is open-source, multiple regional deployments exist under different names, including OscarBC and OSCAR Pro. Each deployment may run a different software version, which any connecting platform must account for during setup and configuration.

OSCAR was originally developed at McMaster University in 2001. Because it is open-source, dozens of regional deployments exist — including OscarBC, OSCAR Pro (now commercialized by WELL Health), and various self-hosted instances maintained by provincial health authorities. This fragmentation is the first challenge any integration must address: the version of OSCAR at a Vancouver community health centre may differ substantially from the one running at a Toronto academic clinic.

The Canadian Institute for Health Information (CIHI) tracks EMR adoption across provinces. According to CIHI's national physician survey data, the proportion of Canadian physicians using any EMR system has grown above 85% in recent years, with OSCAR representing a meaningful share in western and central provinces. For current adoption figures, see the CIHI EMR adoption report at [CIHI physician data](https://www.cihi.ca/en/physicians).

For dermatology use specifically, OSCAR's strength is its open application programming interface (API) layer. Third-party tools — including dermatology image capture tools like DermEngine — have published OSCAR integration guides that illustrate the general approach.

## What is Telus PS Suite and how does it differ from OSCAR?

Telus PS Suite is a commercially licensed electronic medical record (EMR) owned by Telus Health, with more than 20,000 users across Canada. Unlike OSCAR, PS Suite operates on a closed, subscription-based model with structured vendor support and a formal integration partner program. It is particularly strong in Ontario and Quebec private practices, where OHIP (Ontario Health Insurance Plan) billing integration and 24/7 vendor support are priorities. PS Suite exposes integration points through HL7 (Health Level Seven) v2 messaging and the Telus Health Connect program rather than an open API.

Telus Health acquired PS Suite as part of a broader strategy to consolidate Canadian digital health platforms. The product is particularly strong in Ontario and Quebec private practices where administrative features, billing integration with Ontario Health Insurance Plan (OHIP), and 24/7 vendor support are priorities. PS Suite's integration layer relies on HL7 v2 messaging and a proprietary API exposed through the Telus Health Connect program.

The table below compares the two platforms on dimensions relevant to an AI dermatology tool integration:

| EMR | Vendor | Estimated Canadian Users | Integration Method |
|-----|--------|--------------------------|---------------------|
| OSCAR EMR | OSCAR Pro / WELL Health (commercial); community-hosted (open-source) | ~14,000 physicians | HL7 v2, REST API via OSCAR integration layer |
| Telus PS Suite | Telus Health | ~20,000+ physicians | HL7 v2 via Telus Health Connect; PS Suite API |
| OSCAR BC | OscarBC (BC-specific fork) | ~3,500 physicians | HL7 v2, subset of OSCAR API |
| OSCAR (self-hosted) | Various community deployments | Variable | HL7 v2 (version-dependent) |

Both platforms support bidirectional HL7 messaging for demographics, referral notes, and lab results. That shared standard is the foundation for any EMR integration a dermatology tool would build.

## How does an AI dermatology tool exchange data with OSCAR and PS Suite?

Most AI dermatology platforms use HL7 FHIR (Fast Healthcare Interoperability Resources) and HL7 v2 messages to pull patient demographics at the point of referral and push consultation summaries back to the referring physician chart. Patient data should be stored exclusively on Canadian servers, and all transfers should use TLS 1.3 encryption. A well-designed integration covers three stages: demographic pull when the referral is created, image and note transfer during the consultation, and result push when the dermatologist finishes the report — eliminating manual re-entry and reducing transcription errors on both sides of the referral.

The data flow typically works in three stages:

**Stage 1: Demographic pull.** When a referring physician creates a referral, the integration retrieves the patient's name, date of birth, health card number, and active problem list from the EMR. This avoids manual re-entry and reduces transcription errors.

**Stage 2: Image and note transfer.** The dermatologist reviews AI-assisted triage results and any uploaded skin images within the dermatology platform. Consultation notes are structured using standard SNOMED-CT and ICD (International Classification of Diseases) codes so they map cleanly to the referring EMR's chart fields.

**Stage 3: Result push.** The consultation summary — including diagnosis, recommended follow-up, and any prescription notes — is pushed back as an HL7 message into the referring physician's OSCAR or PS Suite chart. The referring physician sees it as an incoming result, the same way they receive a lab report.

For a deeper look at how patient images should be protected during these transfers, see the DermaDex article on [encrypting patient images at rest and in transit](/blog/encrypting-patient-images-at-rest-and-in-transit).

## What compliance rules apply to Canadian EMR integration?

Any integration that moves patient health information between systems in Ontario must comply with PHIPA (Personal Health Information Protection Act). Federally, PIPEDA (Personal Information Protection and Electronic Documents Act) also applies to private-sector health data. A dermatology platform operating as a health information custodian under PHIPA must sign a data-sharing agreement with each connected clinic before any live data flows across the integration. Patients have the right to know where their data goes and to request corrections, and this must be reflected in the clinic privacy policy and, where required, in patient consent forms.

Key compliance checkpoints before enabling any such integration:

- **Data residency**: Patient data must remain on Canadian servers. No patient data should cross the border.
- **Audit logging**: Every data access event should be logged with a timestamp, user ID, and purpose of access.
- **Access control**: Only the treating dermatologist and the referring physician should be able to view the shared record. Administrative staff access requires a separate consent flag.
- **Breach notification**: Both the dermatology platform and the clinic share breach notification obligations under PHIPA and any applicable provincial regulation.

For more on what these rules mean for patients, read the DermaDex guide to [PHIPA, PIPEDA and skin health data](/blog/phipa-pipeda-and-skin-health-data-what-patients-should-know).

The National Institutes of Health (NIH) also publishes interoperability guidance relevant to FHIR implementations at [FHIR interoperability in electronic health records (PubMed)](https://pubmed.ncbi.nlm.nih.gov/38025292/), which Canadian developers use as a technical reference alongside HL7 Canada standards.

## What does the setup process look like for a clinic IT team?

Setup typically takes one to three business days for most clinics once credentials are in place and the data-sharing agreement is signed. The steps differ by EMR:

**OSCAR EMR setup:**
1. Confirm your OSCAR version with your hosting provider or internal IT team. Most third-party integrations require OSCAR 15.x or later.
2. Enable the third-party integration module inside OSCAR's Administration panel.
3. Generate a service account with read/write access to the Demographics and Documents modules.
4. Share the endpoint URL and credentials with the dermatology platform's onboarding team via a secure credential portal.
5. Run a test referral using a dummy patient record to confirm bidirectional data flow.

**Telus PS Suite setup:**
1. Contact Telus Health to register the dermatology platform as an integration partner via the PS Suite integration program. Not all platforms hold approved-partner status; confirm this with the vendor before beginning.
2. Telus Health provisions an HL7 endpoint and provides connection parameters.
3. Share those parameters with the platform's onboarding team.
4. Test with a dummy patient record before going live.

Clinic managers who are not IT-trained can generally follow the same process. The dermatology platform's onboarding team handles the technical configuration on their side. The clinic's role is primarily administrative: obtaining credentials and confirming that the privacy officer has reviewed the data-sharing agreement. Health Canada's digital health resources at [Health Canada health care system](https://www.canada.ca/en/health-canada/services/health-care-system.html) provide additional guidance on privacy requirements for connected health tools.

## Sources

- Canadian Institute for Health Information (CIHI). *Physicians in Canada.* [https://www.cihi.ca/en/physicians](https://www.cihi.ca/en/physicians)
- Jiang G et al. Electronic health record interoperability using FHIR and blockchain. *BMC Medical Informatics and Decision Making* (2023). [https://pubmed.ncbi.nlm.nih.gov/38025292/](https://pubmed.ncbi.nlm.nih.gov/38025292/)
- Health Canada. Health Care System. [https://www.canada.ca/en/health-canada/services/health-care-system.html](https://www.canada.ca/en/health-canada/services/health-care-system.html)

## FAQ
### What is Oscar Pro EMR?
OSCAR Pro is a commercialized version of the original OSCAR (Open Source Clinical Application Resource) EMR, now owned and operated by WELL Health Technologies. It retains the open-source OSCAR codebase but adds a managed hosting layer, 24/7 support, and a curated marketplace of third-party integrations. Family physicians and specialists across Canada use OSCAR Pro as a cloud-hosted alternative to self-managed OSCAR deployments. The Pro version includes the same HL7 integration capabilities as community OSCAR, which means any third-party tool with OSCAR integration support can generally connect to OSCAR Pro clinics using the same technical mechanism used for self-hosted instances.

### What is an EMR integration?
An EMR (electronic medical record) integration is a technical connection between two software systems that allows patient data — demographics, clinical notes, lab results, referrals — to move automatically without manual re-entry. Most Canadian EMR integrations use HL7 v2 messaging or the newer FHIR (Fast Healthcare Interoperability Resources) standard. For a dermatology tool, integration with a referring physician's EMR means the patient's chart updates automatically when a consultation is complete, reducing the administrative burden on both sides and lowering the risk of transcription errors.

### How much does the Oscar EMR cost?
Self-hosted OSCAR is free to license as open-source software, but clinics pay for server hosting, IT support, and configuration — costs that vary widely by province and provider. OSCAR Pro, the commercialized version sold by WELL Health, charges a monthly per-physician subscription fee. Exact pricing is not published publicly and varies based on clinic size and contract terms. Community health centres and academic family medicine programs sometimes access OSCAR through provincial health authority agreements at reduced or no direct cost. Contact WELL Health or your regional health authority for current pricing applicable to your province.

### Is Oscar EMR free?
The OSCAR EMR source code is free under an open-source license. Any clinic with technical capacity can download, install, and run it at no software licensing cost. However, running OSCAR in practice is not cost-free: clinics need a server (on-premises or cloud), database administration, security patching, and ongoing IT support. These infrastructure and support costs can run from a few hundred to several thousand dollars per month depending on clinic size. OSCAR Pro from WELL Health bundles hosting and support into a subscription fee, eliminating self-management overhead at the cost of a recurring charge.

---

# Acne in Adults: What the 2025 Research Says

URL: https://www.dermadex.ca/blog/acne-in-adults-what-the-2025-research-says
Category: Conditions
Author: Mohsen Khoddami
Published: 2025-02-04

## TL;DR
Adult acne affects up to 15% of adult women and 5% of adult men, per AAD data | Hormonal fluctuations (menstrual cycle, PCOS, perimenopause) drive most adult-onset acne in women | Topical retinoids combined with BPO (Benzoyl Peroxide) remain the first-line standard as of 2025 | Spironolactone shows strong evidence for hormonal acne in adult women, confirmed in 2024 NIH-indexed trials | Most prescription treatments take 8-12 weeks to produce visible clearing

*As of February 4, 2025.*

Adult acne is more common than most people expect. If you cleared up at 18 and then watched breakouts return at 28 or 38, you are not unusual. The American Academy of Dermatology (AAD) estimates that acne affects up to 15% of adult women and roughly 5% of adult men at any given time. The drivers are different from teenage acne, and so are the most effective treatments.

This article covers what the most recent clinical research says about adult acne causes, hormonal triggers, and treatment options available to Canadian patients in 2025. [DermaDex connects Canadian patients to certified dermatologists](/) when wait times for in-person specialist care stretch into months.

---

## What actually causes adult acne?

Short answer: Adult acne shares the same four core mechanisms as teenage acne (excess oil, clogged pores, bacteria, inflammation), but hormonal shifts, stress, and certain medications play a much larger role in adults than in adolescents. The four factors are excess sebum production, abnormal follicular shedding, proliferation of *Cutibacterium acnes* bacteria, and an inflammatory immune response. In adults, menstrual cycles, pregnancy, perimenopause, polycystic ovary syndrome (PCOS), and elevated cortisol from chronic stress can spike androgen activity at the sebaceous gland level, increasing oil output and triggering breakouts. Research indexed on the National Institutes of Health (NIH) PubMed database also points to a strong hereditary component, with first-degree relatives of acne patients showing significantly higher rates of the condition.

Diet research has matured alongside these hormonal findings. High-glycemic diets and frequent dairy consumption are associated with acne severity in multiple controlled studies. The NIH acknowledges diet as a contributing factor, though direct causality is still under investigation.

## How is hormonal acne different from regular adult acne?

Short answer: Hormonal acne in adults concentrates along the jawline, chin, and neck, flares predictably in the week before menstruation, and responds poorly to standard topical treatments alone. It is driven by androgen activity at the sebaceous gland, not surface bacteria. The Canadian Dermatology Association (CDA) recommends ruling out PCOS and other endocrine disorders in women with severe or sudden-onset adult acne. Even women with normal serum androgen levels can experience hormonal acne if their skin's androgen receptors are particularly sensitive, which is why a normal testosterone blood test does not rule out the diagnosis.

When breakouts cluster on the lower face and persist despite consistent skincare, systemic hormonal treatment is usually required. Topical antibiotics and BPO (Benzoyl Peroxide) alone rarely resolve hormonally driven acne in adults.

For a broader look at skin conditions that commonly affect Canadian adults, see [5 Common Skin Conditions in Canadian Adults](/blog/5-common-skin-conditions-in-canadian-adults).

## What does the 2025 research say about adult acne treatment options?

Short answer: Topical retinoids combined with BPO (Benzoyl Peroxide) remain the evidence-based first-line standard for mild-to-moderate adult acne. For hormonal acne in adult women, spironolactone has accumulated strong trial data through 2023-2024, with a systematic review on PubMed showing consistent lesion-count reductions at 12 weeks versus placebo. Oral isotretinoin remains the most effective single option for severe or scarring acne at any age, though it requires monitoring under Health Canada-regulated protocols. Adapalene 0.1%, now available over the counter in Canada, combined with BPO 2.5% offers a lower-irritation entry point for patients starting treatment.

The table below compares the main treatment categories by severity target, side effects, and realistic timelines.

| Treatment | Type | Acne severity it treats | Common side effects | Time to visible result |
|---|---|---|---|---|
| BPO (Benzoyl Peroxide) | Topical OTC | Mild to moderate | Dryness, bleaching of fabric | 4-8 weeks |
| Topical retinoid (tretinoin, adapalene) | Topical Rx/OTC | Mild to moderate | Irritation, sun sensitivity | 8-12 weeks |
| Topical antibiotic (clindamycin) | Topical Rx | Mild to moderate | Low systemic risk; resistance concern | 6-10 weeks |
| Oral antibiotic (doxycycline) | Systemic Rx | Moderate | GI upset, photosensitivity | 6-10 weeks |
| Spironolactone | Systemic Rx (women) | Moderate hormonal | Menstrual irregularity, potassium shift | 8-16 weeks |
| Combined oral contraceptive | Systemic Rx (women) | Moderate hormonal | Variable; cardiovascular risk factors | 3-6 months |
| Oral isotretinoin | Systemic Rx | Severe / scarring | Teratogenicity, dryness, liver monitoring | 4-6 months |

The American Academy of Dermatology (AAD) updated its acne guidelines to reflect growing evidence for spironolactone as a first-line systemic option in adult women, alongside combined oral contraceptives. For patients who cannot tolerate oral medications, a combination of topical clindamycin plus BPO (to reduce antibiotic resistance) and a retinoid covers most mild-to-moderate presentations.

## What is the latest acne treatment for 2025?

Short answer: Clascoterone 1% cream (brand name Winlevi), a topical androgen receptor blocker, is the most clinically meaningful new option gaining attention in 2025. It treats hormonal acne by blocking androgen receptors directly in the skin without the systemic hormonal effects of spironolactone, making it potentially viable for male patients and those who cannot tolerate systemic therapies. Studies indexed on PubMed show significant reductions in both inflammatory and non-inflammatory lesion counts versus vehicle. No new first-line treatment has displaced retinoids or BPO in 2025. Canadian prescribers should verify Health Canada approval status before prescribing clascoterone.

Light-based and energy-based devices, including blue-light therapy and certain laser treatments, continue to be studied as adjuncts. Their evidence base remains weaker than for topical or systemic options and they are not recommended as standalone first-line treatment in current guidelines.

## How do you treat adult acne without making skin worse?

Short answer: Start with the least irritating effective option, add one treatment at a time, and protect the skin barrier throughout. Over-washing is one of the most common errors in adult acne management. Washing more than twice daily strips the barrier, triggers compensatory oil production, and worsens inflammation around already-irritated follicles. The AAD recommends a gentle, non-comedogenic cleanser twice daily and after sweating. Patients starting tretinoin or other retinoids should begin two to three nights per week and increase frequency slowly, a technique called retinoid titration. A fragrance-free, non-comedogenic moisturizer used alongside the retinoid offsets dryness and peeling without blocking pores.

For adults with sensitive or reactive skin, an in-person or virtual consultation with a dermatologist before starting prescription treatment can prevent weeks of unnecessary irritation. [Learn more about DermaDex's approach to connecting patients with qualified dermatologists](/about).

## Sources

- American Academy of Dermatology (AAD). "Acne: Overview." [https://www.aad.org/public/diseases/acne](https://www.aad.org/public/diseases/acne)
- National Institutes of Health (NIH) / National Library of Medicine. "Acne Vulgaris." PubMed. [https://pubmed.ncbi.nlm.nih.gov/](https://pubmed.ncbi.nlm.nih.gov/)
- Canadian Dermatology Association (CDA). "Acne." [https://dermatology.ca/public-patients/skin/acne/](https://dermatology.ca/public-patients/skin/acne/)
- Health Canada. Drug Product Database. [https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html)
- NCBI / PubMed: Barbieri JS et al. "Approaches to Limit Systemic Antibiotic Use in Acne." *JAMA Dermatol.* [https://pubmed.ncbi.nlm.nih.gov/31596453/](https://pubmed.ncbi.nlm.nih.gov/31596453/)
- NCBI / PubMed: Geller L et al. "Perceptions of acne treatment in women." *J Drugs Dermatol.* [https://pubmed.ncbi.nlm.nih.gov/24719060/](https://pubmed.ncbi.nlm.nih.gov/24719060/)

## FAQ
### What is the latest acne treatment for 2025?
The most notable newer option gaining attention in 2025 is clascoterone 1% cream (brand name Winlevi), a topical androgen receptor blocker that treats hormonal acne without the systemic hormonal side effects of spironolactone. It works in both men and women. That said, the combination of a topical retinoid such as tretinoin or adapalene with BPO (Benzoyl Peroxide) remains the evidence-based standard first-line treatment for mild-to-moderate adult acne. For severe or scarring acne, oral isotretinoin under close physician supervision is still the most effective option available. Always confirm Health Canada approval and prescription eligibility with your dermatologist before starting any new therapy.

### What is the most effective adult acne treatment?
For mild to moderate adult acne, topical retinoids combined with BPO (Benzoyl Peroxide) have the strongest evidence base. For hormonal acne in adult women, spironolactone (an oral androgen blocker) adds significant benefit, with consistent results in clinical trials indexed on PubMed. For severe acne or cases involving scarring, oral isotretinoin remains the most effective single treatment available, though it requires Health Canada-regulated physician monitoring including regular blood tests and, for women of childbearing age, pregnancy prevention protocols. No topical or light-based treatment currently outperforms oral isotretinoin for severe acne.

### What does B12 acne look like?
Vitamin B12 supplementation has been associated with acne flares in some patients, a phenomenon observed in case reports and small studies published on PubMed. B12-triggered acne typically resembles ordinary inflammatory acne with papules and pustules, often appearing or worsening within weeks of starting high-dose B12 supplements or B12 injections. It tends to affect the face, chest, and back. The proposed mechanism is that excess B12 alters the metabolism of *Cutibacterium acnes* bacteria in the follicle, shifting them toward a more pro-inflammatory state. If you suspect your supplements are contributing to breakouts, speak with your physician before stopping any prescribed supplementation.

### How do Koreans clear acne?
Korean skincare routines are often credited with producing clear skin, and the underlying principles align with dermatological recommendations: gentle double cleansing to remove sunscreen and makeup without stripping the barrier, consistent use of non-comedogenic moisturizers to keep skin hydrated (which reduces compensatory oil production), chemical exfoliants like BHA (salicylic acid) rather than abrasive physical scrubs, and daily SPF application. Koreans also have historically higher rates of dermatologist visits for acne management. The cultural emphasis is on prevention and barrier support rather than aggressive drying treatments. These habits reduce irritation and support the skin barrier, which is consistent with current AAD guidelines for acne management in adults.

---

# How to Perform a Monthly Self-Skin Check Step by Step

URL: https://www.dermadex.ca/blog/how-to-perform-a-monthly-self-skin-check-step-by-step
Category: Prevention
Author: Maryam Sobhkhiz Sabet
Published: 2025-01-14

## TL;DR
Skin cancer is the most common cancer in Canada, with over 80,000 new cases per year (Canadian Cancer Society, 2024) | The American Academy of Dermatology (AAD) recommends a full skin self exam once a month | Melanoma caught at stage I has a 5-year survival rate above 98% (NIH, 2023) | The ABCDE rule -- Asymmetry, Border, Color, Diameter, Evolving -- identifies suspicious moles | Patients who photograph and document changing lesions monthly present with thinner tumours on average (PubMed, 2010)

*As of January 14, 2025.*

Skin cancer is the most common cancer in Canada. Catching it early, before it spreads, is the single biggest factor in a good outcome. A monthly self skin check at home costs nothing, takes less than 10 minutes, and gives you a baseline so any new or changing spot stands out fast.

This guide walks you through the full process: what you need, where to look, what counts as a warning sign, and when to book a dermatologist.

## Why does a monthly skin self exam matter?

Short answer: Monthly checks build a mental map of your skin so you notice changes early. Melanoma detected at stage I carries a five-year survival rate above 98%, compared to roughly 30% at stage IV (National Cancer Institute, 2023). The Canadian Dermatology Association (CDA) estimates that more than 80,000 Canadians receive a skin cancer diagnosis each year. Most of those cases are basal cell and squamous cell carcinomas, which are highly curable when found early. Melanoma is less common but far more dangerous if missed. A monthly skin self exam does not replace an annual professional check, but it dramatically shortens the window between a change appearing and a clinician seeing it. Patients who examine their own skin regularly present with thinner tumors on average, according to data published in the [PubMed: Efficacy of skin self-examination for early detection of melanoma](https://pubmed.ncbi.nlm.nih.gov/20465635/).

## What do you need before you start?

Short answer: A full-length mirror, a hand mirror, good lighting, and a private space are all you need. You can complete a thorough skin self exam with items already in your home. The best time to check is after a shower or bath, when your skin is clean and you are already undressed. Good lighting matters more than any special tool, because shadows hide lesions that flat overhead light reveals. Bring a comb or hair dryer to part the scalp in sections, and keep a smartphone nearby for photographing suspicious spots alongside a ruler for scale.

- A full-length mirror mounted to a wall or door
- A hand-held mirror for hard-to-see areas
- A bright lamp or natural daylight
- A comb or hair dryer to part the scalp
- A smartphone for photographing suspicious spots

## What does the ABCDE rule mean for mole checks at home?

Short answer: The ABCDE rule stands for Asymmetry, Border, Color, Diameter, Evolving and gives you five criteria to assess any mole or spot during a mole check at home. A spot meeting one or more criteria warrants a professional opinion promptly. The AAD (American Academy of Dermatology) developed this framework so patients can spot warning signs without medical training, and it remains the most widely taught self-screening tool for melanoma. Draw an imaginary line through a mole: if the two halves match, that is reassuring. Smooth borders and uniform tan or brown color under 6 mm are also positive signs. The [AAD illustrates these criteria at aad.org](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes).

- **Asymmetry:** The two halves of a mole do not match.
- **Border:** Ragged, notched, or blurred edges.
- **Color:** Multiple shades of brown, black, red, white, or blue in one lesion.
- **Diameter:** Wider than 6 mm, roughly the eraser end of a pencil.
- **Evolving:** Any change in size, shape, color, or texture over weeks to months.

For a deeper look at melanoma detection, see [DermaDex's guide to understanding melanoma and the ABCDEs of skin cancer](/blog/understanding-melanoma-the-abcdes-of-skin-cancer-detection).

## How do you perform a self skin check at home step by step?

Short answer: Start at your scalp and work downward in a fixed sequence, using both mirrors to cover every surface. A structured order prevents missed areas, and the full routine takes under 10 minutes once you learn it. The American Academy of Dermatology recommends performing this exam once a month, ideally at the same time each month so you build a reliable habit. Begin after a shower with good overhead or natural light, and photograph any spot that catches your attention alongside a ruler for scale so you have an objective record to share with a clinician.

### Step 1 - Scalp and hairline

Use a comb and a hand mirror under bright light. Part the hair in sections and check the scalp skin directly. Ask a partner to check the crown if you have limited mobility.

### Step 2 - Face, ears, and neck

Stand in front of the full-length mirror. Check your forehead, nose, lips, chin, and cheeks. Fold each ear forward to inspect behind it and inside the outer canal. Tilt your head back to see the underside of the jaw and the front of the neck.

### Step 3 - Chest and abdomen

Look front-on at the chest. Women should lift the breasts to examine the skin underneath. Scan the abdomen down to the groin.

### Step 4 - Arms and hands

Raise both arms and inspect the underarms. Check the entire arm surface, front, back, and sides. Spread the fingers and look between them and under the nails.

### Step 5 - Back and buttocks

Turn your back to the full-length mirror and use the hand mirror to see the upper and lower back, including the spine and shoulder blades. Check the buttocks and the skin between them.

### Step 6 - Legs and feet

Sit on a chair. Work from the upper thighs down to the ankles. Use the hand mirror for the backs of the knees and calves. Check the soles, between the toes, and under the toenails.

## What should you look for during a self skin screening?

Short answer: Any new growth, any spot that bleeds or itches without injury, and any mole that has changed since last month qualifies as a reason to contact your doctor. The table below serves as a quick reference during your check, pairing each body area with the specific features to inspect and the red flags that warrant a follow-up appointment. Photograph any flagged spot against a plain background with a ruler beside it for scale. Date the photo. This gives you and your clinician an objective baseline for comparison at future visits.

| Body area | What to inspect | Red flag |
|-----------|----------------|----------|
| Scalp | Skin between hair parts | Pink or pearly bump; persistent scaly patch |
| Face and ears | Moles, freckles, sun spots | Asymmetric mole; lesion that bleeds or crusts |
| Neck and chest | Skin folds, decolletage | New dark spot; ulcerated area |
| Back and shoulders | Large surface area; easy to miss | Any evolving mole; irregular colored patch |
| Arms and hands | Dorsal hand, forearms | Rough, scaly growth (possible actinic keratosis) |
| Legs and feet | Shins, soles, between toes | Dark streak under a nail; non-healing sore |
| Genitals | Skin and mucous membrane | Persistent sore or new pigmented lesion |

[DermaDex](/) lets you upload photos directly to an AI-assisted triage tool that flags lesions meeting clinical concern criteria and connects you with a certified Canadian dermatologist, useful if your wait time for a specialist appointment stretches beyond a few weeks.

## When should you see a doctor after a self skin check?

Short answer: Book an appointment within two weeks for any spot meeting one or more ABCDE criteria, any lesion that bleeds spontaneously, or any new growth that has not resolved in four weeks. Self-screening is not diagnosis. A spot that worries you during a mole check at home may turn out to be a harmless seborrheic keratosis or a benign dermatofibroma, and only a trained clinician can tell. The cost of an unnecessary dermatologist visit is far lower than the cost of a delayed melanoma diagnosis. The [Canadian Cancer Society](https://cancer.ca/en/cancer-information/find-cancer-early/get-regular-cancer-exams/skin-exams) recommends an annual professional full-body skin exam for adults with a personal or family history of skin cancer, significant sun exposure, or many moles. Learn more about [DermaDex's AI-assisted screening tools and how they work](/about).

## Frequently asked questions about self skin screening?

Short answer: The questions below cover what a skin self exam is, what warning signs look like, and when to seek care. Each answer draws on current clinical guidance from the AAD (American Academy of Dermatology), the WHO (World Health Organization), and the Canadian Cancer Society. These answers are a starting point for your own research, and a dermatologist's in-person assessment is always the right next step when you have a specific concern about a spot on your skin.

### What is a skin self-exam?

A skin self-exam is a systematic head-to-toe inspection of your own skin that you perform at home, typically once a month. You use a full-length mirror and a hand mirror to check every body surface for new, changing, or unusual spots. The goal is to detect early signs of skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma, when treatment is most effective. You do not need any special equipment or medical training. A clear sequence, good lighting, and consistency month to month are the main requirements. If you find a spot that concerns you, photograph it and contact a doctor or dermatologist for a professional evaluation.

### What are the 7 warning signs of skin cancer?

Dermatologists describe several warning signs, often summarized around ABCDE (Asymmetry, Border, Color, Diameter, Evolving) but extending to additional features: (1) a mole that changes size, shape, or color; (2) a sore that bleeds or fails to heal within four weeks; (3) a shiny, pearly, or translucent bump on sun-exposed skin; (4) a flat, flesh-colored or brown scar-like lesion; (5) a rough, scaly red patch that may crust or bleed; (6) a dark streak running lengthwise under a fingernail or toenail; and (7) persistent itching, tenderness, or pain in a specific skin area without an obvious cause. Any single sign warrants a professional opinion.

### What is 90% of melanoma cancer caused by?

According to the World Health Organization (WHO) and the AAD, approximately 90% of melanoma cases are attributable to ultraviolet (UV) radiation exposure, from both natural sunlight and artificial sources such as tanning beds. UV radiation comes in two forms relevant to skin: UVA (ultraviolet A), which penetrates deeply and drives photoaging and DNA damage, and UVB (ultraviolet B), which causes sunburn and directly damages DNA in skin cells. Repeated UV exposure accumulates over a lifetime. Protective measures, including broad-spectrum sunscreen with a sun protection factor (SPF) of 30 or higher, protective clothing, and shade during peak UV hours (10 a.m. to 4 p.m.), reduce this cumulative risk substantially.

### What does stage 1 skin cancer feel like?

Early-stage skin cancer often produces no pain and no sensation at all, which is one reason regular self skin checks at home matter so much. At stage I, a melanoma typically appears as a small flat or slightly raised discolored patch, which may be tan, brown, dark brown, or multicolored. Basal cell carcinoma at an early stage often looks like a shiny pink or flesh-toned bump, or a flat scar-like lesion. Squamous cell carcinoma may present as a firm, red nodule or a rough, scaly patch. Occasionally a lesion itches or bleeds after minor contact. Because stage I skin cancer rarely causes physical discomfort, visual inspection during a monthly skin self exam is the primary detection method at this stage.

## Sources

- American Academy of Dermatology (AAD). "Find skin cancer: How to perform a skin self-exam." aad.org, May 15, 2023. [https://www.aad.org/public/diseases/skin-cancer](https://www.aad.org/public/diseases/skin-cancer)
- American Academy of Dermatology (AAD). "The ABCDEs of melanoma." aad.org. [https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes](https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes)
- Canadian Cancer Society. "Skin exams." cancer.ca. [https://cancer.ca/en/cancer-information/find-cancer-early/get-regular-cancer-exams/skin-exams](https://cancer.ca/en/cancer-information/find-cancer-early/get-regular-cancer-exams/skin-exams)
- Swetter SM et al. "Melanoma: Overview." PubMed/NIH, 2020. [https://pubmed.ncbi.nlm.nih.gov/32445526/](https://pubmed.ncbi.nlm.nih.gov/32445526/)
- World Health Organization (WHO). "Radiation: Ultraviolet (UV) radiation and skin cancer." who.int. [https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation)

## FAQ
### What is a skin self-exam?
A skin self-exam is a systematic head-to-toe inspection of your own skin that you perform at home, typically once a month. You use a full-length mirror and a hand mirror to check every body surface for new, changing, or unusual spots. The goal is to detect early signs of skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma, when treatment is most effective. You do not need any special equipment or medical training. A clear sequence, good lighting, and consistency month to month are the main requirements. If you find a spot that concerns you, photograph it and contact a doctor or dermatologist for a professional evaluation.

### What are the 7 warning signs of skin cancer?
Dermatologists describe several warning signs, often summarized around ABCDE (Asymmetry, Border, Color, Diameter, Evolving) but extending to additional features: (1) a mole that changes size, shape, or color; (2) a sore that bleeds or fails to heal within four weeks; (3) a shiny, pearly, or translucent bump on sun-exposed skin; (4) a flat, flesh-colored or brown scar-like lesion; (5) a rough, scaly red patch that may crust or bleed; (6) a dark streak running lengthwise under a fingernail or toenail; and (7) persistent itching, tenderness, or pain in a specific skin area without an obvious cause. Any single sign warrants a professional opinion.

### What is 90% of melanoma cancer caused by?
According to the World Health Organization (WHO) and the AAD, approximately 90% of melanoma cases are attributable to ultraviolet (UV) radiation exposure, from both natural sunlight and artificial sources such as tanning beds. UV radiation comes in two forms relevant to skin: UVA (ultraviolet A), which penetrates deeply and drives photoaging and DNA damage, and UVB (ultraviolet B), which causes sunburn and directly damages DNA in skin cells. Repeated UV exposure accumulates over a lifetime. Protective measures, including broad-spectrum sunscreen with a sun protection factor (SPF) of 30 or higher, protective clothing, and shade during peak UV hours (10 a.m. to 4 p.m.), reduce this cumulative risk substantially.

### What does stage 1 skin cancer feel like?
Early-stage skin cancer often produces no pain and no sensation at all, which is one reason regular self skin checks at home matter so much. At stage I, a melanoma typically appears as a small flat or slightly raised discolored patch, which may be tan, brown, dark brown, or multicolored. Basal cell carcinoma at an early stage often looks like a shiny pink or flesh-toned bump, or a flat scar-like lesion. Squamous cell carcinoma may present as a firm, red nodule or a rough, scaly patch. Occasionally a lesion itches or bleeds after minor contact. Because stage I skin cancer rarely causes physical discomfort, visual inspection during a monthly skin self exam is the primary detection method at this stage.

---

# Encrypting Patient Images at Rest and in Transit

URL: https://www.dermadex.ca/blog/encrypting-patient-images-at-rest-and-in-transit
Category: Compliance & Security
Author: Elham Hafezi
Published: 2024-12-24

## TL;DR
AES-256 (Advanced Encryption Standard, 256-bit) is the accepted standard for encrypting patient images at rest under PHIPA (Personal Health Information Protection Act) in Ontario and PIPEDA (Personal Information Protection and Electronic Documents Act) federally | TLS 1.3 (Transport Layer Security) reduces handshake overhead by 50% vs TLS 1.2 while meeting the transmission safeguard requirements of both PHIPA and PIPEDA | A 2023 Canadian healthcare data breach cost an average of $7.13 million CAD (IBM Cost of a Data Breach Report) | PHIPA (Ontario) and PIPEDA (federal) both require 'reasonable safeguards' and encryption is the accepted technical standard | Key management audit logs are required under PHIPA for Ontario custodians to document who accessed which patient's data and when

*As of December 24, 2024.*

Dermatology clinics and digital health platforms generate substantial volumes of sensitive medical images, photos of skin conditions, lesions, and wounds that are among the most personal files a patient can share. Under the Personal Health Information Protection Act (PHIPA) in Ontario and the Personal Information Protection and Electronic Documents Act (PIPEDA) at the federal level, custodians of that data have a legal obligation to protect it with reasonable technical safeguards. Encryption is the accepted answer for both storage and transmission.

This article explains exactly what encryption means in a healthcare imaging context, which algorithms meet Canadian compliance requirements, and what your technical team needs to implement to satisfy PHIPA encryption obligations.

## What is data encryption in healthcare?

_Short answer:_ Encryption converts patient data into ciphertext that only authorized parties with the correct decryption key can read. Two states need protection: data at rest, sitting in databases or cloud storage buckets, and data in transit, moving across networks between applications. In a healthcare context, both expose patients to harm when left unencrypted. Canadian privacy law under PHIPA and PIPEDA requires health information custodians to implement reasonable safeguards proportionate to data sensitivity, and encryption satisfies that standard for electronic personal health information. Dermatology images, which contain photographic identity alongside clinical diagnosis, sit at the high-sensitivity end of that scale.

Data at rest includes servers holding Electronic Medical Records (EMR), cloud buckets containing skin scan images, and local hard drives in clinic workstations. Data in transit covers uploads from a patient's phone to a cloud server, transfers from a clinic's Electronic Health Record (EHR) system to a specialist's inbox, and calls between microservices inside a platform. Both carry risk. A breached storage volume exposes files if they are not encrypted. An intercepted network session exposes transmissions if Transport Layer Security (TLS) is not enforced. The [Government of Canada's guidance on digital security and privacy](https://www.canada.ca/en/government/system/digital-government/online-security-privacy.html) recognizes encryption as the standard control that meets the "reasonable safeguards" bar.

## How does PHIPA define encryption requirements?

_Short answer:_ PHIPA does not name a specific algorithm, but it requires health information custodians to protect personal health information against unauthorized access. Ontario's Information and Privacy Commissioner has consistently identified encryption as the minimum expected technical control for electronic personal health information. The federal PIPEDA framework mirrors this under Principle 7 of Schedule 1. When a breach occurs and data was not encrypted, regulators treat that as a failure to implement reasonable safeguards, triggering mandatory breach reporting and potential findings of non-compliance. Health Canada and the Canadian Centre for Cyber Security both recommend encryption as a foundational control for healthcare data.

For platforms storing dermatology images, which contain both photographic likeness and clinical information, the sensitivity level is high enough that encryption should be treated as mandatory rather than optional. [Health Canada](https://www.canada.ca/en/health-canada.html) confirms this expectation through its published guidance on health data management.

For deeper context on how PHIPA and PIPEDA interact on patient data rights, see [PHIPA, PIPEDA, and Skin Health Data: What Patients Should Know](/blog/phipa-pipeda-and-skin-health-data-what-patients-should-know).

## Which encryption algorithms should healthcare teams use?

_Short answer:_ Advanced Encryption Standard 256-bit (AES-256) is the standard for data at rest; TLS 1.3 is the standard for data in transit. Both are endorsed by the National Institute of Standards and Technology (NIST) and are compatible with PHIPA and PIPEDA compliance frameworks. The National Institutes of Health (NIH) and Canadian Centre for Cyber Security recommend these algorithms for protecting health records. For dermatology platforms, AES-256 in GCM mode is preferred because it provides both confidentiality and integrity authentication in a single pass, reducing implementation complexity compared to CBC mode with a separate HMAC.

The table below summarizes the algorithms relevant to medical image security.

| Algorithm | Type | Use case | Key length | Notes |
|---|---|---|---|---|
| AES-256 | Symmetric block cipher | Encrypting images and PHI at rest | 256-bit | NIST-approved; used by Canadian government for classified data; fast for large files |
| AES-128 | Symmetric block cipher | Lower-overhead storage encryption | 128-bit | Acceptable for many healthcare contexts; less future-proof than AES-256 |
| TLS 1.3 | Asymmetric handshake + symmetric session | Data in transit (HTTPS, API calls) | Negotiated per session | 50% faster handshake than TLS 1.2; removes weak cipher suites by default |
| TLS 1.2 | Asymmetric handshake + symmetric session | Legacy transit encryption | Negotiated per session | Still acceptable but should be migrated to TLS 1.3 |
| RSA-2048 | Asymmetric | Key exchange, certificates | 2048-bit | Used to establish TLS sessions; RSA-4096 preferred for new deployments |
| SHA-256 | Hashing | Integrity verification of stored images | 256-bit output | Not encryption; used alongside encryption to detect tampering |

For medical images specifically, AES-256 in GCM (Galois/Counter Mode) is the recommended mode because it provides both confidentiality and integrity authentication in a single pass. CBC mode requires a separate HMAC for integrity, which adds implementation complexity and room for error.

## How do you encrypt patient images at rest?

_Short answer:_ Store images in encrypted volumes or object storage buckets with server-side AES-256 encryption, manage keys in a dedicated key management service (KMS) that sits separate from the data it protects, and enforce access controls so decryption only occurs for authorized clinical workflows. Three layers matter here: storage-level encryption, application-level encryption, and key management. Each adds a barrier that a breach must overcome. Most Canadian healthcare platforms satisfy PHIPA's reasonable-safeguards requirement by combining all three. The [NIST Special Publication 800-111 guide to storage encryption technologies](https://csrc.nist.gov/pubs/sp/800/111/final) explains how each layer maps to specific threat scenarios.

The three layers of at-rest encryption for medical images are storage-level, application-level, and key management.

**Storage-level encryption** means the underlying disk or object store handles encryption transparently. Cloud providers offer this as a default option (often called server-side encryption or SSE). Enabling SSE with AES-256 means that even if someone extracts the raw storage media, the image files are unreadable without the encryption key. For on-premise clinic servers, full-disk encryption tools achieve the same effect.

**Application-level encryption** adds a second layer. Before an image is written to storage, the application encrypts it using a patient-specific or record-specific key. This means a breach of the storage layer alone does not expose patient data because the application key is stored separately.

**Key management** is where most implementations fail. Storing an encryption key in the same location as the data it protects defeats the purpose. A dedicated KMS, whether a cloud-native service or a hardware security module (HSM), holds keys separately and enforces policies around who can request decryption. For PHIPA compliance, the key management audit log becomes part of the access record that demonstrates you know who accessed which patient's data and when.

For an overview of how [DermaDex](/about) implements these controls for Canadian dermatology workflows, see our security and compliance documentation.

## How does TLS protect patient images in transit?

_Short answer:_ TLS 1.3 encrypts the connection between a client and a server before any data transfers, so intercepting the network traffic yields only ciphertext that cannot be decrypted without the server's private key. A 2024 review of healthcare data security published in PubMed Central found that encryption in transit combined with proper certificate management is the single most effective control against interception of health data ([ref](https://pubmed.ncbi.nlm.nih.gov/31060970/)). Under TLS 1.3, the handshake completes in one round trip rather than two, cutting latency and removing several classes of downgrade attacks present in TLS 1.2.

When a clinician uploads a patient's skin scan from a mobile app to a cloud EMR, or when a patient shares images through a telemedicine platform, the transmission crosses networks that neither party controls. TLS establishes an encrypted tunnel by performing a handshake: the client and server authenticate each other using certificates, agree on session keys using an asymmetric algorithm (typically X25519 or RSA), then encrypt all subsequent traffic with a fast symmetric cipher (AES-128-GCM or AES-256-GCM).

For healthcare platforms, three TLS implementation details matter for compliance:

1. **Certificate pinning** for mobile apps prevents man-in-the-middle attacks even on compromised Wi-Fi networks in clinics or hospitals.
2. **HSTS (HTTP Strict Transport Security)** headers ensure that browsers and clients never fall back to unencrypted HTTP, even if a user types a plain HTTP URL.
3. **Cipher suite restrictions** should disable RC4, 3DES, and export-grade ciphers, all of which have known vulnerabilities. TLS 1.3 removes these by default, which is a primary reason to migrate off TLS 1.2.

## Does HIPAA require healthcare providers to encrypt all electronic patient data?

_Short answer:_ In the US, HIPAA's Security Rule treats encryption as an "addressable" specification rather than a strict requirement, meaning covered entities must either implement it or document why an equivalent safeguard is in place. In practice, most legal and compliance experts treat encryption as mandatory because a post-breach justification is very difficult to defend. For Canadian providers, PHIPA and PIPEDA apply the "reasonable safeguards" standard instead, and Ontario regulators have found organizations non-compliant when encrypted alternatives were available and not used. Canadian healthcare platforms should treat encryption as required in all cases.

For Canadian healthcare providers and healthtech platforms, HIPAA is a US regulation and does not apply directly. However, many Canadian organizations handling cross-border patient data or using US-based cloud infrastructure must understand both frameworks. Under PHIPA (Ontario) and PIPEDA (federal), there is no "addressable vs. required" distinction: custodians must implement safeguards proportionate to the sensitivity of the data. Because dermatology images combine photographic identity with clinical diagnosis, the sensitivity level is high, and encryption is a proportionate control.

## How to keep patient data secure?

_Short answer:_ Encrypting stored and transmitted data is the foundation, but complete patient data security also requires strict access controls, audit logging, regular vulnerability testing, staff training, and an incident response plan that satisfies PHIPA breach notification requirements. Encryption prevents unauthorized parties from reading data they obtain. Access controls prevent them from obtaining it in the first place. Audit logs prove who accessed what and when, which matters both for PHIPA compliance and for breach investigation. A program that combines all four layers substantially reduces both the likelihood and the impact of a breach affecting patient images.

Encryption alone does not prevent all breaches. A clinician with legitimate decryption access who clicks a phishing link can expose data without ever breaking the encryption. A complete healthcare data security program includes:

- Role-based access controls so only clinicians treating a specific patient can decrypt their images
- Immutable audit logs recording every access, export, and sharing event
- Regular penetration testing and vulnerability scanning of the systems holding PHI
- Staff training on phishing, physical security of devices, and PHIPA obligations
- A documented breach response procedure covering PHIPA's 90-day notification window to the Information and Privacy Commissioner
- Data minimization: do not store images longer than clinically necessary

Patients also have rights under PHIPA to request access to their own records and to know who has accessed their information. Building encryption into the system from the start, rather than retrofitting it, makes it far easier to demonstrate compliance when an audit or access request arrives.

Learn more about [DermaDex's approach to privacy-first dermatology care](/).

## Sources

- Government of Canada. *Online Security and Privacy*. Government of Canada. [canada.ca](https://www.canada.ca/en/government/system/digital-government/online-security-privacy.html)
- Government of Canada. *Health Canada*. Health Canada. [canada.ca](https://www.canada.ca/en/health-canada.html)
- National Library of Medicine. *Healthcare data security*. PubMed, 2019. [ref](https://pubmed.ncbi.nlm.nih.gov/31060970/)
- National Institute of Standards and Technology. *SP 800-111: Guide to Storage Encryption Technologies for End User Devices*. NIST. csrc.nist.gov/pubs/sp/800/111/final

## FAQ
### What is data encryption in healthcare?
Data encryption in healthcare converts patient records, images, and health information into ciphertext that only authorized parties with the correct decryption key can read. There are two states to protect: data at rest (stored on servers, disks, or cloud buckets) and data in transit (moving across networks between applications). In Canada, PHIPA and PIPEDA require health information custodians to implement reasonable safeguards proportionate to the sensitivity of the data. Dermatology images, which contain both photographic identity and clinical information, sit at the high-sensitivity end. AES-256 for storage and TLS 1.3 for transmission are the accepted standards that satisfy these obligations.

### Is PGP still relevant today?
PGP (Pretty Good Privacy) remains relevant for encrypting email and individual files, but it is rarely the right choice for encrypting healthcare images at scale. PGP uses asymmetric key pairs well, but its key management model requires every sender and recipient to maintain and exchange public keys, which becomes operationally difficult in clinical workflows involving many providers and patients. Modern healthcare platforms use AES-256 for at-rest encryption managed through a dedicated key management service, and TLS 1.3 for in-transit encryption. These approaches are better suited to PHIPA compliance because they integrate with audit logging and access controls that PGP does not provide out of the box.

### How to keep patient data secure?
Keeping patient data secure in a healthcare platform requires layered controls beyond encryption alone. Start with AES-256 encryption at rest and TLS 1.3 in transit. Add role-based access controls so only treating clinicians can decrypt specific patient records. Maintain immutable audit logs of every access and export event. Run regular vulnerability assessments and penetration tests. Train staff on phishing and physical device security. Under PHIPA, you also need a documented breach response procedure that covers notification to Ontario's Information and Privacy Commissioner within 90 days of discovering a reportable breach. Data minimization matters too: only retain images for as long as clinically necessary.

### Does HIPAA require healthcare providers to encrypt all electronic patient data?
HIPAA's Security Rule classifies encryption as an 'addressable' specification, meaning US covered entities must implement it or document an equivalent safeguard. In practice, most healthcare legal counsel treats encryption as required because documenting a justified alternative is difficult to defend after a breach. For Canadian providers, HIPAA does not apply directly. PHIPA (Ontario) and PIPEDA (federal) use a 'reasonable safeguards' standard instead. Because regulators have found organizations non-compliant when encryption was available and not implemented, Canadian healthcare platforms should treat encryption as required rather than optional. Cross-border platforms handling both Canadian and US patient data should satisfy both frameworks.

---

# Eczema in Winter: Why Canadian Skin Suffers October to March

URL: https://www.dermadex.ca/blog/eczema-in-winter-why-canadian-skin-suffers-october-to-march
Category: Conditions
Author: Mohsen Khoddami
Published: 2024-12-03

## TL;DR
Canadian indoor humidity drops below 30% in winter, well under the 45-55% skin needs | Atopic dermatitis (eczema) affects roughly 17% of Canadian children and 7% of adults (Canadian Dermatology Association) | Applying a fragrance-free moisturizer within 3 minutes of bathing can reduce transepidermal water loss by up to 50% | Temperatures below -10 degrees Celsius, common in most provinces November through February, trigger cold urticaria and barrier breakdown | Ontario patients wait a median 78 days for a routine dermatology appointment; teledermatology services can provide clinical advice within days (CIHI, 2024)

*As of December 3, 2024.*

Canadian winters are hard on skin. From Halifax to Vancouver, the combination of sub-zero outdoor air, blasting furnace heat, and indoor humidity that can fall below 25% creates a perfect environment for eczema flares. If your skin gets worse every October and slowly recovers in April, you are not imagining it -- the pattern is real and well-documented.

This article explains the science behind winter eczema in Canada, what you can do about it, and when to see a dermatologist. Internal links connect you to [DermaDex's full skin conditions library](/) and a [guide to identifying common skin conditions in Canadian adults](/blog/5-common-skin-conditions-in-canadian-adults).

## Why am I getting eczema in winter?

Cold outdoor air holds very little moisture, and forced-air heating removes what remains indoors. **Short answer:** This double humidity crash strips your skin's protective barrier, triggering inflammation, itch, and the red, cracked skin typical of atopic dermatitis (AD). Your skin barrier is a layered structure of lipids and proteins that keeps water in and irritants out. When relative humidity drops below roughly 40%, that barrier loses moisture faster than it can replenish it. Outdoor air at -15 degrees Celsius in Winnipeg holds almost no water vapour. Step inside, and the furnace heats that dry air further, dropping relative humidity to 20-25% in many Canadian homes, well below the 45-55% range skin prefers.

Cold air also triggers the release of inflammatory cytokines and reduces blood flow to the skin's surface, which slows repair. In people with atopic dermatitis (AD), who already have a mutation in the filaggrin protein that weakens the skin barrier, this seasonal stress tips the immune system into overdrive. The result is the classic winter eczema flare: intense itch, redness, and cracked, weeping patches that concentrate on the hands, forearms, the backs of knees, and the face.

According to the [Canadian Dermatology Association (CDA)](https://www.dermatology.ca/), atopic dermatitis affects approximately 17% of Canadian children and 7% of adults, making it one of the most common chronic skin conditions in the country.

## How do you treat eczema in the winter?

Consistent moisturizing, humidity control, and prescription treatments when needed form the core of winter eczema management. **Short answer:** The goal is to restore the skin barrier before inflammation takes hold, and the single most impactful daily habit is applying a fragrance-free emollient immediately after bathing, within three minutes, while skin is still damp. Water left on skin after a bath temporarily plumps the stratum corneum, and sealing it with a thick cream locks that moisture in. Research endorsed by the [American Academy of Dermatology (AAD) guide to treating eczema in children](https://www.aad.org/public/diseases/eczema/childhood/treating) confirms this soak-and-seal approach measurably reduces transepidermal water loss.

Beyond moisturizing, the following winter skincare routine table summarizes a practical daily plan:

| Time | Step | Product type | Why it helps |
|------|------|-------------|---------------|
| Morning shower | Lukewarm water, 5-10 min max | N/A | Hot water dissolves lipids in the barrier |
| Immediately after shower | Apply all-over emollient | Thick cream or ointment (no fragrance) | Seals moisture before evaporation |
| After hand washing | Reapply hand cream | Fragrance-free cream with ceramides | Hands lose barrier lipids every wash |
| Bedtime | Spot-treat active patches | Prescription topical corticosteroid or calcineurin inhibitor | Night is when skin repairs fastest |
| All day | Run humidifier in bedroom/living area | Cool-mist humidifier, 45-55% RH target | Counters furnace-driven humidity loss |

For moderate to severe flares, topical corticosteroids prescribed by a dermatologist remain the first-line treatment recommended by both the [eczema overview in the NCBI StatPearls library](https://www.ncbi.nlm.nih.gov/books/NBK538209/) and the CDA. Newer options include dupilumab (a biologic) and topical JAK inhibitors for patients whose eczema does not respond to steroids.

## What is the 3-minute rule for eczema?

The 3-minute rule means applying moisturizer within three minutes of stepping out of a lukewarm bath or shower, before the skin surface has time to dry out completely. **Short answer:** When you bathe in lukewarm water, the outermost skin layer absorbs a small amount of water, temporarily increasing its hydration, and that window closes fast once evaporation begins. Applying a thick emollient, such as a ceramide-containing cream or a petrolatum-based ointment, within those first three minutes traps the absorbed water before it escapes. In practice, pat (do not rub) with a soft towel, leave skin slightly damp, then apply moisturizer head to toe. For children with AD, caregivers should do this step before putting on pyjamas.

The [National Institutes of Health (NIH) atopic dermatitis resource](https://www.niams.nih.gov/health-topics/atopic-dermatitis) notes that consistent emollient use in infants at high eczema risk can meaningfully reduce the chance of developing AD in the first six months of life. Perfumed lotions and alcohol-based products undo the benefit by disrupting the barrier themselves. Stick to unscented creams with ingredients such as ceramides, glycerin, and shea butter.

## Does cold weather make atopic dermatitis worse for everyone?

Cold weather worsens atopic dermatitis in most patients, but the trigger is usually low humidity and rapid temperature change rather than cold alone. **Short answer:** Some patients also flare from sweating under heavy winter clothing, because sweat is a known eczema trigger in people sensitised to their own perspiration components. The repeated cycle of going from freezing outdoors to overheated indoors stresses the barrier with rapid temperature and humidity swings. Heavy wool or synthetic layers trap sweat against the skin and compound that effect. In Canada, the highest-risk period runs from late October through March, with provinces showing the most extreme temperature swings -- Alberta, Saskatchewan, Manitoba, and interior British Columbia -- generating the most severe seasonal flares.

Coastal cities like Vancouver experience milder cold but still drop indoor humidity enough to drive flares. If you are not sure whether your winter skin symptoms are eczema or another condition, the [monthly self-skin check guide on DermaDex](/blog/how-to-perform-a-monthly-self-skin-check-step-by-step) walks you through what to look for. A telemedicine dermatology consult can confirm the diagnosis without a months-long wait.

## Sources

- Canadian Dermatology Association (CDA). *Atopic Dermatitis (Eczema)*. dermatology.ca. https://www.dermatology.ca/
- American Academy of Dermatology (AAD). *Treating Childhood Eczema*. aad.org. https://www.aad.org/public/diseases/eczema/childhood/treating
- National Center for Biotechnology Information. *Eczema -- StatPearls*. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK538209/
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). *Atopic Dermatitis*. nih.gov. https://www.niams.nih.gov/health-topics/atopic-dermatitis

## FAQ
### Why am I getting eczema in winter?
Cold outdoor air holds almost no moisture, and indoor forced-air heating removes what little remains. This double humidity drop, common across Canada from October to March, weakens the skin barrier and triggers the inflammation, itch, and cracking characteristic of atopic dermatitis. People with a filaggrin gene variant, which is present in many eczema patients, are especially vulnerable because their barrier is already compromised. The furnace-heated indoor air in most Canadian homes falls to 20-25% relative humidity in winter, well below the 45-55% range skin needs to stay intact. Layering wool or synthetic fabrics that trap sweat adds a second trigger on top of the dryness.

### What is the 3 minute rule for eczema?
The 3-minute rule means applying a thick, fragrance-free moisturizer within three minutes of getting out of a lukewarm bath or shower. During bathing, the outer skin layer absorbs some water. Once you are out, that water evaporates quickly, often within a few minutes. Applying an emollient before the skin surface dries seals in that moisture and measurably reduces transepidermal water loss. Pat the skin gently with a soft towel, leave it slightly damp, then apply cream or ointment from head to toe before dressing. Use a fragrance-free product with ceramides, glycerin, or petrolatum. Perfumed lotions and alcohol-based gels defeat the purpose.

### How do you treat eczema in the winter?
The core strategy is: moisturize consistently, control indoor humidity, avoid known triggers, and use prescription treatments when flares break through. Apply a thick, fragrance-free emollient immediately after bathing (the 3-minute rule) and reapply to hands every time you wash them. Run a cool-mist humidifier in rooms where you spend the most time, aiming for 45-55% relative humidity. Avoid hot showers, heavily scented products, and wool directly against the skin. For moderate to severe flares, a dermatologist may prescribe a topical corticosteroid, a calcineurin inhibitor, or a biologic such as dupilumab for persistent disease. The Canadian Dermatology Association recommends a formal diagnosis before starting any prescription therapy.

### What do Chinese people use for eczema?
Traditional Chinese medicine (TCM) practitioners use herbal formulations including liquorice root (Glycyrrhiza), cnidium fruit (Cnidii Fructus), and compound preparations such as Zemaphyte for atopic dermatitis. Some small clinical trials have shown modest symptom improvement, but the evidence base is limited and several herbal products carry risks of hepatotoxicity. The World Health Organization (WHO) and the AAD note that herbal approaches lack the large randomised controlled trial data required for formal clinical endorsement. If you are interested in integrative options, discuss them with a certified dermatologist first to assess safety and potential interactions with any prescription therapy you are already using.

---

# Teledermatology vs In-Person Visits: When to Choose Which

URL: https://www.dermadex.ca/blog/teledermatology-vs-in-person-visits-when-to-choose-which
Category: Telemedicine
Author: Maryam Sobhkhiz Sabet
Published: 2024-11-12

## TL;DR
Diagnostic concordance between teledermatology and in-person dermatology ranges from 46% to 99% depending on condition type (NIH, 2021) | Wait times for an in-person Canadian dermatologist average over 4 months in most provinces (CIHI, 2023) | Store-and-forward teledermatology resolves 60-80% of cases without an in-person follow-up | Virtual dermatology consultations can be completed in under 24 hours vs weeks for a specialist referral | Online dermatologists can prescribe topical and oral medications in all Canadian provinces

*As of November 12, 2024.*

Canadians wait an average of four to six months to see a dermatologist in person. That delay is not a minor inconvenience for someone watching a suspicious mole change colour, or a teenager whose acne is affecting how they show up at school. Virtual dermatology (also called teledermatology) has moved from a pandemic workaround to a permanent fixture of Canadian skin care, and the question most patients now ask is practical: which option actually fits my situation?

This article answers that question directly, drawing on published diagnostic concordance data and 28 years of clinical dermatology practice. No single model is always better. The right choice depends on what you need to find out and how fast you need to find it.

## What is teledermatology and how does it work?

Teledermatology is the delivery of dermatology care at a distance, either through real-time video or by submitting photos for a specialist to review. In Canada, most platforms use a "store-and-forward" model where you upload images and receive a written assessment, often within 24 hours. The two main formats are store-and-forward (photos reviewed asynchronously) and live video consultation (real-time). Both are medically valid for the majority of common skin concerns.

Store-and-forward teledermatology means you photograph the affected skin area and submit those images, along with a brief history, to a dermatologist. The specialist reviews them on their own schedule and sends back a written report. Live video teledermatology means you speak with a dermatologist in real time, which allows for direct questions but depends on image quality from your device camera. A [2022 review published in PMC (National Institutes of Health, NIH)](https://pubmed.ncbi.nlm.nih.gov/35208024/) found that both formats achieved high diagnostic accuracy for the most common skin presentations, and that patient satisfaction was comparable to in-person care for conditions that do not require physical examination. The artificial intelligence (AI) triage tools that platforms like [DermaDex](/) now use can flag urgent findings and route cases before a dermatologist even reviews the file, which further reduces delays.

## Is teledermatology accurate?

For the majority of common skin conditions, yes. Published concordance studies show agreement between teledermatology and in-person diagnoses ranging from 46% to 99%, with the highest accuracy for conditions that present visually and the lowest for conditions requiring touch or biopsy. The most reliable results are seen for acne, eczema, psoriasis, and seborrheic keratoses, which together account for the bulk of dermatology referrals in Canada.

The wide concordance range is the honest answer. A [2021 NIH-funded review by Bastola et al.](https://pubmed.ncbi.nlm.nih.gov/34557862/) found concordance sits above 85% for conditions like acne, eczema, psoriasis, and seborrheic keratoses, which together represent the bulk of dermatology referrals. Concordance drops for pigmented lesions that require dermoscopy, bullous diseases that need palpation, and inflammatory conditions where distribution across the body matters. What this means practically: if your concern is a rash, acne, or a mole that looks stable and has not changed recently, a virtual assessment is medically sound. If a mole has changed in the last four to six weeks, bleeds, or has irregular borders, an in-person examination with dermoscopy is the safer path.

## How much does virtual dermatology cost in Canada?

Cost varies by province and platform. Some virtual dermatology services are covered under provincial health plans, including Ontario Health Insurance Plan (OHIP) for physician-referred teleconsults, while direct-to-patient platforms typically charge between $50 and $150 per consultation. Patients who access virtual care through a GP referral often pay nothing out of pocket, while self-booked appointments on consumer platforms carry a flat fee that most extended health plans will reimburse.

In Ontario, a teledermatology consultation requested by a family physician can be billed through OHIP at the same rate as a specialist referral, meaning no out-of-pocket cost for the patient. British Columbia, Alberta, and Quebec have similar provisions under their respective provincial plans. Direct-access platforms that allow patients to book without a GP referral generally charge a flat fee, though several offer extended health insurance receipts. The cost advantage of virtual care compounds when you factor in transportation, time off work, and parking for in-person specialist visits, especially for patients in rural or northern communities. [Health Canada's health care system framework](https://www.canada.ca/en/health-canada/services/health-care-system.html) identifies improving access in underserved regions as a primary driver for telemedicine investment across Canada.

## When should you choose teledermatology vs in-person?

Choose teledermatology for stable, visually diagnosable conditions and follow-up care. Choose in-person when physical examination, dermoscopy, or a biopsy is needed, or when a lesion has changed rapidly. For the majority of Canadians dealing with acne, eczema, psoriasis, or prescription renewals, a virtual visit is the faster and equally effective option. In-person care remains necessary when the clinical question cannot be answered from a photograph alone.

The table below summarises the decision criteria across common scenarios.

| Aspect | Teledermatology | In-Person Visit |
|---|---|---|
| Acne (mild to moderate) | Well-suited; diagnosis and prescription in one consult | Option if treatments have failed repeatedly |
| Eczema / psoriasis management | Well-suited for known, stable disease | Preferred for new presentation or treatment escalation |
| Suspicious or changing mole | Appropriate for initial triage; refer if flags present | Required for dermoscopy and possible biopsy |
| Rash of unknown cause | Good for common presentations; image quality matters | Better when distribution, texture, or systemic signs are unclear |
| Prescription renewal | Fully appropriate | Necessary only if clinical reassessment is needed |
| Paediatric skin conditions | Feasible for common conditions with clear photos | Preferred for infants and young children |
| Wound or post-procedure review | Good for stable healing check | Required if infection, dehiscence, or complications arise |
| Urgent / rapidly progressing rash | Use to triage and route; may direct to ER or urgent clinic | Preferred if patient is systemically unwell |

For anyone who wants to understand what the dermatologist is looking for when assessing a mole, the Asymmetry, Border, Color, Diameter, Evolving (ABCDE) [skin check guide at DermaDex](/blog/how-to-perform-a-monthly-self-skin-check-step-by-step) walks through the criteria step by step before you book any consultation.

## Can an online dermatologist prescribe medication?

Yes. In all Canadian provinces, a licensed dermatologist conducting a virtual consultation can prescribe both topical and oral medications, subject to the same clinical standards as an in-person visit. This covers the full range of common dermatology treatments including topical corticosteroids, retinoids, antibiotics, antifungals, and most oral medications. The one notable exception is isotretinoin, which requires at least one in-person visit for mandatory Health Canada monitoring before a prescription can be issued.

This includes topical corticosteroids, retinoids, antibiotics for acne, antifungals, and oral medications such as doxycycline or isotretinoin with appropriate monitoring. The prescribing physician must hold a licence in the province where the patient is located, which is why provincial licensing matters when selecting a platform. Electronic medical record (EMR) integration allows prescriptions to go directly to a pharmacy in most cases. One practical note: isotretinoin requires mandatory pregnancy prevention monitoring under Health Canada regulations, which typically means at least one in-person blood draw and pregnancy test before a prescription is issued, even when the consultation itself is virtual.

## What are the red flags that mean you need to see a dermatologist in person?

Rapidly changing pigmented lesions, blistering diseases, skin infections that are spreading, and any presentation accompanied by systemic symptoms such as fever or joint pain warrant an in-person visit. These findings require physical examination, dermoscopy, or biopsy that cannot be replicated remotely. When in doubt, a virtual triage call can still help you get onto the right in-person care pathway faster than waiting for an unguided GP referral.

The Canadian Dermatology Association (CDA) and the American Academy of Dermatology (AAD) both note that the following presentations should not be managed purely by telemedicine:

- A mole or pigmented lesion that has changed in colour, border, or size within four to six weeks
- Any bleeding or crusting lesion that has not healed in more than three weeks
- Widespread blistering rash, especially if mucous membranes are involved
- Skin infections showing red streaks or rapid spread (suggesting cellulitis)
- Nodular or firm lumps beneath the skin surface that cannot be adequately imaged
- Children under two years with an undiagnosed rash and fever

For any of these, use virtual triage only to get the fastest possible pathway to in-person care, not as a substitute for it. If you are unsure about Canada's current dermatology access landscape, the [state of dermatology access in Canada in 2024](/blog/the-state-of-dermatology-access-in-canada-in-2024) provides detailed wait-time data by province.

## What happens at a teledermatology appointment?

A teledermatology appointment involves submitting photos or joining a video call, providing your skin history, and receiving a diagnosis and treatment plan. The workflow varies slightly by platform but typically concludes with a written report and, where appropriate, an electronic prescription sent directly to your pharmacy. Most store-and-forward consultations are completed within 2 to 24 hours of submission.

For a store-and-forward consultation, you photograph the affected area in good natural light against a plain background, complete a brief intake form covering how long the issue has been present, any triggers, treatments tried, and current medications, then submit everything through the platform. A board-certified dermatologist reviews the file, typically within 2 to 24 hours, and returns a written assessment with a diagnosis or differential, a treatment recommendation, a prescription if needed, and clear guidance on whether an in-person follow-up is required. For a live video appointment, the workflow is similar but happens in real time. Image quality from a smartphone is now sufficient for most visual diagnoses, though a second take in better light is often worth it for lesion close-ups.

## Sources

- Bastola M, et al. "Diagnostic Reliability of In-Person Versus Remote Dermatology." *PMC / NIH*, 2021. [https://pubmed.ncbi.nlm.nih.gov/34557862/](https://pubmed.ncbi.nlm.nih.gov/34557862/)
- López-Liria R, et al. "Teledermatology versus Face-to-Face Dermatology." *PMC / NIH*, 2022. [https://pubmed.ncbi.nlm.nih.gov/35208024/](https://pubmed.ncbi.nlm.nih.gov/35208024/)
- Music M, et al. "Canadian patient attitudes toward virtual dermatology care." *PMC / NIH*, 2023. [https://pubmed.ncbi.nlm.nih.gov/36683398/](https://pubmed.ncbi.nlm.nih.gov/36683398/)
- Lee KJ, et al. "Teledermatology: A Review and Update." *Dermatology and Therapy, PMC / NIH*, 2021. [https://pubmed.ncbi.nlm.nih.gov/33449103/](https://pubmed.ncbi.nlm.nih.gov/33449103/)
- Health Canada. "Digital health in Canada." Canada.ca, 2024. [https://www.canada.ca/en/health-canada/services/health-care-system.html](https://www.canada.ca/en/health-canada/services/health-care-system.html)

## FAQ
### Is teledermatology accurate?
For the most common skin conditions, yes. Published research shows diagnostic concordance between teledermatology and in-person assessments ranging from 46% to 99%, with the highest agreement for visually diagnosable conditions like acne, eczema, psoriasis, and seborrheic keratoses. A 2021 NIH-funded review found concordance above 85% for these conditions, which make up the majority of dermatology referrals. Accuracy is lower for conditions that require dermoscopy, palpation, or biopsy, such as rapidly changing pigmented lesions. A well-lit, focused photograph significantly improves diagnostic accuracy in a virtual consultation.

### What happens at a teledermatology appointment?
A teledermatology appointment follows one of two formats. In a store-and-forward consultation, you photograph the affected skin area, complete a short intake form about your symptoms and history, and submit everything through the platform. A licensed dermatologist reviews the file, usually within 2 to 24 hours, and sends back a written report with a diagnosis, treatment plan, and any prescription. In a live video consultation, you speak directly with a dermatologist in real time. Either way, you receive clear guidance on whether an in-person follow-up is needed.

### How much does virtual dermatology cost?
In Canada, cost depends on whether you access virtual dermatology through your family physician or directly through a consumer platform. GP-referred teledermatology consultations are covered under most provincial health plans, including OHIP in Ontario, with no out-of-pocket cost. Direct-access platforms that allow you to book without a referral typically charge between $50 and $150 per consultation. Some platforms provide receipts for extended health insurance reimbursement. For patients in rural or remote areas, virtual care also saves the indirect costs of travel, parking, and time off work associated with in-person specialist visits.

### Are virtual dermatology visits worth it?
For most routine skin concerns, yes. Virtual dermatology visits are faster, more accessible, and clinically sound for the majority of conditions that dermatologists see. When a family physician refers through a provincial plan, they are also free. The main limitations are physical: a virtual dermatologist cannot perform dermoscopy, take a biopsy, or feel a lump beneath the skin. For any lesion that has changed recently, bleeds, or requires a procedure, an in-person visit is the right call. For acne, eczema management, prescription renewals, and stable rashes, a virtual visit is a practical and evidence-backed option.

### Can you see a dermatologist via telehealth?
Yes. In Canada, licensed dermatologists practice via telehealth on several platforms, including GP-referred provincial teleconsult programs and direct-access services. Telehealth dermatology is legally equivalent to in-person care when conducted by a physician licensed in the patient's province. The dermatologist can diagnose, recommend treatment, and prescribe medication through a virtual visit. Most provincial colleges of physicians now have specific guidance on telehealth standards of practice, and Health Canada has supported telemedicine expansion as part of its digital health strategy.

### Can an online dermatologist prescribe?
Yes. A licensed dermatologist in Canada can prescribe both topical and oral medications during a virtual consultation, subject to the same clinical standards as an in-person visit. This includes topical retinoids, corticosteroids, antibiotics, antifungals, and oral medications such as doxycycline. Isotretinoin requires additional monitoring under Health Canada regulations and typically needs at least one in-person blood draw before a prescription is issued, even when the consultation is virtual. Always confirm the dermatologist holds a licence in your province before booking.

---

# 5 Common Skin Conditions in Canadian Adults

URL: https://www.dermadex.ca/blog/5-common-skin-conditions-in-canadian-adults
Category: Conditions
Author: Mohsen Khoddami
Published: 2024-10-22

## TL;DR
Acne affects roughly 5.6 million Canadian adults, making it the most common skin condition seen in dermatology clinics | Atopic dermatitis (eczema) affects up to 17% of Canadians at some point in their lives (CDA, 2024) | Psoriasis affects approximately 1 million Canadians, with immune-mediated plaques as the hallmark sign | Rosacea is diagnosed in about 3% of Canadians, with fair-skinned adults most affected | Contact dermatitis accounts for 15–20% of all occupational skin disease cases reported in Canada

*As of October 22, 2024.*

Skin disease is among the most common reasons Canadians visit a family doctor or seek specialist referral. Yet many adults go years without a clear diagnosis, mistaking one condition for another or managing symptoms with over-the-counter products that target the wrong problem. This overview covers the five skin conditions dermatologists in Canada see most often in adult patients: acne, atopic dermatitis (eczema), psoriasis, rosacea, and contact dermatitis.

If you are waiting weeks or months for a dermatology appointment, [DermaDex](/) connects patients across Canada to certified dermatologists using AI-assisted triage tools.

---

## How prevalent are the most common skin conditions in Canada?

The five most common skin conditions seen by Canadian dermatologists are acne, atopic dermatitis (eczema), psoriasis, rosacea, and contact dermatitis. **Short answer:** Together they affect tens of millions of Canadian adults and account for the majority of outpatient dermatology visits. The table below summarises estimated Canadian prevalence, typical age of onset, and accepted first-line treatment for each condition.

| Condition | Estimated Canadian Prevalence | Typical Age of Onset | First-Line Treatment |
|---|---|---|---|
| Acne (acne vulgaris) | ~5.6 million adults | Adolescence; persists or recurs in adulthood | Topical retinoids ± benzoyl peroxide |
| Atopic dermatitis (eczema) | Up to 17% lifetime prevalence | Childhood; adult-onset possible | Moisturizers + topical corticosteroids |
| Psoriasis | ~1 million (~3% of population) | 20s–30s or 50s–60s (bimodal) | Topical corticosteroids; phototherapy |
| Rosacea | ~3% of adults | 30s–50s | Topical metronidazole or azelaic acid |
| Contact dermatitis | 15–20% of occupational skin disease | Any age | Allergen/irritant avoidance + topical steroids |

---

## How common is adult acne?

Adult acne affects millions of Canadians well past their teenage years, and it is far more common in adults than most people expect. **Short answer:** Women over 25 show the highest rates of post-adolescent breakouts, with hormonal fluctuations, stress, and comedogenic skin-care products as the main drivers. The Canadian Dermatology Association (CDA) ranks acne among the top five reasons adults seek dermatology care in Canada.

Acne vulgaris is the most frequently diagnosed skin condition in North America. While it is strongly associated with adolescence, studies published in the *Journal of the American Academy of Dermatology* show that up to 50% of women and 25% of men in their 20s still meet diagnostic criteria for acne, and a meaningful subset continues to experience breakouts into their 40s and 50s. In Canada, the Canadian Dermatology Association (CDA) identifies acne as one of the top five reasons adults seek dermatology care.

Adult acne tends to cluster on the lower face, jaw, and neck rather than the forehead and nose typical of teenage acne. Hormonal cycling, dairy intake, high-glycaemic diets, and certain medications can all worsen it. First-line treatment for mild-to-moderate acne is topical retinoids combined with benzoyl peroxide. For moderate-to-severe acne, topical or oral antibiotics are added, and isotretinoin remains the most effective option for severe nodular cases under a dermatologist's supervision.

The American Academy of Dermatology (AAD) publishes evidence-based acne guidelines at [aad.org/member/clinical-quality/guidelines/acne](https://www.aad.org/member/clinical-quality/guidelines/acne).

---

## What is atopic dermatitis and how widespread is it among Canadian adults?

Atopic dermatitis (the clinical name for the most common form of eczema) is a chronic, inflammatory skin condition. **Short answer:** It is driven by a defective skin barrier and immune dysregulation, affects up to 17% of Canadians at some point in their lives, and adult-onset cases are increasingly recognized.

The Canadian Dermatology Association notes that atopic dermatitis (AD) is not simply a childhood condition. Adult patients often present with thickened, lichenified plaques on the hands, wrists, neck, and flexural areas rather than the weeping rash seen in infants. Itch is the dominant symptom and frequently disrupts sleep, contributing to anxiety and depression in chronic cases.

Management centres on restoring the skin barrier. Daily emollient use is non-negotiable, and mid-potency topical corticosteroids are the standard second step during flares. Newer options include topical calcineurin inhibitors (tacrolimus, pimecrolimus) for sensitive areas and the biologic dupilumab for moderate-to-severe disease refractory to topical therapy. The National Institutes of Health (NIH) maintains a clinical overview of atopic dermatitis at [niams.nih.gov/health-topics/atopic-dermatitis](https://www.niams.nih.gov/health-topics/atopic-dermatitis).

For Canadians wondering about dermatology wait times and access, read our article on [the state of dermatology access in Canada in 2024](/blog/the-state-of-dermatology-access-in-canada-in-2024).

---

## Is psoriasis only a skin condition?

Psoriasis is not only a skin condition, and this distinction matters for how it is managed and monitored. **Short answer:** It is a systemic immune-mediated disease that primarily manifests as well-defined, scaly plaques on the skin, but is associated with psoriatic arthritis in up to 30% of patients and carries elevated cardiovascular risk that warrants regular screening.

Psoriasis affects approximately 1 million Canadians, or about 3% of the population. The condition follows a relapsing-remitting course, with triggers including streptococcal infections, stress, certain medications (beta-blockers, lithium, antimalarials), and physical skin trauma (the Koebner phenomenon). Plaques most commonly appear on the scalp, elbows, knees, and lower back.

Diagnosis is clinical in most cases. Skin biopsy is reserved for atypical presentations. Treatment is guided by severity:

- **Mild (less than 3% body surface area):** Topical corticosteroids and vitamin D analogues (calcipotriol).
- **Moderate-to-severe:** Phototherapy (narrowband ultraviolet B) or systemic agents (methotrexate, cyclosporine, acitretin).
- **Biologic era:** Tumour necrosis factor inhibitors and interleukin-17/23 inhibitors have transformed outcomes for patients with extensive or joint-involvement disease.

Health Canada has approved multiple biologic therapies for psoriasis. Canadians with provincial coverage through Ontario Health Insurance Plan (OHIP) or equivalent provincial plans may access some biologics under special authorization. The CDA provides patient resources at [dermatology.ca/skin-hair-nails/skin/psoriasis](https://dermatology.ca/skin-hair-nails/skin/psoriasis/).

---

## What triggers rosacea flares in adults?

Rosacea flares are triggered by a predictable set of exposures that vary between patients but follow recognizable patterns. **Short answer:** Sun exposure, heat, spicy food, alcohol, and emotional stress are the most consistently reported triggers among Canadian patients. Identifying and avoiding your personal triggers is as important as topical or oral medication prescribed by a dermatologist.

Rosacea affects an estimated 3% of Canadian adults, with the highest prevalence in individuals of northern European descent with fair skin. The condition has four clinical subtypes: erythematotelangiectatic (flushing and redness), papulopustular (resembles acne), phymatous (skin thickening, most visible on the nose as rhinophyma), and ocular (eye irritation). Many patients have overlapping subtypes.

Diagnosis is clinical. There is no single definitive test. Differentiating rosacea from adult acne matters because treatments diverge: benzoyl peroxide, a mainstay for acne, can aggravate rosacea. First-line topical therapies are metronidazole gel or cream and azelaic acid. Oral doxycycline at sub-antimicrobial doses (40 mg modified-release) reduces inflammatory lesions without contributing to antibiotic resistance. Laser and light-based therapies address persistent erythema and telangiectasias.

The AAD's rosacea patient page at [aad.org/public/diseases/rosacea](https://www.aad.org/public/diseases/rosacea) provides a vetted trigger checklist useful for patient self-monitoring.

---

## How do you tell contact dermatitis apart from other rashes?

Contact dermatitis presents as an itchy, red, sometimes blistered rash at the site of skin contact. **Short answer:** The shape and location of the rash closely match the exposure pattern, which is the key diagnostic clue that distinguishes it from eczema or psoriasis.

Contact dermatitis divides into two types. Irritant contact dermatitis (ICD) accounts for about 80% of cases and results from direct chemical damage, with no immune sensitization required. Repeated hand-washing, cleaning products, and occupational chemical exposure are the most common Canadian causes. Allergic contact dermatitis (ACD) is immune-mediated and requires prior sensitization; nickel (found in jewellery and belt buckles), fragrance mixes, and preservatives like methylisothiazolinone are frequent culprits.

Patch testing, performed by a dermatologist over 48–72 hours using a standardized series of allergens, is the gold-standard investigation for ACD. Treatment centres on identifying and removing the offending agent. Topical corticosteroids reduce acute inflammation; barrier creams and nitrile gloves prevent recurrence in occupational cases. A 2018 review in *Contact Dermatitis* published on PubMed confirms that contact dermatitis is among the leading occupational skin diseases in North America. See [pubmed.ncbi.nlm.nih.gov/29573472](https://pubmed.ncbi.nlm.nih.gov/29573472).

Learn more about DermaDex's approach to fast specialist referrals on our [about page](/about).

---

## Frequently Asked Questions

The four questions below come directly from Google's People Also Ask results for the search query "common skin conditions adults," retrieved October 2024. Each answer is written from the perspective of Mohsen Khoddami, MD, a dermatologist with over 30 years of clinical practice at Canadian dermatology clinics. Answers are meant to be informative, not a substitute for a clinical consultation.

### What are the 10 most common skin disorders?

The ten most commonly diagnosed skin disorders worldwide include acne vulgaris, atopic dermatitis (eczema), psoriasis, rosacea, contact dermatitis, seborrheic dermatitis, tinea infections (ringworm, athlete's foot), warts (human papillomavirus), urticaria (hives), and actinic keratosis. In Canadian adults specifically, acne, eczema, and psoriasis lead in dermatology clinic volume. The relative frequency shifts by age group: acne peaks in younger adults, while actinic keratosis and rosacea are more prevalent after age 40. Many of these conditions are chronic and require ongoing management rather than a single cure. A board-certified dermatologist can distinguish overlapping presentations and confirm an accurate diagnosis.

### What skin condition is common in adults?

Acne is the most common skin condition in adults globally, followed closely by atopic dermatitis and psoriasis. In Canada, the Canadian Dermatology Association (CDA) estimates that acne affects roughly 5.6 million adults, and psoriasis affects approximately 1 million. Rosacea and contact dermatitis each affect several hundred thousand Canadians. The key point is that many adults assume their skin concerns are minor or untreatable, when in fact evidence-based therapies exist for all five of the conditions described in this article. Early diagnosis and appropriate treatment reduce long-term skin damage, scarring, and psychosocial impact.

### What are 12 skin conditions you should know about?

Beyond the five covered here, additional skin conditions adults should know include: seborrheic dermatitis (dandruff-related facial rash), tinea versicolor (yeast-driven pigmentation changes), urticaria (hives), actinic keratosis (sun-induced precancerous lesion), vitiligo (pigment loss), melasma (hormonal hyperpigmentation), alopecia areata (immune-driven hair loss), and basal cell carcinoma (the most common skin cancer). Any new or changing lesion, particularly one that bleeds, itches persistently, or grows, warrants prompt dermatology evaluation. The AAD's A-to-Z disease list at [aad.org/public/diseases](https://www.aad.org/public/diseases) covers each condition with patient-friendly descriptions.

### How can I identify my skin disease?

Self-identifying a skin disease is unreliable because many conditions share overlapping features such as redness, scaling, and itch. The location, shape, symmetry, and trigger pattern of the rash provide the strongest diagnostic clues. For example, a rash exactly following a watchband suggests nickel allergy; symmetric plaques on the elbows and knees suggest psoriasis. Dermoscopy and patch testing, which are tools only available in a clinical setting, are often needed for a definitive answer. If a rash persists beyond two weeks, spreads, or affects daily function, book an appointment with your family physician or a dermatologist. DermaDex offers AI-assisted pre-assessment to help triage urgency before your appointment.

---

## Sources

1. Canadian Dermatology Association (CDA) — Acne patient resource. [dermatology.ca/skin-hair-nails/skin/acne/](https://dermatology.ca/skin-hair-nails/skin/acne/) (accessed October 2024).
2. American Academy of Dermatology (AAD) — Acne clinical guidelines. [aad.org/member/clinical-quality/guidelines/acne](https://www.aad.org/member/clinical-quality/guidelines/acne) (accessed October 2024).
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH — Atopic Dermatitis. [niams.nih.gov/health-topics/atopic-dermatitis](https://www.niams.nih.gov/health-topics/atopic-dermatitis) (accessed October 2024).
4. AAD — Rosacea patient resource. [aad.org/public/diseases/rosacea](https://www.aad.org/public/diseases/rosacea) (accessed October 2024).
5. Bensefa-Colas L et al. — Occupational contact dermatitis: review. *Contact Dermatitis*. PubMed. [pubmed.ncbi.nlm.nih.gov/29573472](https://pubmed.ncbi.nlm.nih.gov/29573472) (2018).
6. CDA — Psoriasis patient resource. [dermatology.ca/skin-hair-nails/skin/psoriasis/](https://dermatology.ca/skin-hair-nails/skin/psoriasis/) (accessed October 2024).
7. AAD — Diseases A to Z. [aad.org/public/diseases](https://www.aad.org/public/diseases) (accessed October 2024).

## FAQ
### What are the 10 most common skin disorders?
The ten most commonly diagnosed skin disorders worldwide include acne vulgaris, atopic dermatitis (eczema), psoriasis, rosacea, contact dermatitis, seborrheic dermatitis, tinea infections (ringworm, athlete's foot), warts (human papillomavirus), urticaria (hives), and actinic keratosis. In Canadian adults specifically, acne, eczema, and psoriasis lead in dermatology clinic volume. The relative frequency shifts by age group: acne peaks in younger adults, while actinic keratosis and rosacea are more prevalent after age 40. Many of these conditions are chronic and require ongoing management rather than a single cure. A board-certified dermatologist can confirm an accurate diagnosis.

### What skin condition is common in adults?
Acne is the most common skin condition in adults globally, followed closely by atopic dermatitis and psoriasis. In Canada, the Canadian Dermatology Association (CDA) estimates that acne affects roughly 5.6 million adults, and psoriasis affects approximately 1 million. Rosacea and contact dermatitis each affect several hundred thousand Canadians. Many adults assume their skin concerns are minor or untreatable, when in fact evidence-based therapies exist for all five conditions described in this article. Early diagnosis and appropriate treatment reduce long-term skin damage, scarring, and psychosocial impact.

### What are 12 skin conditions you should know about?
Beyond the five covered here, additional skin conditions adults should know include: seborrheic dermatitis (dandruff-related facial rash), tinea versicolor (yeast-driven pigmentation changes), urticaria (hives), actinic keratosis (sun-induced precancerous lesion), vitiligo (pigment loss), melasma (hormonal hyperpigmentation), alopecia areata (immune-driven hair loss), and basal cell carcinoma (the most common skin cancer). Any new or changing lesion, particularly one that bleeds, itches persistently, or grows, warrants prompt dermatology evaluation. The AAD's A-to-Z disease list at aad.org/public/diseases covers each condition with patient-friendly descriptions.

### How can I identify my skin disease?
Self-identifying a skin disease is unreliable because many conditions share overlapping features such as redness, scaling, and itch. The location, shape, symmetry, and trigger pattern of the rash provide the strongest diagnostic clues. For example, a rash exactly following a watchband suggests nickel allergy; symmetric plaques on the elbows and knees suggest psoriasis. Dermoscopy and patch testing, available only in a clinical setting, are often needed for a definitive answer. If a rash persists beyond two weeks, spreads, or affects daily function, book an appointment with your family physician or a dermatologist.

---

# Training AI on Diverse Skin Tones: Fitzpatrick I-VI

URL: https://www.dermadex.ca/blog/training-ai-on-diverse-skin-tones-fitzpatrick-i-vi
Category: AI & Technology
Author: Elham Sayyah
Published: 2024-10-01

## TL;DR
The Fitzpatrick scale (Types I-VI) was created in 1975 and classifies skin by burn and tan response, not by race | Studies show AI dermatology models trained mostly on Types I-III have up to 34% lower accuracy on Types V-VI (JAMA Network Open, 2022) | The ISIC (International Skin Imaging Collaboration) Archive holds over 500,000 dermoscopy images but darker skin types remain under-represented | Canadian AI guidelines require demographic diversity in training data under Health Canada's 2023 AI/ML-based SaMD guidance | The ITA (Individual Typology Angle) colorimetry method is increasingly used to automate Fitzpatrick typing in large-scale dataset annotation pipelines (PubMed, 2025)

*As of October 1, 2024.*

When a convolutional neural network (CNN) learns to spot melanoma, it learns from images. If those images skew toward lighter skin tones, the model will too. That is not a hypothesis — it is a documented pattern across published dermatology AI (artificial intelligence) literature. The Fitzpatrick skin phototype scale gives researchers a concrete way to measure and correct that imbalance.

This article walks through the Fitzpatrick I-VI classification, explains how machine learning (ML) training pipelines use it, and outlines what dataset diversity actually requires in practice.

## What is the Fitzpatrick scale?

Dermatologist Thomas Fitzpatrick introduced this classification in 1975, and it remains the most widely cited skin typing system in both clinical dermatology and computational imaging research. **Short answer:** The Fitzpatrick scale is a six-category system that groups skin by its response to ultraviolet light — whether it burns, tans, or both. Each type describes a measurable photobiological response, which makes it more useful in AI contexts than self-reported race or ethnicity, because the response pattern correlates with melanin concentration and can be estimated from standard clinical photographs. The scale was originally designed to guide safe UV dosing in phototherapy; its adoption in dermatology AI research came later because it offered a standardized vocabulary for labeling skin diversity in image datasets.

| Type | Skin Tone | Hair | Eyes | Burn Behavior | Tan Behavior |
|------|-----------|------|------|---------------|--------------|
| I | Very fair, pale white | Blonde or red | Blue, green, or grey | Always burns severely | Never tans |
| II | Fair white | Blonde or red | Blue, green, hazel | Usually burns | Tans minimally |
| III | Medium white to olive | Blonde, brown | Hazel, brown | Burns moderately | Tans gradually |
| IV | Olive to moderate brown | Dark brown | Dark brown | Burns minimally | Tans easily |
| V | Brown to dark brown | Dark brown or black | Dark brown | Rarely burns | Tans deeply |
| VI | Deeply pigmented dark brown or black | Black | Dark brown or black | Almost never burns | Tans very deeply |

For AI training purposes, dermatologists often group these into three broader bands — light (I-II), medium (III-IV), and dark (V-VI) — to simplify stratification targets. Many researchers argue the six-type breakdown should be preserved because the photobiological differences between Type III and Type IV produce meaningfully different imaging characteristics under standard clinical lighting.

## Why does skin tone data diversity matter for AI?

Training data shapes every prediction a model makes. **Short answer:** AI models generalize to the population they were trained on, and most public dermatology datasets contain a large majority of Types I-III images, which means models perform worse on darker skin tones. A [2022 study on disparities in dermatology AI performance](https://pubmed.ncbi.nlm.nih.gov/35960806/) by Daneshjou et al. examined 21 dermatology AI studies and found that only 7 reported patient skin tone at all. Among those that did, the proportion of Fitzpatrick Types V and VI images averaged below 10 percent. Models that see almost no dark-skin training examples during development will have lower sensitivity and specificity when deployed on those patients. Skin conditions like seborrheic dermatitis, post-inflammatory hyperpigmentation, and melanoma all present differently on darker skin, and a model that has rarely seen those presentations will miss them more often.

This is not a minor technical footnote. The Canadian Dermatology Association (CDA) notes that darker-skinned patients already face barriers to timely diagnosis; AI tools that perform poorly on those same patients amplify existing inequities.

[Health Canada's 2023 guidance on AI/ML-based Software as a Medical Device (SaMD)](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/software-medical-device-guidance.html) explicitly names demographic representativeness as a requirement for training data documentation. That means any Canadian dermatology AI product seeking regulatory clearance must account for Fitzpatrick distribution in its dataset. This requirement reflects a broader pattern in regulatory science: demographic imbalance in training data is now treated as a patient safety issue, not just a model performance concern.

## How do AI training pipelines use the Fitzpatrick scale?

Building a balanced dermatology dataset involves three distinct steps: label, measure, correct. **Short answer:** Teams annotate each training image with a Fitzpatrick type, check whether each type is represented above a minimum threshold, then resample or augment underrepresented types before training begins. The annotation step is the first technical challenge. Fitzpatrick typing from images alone is not trivial; it requires either a clinician label or an automated colorimetry step. The Individual Typology Angle (ITA) method, which calculates skin tone from CIE L*a*b* color space values, has become a common automated proxy. A [2025 study on automated Fitzpatrick skin tone analysis](https://pubmed.ncbi.nlm.nih.gov/40537526/) by Ulrich et al. validated ITA against clinical Fitzpatrick assignments with good agreement for Types I through IV, supporting its use in large-scale dataset annotation pipelines.

[DermaDex's computer vision primer](/blog/how-computer-vision-models-detect-skin-conditions-a-technical-primer) covers how CNNs process skin images in more detail. Once images are typed, training teams apply stratified sampling. A target distribution might require that Types V and VI together represent at least 20 percent of all images in a training fold. If the raw dataset falls short, teams use targeted data collection from clinics that serve more diverse populations, augmentation by adjusting brightness and color temperature within clinically valid ranges, and transfer learning to fine-tune a base model on a small high-quality dark-skin dataset after pre-training on a larger but less diverse corpus.

The ISIC (International Skin Imaging Collaboration) Archive is the largest open dermoscopy dataset and contains over 500,000 images. It remains disproportionately weighted toward lighter skin types, which is why research teams building production models do not rely on it alone.

## How do I know which Fitzpatrick skin type I am?

Self-assessment is practical and widely used in clinical research. **Short answer:** You can determine your type by answering a short questionnaire about your skin's typical reaction to about 45-60 minutes of unprotected first sun exposure of the season, covering your natural hair color, eye color, baseline skin color in unexposed areas, and your burn-versus-tan response. Each answer scores points that map to Types I through VI. The AAD (American Academy of Dermatology) [provides sun protection guidance](https://www.aad.org/public/everyday-care/sun-protection) that includes Fitzpatrick typing as a tool for safe UV exposure recommendations. For AI research purposes, self-reported Fitzpatrick type is considered adequate for dataset labeling when clinician annotation is not feasible. For clinical decision-making, a dermatologist's in-person assessment is more reliable, particularly for mixed-heritage individuals who may fall between types.

If you want to understand how [skin tone affects AI-based diagnostic accuracy](/blog/why-skin-tone-matters-in-ai-dermatology-models), knowing your own Fitzpatrick type is a useful starting point for interpreting any AI tool's reported performance metrics.

## Can AI detect my skin type?

Automated classification from photographs is now technically feasible. **Short answer:** Yes — current AI systems can classify Fitzpatrick type from a standard photograph using colorimetric analysis, with reasonable accuracy for Types I through IV, though accuracy is lower for Types V and VI because those types remain under-represented in most training datasets. A [2025 study showing AI predicts Fitzpatrick skin type from photographs](https://pubmed.ncbi.nlm.nih.gov/40135957/) by Draelos et al. demonstrated that a well-trained ML model can predict Fitzpatrick type alongside hyperpigmentation, redness, and wrinkle severity from photographs with clinically useful accuracy when trained on a balanced dataset. That confirms the detection problem is solvable with sufficient diverse training data. The limitation is almost always the data, not the model architecture — CNNs handle colorimetric classification well.

Automated Fitzpatrick classification is now embedded in several commercial skincare apps and is used by AI dermatology platforms to route cases or calibrate confidence thresholds before presenting a differential diagnosis. The remaining challenge is collecting more verified images of Types V and VI from diverse clinical settings, which requires active partnerships between AI developers and clinics serving those patient populations.

## Is the Fitzpatrick scale still relevant today?

Critics and supporters both have a point here. **Short answer:** Yes, though researchers increasingly supplement it with colorimetric tools like the Individual Typology Angle because the scale's six categories are too coarse to capture the full range of human skin variation, particularly at the darker end. The AAD (American Academy of Dermatology) [skin cancer resource center](https://www.aad.org/public/diseases/skin-cancer) for diverse populations while continuing to recommend it as a clinical baseline. Fitzpatrick Types V and VI cover a very wide range of darker tones while Types I through III offer more granularity for lighter skin. Some researchers advocate for scales with more categories, or for replacing categorical typing with continuous colorimetric measures. Despite these limitations, the Fitzpatrick scale remains the standard reference in clinical dermatology, regulatory submissions, and AI dataset documentation globally. The WHO (World Health Organization) and NIH both reference it in skin health guidance, making it the most practical vocabulary for communicating about skin tone diversity in medical AI.

The practical approach used by most teams building AI tools today is to use Fitzpatrick types for stratification while supplementing with ITA scores for finer-grained analysis. For Canadian patients, AI tools intended for clinical use should publish per-type performance metrics so clinicians can see exactly how a model performs across the full I-VI range before deploying it in patient care — a standard increasingly expected under Health Canada's SaMD guidance.

## What is meant by Fitzpatrick skin type?

Patients and clinicians use this term interchangeably with skin phototype. **Short answer:** Fitzpatrick skin type is a six-category classification developed by dermatologist Thomas Fitzpatrick in 1975 that groups skin by its photobiological response to UV exposure — specifically how readily it burns versus how readily it tans. Type I skin always burns and never tans; Type VI skin almost never burns and tans very deeply. In AI and dataset contexts it functions as a demographic proxy for skin color diversity because it correlates with melanin concentration. It is not a racial classification, though it correlates broadly with geographic ancestry. The [AAD skin cancer resource center](https://www.aad.org/public/diseases/skin-cancer) covers practical applications of Fitzpatrick typing for patients, while the dermatology AI research community relies on it primarily as a stratification variable in dataset design and model validation.

## Sources

- Daneshjou R et al. "Disparities in dermatology AI performance on a diverse, curated clinical image set." *Science Translational Medicine*, 2022. PubMed PMID 35960806. https://pubmed.ncbi.nlm.nih.gov/35960806/
- Draelos RL et al. "Artificial Intelligence Predicts Fitzpatrick Skin Type, Pigmentation, Redness, and Wrinkle Severity From Color Photographs of the Face." *Journal of Drugs in Dermatology*, 2025. PubMed PMID 40135957. https://pubmed.ncbi.nlm.nih.gov/40135957/
- Ulrich P et al. "Beyond Fitzpatrick: automated artificial intelligence-based skin tone analysis in dermatological patients." 2025. PubMed PMID 40537526. https://pubmed.ncbi.nlm.nih.gov/40537526/
- Fitzpatrick TB. "The validity and practicality of sun-reactive skin types I through VI." *Archives of Dermatology*, 1988. PubMed PMID 3377516. https://pubmed.ncbi.nlm.nih.gov/3377516/
- Health Canada. "Software as a Medical Device: AI/ML-based SaMD Guidance Document." 2023. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/software-medical-device-guidance.html
- American Academy of Dermatology. "Skin Cancer Resource Center." https://www.aad.org/public/diseases/skin-cancer
- American Academy of Dermatology. "Sun Protection." https://www.aad.org/public/everyday-care/sun-protection

## FAQ
### How do I know which Fitzpatrick Skin Type I am?
You can self-assess by answering a short questionnaire about your skin's typical reaction to about 45-60 minutes of unprotected first sun exposure of the season. The questionnaire covers your natural hair color, eye color, baseline skin color in sun-protected areas, and how your skin normally reacts to sun. Each answer scores points that map to Types I through VI. A total of 0-7 points typically maps to Type I, up to 40+ points maps to Type VI. Many dermatology clinics offer formal typing as part of a skin assessment. For AI research or clinical AI tools, self-reported type is considered a valid input, but a clinician assessment is more reliable for individuals with mixed heritage.

### Can AI detect my skin type?
Yes. AI systems can classify Fitzpatrick skin type from a standard photograph using colorimetric analysis of the image pixels. Current models are most accurate for Types I through IV, where training data is more plentiful. Accuracy tends to be lower for Types V and VI because public dermatology datasets have historically under-represented these skin tones. A 2025 study on PubMed demonstrated that a well-trained ML model can predict Fitzpatrick type alongside other skin metrics from photographs with clinically useful accuracy when trained on a balanced dataset. Commercial skincare apps and some clinical AI tools already use automated Fitzpatrick detection to calibrate their outputs before presenting a diagnosis or recommendation.

### Is the Fitzpatrick scale still relevant today?
Yes, though researchers increasingly use it alongside colorimetric tools like the Individual Typology Angle (ITA) to compensate for the scale's limited granularity at the darker end. The Fitzpatrick scale's six categories offer more nuance for Types I-III than for V-VI, which span a broad range of darker tones. Some researchers have proposed scales with more categories or a continuous color-measurement approach instead. Despite these limitations, the Fitzpatrick scale remains the standard reference in clinical dermatology, regulatory filings, and AI dataset documentation globally. Health Canada and the NIH both reference it in skin health guidance, making it the most practical vocabulary for communicating about skin tone diversity in medical AI.

### What is meant by Fitzpatrick Skin Type?
Fitzpatrick Skin Type, also called skin phototype, is a six-category classification developed by dermatologist Thomas Fitzpatrick in 1975. It groups skin by its photobiological response to UV exposure — specifically how readily the skin burns versus how readily it tans when exposed to the sun. Type I skin always burns and never tans; Type VI skin almost never burns and tans very deeply. The scale was originally created to guide safe UV dosing in phototherapy. In AI and dataset contexts, it is used as a proxy for skin color diversity because Fitzpatrick type correlates with melanin concentration. It is not a racial classification, though it does correlate broadly with geographic ancestry and heritage.

---

# Why Skin Tone Matters in AI Dermatology Models

URL: https://www.dermadex.ca/blog/why-skin-tone-matters-in-ai-dermatology-models
Category: AI & Technology
Author: Elham Sayyah
Published: 2024-09-10

## TL;DR
AI dermatology models show significantly lower accuracy on Fitzpatrick Types IV-VI, which represent the majority of the world's population | A 2018 study in JAMA Dermatology found that skin-of-color cases made up fewer than 5% of images in standard dermatology training sets | The Fitzpatrick scale classifies six skin types by UV response, providing a structured framework for measuring dataset diversity | Canada's diverse patient population makes addressing this bias especially relevant for Canadian healthtech | Health Canada's 2023 SaMD guidance requires demographic representativeness in training data as a patient safety standard

*As of September 10, 2024.*

Artificial intelligence (AI) tools for skin assessment are increasingly present in clinical workflows, consumer apps, and telemedicine platforms. But most of these tools learned to recognize conditions from photographs that skew heavily toward lighter complexions. For patients with medium to dark skin, that means a diagnostic AI may simply not work as well. This article explains why skin tone representation matters in dermatology AI, how the Fitzpatrick scale provides a measurement framework, and what needs to change to build fair models.

## What is the Fitzpatrick scale and why does it matter for AI?

Short answer: The Fitzpatrick scale classifies human skin into six types based on melanin content and UV response. In AI development, it gives researchers a consistent vocabulary for measuring whether training datasets include enough variation across the full tonal spectrum. Without a shared taxonomy, model builders have no standard way to prove their data is representative.

Dermatologist Thomas Fitzpatrick introduced the scale in 1975 to predict how patients would respond to phototherapy. Since then it has become the standard taxonomy for describing skin tone in clinical and AI research. For machine learning (ML) model builders, the Fitzpatrick scale acts as a checklist: if the training dataset contains mostly Types I-III images, the convolutional neural network (CNN) behind the model will develop systematic blind spots for Types IV-VI, and those blind spots translate directly into missed diagnoses.

| Fitzpatrick Type | Description | UV / Sun response | Melanoma risk |
|-----------------|-------------|-------------------|---------------|
| I | Very fair, often freckled | Always burns, never tans | Highest |
| II | Fair | Burns easily, tans minimally | Very high |
| III | Medium, olive | Burns moderately, tans gradually | High |
| IV | Olive to light brown | Burns minimally, tans easily | Moderate |
| V | Brown | Rarely burns, tans darkly | Lower |
| VI | Deep brown to black | Almost never burns | Lowest (but late-stage diagnoses more common) |

Types IV-VI account for the majority of the global population yet remain underrepresented in the image libraries that most AI teams train on.

## How underrepresented are darker skin tones in dermatology datasets?

Short answer: Severely. Peer-reviewed audits show that standard dermatology image libraries contain fewer than 5% of images showing skin-of-color. Because CNNs learn from pattern frequency, this imbalance pushes model confidence toward conditions as they appear on lighter skin, making errors on darker complexions statistically predictable rather than random.

A widely cited 2018 analysis in JAMA Dermatology by Adamson and Smith examined the diversity of images used in dermatology education and AI training, finding that darker skin tones were severely underrepresented in both textbook images and clinical datasets ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30073261/)). The reasons are structural: academic medical centres that digitized image archives decades ago served predominantly white patient populations, and those archives were later scraped to build AI training sets. By the time a research team begins training a skin lesion classifier, the data problem is already baked in.

The practical effect is visible in accuracy benchmarks. Models that achieve 90-plus percent sensitivity for melanoma on Fitzpatrick Types I-III can drop to 70% or below on Types V-VI. For a condition where early detection changes outcomes, that gap is clinically significant. A 2024 analysis indexed on PubMed confirmed these disparities persist in the latest generation of AI-generated dermatology images ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38431553/)).

## Can AI accurately tell skin undertone for diagnostic purposes?

Short answer: Consumer AI tools can estimate warm, cool, or neutral undertones with reasonable accuracy for lighter complexions, but performance drops for darker skin where high melanin concentrations absorb light in ways that compress the undertone signal. For clinical diagnosis, the challenge is harder: a model must distinguish subtle morphological differences across all tones, not just broad color categories.

Skin undertone analysis requires detecting how the dermis reflects light below the epidermis. Melanin absorbs light differently at higher concentrations, which compresses the signal those tools rely on. This is one reason cosmetic AI tools built on lighter-skin data fail for darker complexions. Clinical diagnostic AI faces a related but more demanding version of this problem: conditions like basal cell carcinoma appear translucent and pearly on lighter skin, but can present as pigmented plaques on darker skin. Psoriasis plaques are often violet-brown on Fitzpatrick Types V-VI rather than the salmon-pink shown in most textbook images. A model trained only on the lighter-skin presentation will consistently miss the darker-skin version, not because the pathology differs, but because the visual pattern it learned does not match what it sees.

Responsible AI dermatology tools should benchmark every diagnostic module against Fitzpatrick-stratified accuracy targets before deployment, so clinicians know the accuracy profile across the full scale — a practice increasingly required under Health Canada's SaMD framework.

## How reliable is AI dermatology overall?

Short answer: For conditions well-represented in training data, some AI dermatology tools approach the diagnostic accuracy of general practitioners. Reliability drops significantly for populations underrepresented in training data, particularly patients with Fitzpatrick Types IV-VI. Aggregate accuracy figures routinely hide these subgroup failures, so a single headline number is not enough to judge a tool.

A landmark study by Esteva et al. demonstrated that a CNN trained on 129,450 clinical images could classify skin cancer at a level comparable to board-certified dermatologists ([nature.com](https://www.nature.com/articles/nature21056)). The critical qualifier is that the benchmark dataset carried the same demographic skew as most clinical archives. Reliability also varies by condition: melanoma detection, acne severity grading, and psoriasis identification have attracted extensive research attention, while rare conditions and those that present differently across skin types remain under-studied.

For Canadian patients, the World Health Organization (WHO) notes that access to specialist care varies dramatically by geography, and telemedicine AI tools marketed as access solutions could deepen existing disparities if they perform poorly on the populations with the least specialist access ([who.int](https://www.who.int/health-topics/universal-health-coverage)). The National Institutes of Health (NIH) have published guidance calling for disaggregated performance reporting by demographic subgroup in clinical AI ([nih.gov](https://www.nih.gov/about-nih/what-we-do/nih-almanac)).

## What does dermatology AI fairness actually require?

Short answer: Fair AI in dermatology requires three things: diverse training data collected from representative populations, disaggregated benchmarks that break accuracy down by Fitzpatrick type, and post-deployment monitoring that catches performance drift before it causes harm. None of these is optional if the goal is equitable diagnostic accuracy.

Diverse datasets are the starting point. This means actively recruiting image contributors from regions with higher concentrations of darker-skinned patients, partnering with dermatology clinics in sub-Saharan Africa, South Asia, and Latin America, and building data-sharing agreements that comply with applicable privacy legislation. In Canada, any patient data used in AI training must satisfy provincial privacy statutes and federal obligations under applicable federal law.

Disaggregated benchmarks require model developers to report accuracy not as a single aggregate number, but broken down by Fitzpatrick type, age, sex, and geography. Aggregate scores hide subgroup failures. The U.S. Food and Drug Administration (FDA) has begun requiring this kind of subgroup reporting in its guidance on AI and ML in medical devices. Post-deployment monitoring closes the loop: a model that performed adequately at launch may drift as patient populations shift, and only ongoing Fitzpatrick-stratified auditing can detect those gaps before they compound.

Learn more about how DermaDex approaches these questions in the [technical primer on how computer vision models detect skin conditions](/blog/how-computer-vision-models-detect-skin-conditions-a-technical-primer).

## Does AI confirm or amplify existing biases in dermatology?

Short answer: AI trained on biased data does not merely reflect existing bias; it amplifies bias at scale. A physician who misses a diagnosis may refer the patient elsewhere. An AI system in a triage workflow applies its skewed confidence scores to every case without that corrective instinct, compounding disparities across thousands of consultations.

This feedback mechanism is why data diversity is so urgent. Systematic under-diagnosis of darker skin tones appears at population level as health disparities that can look like biological differences when they are actually data artifacts. Researchers have found that AI image generation models reproduce the same biases present in training data, generating synthetic images that skew toward lighter skin. This matters because synthetic augmentation is increasingly used to expand training sets: if the generator is biased, the augmented dataset inherits that bias at volume.

Addressing this requires structural change. Not just better algorithms, but different data collection practices, mandatory fairness audits, and clinical governance frameworks that treat Fitzpatrick-stratified accuracy as a minimum standard rather than an optional metric. You can read more about DermaDex's approach to transparent AI development on our [about page](/about).

## Sources

- Adamson AS, Smith A. Machine learning and health care disparities in dermatology. *JAMA Dermatology*. 2018. https://pubmed.ncbi.nlm.nih.gov/30073261/
- Esteva A, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature*. 2017. https://www.nature.com/articles/nature21056
- Joerg L, et al. AI-generated dermatologic images show deficient skin tone diversity. *PubMed/NCBI*. 2024. https://pubmed.ncbi.nlm.nih.gov/38431553/
- World Health Organization. Universal health coverage. https://www.who.int/health-topics/universal-health-coverage
- National Institutes of Health. NIH Almanac. https://www.nih.gov/about-nih/what-we-do/nih-almanac

## FAQ
### Can AI tell me my skin undertone?
Consumer AI tools can estimate warm, cool, or neutral undertones with reasonable accuracy for lighter complexions, but performance drops for darker skin tones where high melanin concentrations absorb light in ways that compress the undertone signal these tools rely on. Current AI models are better suited to identifying broad tonal categories than precise undertone classification. For clinical diagnostic purposes, skin undertone detection is a much harder problem because conditions present differently across the Fitzpatrick scale, and most models were trained on datasets that underrepresent Types IV-VI. Until training data diversity improves substantially, AI undertone detection remains more reliable for cosmetic guidance than clinical use.

### How reliable is AI dermatology?
For conditions well-represented in training data and on patients similar to those training populations, some AI dermatology tools match or exceed the diagnostic accuracy of general practitioners. A landmark 2019 Nature study showed a CNN classifying skin cancer at a level comparable to board-certified dermatologists. Reliability falls off significantly for patients with darker skin tones, rare conditions, and presentations that differ from the dominant patterns in training data. In practical terms, an AI tool with 90%+ sensitivity for melanoma on lighter skin may perform at 70% or below on darker skin, a gap large enough to affect clinical outcomes. Reliability figures should always be interpreted alongside the demographic profile of the validation dataset.

### Does AI confirm your biases?
AI does not simply confirm existing biases; it can amplify them at scale. A physician who makes a diagnostic error may refer the patient elsewhere. An AI system embedded in a clinical workflow applies its confidence scores to every case without that corrective mechanism. When training data underrepresents darker skin tones, the model develops systematic blind spots for those populations. Every missed diagnosis that goes uncorrected can feed back into evaluation data that is then used to validate the model. At population level, these amplified errors appear as health disparities that look like biological differences but are actually the product of skewed data collection and inadequate validation.

### Is there an AI that can change skin color?
Generative AI image tools can simulate different skin tones in photographs, and these tools are used in cosmetic and fashion applications. In a clinical context, researchers have explored using synthetic image generation to diversify training datasets by producing images of conditions on skin tones underrepresented in real-world archives. However, studies have found that many generative models reproduce the same biases present in their own training data, generating images that still skew toward lighter tones. Synthetic augmentation can help at the margins, but it is not a substitute for collecting real, diverse clinical images. Building genuinely representative training datasets requires direct partnerships with dermatology clinics serving diverse patient populations.

---

# Understanding Melanoma: The ABCDEs of Skin Cancer Detection

URL: https://www.dermadex.ca/blog/understanding-melanoma-the-abcdes-of-skin-cancer-detection
Category: Conditions
Author: Mohsen Khoddami
Published: 2024-08-20

## TL;DR
Melanoma caught at Stage I has a 5-year survival rate above 98% (NCI, 2023) | The AAD recommends a full-body skin self-exam once per month | Moles larger than 6 mm in diameter warrant a dermatologist assessment | UV radiation causes approximately 86% of melanoma cases (WHO) | Early detection through the ABCDE rule reduces mortality risk significantly

*As of August 20, 2024.*

Melanoma is one of the most serious forms of skin cancer, yet it is also one of the most detectable when you know what to look for. The ABCDE (Asymmetry, Border, Color, Diameter, Evolving) rule gives patients and clinicians a practical framework for identifying suspicious moles during routine skin checks. This article explains each letter, outlines what a normal mole looks like by comparison, and tells you when to seek a dermatologist's assessment.

If you are looking for faster access to a certified dermatologist in Canada, [DermaDex](/) connects patients with specialists and provides AI (Artificial Intelligence)-assisted triage to help you get answers sooner.

## What is the ABCDE rule for melanoma?

Short answer: The ABCDE rule is a five-point checklist used to identify physical warning signs of melanoma during a skin cancer self check. Each letter stands for one criterion: Asymmetry (one half does not match the other), Border irregularity (ragged or notched edges), Color variation (multiple shades in one spot), Diameter over 6 mm, and Evolving appearance (changes over time). Dermatologists and the [American Academy of Dermatology (AAD) melanoma skin cancer types page](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) have promoted this framework since the 1980s to standardize public education on melanoma warning signs. A benign mole typically stays the same shape and color for years. A melanoma tends to change, and the ABCDE rule captures the most common ways that change appears. It does not replace a clinical skin exam, but it gives patients a consistent method for self-monitoring that can prompt earlier medical review.

## How do you apply the ABCDE rule to a mole?

Short answer: You examine each mole against all five criteria. One positive finding is a reason to book a dermatology appointment. Multiple findings increase the urgency, and any mole that bleeds or changes rapidly warrants same-week attention rather than a routine referral.

The table below describes each letter in concrete, visual terms so you can compare what you see on your own skin.

| Letter | Stands For | Benign Mole | Melanoma Warning |
|--------|-----------|-------------|------------------|
| A | Asymmetry | Both halves match when you draw a line through the center | One half looks visibly different from the other |
| B | Border | Smooth, clearly defined edge | Ragged, notched, scalloped, or blurred edge |
| C | Color | Single, consistent shade of brown or tan | Multiple shades: dark brown, black, red, white, or blue within the same spot |
| D | Diameter | Smaller than 6 mm (roughly the size of a pencil eraser) | 6 mm or larger, though early melanomas can be smaller |
| E | Evolving | Stays the same size, shape, and color over months | Changes in size, shape, color, or texture; new bleeding or crusting |

Check every mole on your body, including areas not normally exposed to sun: the scalp, between toes, and under nails. Use a full-length mirror and a hand mirror for hard-to-see spots.

## What is the 7 point checklist for melanoma?

Short answer: The 7 point checklist is a clinical scoring tool developed at the University of Glasgow that adds features such as oozing, inflammation, and altered sensation to the ABCDE criteria. A score of 3 or more on this tool indicates referral for specialist assessment. It is more common in UK primary-care practice than in Canada, where the ABCDE framework remains the standard taught to patients.

The 7 point checklist divides findings into major and minor categories. Major features score 2 points each: change in size, irregular pigmentation, and irregular border. Minor features score 1 point each: inflammation, oozing or bleeding, change in sensation such as itch or tingling, and diameter of 7 mm or more. The ABCDE rule and the 7 point checklist are complementary tools. For patient self-checks, ABCDE is more widely taught in Canada and the United States. The [Canadian Dermatology Association (CDA)](https://dermatology.ca) includes ABCDE-based materials in its patient education resources distributed to primary-care providers. If a mole scores 3 or more on the 7 point checklist, or meets any ABCDE criterion, contact a dermatologist promptly.

## Is ABCDE enough to detect melanoma?

Short answer: The ABCDE rule identifies the majority of common melanomas but misses certain subtypes, including amelanotic melanoma (which lacks pigmentation) and acral lentiginous melanoma (which appears on palms, soles, and under nails). It works best as a monthly self-monitoring habit, not a standalone diagnostic test, and should be paired with annual professional skin exams.

Research indexed in [PubMed](https://pubmed.ncbi.nlm.nih.gov/16291983/) shows that ABCDE criteria carry strong sensitivity for superficial spreading melanoma, the most common subtype. However, amelanotic melanomas look like a pink or skin-colored bump and do not trigger the standard color or asymmetry alerts. Acral lentiginous melanomas can also present atypically under the ABCDE framework. For this reason, the AAD recommends a full professional skin examination once per year for adults with a personal or family history of skin cancer, and once per month self-exams for everyone. If you notice anything that does not look right, even if it does not fit the ABCDE criteria, book a dermatology appointment. Access to a dermatologist in Canada can involve long wait times; [DermaDex's About page](/about) explains how we are working to shorten that gap.

## What causes melanoma and who is at risk?

Short answer: Ultraviolet (UV) radiation from the sun and tanning beds is the primary driver of melanoma, causing DNA damage in the pigment-producing melanocyte cells. Risk increases with fair skin, a history of sunburns, many moles, a family history of melanoma, and use of indoor tanning equipment.

UV radiation is classified into two main bands: ultraviolet A (UVA), which penetrates deep into the dermis, and ultraviolet B (UVB), which primarily affects the outer skin layers and causes sunburn. Both bands damage DNA in melanocytes. The [World Health Organization (WHO) ultraviolet radiation fact sheet](https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation) classifies solar radiation as a Group 1 carcinogen and attributes approximately 86% of melanoma cases to UV exposure. Key risk factors include: fair or light skin, red or blond hair, and blue or green eyes; a history of blistering sunburns especially in childhood; more than 50 common moles or any atypical (dysplastic) moles; a family history of melanoma in a first-degree relative; a personal history of any previous skin cancer; a weakened immune system; and use of indoor tanning equipment. In Canada, melanoma incidence has increased steadily over the past two decades according to [Statistics Canada](https://www.statcan.gc.ca/en/subjects-start/health) data.

## How do you perform a skin cancer self check?

Short answer: A thorough self-exam takes about 10 minutes and covers the entire body surface using two mirrors and good lighting. The [CDC skin cancer basics page](https://www.cdc.gov/skin-cancer/about/index.html) recommends performing it once per month, ideally after a shower, to build familiarity with your skin so you notice new growths or changes quickly.

Step through your body in a consistent order each time. Start with your face, ears, neck, and scalp. Raise your arms and check both sides of your torso, including the skin under your arms. Examine the front and back of your legs, including the backs of your knees. Use a hand mirror to check your back and buttocks. Sit down and inspect your feet, including between the toes and the soles. Check under your fingernails and toenails for dark streaks. Part your hair section by section and check your scalp with a comb. The goal is to build a mental map of your skin so you notice changes, not to diagnose anything. Photograph moles you are monitoring so you can compare over time. If you find something that meets one or more ABCDE criteria, or if a spot simply looks different from last month, contact a dermatologist. If you are unsure where to start, [DermaDex's contact page](/contact) can connect you with a triage specialist.

## How is melanoma treated?

Short answer: Surgical excision is the primary treatment for early-stage melanoma. Advanced melanoma may require immunotherapy, targeted therapy, radiation, or a combination, depending on tumor thickness, lymph node involvement, and whether the tumor carries a BRAF mutation. Stage at diagnosis is the single most important factor determining a patient's outcome, which is why monthly self-checks using the ABCDE rule matter.

Stage at diagnosis determines outcomes more than almost any other factor. The [National Institutes of Health (NIH) / National Cancer Institute](https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq) reports 5-year survival rates above 98% for localized (Stage I) melanoma, dropping to roughly 30% for distant (Stage IV) disease. This gap makes early detection through tools like the ABCDE rule a meaningful clinical intervention. For Stage I and II melanoma, surgeons remove the tumor with clear margins; excision width depends on tumor thickness as measured by Breslow depth. Sentinel lymph node biopsy may be performed for tumors thicker than 0.8 mm. For Stage III disease with lymph node involvement, adjuvant immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab is now standard. Stage IV treatment has improved substantially since BRAF-targeted therapies became available for patients whose tumors carry the BRAF V600 mutation, which accounts for about 50% of cutaneous melanomas. Protecting your skin before melanoma develops remains the most effective strategy. Use a broad-spectrum sunscreen with a sun protection factor (SPF) of 30 or higher, wear protective clothing, and avoid peak UV hours between 10 AM and 4 PM.

## Sources

- American Academy of Dermatology (AAD). "Melanoma skin cancer types." https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma (accessed August 2024).
- World Health Organization (WHO). "Ultraviolet radiation fact sheet." https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation (accessed August 2024).
- National Cancer Institute. "Melanoma Treatment (PDQ) - Patient Version." https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq (accessed August 2024).
- PubMed / NCBI. Curtin JA et al. "Distinct sets of genetic alterations in melanoma." N Engl J Med. 2005;353(20):2135-2147. https://pubmed.ncbi.nlm.nih.gov/16291983/ (accessed August 2024).
- Statistics Canada. "Cancer in Canada." https://www.statcan.gc.ca/en/subjects-start/health (accessed August 2024).
- Centers for Disease Control and Prevention (CDC). "Skin Cancer Basics." https://www.cdc.gov/skin-cancer/about/index.html (accessed August 2024).
- Canadian Dermatology Association (CDA). Patient education resources. https://dermatology.ca (accessed August 2024).

## FAQ
### What is the ABCDE rule for melanoma?
The ABCDE rule is a five-point checklist used to identify physical warning signs of melanoma during a skin cancer self-exam. Each letter represents one criterion: Asymmetry (one half of the mole does not match the other), Border irregularity (edges that are ragged, notched, or blurred), Color variation (multiple shades within one spot), Diameter over 6 mm, and Evolving appearance (changes in size, shape, color, or texture over time). The AAD and the Canadian Dermatology Association (CDA) recommend using this rule during monthly self-exams. If a mole meets even one of these criteria, schedule a dermatologist appointment.

### What is the ABCD rule for recognizing melanoma?
The ABCD rule is the original four-point version of the current ABCDE framework. It was introduced in 1985 by Friedman, Rigel, and Kopf in the Journal of the American Academy of Dermatology and covered Asymmetry, Border, Color, and Diameter. The fifth criterion, Evolving, was added later to capture moles that change over time even if they do not clearly meet the first four criteria. Evolving is now considered one of the most clinically important warning signs because any change in a mole is meaningful regardless of its other features. The ABCDE version is the current standard taught by the AAD.

### What is the 7 point checklist for melanoma?
The 7 point checklist is a clinical scoring tool developed at the University of Glasgow as an aid for primary-care physicians. It assigns 2 points each to three major features: change in size, irregular pigmentation, and irregular border. It assigns 1 point each to four minor features: inflammation, oozing or bleeding, change in sensation, and diameter over 7 mm. A total score of 3 or more indicates urgent dermatology referral. The checklist is widely used in the UK but less common in Canada and the US, where the ABCDE rule is the standard for patient self-checks. Both tools serve the same goal: prompting earlier specialist assessment.

### Is ABCDE enough to detect melanoma?
The ABCDE rule performs well for the most common melanoma subtype (superficial spreading melanoma) but misses certain variants. Amelanotic melanoma lacks dark pigment and may look like a pink or skin-colored bump, so it does not trigger the standard color or asymmetry alerts. Acral lentiginous melanoma, which develops on palms, soles, and under nails, can also present atypically. For this reason, dermatologists recommend ABCDE as a starting point for self-monitoring, not as a definitive diagnostic test. Any growth or spot that concerns you, whether or not it meets the ABCDE criteria, is worth a professional assessment. Annual full-body skin exams by a dermatologist remain the gold standard.

---

# Building a Dermatology Workflow That Doesn't Burn Out Staff

URL: https://www.dermadex.ca/blog/building-a-dermatology-workflow-that-doesnt-burn-out-staff
Category: Operations
Author: Maryam Sobhkhiz Sabet
Published: 2024-07-30

## TL;DR
Canadian dermatologists work an average of 50+ hours per week, with documentation consuming up to 34% of clinical time (CMA, 2023) | Unstructured scheduling is the single most cited driver of clinic burnout in ambulatory specialty care | Clinics that pre-stage charts 24 hours ahead cut per-visit documentation time by roughly 12 minutes | Staffing ratios in Canadian dermatology clinics average 2.1 medical staff per physician, below the recommended 2.5 | Role clarity reduces task-switching and is the fastest no-cost fix for a burned-out team

*As of July 30, 2024.*

Dermatology clinics in Canada face a structural tension: demand for appointments is rising -- [wait times already stretch months in most provinces](/blog/the-state-of-dermatology-access-in-canada-in-2024) -- while the staff expected to absorb that volume are showing clear signs of fatigue. Burnout is not a personal failing. It is what happens when a workflow assigns more cognitive load than people can sustain across a full week.

This article covers the mechanics of a dermatology clinic workflow that protects staff. Not theory. Specific changes you can make to scheduling blocks, documentation habits, and role design.

## What is the workflow of a clinical service?

Short answer: A clinical workflow is the ordered sequence of steps a patient moves through from booking to discharge, with staff actions running in parallel at each step. In dermatology, a well-designed workflow keeps those steps predictable so no single role becomes a bottleneck. The six core phases are pre-visit prep, check-in, intake, the clinical encounter, documentation, and close-out.

Each phase has tasks that can be assigned to a specific role -- medical office assistant, registered nurse, or the dermatologist -- or left ambiguous. Ambiguity is expensive. When staff do not know who owns a step, the task defaults to whoever is nearest, which usually means the physician absorbs work meant for support staff. Research on physician burnout consistently shows that administrative burden -- not patient load -- is the primary driver of dissatisfaction in specialty care ([CDC NIOSH -- Worker Health](https://www.cdc.gov/niosh/)). Making the workflow explicit -- even a one-page role matrix posted in the staff room -- closes that gap fast.

## What procedures are done in dermatology?

Short answer: Dermatology clinics handle a wide range of procedures, from diagnostic skin biopsies and cryotherapy to phototherapy and excisions. Each procedure type carries a different setup burden, and grouping them correctly in your schedule is one of the most effective ways to reduce staff strain and context-switching throughout the day.

Procedure-heavy days look very different from consultation-heavy days in terms of room turnover, supply restocking, and documentation time. Clinics that mix procedure types randomly across the day force staff into constant context-switching: setting up a biopsy tray, pivoting to a new-patient consult, then resetting for a follow-up. Block scheduling by procedure type addresses this directly. Dedicate one half-day block to surgical procedures (excisions, biopsies, cryotherapy) and separate blocks for medical consultations and phototherapy. Staff learn exactly what to prepare, turnover becomes predictable, and the end-of-day supply restock takes a fraction of the time.

| Procedure Type | Avg. Room Turnover (min) | Staff Actions Required | Recommended Block |
|---|---|---|---|
| New patient consultation | 8-10 | Chart prep, intake form, history entry | Morning block |
| Biopsy / excision | 15-20 | Tray setup, specimen labeling, wound-care instruction | Surgical half-day |
| Cryotherapy | 5-8 | Liquid nitrogen prep, post-treatment notes | Procedure block |
| Phototherapy (UVB) | 10-12 | Dosage log, booth sanitation, patient timing | Dedicated PM slot |
| Follow-up / review | 5-7 | Chart pull, result flagging | End-of-day block |

UVB stands for ultraviolet B, a specific wavelength used in phototherapy for conditions such as psoriasis and eczema.

## What is a red flag in dermatology?

Short answer: In dermatology, a red flag is a clinical finding that requires urgent or same-day action -- features suggesting melanoma, rapidly spreading infection, or signs of a systemic condition presenting on the skin. From a workflow standpoint, red flags need a triage pathway that bypasses the standard booking queue without disrupting the day's schedule.

The most common red flags staff encounter include lesions meeting the ABCDE criteria (Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, Evolution), signs of cellulitis with fever, and sudden-onset blistering. When a red flag arrives without a triage slot in the schedule, the physician absorbs the time -- often by running late through the rest of the afternoon, which compounds fatigue for the entire team. A practical fix: hold one 20-minute slot per half-day as an unbooked buffer. Clinics that do this report fewer schedule overruns and fewer after-hours calls. The Canadian Dermatology Association (CDA) recommends documented triage protocols for urgent lesion referrals as part of standard practice management. Staff at the front desk should also have a one-page red-flag reference card covering what to escalate immediately versus book within a week. More information on CDA practice standards is available at [dermatology.ca](https://www.dermatology.ca).

## How to run a successful dermatology practice?

Short answer: A successful dermatology practice balances patient volume with staff capacity by designing workflows that distribute cognitive load fairly, document efficiently inside the encounter, and give each role clear ownership over its tasks. Sustainability is the real metric; a practice that burns through staff every two years is not successful by any useful measure.

Three operational areas have the highest return on investment for clinic managers working on burnout prevention. Documentation load is first: Electronic Health Record (EHR) and Electronic Medical Record (EMR) systems are the source of most after-hours work in Canadian specialty clinics. The Ontario Health Insurance Plan (OHIP) and most provincial billing systems require structured encounter notes, but the format is often left to the physician. Condition-specific macro templates for the most common 20 diagnoses cut average documentation time significantly. A pre-visit chart review protocol -- where a nurse or medical office assistant stages the chart the afternoon before the appointment -- removes another 10-12 minutes of physician prep time per visit. Staffing ratios are second: the Canadian Medical Association (CMA) tracks physician support staffing in ambulatory specialty care, and clinics that operate above 2.5 support staff per dermatologist report lower burnout scores and shorter wait times. The CMA's advocacy on physician well-being is documented at [cma.ca](https://www.cma.ca). Meeting cadence is third: a short weekly check-in -- 15 minutes, standing, at the end of Friday -- gives staff a low-stakes channel to flag friction before it accumulates into attrition.

Tools like [DermaDex](/about) are designed specifically for Canadian dermatology clinics, aiming to reduce front-desk decision load through AI-assisted triage and workflows aligned with provincial billing requirements.

## Burnout risk zones: where does your clinic stand?

Short answer: Clinic burnout risk is highest when documentation overflows into personal time, triage is unstructured, and role boundaries are undefined. The matrix below maps four risk zones against common clinic configurations, so you can locate your own practice and prioritize the right fix.

Statistics Canada data on healthcare workforce conditions confirm that specialty clinic workers report higher rates of work-related stress than most other regulated health professions ([Statistics Canada Healthcare Employment](https://www.statcan.gc.ca/)). Those workforce pressures map directly onto clinic design choices. The American Academy of Dermatology (AAD) recommends workflow standardization as a core strategy for reducing physician and staff fatigue in ambulatory dermatology settings ([American Academy of Dermatology](https://www.aad.org/)). A clinic in the High or Critical zone on two or more dimensions below needs a workflow redesign before adding headcount.

| Risk Zone | Schedule Design | Documentation Habit | Role Clarity | Key Signal |
|---|---|---|---|---|
| Low | Blocked by type; buffer slots held | Macros; chart pre-staged | Written role matrix | Staff tenure over 2 years |
| Moderate | Mostly blocked; occasional overbooks | Partial templates | Informal understanding | 1-2 after-hours docs per week |
| High | Mixed types; no buffer | End-of-day catch-up | Tasks default to physician | Schedule overruns daily |
| Critical | Fully open booking | Documentation spills into evenings | No defined handoffs | Active attrition |

## Sources

- [CDC NIOSH -- Worker Health](https://www.cdc.gov/niosh/) -- Centers for Disease Control and Prevention, 2024.
- [Canadian Medical Association -- Physician Well-Being](https://www.cma.ca) -- CMA, 2024.
- [Canadian Dermatology Association -- Practice Resources](https://www.dermatology.ca) -- CDA, 2024.
- [Statistics Canada -- Healthcare Employment](https://www.statcan.gc.ca/) -- Statistics Canada, 2024.
- [American Academy of Dermatology](https://www.aad.org/) -- AAD, 2024.

## FAQ
### What is the workflow of a clinical service?
A clinical workflow is the ordered sequence of steps a patient moves through from booking to discharge, with parallel staff actions at each stage. In dermatology, a typical visit covers six phases: pre-visit prep, check-in, intake, the clinical encounter, documentation, and close-out. Each phase should have a clearly assigned role owner -- medical office assistant, nurse, or dermatologist. When ownership is left ambiguous, tasks default to whoever is nearest, usually the physician, pulling them away from direct patient care. Mapping the workflow on a single role matrix and reviewing it quarterly is the lowest-cost way to prevent task overflow and reduce burnout risk.

### What procedures are done in dermatology?
Dermatology clinics perform a broad range of procedures: diagnostic skin biopsies, cryotherapy, excisions of benign and malignant lesions, phototherapy (UVB and PUVA), patch testing for contact dermatitis, and cosmetic procedures such as mole mapping. From a workflow standpoint, the key distinction is between procedure-type visits and consultation-type visits, because each category requires different room setup, supply levels, and documentation time. Mixing them randomly across a schedule forces constant context-switching for staff. Block scheduling -- grouping surgical procedures in dedicated half-day slots and medical consultations separately -- keeps room turnover predictable and reduces preparation errors.

### What is a red flag in dermatology?
A dermatology red flag is a finding that requires urgent action rather than routine booking. The most widely used framework is the ABCDE criteria for melanoma: Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, and Evolution (change over time). Other red flags include rapidly spreading cellulitis with systemic signs, sudden-onset blistering that may indicate pemphigus or Stevens-Johnson syndrome, and nodular lesions with irregular vessels on dermoscopy. From a clinic operations perspective, red flags need a triage pathway that creates a same-day slot without disrupting scheduled patients -- typically a held 20-minute buffer per half-day.

### How to run a successful dermatology practice?
Running a successful dermatology practice requires balancing patient throughput with staff capacity. The three highest-leverage operational changes are: reducing documentation load through EMR templates and pre-visit chart staging; maintaining adequate staffing ratios (the Canadian Medical Association recommends at least 2.5 support staff per dermatologist in specialty ambulatory care); and building a short weekly feedback loop where staff can flag workflow friction before it accumulates into attrition. Sustainability is the core metric. A practice that consistently burns through trained staff pays a real cost in recruiting, onboarding, and institutional knowledge loss that far exceeds the short-term savings from understaffing.

---

# PHIPA, PIPEDA, and Skin Health Data: What Patients Should Know

URL: https://www.dermadex.ca/blog/phipa-pipeda-and-skin-health-data-what-patients-should-know
Category: Compliance & Security
Author: Elham Hafezi
Published: 2024-07-09

## TL;DR
PHIPA (Personal Health Information Protection Act) applies to Ontario health information custodians and covers dermatology records, images, and AI scan data — it is an Ontario provincial law, not a national standard | PIPEDA (Personal Information Protection and Electronic Documents Act) is the federal baseline for private-sector health data across Canada | Patients have the right to access, correct, and request deletion of their health records under both laws | The Office of the Privacy Commissioner of Canada received 314 health-sector complaints in 2022-23 | Dermatology platforms operating in Ontario must satisfy PHIPA; platforms operating across Canada must satisfy PIPEDA and applicable provincial equivalents — all require explicit consent for AI analysis

*As of July 9, 2024.*

When you photograph a mole and send it to a dermatology platform, you are handing over something highly personal: an image of your body tied to a potential medical concern. Canadian law draws a clear boundary around that data. Two overlapping frameworks govern what happens next: PHIPA (Personal Health Information Protection Act) at the provincial level in Ontario, and PIPEDA (Personal Information Protection and Electronic Documents Act) at the federal level. Understanding both helps you ask the right questions before you share.

[DermaDex](/) is built on the premise that AI (Artificial Intelligence)-assisted dermatology should be trustworthy, not just fast. That means being transparent about how the laws that protect you actually work. [Learn more about us](/about) or [contact our privacy team](/contact) if you have specific questions about your data.

---

## Is Canada HIPAA or PIPEDA?

> **Short answer:** Canada uses PIPEDA, not HIPAA. PIPEDA is Canada's federal private-sector privacy law, and provinces like Ontario have layered PHIPA on top for health-specific contexts. These two systems address similar goals but operate under different scopes and enforcement bodies.

In the United States, the Health Insurance Portability and Accountability Act sets a single national standard for protected health information. Canada took a different path. PIPEDA, passed in 2000 and fully in force by 2004, covers all personal information collected, used, or disclosed by private-sector organizations in the course of commercial activity. It applies coast to coast but was designed as a broad baseline, not a health-specific statute. Ontario responded with PHIPA in 2004, a detailed provincial law aimed at health information custodians: hospitals, physicians, pharmacists, and any organization that collects health data on their behalf. When both laws apply to the same situation in Ontario, PHIPA generally takes precedence because it is the more specific statute. Other provinces have their own health privacy legislation. The result is a patchwork that patients encounter without always knowing which law applies. Health Canada summarizes federal privacy governance at [canada.ca](https://www.canada.ca/en/health-canada/corporate/about-health-canada/activities-responsibilities/access-information-privacy.html).

---

## What does PIPEDA not cover?

> **Short answer:** PIPEDA does not apply to non-commercial activities, personal or journalistic use, or the core health functions of provincially regulated public institutions like public hospitals. Those gaps matter for patients who assume one federal law covers all their health data.

Public hospitals, provincial health authorities, and publicly funded long-term care facilities fall outside PIPEDA's scope for their core clinical functions. They are subject instead to provincial freedom-of-information and health privacy statutes. In Ontario, that means PHIPA governs those institutions. Federally regulated employers such as airlines and banks that collect employee health data are covered by PIPEDA, but the physicians treating those employees are not. For patients using private dermatology platforms, PIPEDA almost certainly applies to the platform itself. If the platform operates in Ontario or handles Ontario residents' data, PHIPA may apply simultaneously. A dermatology app that processes skin images for commercial AI analysis is exactly the kind of private-sector activity PIPEDA was designed to govern. Canada's federal privacy framework overview is published at [canada.ca](https://www.canada.ca/en/health-canada/corporate/about-health-canada/activities-responsibilities/access-information-privacy.html).

---

## What is a HIPAA violation called in Canada?

> **Short answer:** The equivalent is a privacy breach. Under PHIPA, unauthorized use or disclosure of personal health information is called a privacy breach. Under PIPEDA it is called a breach of security safeguards. Both trigger mandatory notification requirements and carry substantial financial penalties.

Under PHIPA, a health information custodian who loses control of personal health information must notify affected individuals and the Information and Privacy Commissioner of Ontario. Fines for organizations can reach $500,000 per offence. Under PIPEDA breach notification regulations in force since November 2018, private-sector organizations must report breaches that create a real risk of significant harm to both the Privacy Commissioner of Canada and affected individuals. Skin health data is especially sensitive. A dermatology image that reveals a hereditary condition or a medication's side effect can affect insurance eligibility and employment. The threshold for what counts as significant harm is lower than most patients expect. If your data is involved in a breach, you have a right to receive direct notification. The CMA (Canadian Medical Association) publishes guidance on physician obligations at [cma.ca](https://www.cma.ca/).

---

## What is the PIPEDA in Canada?

> **Short answer:** PIPEDA (Personal Information Protection and Electronic Documents Act) is Canada's federal private-sector privacy law, passed in 2000 and fully in force by 2004. It establishes 10 fair-information principles that every covered organization must follow when collecting, using, or disclosing personal information, including health data collected by dermatology platforms.

The 10 principles are: accountability, identifying purposes, consent, limiting collection, limiting use and disclosure, accuracy, safeguards, openness, individual access, and challenging compliance. For dermatology patients, the most actionable are consent, individual access, and safeguards. Consent means the platform must tell you what it will do with your skin images before it does so. Individual access means you can request a copy of all data held about you and ask for corrections within 30 days. Safeguards means the organization must protect your data with security proportional to its sensitivity, which for identifiable health images is high. A 2022 study in PMC examined how Canada's layered privacy framework performs for health data: [pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9534800/). The Canadian Dermatology Association also maintains patient-facing guidance at [dermatology.ca](https://dermatology.ca/).

---

## How do PHIPA and PIPEDA protect skin health data specifically?

> **Short answer:** Both laws treat photographs, AI analysis results, EMR (Electronic Medical Record) entries, and EHR (Electronic Health Record) fields about skin conditions as sensitive personal information that requires explicit consent, strict storage limits, and breach notification. Together they create a two-layer protection for dermatology data in Ontario.

The table below compares the two frameworks across dimensions that matter most for dermatology patients.

| Dimension | PHIPA (Ontario) | PIPEDA (Federal) |
|---|---|---|
| Scope | Health information custodians in Ontario and their agents | Private-sector organizations across Canada in commercial activity |
| Data covered | All personal health information: diagnoses, images, AI scan results | All personal information including health data in commercial contexts |
| Consent model | Express consent for sensitive uses; implied consent for treatment | Meaningful consent; express consent for sensitive information |
| Patient access right | Request records within 30 days | Request access; organization has 30 days to respond |
| Breach notification | Notify IPC Ontario and affected individuals | Notify Privacy Commissioner and affected individuals if real risk of harm |
| Enforcement body | Information and Privacy Commissioner of Ontario | Office of the Privacy Commissioner of Canada |
| Maximum fine | $500,000 per offence | $100,000 per summary conviction offence |
| Retention | As long as needed to exhaust legal recourse | Only as long as necessary for identified purpose |

For a patient using a private dermatology platform in Ontario, both rows apply simultaneously if the platform qualifies as a health information agent under PHIPA.

---

## What rights do patients have over their skin health records?

> **Short answer:** You have the right to access your records, correct inaccuracies, withdraw consent for non-treatment purposes, and file a complaint with the relevant commissioner. Exercising these rights costs nothing, and organizations cannot refuse or charge excessive fees for complying.

In practice, exercising these rights starts with a written request to the platform or provider holding your data. Under PHIPA, custodians must respond within 30 days. They can charge a reasonable fee for producing the records but cannot refuse simply because the request is inconvenient. If a platform is using your de-identified skin images to train an AI model, it must have obtained your separate consent for that purpose. Many platforms bundle this into lengthy terms of service. Under PIPEDA's principle of identifying purposes, they are required to state the purpose at or before the time of collection in language you can reasonably understand. Complaints about a private dermatology platform go to the federal Privacy Commissioner. Complaints about a physician or hospital go to the Information and Privacy Commissioner of Ontario. A peer-reviewed study on Canadian health data privacy regulations published on PubMed provides further background: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36340704/).

---

## Sources

- Health Canada. *Access to information and privacy*. [canada.ca](https://www.canada.ca/en/health-canada/corporate/about-health-canada/activities-responsibilities/access-information-privacy.html) (updated July 2022)
- Canadian Medical Association. *CMA home page*. [cma.ca](https://www.cma.ca/)
- Canadian Dermatology Association. [dermatology.ca](https://dermatology.ca/)
- Sarabdeen J et al. *Creating standards for Canadian health data protection during and after COVID-19*. PMC, 2022. [pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9534800/)
- Sarabdeen J. *Health information privacy regulations in Canada*. PubMed, 2022. [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36340704/)

## FAQ
### Is Canada HIPAA or PIPEDA?
Canada does not use HIPAA. HIPAA is a US law. Canada's federal private-sector privacy framework is PIPEDA (Personal Information Protection and Electronic Documents Act), which covers organizations collecting personal information for commercial purposes. Provinces have added their own health-specific statutes on top of it. Ontario's PHIPA (Personal Health Information Protection Act) is the most comprehensive, applying to physicians, hospitals, labs, and any platform acting as their health information agent. When both PHIPA and PIPEDA apply to the same situation, PHIPA takes precedence in Ontario. Other provinces — including Alberta and British Columbia — have their own substantially similar legislation. The result is layered protection rather than a single national health privacy standard.

### What does PIPEDA not cover?
PIPEDA does not apply to federal or provincial government institutions (covered by the federal Privacy Act or provincial access-to-information laws), non-commercial activities, personal or journalistic use, or the core clinical activities of publicly funded hospitals and health authorities. In the health sector specifically, public hospitals run by provincial governments fall outside PIPEDA for their primary functions and are governed by provincial health privacy legislation instead. Employee health records at federally regulated employers are an exception where PIPEDA does apply. Private dermatology platforms, telehealth companies, and AI skin analysis tools that operate commercially are squarely within PIPEDA's scope.

### What is a HIPAA violation called in Canada?
Canada does not use the term HIPAA violation. Under PHIPA in Ontario, unauthorized collection, use, or disclosure of personal health information is called a privacy breach. Under PIPEDA, it is a breach of security safeguards. Both require the organization to notify affected individuals and the relevant commissioner if there is a real risk of significant harm. Under PHIPA, fines for organizations can reach $500,000 per offence. PIPEDA breach notification regulations, in force since November 2018, require organizations to keep records of all breaches for 24 months and produce them to the Privacy Commissioner on request. Patients who suspect their health data was improperly shared can file a complaint directly with the Office of the Privacy Commissioner of Canada or the Information and Privacy Commissioner of Ontario.

### What is the PIPEDA in Canada?
PIPEDA (Personal Information Protection and Electronic Documents Act) is Canada's federal private-sector privacy law, passed in 2000 and fully in force by 2004. It establishes 10 fair-information principles: accountability, identifying purposes, consent, limiting collection, limiting use and disclosure, accuracy, safeguards, openness, individual access, and challenging compliance. Any private organization — including a dermatology app or AI skin analysis platform — that collects, uses, or discloses personal information in the course of commercial activity must comply. Patients have the right to know what data is collected, why it is collected, how long it is kept, and who can access it. They can also request corrections and file complaints at no charge with the Office of the Privacy Commissioner of Canada.

---

# How Computer Vision Models Detect Skin Conditions: A Technical Primer

URL: https://www.dermadex.ca/blog/how-computer-vision-models-detect-skin-conditions-a-technical-primer
Category: AI & Technology
Author: Elham Sayyah
Published: 2024-06-18

## TL;DR
A 2017 Nature study showed a CNN matched board-certified dermatologists at diagnosing keratinocyte carcinomas and melanoma | The ISIC 2020 challenge dataset contains over 33,000 labelled dermoscopy images used to train modern skin AI models | EfficientNet-B4 achieves roughly 89% top-1 accuracy on the ISIC benchmark as of 2024 | Canada has approximately 800 practising dermatologists serving 38 million people, creating demand for AI triage tools | Canadian healthtech platforms are applying deep learning classification with privacy-compliant storage under PHIPA (Ontario) and PIPEDA (federal) to reduce specialist access delays

*As of June 18, 2024.*

Artificial Intelligence (AI) has entered dermatology not as a distant promise but as working software. [DermaDex](/) is one example of how Canadian healthtech teams are applying these methods to close the gap between patients and specialists. This primer explains the machine learning (ML) mechanics behind AI skin diagnosis: how models are built, what they actually measure, and where they still fall short.

## What is AI skin diagnosis?

In short: AI skin diagnosis is the automated classification of skin lesion images using deep learning models, primarily Convolutional Neural Networks (CNNs), trained on large labelled dermoscopy or clinical photograph datasets. When a patient uploads a photo of a suspicious mole, a CNN scans that image through dozens of learned filter layers. Each layer detects progressively abstract patterns: edges and colour gradients in early layers, then texture patterns, then higher-level structures like asymmetric borders or pigmentation networks. The final layer outputs probability scores across condition categories such as melanoma, basal cell carcinoma, and seborrheic keratosis. In a landmark 2017 paper published in *Nature*, Esteva et al. demonstrated that a single CNN trained on 129,450 clinical images classified keratinocyte carcinomas and melanoma at a level comparable to 21 board-certified dermatologists ([Esteva et al., Nature, 2017](https://www.nature.com/articles/nature21056)).

## How does a CNN actually process a skin image?

A CNN applies a series of learned convolutional filters to an input image, reducing it to a compact feature vector that a classification head maps to a disease probability distribution. Start with a 224 x 224 pixel dermoscopy photograph. The first convolutional layer applies, say, 64 small 3 x 3 filters across every spatial position, producing 64 feature maps. A max-pooling step halves the spatial resolution. This repeats through many blocks. By the final convolutional layer the network holds a dense, spatially compressed representation of the image contents. A global average pooling step collapses spatial dimensions to a single vector. A fully connected head then maps that vector to class probabilities via a softmax function. During training, the model adjusts every filter weight to minimise cross-entropy loss against the ground-truth labels. After hundreds of thousands of gradient updates across a labelled dataset like the ISIC (International Skin Imaging Collaboration) collection, the filters encode genuine diagnostic features rather than noise.

## Which model architectures are used in computer vision dermatology?

ResNet, EfficientNet, and Vision Transformer variants dominate published benchmarks; EfficientNet-B4 and EfficientNet-B7 currently offer the best accuracy-to-parameter tradeoff on dermoscopy classification tasks. The table below compares key architectures evaluated on ISIC challenge data.

| Model | Year | Approx. Top-1 Accuracy (ISIC) | Notes |
|---|---|---|---|
| ResNet-50 | 2015 | ~82% | First deep residual architecture; widely used baseline |
| Inception-v3 | 2015 | ~83% | Used in the Esteva 2017 *Nature* study |
| DenseNet-121 | 2017 | ~84% | Dense skip connections; strong for medical imaging |
| EfficientNet-B4 | 2019 | ~89% | Compound scaling; best accuracy-to-compute tradeoff |
| EfficientNet-B7 | 2019 | ~90% | Highest accuracy in class; 4x the parameters of B4 |
| ViT-Large (fine-tuned) | 2021 | ~91% | Vision Transformer; requires large pre-training corpus |

Accuracies are approximate and vary by dataset split, preprocessing, and augmentation strategy. The ISIC 2020 challenge dataset contains over 33,000 dermoscopy images with expert labels, making it the standard public benchmark for deep learning skin disease classification. For a full review of CNN performance on skin lesion tasks, see the systematic review published in PMC: [Jeong et al., PMC/NCBI, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9324826/).

## What training data does deep learning skin disease classification require?

Models require tens of thousands of labelled dermoscopy or clinical photos covering diverse skin tones and condition subtypes; dataset bias toward lighter Fitzpatrick skin types remains an active research problem. A CNN trained exclusively on dermoscopy images from European patients will underperform on darker skin tones because the pigmentation patterns differ. The American Academy of Dermatology (AAD) has called for greater diversity in dermatology AI training datasets because of this gap. ISIC has progressively added images from more diverse populations, but published audits still show lower sensitivity for conditions like melanoma in Fitzpatrick types V and VI. Canadian cohorts are underrepresented in most public datasets, which is part of why Canadian healthtech companies building on top of these base models need additional fine-tuning on locally collected data. The [Canadian Dermatology Association (CDA)](https://www.dermatology.ca) supports research efforts to improve diagnostic equity across skin tones.

From a data engineering standpoint, training a competitive CNN skin classifier from scratch needs at minimum:

- 20,000 to 50,000 labelled images across target classes
- Dermoscopy metadata (magnification, equipment type)
- Fitzpatrick skin type labels where available
- Expert consensus labels, not single-annotator assignments
- Strict train/validation/test splits with no patient-level leakage

## How do researchers evaluate CNN skin classification accuracy?

The standard metrics are AUC-ROC, sensitivity, specificity, and balanced accuracy; a confusion matrix across condition classes exposes which conditions a model conflates most often. AUC-ROC (Area Under the Receiver Operating Characteristic curve) measures a model's ability to distinguish one class from all others across all classification thresholds. An AUC of 1.0 is perfect; 0.5 is random. Published dermoscopy models typically reach AUC values between 0.87 and 0.95 on held-out test sets. But AUC alone hides clinically important failure modes. A model that misclassifies melanoma as a benign nevus 15% of the time has dangerous false-negative behaviour regardless of its overall AUC.

The confusion matrix below shows a stylised example of where a ResNet-50 baseline loses confidence between visually similar conditions:

| True class / Predicted | Melanoma | Nevus | BCC | Seborrheic keratosis |
|---|---|---|---|---|
| Melanoma | 81% | 12% | 4% | 3% |
| Nevus | 7% | 87% | 2% | 4% |
| BCC | 3% | 3% | 88% | 6% |
| Seborrheic keratosis | 4% | 5% | 3% | 88% |

The melanoma row shows the highest off-diagonal confusion, which is clinically the most consequential error. Production AI skin diagnosis systems therefore typically set a high-sensitivity operating point that accepts more false positives to minimise missed melanomas.

## What are the regulatory and ethical limits of AI skin diagnosis in Canada?

AI tools used in clinical diagnosis in Canada require Health Canada (HC) approval as a Class II or Class III medical device under the Medical Devices Regulations; unapproved tools may only be used as patient-facing wellness or triage aids, not as diagnostic instruments. Health Canada regulates software that meets the definition of a medical device. An AI application that purports to diagnose a specific skin disease falls under Class II or III, requiring a premarket review. This mirrors the approach of the U.S. Food and Drug Administration (FDA), which has cleared over 500 AI/ML-enabled medical devices as of early 2024, including several dermatology tools. The World Health Organization (WHO) has published guidance on ethical digital health, including principles of transparency, equity, and accountability that apply directly to skin AI deployment. A 2022 systematic review in *Frontiers in Medicine* ([Duong et al., PMC, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9366122/)) catalogued over 40 AI dermatology studies and found that external validation on independent patient cohorts remains the biggest gap between benchmark performance and clinical readiness.

For patients using AI-assisted triage tools like [DermaDex](/), the distinction matters: a triage score that routes you toward a dermatologist faster is not the same as a clinical diagnosis. Clinicians remain the decision-makers. Learn more [about DermaDex's approach](/about) to responsible AI in Canadian dermatology.

## How accurate is AI at detecting melanoma compared to dermatologists?

Trained CNNs match or exceed general practitioners at melanoma detection and perform comparably to dermatologists on dermoscopy images, but only under controlled conditions that do not reflect the full complexity of a clinical visit. The Esteva 2017 *Nature* paper is the most cited benchmark: a CNN matched dermatologist performance on two binary classification tasks using dermoscopy images. A 2018 study published in Annals of Oncology found that a CNN matched or exceeded dermatologist-level diagnosis on dermoscopy images, a result confirmed across multiple reader studies ([Haenssle et al., 2018, PubMed](https://pubmed.ncbi.nlm.nih.gov/29846502/)). The practical gap is narrowing, but AI models are tested on curated image sets. They do not examine patients, take histories, or factor in symptoms. See our article on [understanding the ABCDE framework for skin cancer detection](/blog/understanding-melanoma-the-abcdes-of-skin-cancer-detection) for the clinical context that surrounds any AI output.

## Where does computer vision dermatology still fall short?

Despite strong benchmark results, current CNN models for skin conditions have several documented limitations that matter in real clinical settings. First, image quality dependency: models trained on standardised dermoscopy images degrade noticeably when given photographs taken with varying angles, lighting, or consumer smartphone cameras. Second, the long-tail problem: conditions that appear rarely in training datasets such as morphea or lichen sclerosus get systematically low accuracy because the model has seen too few examples. Third, single-modality blindness: CNNs read only the image. They have no access to patient age, symptom duration, medication history, or the kind of contextual reasoning a clinician brings to a diagnosis. The [National Institutes of Health (NIH)](https://www.nih.gov) has flagged all three as active research priorities in its AI in medical imaging strategy. Addressing them requires better datasets, multimodal model architectures, and rigorous prospective clinical trials, not just improved benchmark scores.

## Sources

- Esteva A et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature* 542, 115-118 (2017). https://www.nature.com/articles/nature21056
- Jeong HK et al. Deep Learning in Dermatology: A Systematic Review of Current Approaches, Opportunities, and Limitations. *Front Med (Lausanne)*. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9324826/
- Haenssle HA et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition. *Ann Oncol.* 2018. https://pubmed.ncbi.nlm.nih.gov/29846502/
- Duong DK et al. Artificial Intelligence for Dermoscopy Image Analysis. *Front Med*. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9366122/
- Canadian Dermatology Association (CDA). https://www.dermatology.ca

## FAQ
### How accurate is AI in diagnosing skin conditions?
Trained deep learning models match general practitioners and perform comparably to dermatologists on dermoscopy image classification tasks. A 2018 meta-analysis found AI achieving roughly 77% sensitivity and 83% specificity for melanoma, compared to 74% sensitivity and 84% specificity for dermatologists on the same image types. Accuracy varies significantly by condition, image quality, and the diversity of the training dataset. Models tested on curated benchmarks like the ISIC dataset consistently outperform random chance by wide margins, but clinical validation under real-world conditions is still catching up to benchmark results.

### Can a computer vision model diagnose melanoma?
Computer vision models can classify dermoscopy images as suspicious for melanoma with accuracy that rivals board-certified dermatologists under controlled benchmark conditions. The 2017 Nature study by Esteva et al. is the most cited demonstration: a CNN trained on over 129,000 clinical images performed on par with 21 dermatologists at distinguishing malignant skin lesions. However, no AI tool is approved in Canada as a standalone diagnostic device for melanoma. AI models flag risk and route patients toward specialist review; the final diagnosis remains with a licensed clinician.

### What data is used to train AI skin disease models?
The main public training sources are dermoscopy image datasets curated by the International Skin Imaging Collaboration (ISIC), which contains over 33,000 expert-labelled images as of the 2020 challenge. Additional datasets include HAM10000, the PH2 dataset, and proprietary clinical collections held by academic medical centres. A persistent problem is that most public datasets over-represent lighter Fitzpatrick skin types, which leads to lower model accuracy on darker skin tones. High-quality labels from multiple board-certified dermatologists, along with metadata about imaging equipment and patient demographics, are essential for building generalizable models.

### What is a CNN in skin cancer detection?
A CNN (Convolutional Neural Network) is a type of deep learning architecture that processes images by applying learned filters across spatial regions. In skin cancer detection, a CNN takes a dermoscopy photograph as input and passes it through many convolutional layers, each detecting progressively complex visual patterns: from edges and colour gradients to the irregular borders and atypical pigmentation networks characteristic of melanoma. The network's final layer outputs probability scores across condition categories. CNNs became the dominant approach in medical image analysis after achieving breakthrough performance on ImageNet in 2012 and have since been adapted extensively for dermatology.

### Is AI skin diagnosis approved by Health Canada?
As of June 2024, AI tools that claim to diagnose specific skin diseases in Canada require review and clearance from Health Canada as a medical device under the Medical Devices Regulations. Software that provides a diagnostic conclusion falls into Class II or Class III device categories, requiring premarket review. AI-assisted triage tools that route patients toward care without issuing a clinical diagnosis operate in a different regulatory space. Health Canada's guidance on software as a medical device continues to evolve; any team deploying AI skin tools in a clinical workflow should verify current requirements directly with Health Canada.

---

# The State of Dermatology Access in Canada in 2024

URL: https://www.dermadex.ca/blog/the-state-of-dermatology-access-in-canada-in-2024
Category: Healthcare Access
Author: Mohsen Khoddami
Published: 2024-05-28

## TL;DR
Dermatology wait times in Canada average 40+ weeks in several provinces (CIHI, 2024) | Ontario patients wait a median 78 days for a dermatology referral, among the highest nationally | Canada has fewer than 600 active dermatologists for 40 million people (CMA, 2023) | Skin cancer is the most common cancer in Canada, with 80,000+ new cases annually (Canadian Cancer Society, 2024) | Teledermatology and eConsult services have demonstrated median response times of under 5 business days compared to the standard 78-day wait (Ontario Health, 2023)

*As of May 28, 2024.*

Canadians living with suspicious moles, worsening psoriasis, or uncontrolled eczema often discover the same hard truth: getting in front of a dermatologist takes months, sometimes well over a year. This article breaks down where wait times stand in 2024, what is driving the shortage, and what patients can do today.

## How long do Canadians typically wait for dermatology care?

Wait times for a dermatologist in Canada range from 3 months to well over a year depending on province, with Ontario and rural areas facing the worst delays. The [Canadian Institute for Health Information (CIHI)](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) reports that specialist wait times across all disciplines have grown steadily since 2019. The national median for dermatology now sits above 60 days in most urban centres and well beyond 180 days in rural regions. According to the [Canadian Medical Association (CMA)](https://www.cma.ca/), Canada has fewer than 600 practicing dermatologists serving a population of approximately 40 million people, a ratio significantly below the OECD average. Most dermatology referrals originate with a family physician, and the patient waits weeks for the specialist appointment. In Ontario, the median wait from referral to first dermatology appointment sits at approximately 78 days in urban centres, and substantially longer in rural or remote communities.

| Province | Estimated Median Wait (Referral to Appointment) | Notes |
|---|---|---|
| Ontario | 78 days | Urban centres; rural waits longer |
| British Columbia | 60-90 days | Varies by health authority |
| Alberta | 50-80 days | Calgary/Edmonton shorter than rural |
| Quebec | 90-120 days | Majority in Montreal/Quebec City |
| Nova Scotia | 120-180 days | Single tertiary centre |
| Newfoundland and Labrador | 180+ days | Fewer than 5 dermatologists province-wide |

*Sources: CIHI Health System Performance, 2024; CMA Physician Data Centre, 2023.*

## Why is there a dermatologist shortage in Canada?

Canada trains far fewer dermatologists than its population needs, and retaining them is complicated by geography, compensation gaps, and an aging physician workforce. Dermatology residency programs across Canada accept only 30-40 new residents per year nationally, one of the lowest intake rates relative to demand of any specialty. Because dermatology is among the most competitive medical specialties to enter, many qualified applicants do not match. At the same time, approximately one-third of current Canadian dermatologists are over age 55, meaning a retirement wave is approaching within this decade. Internationally trained dermatologists face lengthy licensing processes under each provincial college, limiting the pipeline from abroad. Meanwhile, demand is rising: skin cancer rates in Canada have increased by roughly 30% over the past 20 years according to [Statistics Canada](https://www150.statcan.gc.ca/n1/pub/82-625-x/2023001/article/00001-eng.htm), and skin cancer is now the most common cancer in Canada with over 80,000 new cases diagnosed each year. That volume alone strains a specialty that was already short-staffed.

For a broader picture of the dermatologist shortage across Canada, the [DermaDex team](/about) tracks referral trends and availability data from clinic partners nationwide.

## How does the referral pathway work, and where does it slow down?

Most patients reach a dermatologist through a primary care referral, and delays accumulate at two chokepoints: getting a family doctor who will refer, and then waiting for the specialist appointment itself. Understanding each step helps patients push for faster care and identify where the system is most likely to fail them. In Ontario, roughly 1 in 5 adults does not have a regular family physician, meaning those patients often rely on walk-in clinics whose referral letters receive lower triage priority. The Ministry of Health (MOH) for Ontario has acknowledged the gap but structural solutions remain years away. Urgent referrals for suspected melanoma or rapidly spreading conditions are supposed to be seen within 2 weeks under national guidelines, but audits suggest that benchmark is frequently missed outside major cancer centres. Patients who need biopsies or follow-up often restart the queue from the beginning. If you are trying to get care faster, teledermatology platforms and eConsult services can help document your concern and reach a certified dermatologist without the standard referral queue.

The standard pathway in Canada:

1. Patient notices a skin concern.
2. Patient books a family physician or nurse practitioner appointment, itself often a 2-6 week wait.
3. Clinician writes a referral to a dermatologist.
4. Dermatologist's office triages the referral and books an appointment.
5. Patient attends the specialist appointment.

## Which provinces have the worst specialist wait times for dermatology?

Atlantic Canada and rural parts of every province face the longest waits, while Ontario has the highest absolute number of patients waiting due to its population size. [CIHI's annual health system performance data](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada) shows that for dermatology specifically, Atlantic provinces consistently rank at the bottom for specialist access. Prince Edward Island has a single hospital-based dermatology service and no private dermatology clinics. New Brunswick residents in rural areas routinely travel to Fredericton or Moncton for specialist appointments, adding cost and time. In Quebec, waits through the provincial insurer can exceed four months. British Columbia's geography creates similar problems: interior and northern communities rely on visiting dermatologists who schedule clinics once a month or less frequently. For Canadians in these underserved regions, telehealth and AI-assisted dermatology platforms like [DermaDex](/) offer a practical alternative while waiting for an in-person appointment.

## What do the 2024 wait time numbers actually show?

National data published by CIHI and the [CMA for 2024](https://www.cma.ca/) confirms that dermatology wait times have not improved since 2019, and in several provinces they have worsened by 10-20%. Post-pandemic, elective referrals deferred in 2020 and 2021 flooded back into the system in 2022 and 2023 without a corresponding increase in dermatologist capacity. Ontario Health Insurance Plan (OHIP) data shows a 22% increase in dermatology billings from 2021 to 2023, while the number of billing dermatologists grew by less than 4% in the same period. The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) has documented similar pressure in the United States, where the specialist-to-patient ratio tracks closely to Canadian figures. The data shows a clear urban-rural divide and a growing backlog that patients and referring clinicians must plan around.

| Access Route | Typical Wait | Provincial Coverage |
|---|---|---|
| Standard GP referral to dermatologist | 60-180 days | Yes |
| Urgent cancer referral (2-week pathway) | 14 days (target) | Yes |
| Private direct-access dermatology clinic | 1-4 weeks | Partial or no |
| Teledermatology asynchronous review | 24-72 hours | Varies by province |
| AI-assisted triage and specialist review | Under 3 minutes triage | Platform-dependent |

## What steps can patients take while waiting for a dermatology appointment?

Patients have several concrete options to either speed up access or manage their condition safely while waiting, and the two highest-impact actions are photographing the lesion and requesting an urgent referral. First, photograph any concerning skin changes with a dated photo at least once a week. This creates a visual record that supports an urgent referral request and gives the dermatologist a progression timeline even before the appointment. Second, ask your family physician or walk-in clinician explicitly whether the referral should be marked urgent, and what criteria would qualify. Third, check whether your province offers a teledermatology program: several provinces have piloted digital dermatology services that allow a dermatologist to review photos asynchronously and provide a preliminary opinion within days. Fourth, use a Personal Health Information Protection Act (PHIPA)-compliant platform to share your case securely with a certified dermatologist. PHIPA (Personal Health Information Protection Act) governs health data privacy in Ontario; equivalent protection applies nationally under PIPEDA (Personal Information Protection and Electronic Documents Act). [DermaDex](/) offers privacy-compliant AI-assisted triage and specialist access for patients across Canada, meeting PHIPA requirements in Ontario and PIPEDA requirements federally.

## What are the most frequently asked questions about dermatology wait times in Canada?

The four questions Canadians ask most often about dermatology access address appointment timing, clinical urgency, referral pathways, and faster access routes. Each answer below draws on current Canadian clinical guidelines and national wait time data. Understanding these answers helps patients advocate more effectively with their referring clinician, prioritize their own case appropriately, and find alternatives when the standard pathway is too slow. If your concern is time-sensitive, do not wait for a routine appointment slot. Use the resources below and reach out to a dermatologist through an alternative channel while the referral is being processed.

### How long will I wait for a dermatology appointment?

Wait times vary significantly by province and whether your concern is classified as urgent or routine. In major Canadian cities, expect 6-16 weeks from referral to appointment for a non-urgent concern. In rural areas or Atlantic provinces, waits of 6 months to over a year are common. Urgent referrals for suspected skin cancer are supposed to be seen within 2 weeks, but capacity constraints mean this target is often missed outside large cancer centres. If your concern is changing rapidly, worsening, or involves a new pigmented lesion, ask your referring physician to mark the referral urgent. You can also use an AI-assisted triage service to document your concern and get faster clinical prioritization.

### What is a red flag in dermatology?

Red flags in dermatology are findings that require prompt specialist assessment rather than routine monitoring. These include: a mole or lesion that changes shape, color, or size over weeks; a spot that bleeds without injury; a non-healing ulcer lasting more than 6 weeks; widespread rash with systemic symptoms such as fever or joint pain; and sudden hair loss in patches. The ABCDE rule (Asymmetry, Border, Color, Diameter, Evolution) is the standard screening tool for suspicious pigmented lesions. The [American Academy of Dermatology (AAD)](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma) lists rapid growth and satellite lesions as additional warning signs. If you notice any of these, book a same-day walk-in or use a teledermatology service rather than waiting months for a routine referral.

### What is the 2 week wait referral criteria for dermatology?

The 2-week wait referral pathway is designed to fast-track patients with suspected skin cancer to a specialist within 14 days of referral. In Canada, the criteria vary slightly by province, but generally include: a lesion suspicious for melanoma using the ABCDE rule; suspected squamous cell carcinoma (SCC) that has grown or bled; a nodular basal cell carcinoma on the face or scalp; and suspected Merkel cell carcinoma. Your family physician or nurse practitioner must flag the referral as urgent and document the clinical rationale. Not all Canadian provinces have a formal 2-week wait protocol, but most regional cancer programs have triage criteria that should produce comparable access for high-risk patients. Ask your referring clinician explicitly about urgent pathways if your lesion qualifies.

### What is the fastest way to see a dermatologist?

The fastest options in Canada, from quickest to slowest, are: first, a teledermatology platform where a board-certified dermatologist reviews photos of your concern asynchronously within 24-72 hours; second, a direct-access dermatology clinic that accepts self-referrals (available in several provinces, though often not covered by the Ontario Health Insurance Plan or OHIP); third, a walk-in clinic whose physician can write an urgent referral; and fourth, the standard family physician referral pathway. For patients covered by provincial insurance, the fastest insured route is an urgent referral from any physician. AI-assisted triage tools can help document your concern in a format that supports faster specialist prioritization, which is central to what [DermaDex](/) offers.

## Sources

- [CIHI — Wait Times for Priority Procedures in Canada](https://www.cihi.ca/en/wait-times-for-priority-procedures-in-canada). Canadian Institute for Health Information, 2024.
- [CMA Physician Data Centre](https://www.cma.ca/). Canadian Medical Association, 2023.
- [Statistics Canada — Health characteristics, annual estimates](https://www150.statcan.gc.ca/n1/pub/82-625-x/2023001/article/00001-eng.htm). Statistics Canada, 2023.
- [AAD — Melanoma Warning Signs](https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma). American Academy of Dermatology, 2024.
- [Statistics Canada — Primary health care providers](https://www150.statcan.gc.ca/n1/pub/82-625-x/2023001/article/00001-eng.htm). Statistics Canada, 2023.

## FAQ
### How long will I wait for a dermatology appointment?
Wait times vary significantly by province and whether your concern is classified as urgent or routine. In major Canadian cities, expect 6-16 weeks from referral to appointment for a non-urgent concern. In rural areas or Atlantic provinces, waits of 6 months to over a year are common. Urgent referrals for suspected skin cancer are supposed to be seen within 2 weeks, but capacity constraints mean this target is often missed outside large cancer centres. If your concern is changing rapidly, worsening, or involves a new pigmented lesion, ask your referring physician to mark the referral urgent. You can also use an AI-assisted triage service to document your concern and get faster clinical prioritization.

### What is a red flag in dermatology?
Red flags in dermatology are findings that require prompt specialist assessment rather than routine monitoring. These include: a mole or lesion that changes shape, color, or size over weeks; a spot that bleeds without injury; a non-healing ulcer lasting more than 6 weeks; widespread rash with systemic symptoms such as fever or joint pain; and sudden hair loss in patches. The ABCDE rule (Asymmetry, Border, Color, Diameter, Evolution) is the standard screening tool for suspicious pigmented lesions. The American Academy of Dermatology (AAD) lists rapid growth and satellite lesions as additional warning signs. If you notice any of these, book a same-day walk-in or use a teledermatology service rather than waiting months for a routine referral.

### What is the 2 week wait referral criteria for dermatology?
The 2-week wait referral pathway is designed to fast-track patients with suspected skin cancer to a specialist within 14 days of referral. In Canada, the criteria vary slightly by province, but generally include: a lesion suspicious for melanoma using the ABCDE rule; suspected squamous cell carcinoma (SCC) that has grown or bled; a nodular basal cell carcinoma on the face or scalp; and suspected Merkel cell carcinoma. Your family physician or nurse practitioner must flag the referral as urgent and document the clinical rationale. Not all Canadian provinces have a formal 2-week wait protocol, but most regional cancer programs have triage criteria that should produce comparable access for high-risk patients. Ask your referring clinician explicitly about urgent pathways if your lesion qualifies.

### What is the fastest way to see a dermatologist?
The fastest options in Canada, from quickest to slowest, are: first, a teledermatology platform where a board-certified dermatologist reviews photos of your concern asynchronously within 24-72 hours; second, a direct-access dermatology clinic that accepts self-referrals (available in several provinces, though often not covered by the Ontario Health Insurance Plan or OHIP); third, a walk-in clinic whose physician can write an urgent referral; and fourth, the standard family physician referral pathway. For patients covered by provincial insurance, the fastest insured route is an urgent referral from any physician. AI-assisted triage tools can help document your concern in a format that supports faster specialist prioritization, which is central to what DermaDex offers.

---